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Introduction 
It is once again a pleasure to 
present the surveillance report 
for infectious diseases in Ireland 
for 2012. 
There continued to be 
encouraging trends in some 
areas of infectious disease 
prevention and control affecting 
those living in Ireland in 2012. 
Improvements were sustained in the uptake of the 
childhood vaccination programme with 95% of children 
vaccinated against diseases in the primary schedule 
by the age of 24 months in all HSE areas, and 92% 
of children vaccinated with one dose of MMR by 24 
months. The uptake of HPV vaccine in second level 
schools has also been very encouraging with 86% 
uptake recorded in first year girls’ classes. These results 
compare favourably with those reported from other 
countries and reflect the effort and support put in by 
staff and schools involved in the school vaccination 
programme.
The number of measles cases reported continued to 
decline apart from a large outbreak in teenagers in West 
Cork. Ninety percent of cases in this outbreak were 
unvaccinated as many came from families opposed to 
vaccination. 
Meningococcal disease continues the downward trend 
observed over the past decade with a decline in cases 
of more than 87% since 1999. Despite the marked 
decline meningococcal disease is still an important 
public health concern due to its associated severity, 
high mortality rate and serious adverse sequelae. 
Consideration is currently being given as to how best 
to use the new meningococcal B vaccine in the Irish 
setting. 
TB rates in Ireland continued to decline in 2012 with 
364 cases reported, a rate 7.9 per 100,000 population, 
the lowest recorded since surveillance began. While 
encouraging, strengthening of TB prevention and 
control strategies needs to be sustained in order to 
reach the WHO target of 1 case per 100,000 population 
by 2050. 
As discussed in the 2011 annual report there has been 
an unwelcome increase in cases of pertussis. Newborn 
infants are most at risk and the highest incidence in 
2012 was in children aged under six months. This 
unfortunately resulted in the deaths of two young 
infants under the age of 3 months. In August 2012 an 
additional pertussis booster was recommended for 
health care workers and pregnant women. Further 
information on these recommendations is available at 
www.immunisation.ie
The 2012-2013 influenza season was unusual in that 
the usual seasonal epidemic lasted for 14 consecutive 
weeks, one of the longest seasons on record, with 
the exception of the pandemic period. Seventy two 
outbreaks were reported to public health departments 
around the country. These outbreaks mainly occurred 
in healthcare facilities and residential institutions. As 
the influenza vaccine is less effective in the very elderly 
it is important that those with whom the elderly have 
contact receive the vaccine. At the other end of the 
age spectrum the under one year-olds were the age 
group who were most often hospitalised with influenza 
and had the highest rate of admission to ICU. Four 
pregnant women were also admitted to ICU. Influenza 
vaccine is now advised for pregnant women at all stages 
of pregnancy. Two novel respiratory viruses emerged 
during the 2012/2013 season, Middle East Respiratory 
Syndrome coronavirus (MERS-CoV) in the Middle East 
and avian origin influenza A(H7N9) in Eastern China. 
Both have high reported case fatality ratios but as yet 
do not transmit easily from person-to-person. Further 
information is available at www.hpsc.ie. 
In 2012, 122 cases of iGAS infection were notified in 
Ireland which is the highest number reported to date 
and an increase of 82% on 2011. iGAS is a potentially 
life threatening disease with an overall case fatality 
rate of 13% and a case fatality rate of 19% in those 
who present with streptococcal toxic shock syndrome. 
Further information on iGAS disease including fact 
sheets for patients and contacts, national guidelines 
for healthcare professionals and surveillance reports 
are available at http://www.hpsc.ie/hpsc/A-Z/Other/
GroupAStreptococcalDiseaseGAS/
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2012 also saw a large increase ( 90% over the last 
two years) in the number of cases of Cryptosporidium 
diarrhoeal illness in Ireland, the second highest rate 
of countries reporting on the disease in the European 
Union. Possible contributing factors include the 
prolonged rainfall in the summer of 2012 as this illness 
is often associated with the contamination of drinking 
water by livestock effluent. Another zoonotic or 
animal associated infection which is a serious problem 
in Ireland continues to be verotoxigenic E.coli. The 
number of reported cases almost doubled in 2012. This 
may have been due to improved detection methods 
in the laboratory but was also likely to have been 
influenced by the high rainfall in 2012. 
Hepatitis C continues to be one of the most frequently 
notified infectious diseases in Ireland. 75% of those 
infected go on to develop chronic infection and are at 
risk of severe complications such as cirrhosis and liver 
cancer. Fortunately, recently introduced new treatment 
regimes can successfully eradicate the virus in the 
majority of patients treated but the challenge remains to 
improve prevention in high risk groups and to improve 
access to therapy for those already infected. The overall 
trend in newly diagnosed HIV cases has been stable in 
recent years. However the proportion of cases in MSM 
has been increasing and sex between men has been 
the commonest mode of transmission since 2010. The 
proportion of those diagnosed late varies by risk group 
and was highest among heterosexual males. Strategies 
to improve uptake of testing need to be strengthened 
to enable earlier detection of the disease. The number 
of cases of gonorrhoea notified in 2012 is the highest 
ever recorded in Ireland. A multidisciplinary group was 
established in 2012 to investigate the reasons for this 
increase and to make recommendations for prevention 
in both the heterosexual and MSM community. 
In the area of health care associated infections there was 
a 12% decrease in cases of Clostridium difficile infection 
from 2011. The National guidelines were updated in 
2012 by a sub-committee of the scientific advisory 
committee of HPSC and are available at 
www.hpsc.ie The national report on the point 
prevalence survey of Hospital-Acquired Infections and 
Antimicrobial use took place in May 2012 and was 
published in November 2012. The full report and full 
list of recommendations can be accessed on the HPSC 
website. A voluntary survey of Hygiene and HCAI 
preventive practices in Irish critical care units took 
place in January 2012. A summary is included in this 
annual report and the full report is also available on the 
website. 
The underlying trend for outpatient antimicrobial 
consumption has been increasing. There is still marked 
fluctuation in usage with the highest levels occurring 
during periods of increased influenza activity. While 
there is a welcome trend in the continued reduction in 
MRSA proportion of S.aureus blood stream infections, 
antimicrobial resistance in invasive infections caused 
by Enterbacteriaceae ( E. coli, K. pneumoniae), P 
aeruginosa and Enterococcus faecium continues to 
increase. Rising levels of resistance threaten many 
aspects of healthcare that we currently take for granted 
It is therefore vital that we strive to implement the 
recommendations and guidelines produced by the HSE/ 
RCPI AMR and HCAI clinical advisory group.
Once again I want to express gratitude to all those who 
provide data and participate in committees and to staff 
in HPSC and elsewhere in the HSE. To all those who are 
managing to do more with less and continue to support 
the prevention and control of infectious disease in 
Ireland, thank you!
Dr Darina O’Flannigan
Director
HPSC
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Vaccine Preventable Diseases
01
In 2012, 41 cases of invasive Haemophilus 
influenzae disease were notified in Ireland 
(0.9/100,000 total population). This is a slight 
reduction compared to 2011 when 44 cases were 
notified, but is still considerably higher than the 
28 cases reported in 2010 (figure 1). No imported 
cases were reported in 2012.
The main change in 2012, when compared to 
2011, is the marked reduction in the number of 
non-typeable/non-capsular strains from 34 to 26 
and the increase in the type f strains from one to 
five (figure 1). No other noteworthy change in the 
overall number of cases due to other serotypes has 
been observed since 2004 apart from the decline 
in the proportion of type b cases and the rise of 
non-typeable/non-capsular strains (figure 1).
Non-typeable/non-capsular cases accounted for 
the majority of the invasive H. influenzae cases 
notified in 2012 (63.4%, n=26/41). The remaining 
cases were due to H. influenzae type b (7.3%, 
n=3), type f (12.2%; n=5), not type b (2.4%; n=1) 
and isolates that were not typed (14.6%; n=6). 
The cases ranged in age from three months to 89 
years (median 56 years). The incidence rates were 
highest in infants <1 year (4.1/100,000) and those 
aged 15-19 years (1.4/100,000) (table 1).
Cases occurring in children <10 years of age (n=9) 
and elderly adults over 65 years of age (n=17) 
accounted for 63.4% of all invasive H. influenzae 
notifications in 2012 (table 1). One notable trend 
since 2004 is the increase in the overall proportion 
of cases over 65 years of age from 26.3% to 41.5% 
compared to the declines in those aged less than 
five years from 26.3% to 14.6% and those aged 
between 5 and 64 years from 47.4% to 43.9% 
(figure 2).
In 2011, male cases (n=21) marginally exceeded 
female cases (n=20), resulting in a male to female 
ratio of 1.1:1.0.
1.1 Haemophilus influenzae (invasive) 
Number of cases, 2012: 41
Number of cases, 2011: 44
Number of cases, 2010: 28
Crude incidence rate, 2012: 0.9/100,000
Summary
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Figure 1. Number of invasive H. influenzae cases notified in Ireland and proportion of annual cases attributable to type b and 
non-typeable strains with 95% confidence intervals, 2004-2012
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The clinical manifestations of invasive H. influenzae 
disease in the nine children < 10 years of age in 
2012 were three cases of septicaemia, two cases of 
pneumonia, one case of meningitis, one case with 
a clinical diagnosis reported as ‘other’ and two 
cases where the clinical diagnosis was not known. 
A breakdown by clinical diagnosis for all age 
groups by year between 2004 and 2012 is 
presented in table 2. Of note is the proportion of 
cases notified each year with an unknown clinical 
diagnosis, accounting for an annual average of 
34.2% since 2004.
One death in a child < 6 months was reported in 
2012, the infection was not typed, no vaccination 
history was available and the coroner’s report is 
still awaited at the time of writing. 
In 2012 three cases of H. influenzae type b (Hib) 
occurred, two of whom were <5 years of age: one 
was unvaccinated and the other was incompletely 
vaccinated having received only three doses of the 
Hib vaccine; the remaining third case occurred in 
an adult aged 45-49 years and was unvaccinated. 
In the previous year, three cases of Hib also 
occurred in adults >65 years who were either 
unvaccinated or whose vaccination status was 
unknown.
Between Q3-2007 and Q4-2012, only one true 
Hib vaccine failure was reported, highlighting the 
positive impact the Hib booster catch up campaign 
has had in Ireland. 
Since September 2008, the, Hib booster dose has 
been administered at 13 months of age as part 
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Figure 2. Percentage and number of annual cases of invasive H. influenzae cases notified in 
Ireland annually by age group (years), 2004-2012
Table 1. Number and incidence rates of invasive H. influenzae cases by serotype, 2012
Age 
Group
Type b Type e Type f
Not 
type b
Non-typeable/
non-capsular
Not Typed* Total ASIR of Hib
ASIR of all H. 
influenzae
<1 1 0 0 0 1 1 3 1.38 4.14
1-4 1 0 1 0 0 1 3 0.31 0.94
5-9 0 0 1 0 1 1 3 0.00 0.99
10-14 0 0 0 0 0 0 0 0.00 0.00
15-19 0 0 0 0 4 0 4 0.00 1.35
20-24 0 0 0 0 0 1 1 0.00 0.13
25-34 0 0 0 0 0 1 1 0.00 0.14
35-44 0 0 1 0 3 0 4 0.00 0.69
45-54 1 0 0 0 0 0 1 0.22 0.22
55-64 0 0 1 0 3 0 4 0.00 0.75
65+ 0 0 1 1 14 1 17 0.00 0.37
All Ages 3 0 5 1 26 6 41 0.07 0.89
CIR 0.07 0.11 0.02 0.57 0.13 0.07 0.89 - -
CIR, crude incidence rate per 100,000 total population
ASIR, age specific incidence rate per 100,000 population
*No isolate available for typing for three of the H. influenzae not typed cases, as PCR positive (culture negative) only
Table 2. Number of invasive H. influenzae cases by clinical diagnosis, 2004-2012
Clinical Diagnosis 2004 2005 2006 2007 2008 2009 2010 2011 2012 Total
% of 
Total
Septicaemia 8 14 13 6 3 9 9 11 11 84 26.3%
Pneumonia 5 0 3 6 3 8 5 12 12 54 16.9%
Meningitis 3 9 3 2 2 2 1 3 2 27 8.5%
Bacteraemia (without focus) 1 0 1 1 2 0 0 3 5 13 4.1%
Epiglottitis 1 3 3 1 1 0 2 0 0 11 3.4%
Cellulitis 1 1 2 1 1 0 0 1 0 7 2.2%
Meningitis & septicaemia 1 0 1 0 1 1 1 1 1 7 2.2%
Other 0 0 0 0 0 0 0 3 1 4 1.3%
Septic arthritis 0 1 0 0 1 0 0 0 0 2 0.6%
Osteomyelitis 1 0 0 0 0 0 0 0 0 1 0.3%
Unknown 17 6 12 14 8 23 10 10 9 109 34.2%
Total 38 34 38 31 22 43 28 44 41 319 100%
 Table 3. Incidence rates per 100,000 population of invasive H. influenzae by HSE area, 2004-2012
HSE Area 2004 2005 2006 2007 2008 2009 2010 2011 2012
E 1.1 1.0 0.9 0.8 0.5 0.7 0.6 1.1 1.1
M 1.2 1.2 0.4 1.2 0.8 1.1 0.4 1.1 0.4
MW 0.8 0.3 0.8 0.6 0.8 2.1 0.5 0.5 1.1
NE 0.3 1.3 0.3 0.0 0.0 0.2 0.5 1.6 0.9
NW 0.4 0.0 2.1 0.4 0.0 0.4 0.4 0.8 0.8
SE 1.1 0.4 0.9 1.1 0.7 1.0 1.0 0.8 1.2
S 1.1 0.3 1.3 0.3 0.6 1.2 1.1 0.3 0.6
W 0.5 1.4 0.7 1.4 0.5 1.1 0.2 1.3 0.4
Ireland 0.9 0.8 0.9 0.7 0.5 0.9 0.6 1.0 0.9
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of the routine childhood immunisation schedule in 
addition to the three doses given during infancy (at 
2, 4 and 6 months of age). Furthermore, vaccination 
is routinely recommended for those at increased 
risk of Hib disease.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 29th July, 2013. 
These figures may differ from those published 
previously due to ongoing updating of notification 
data on CIDR.
    
In 2012, there were 103 measles cases (2.2/100,000) 
notified compared to 267 cases (5.8/100,000) in 2011 
and 403 cases (8.8/100,000) in 2010.  Measles cases by 
HSE Area and week and month of notification in 2012 
are shown in figure 1. Sixty-eight percent (n=70/103) of 
cases in 2012 were notified from early May to late June 
(Weeks 18-25). This increase in cases was mainly due 
to a measles cluster (n=59) in teenagers in West Cork 
in the HSE-S.  The probable country of infection of the 
first case in the outbreak was Portugal.  The infection 
then spread to their relatives and school contacts.  
Ninety-percent (n=53/59) of cases in this outbreak 
were unvaccinated.  The HSE-S outbreak and control 
measures are described in detail in Epi-Insight.1  The 
majority (62%, n=64/103) of cases notified in Ireland in 
2012 and the highest crude incidence rate was in the 
HSE-S (table 1).  
In 2012, new case definitions were introduced in Ireland. 
Two of the changes to the measles case definition 
include a change to the definition of a confirmed case 
and introduction of a probable case classification.  
1.2 Measles 
Summary
Number of cases, 2012: 103
Number of confirmed cases, 2012: 26
Crude incidence rate, 2012: 2.2/100,000
Crude confirmed incidence rate, 2012: 0.6/100,000
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Figure 1. Number of notified measles cases by week and month in 2012 and by HSE Area
HSE-S indicates measles cases notified in the HSE-S
Non HSE-S indicates measles cases notified in the HSE-E, M, MW, NE, NW, SE and W
Under the previous case definition a measles case 
classified as confirmed was a case that was laboratory 
confirmed in absence of recent vaccination or a 
clinically compatible case which was epidemiologically 
linked to a laboratory confirmed case.  Under the new 
2012 measles case definition a measles case classified 
as confirmed is any person not recently vaccinated 
and meeting the clinical and the laboratory criteria. 
A probable case is any person meeting the clinical 
criteria and with an epidemiological link to a laboratory 
confirmed case.  The case definitions are available at 
www.hpsc.ie.  Of the 103 measles cases notifed in 2012, 
23% (n=24) were classified as possible, 51% (n=53) were 
classified as probable while 25% (n=26) were classified 
as confirmed, giving a crude confirmed incidence rate of 
0.6 per 100,000 population.  
In 2012, measles cases ranged in age from five months 
to 40 years; with a mean age of twelve years and a 
median age of thirteen years.  The number of cases 
by age group and the age specific incidence rates are 
shown in figures 2 and 3.  The largest number of cases 
and the highest age specific incidence rates were in 
those aged 10-14 years and 15-19 years (figures 2 and 
3).  Of the 103 measles cases, 54% (n=56) were female 
and 46% (n=47) were male.
Laboratory results were provided for 34% (n=35/103) 
of cases in 2012.  Twenty-five percent (n=26/103) of 
cases were laboratory test positive for measles.  The 
laboratory results for four percent (n=4/103) were 
recorded as inconclusive/weakly positive.  
Five percent (n=5/103) of cases were laboratory 
negative for measles, however, for 40% (n=2/5) of 
these the specimens were not taken at the optimal time 
following disease onset.  Sixty percent (n=3/5) of the 
cases that were laboratory negative for measles were 
known to have a specimen collected at the optimal 
time.  All of these were classified as possible cases. 
Measles vaccine in Ireland is available as part of the 
combined measles-mumps-rubella (MMR) vaccine.  
In Ireland, vaccination with the first dose of MMR is 
routinely recommended at twelve months of age and 
the second dose at four to five years of age.
Vaccination data were reported for 88% (n=91/103) 
of measles cases in 2012.  Seventy-three percent 
(n=75/103) of cases were unvaccinated; of these only 
five percent (n=4/75) were less than 12 months of age.
Fourteen percent (n=14/103) of cases were reported 
to have one dose of MMR vaccine; the majority (71%, 
n=10/14) of these were less than six years of age.  Sixty-
four percent (n=9/14) of those reported to have one 
dose of MMR were classified as confirmed or probable.  
Ninety-three percent (n=13/14) with one dose of MMR 
had a vaccination date reported.
Two percent (n=2/103) of cases were reported as having 
received two doses of MMR.  One of these cases had 
both vaccination dates reported and was classified as 
confirmed.
Seven cases were reported as hospitalised, representing 
seven percent (n=7/103) of all cases.  The median and 
mean age of hospitalised cases was 16 years (range one 
to 33 years). Four (57%, n=4/7) hospitalised cases were 
classified as confirmed, two were classified as probable 
(29%, n=2/7) and one (14%, n=1/7) as possible.  Length 
of hospitalisation was reported for all seven cases with 
a median duration of stay of two days (range one to 
five days).  Of the seven hospitalised cases, two (29%) 
had no MMR details reported while four (57%) were 
unvaccinated.  One case (14%) was reported to have 
one dose of MMR; this case had a vaccination date 
recorded.
Reported complications of measles included pneumonia 
(3%, n=1/31), chest infection (n=2), dehydration (n=1) 
and ear infection (n=1).
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Table 1. Number of notified measles cases and the crude 
incidence rate per 100,000 population (CIR) by HSE Area in 
2012
HSE Area Number CIR
HSE-E 24 1.5
HSE-M 0 0.0
HSE-MW 2 0.5
HSE-NE 5 1.1
HSE-NW 3 1.2
HSE-SE 0 0.0
HSE-S 64 9.6
HSE-W 5 1.1
Total 103 2.2
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Of the 103 cases, the setting where the case most likely 
acquired measles was reported as secondary school 
(34%, n=35), home (26%, n=27), day-care or pre-school 
(7%, n=7), overseas (4%, n=4), summer camp/school 
(1%, n=1), third level (1%, n=1) and was unreported for 
the remainder (27%, n=28).
Three localised measles outbreaks were notified 
during 2012, with 68 associated cases of illness.  The 
outbreak locations included one general outbreak 
(family and school outbreak) with 59 ill, one outbreak in 
a childminders with 6 ill and one crèche outbreak with 3 
ill.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 30th August 2013.  
These figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR. 
1.  Cotter S,  Ryan F, MacSweeney Mary, Coughlan H. Measles 
outbreak West Cork May 2012. Epi-Insight. 2012;13(6). Available 
online: http://ndsc.newsweaver.ie/epiinsight/dllmrzt7dc07guhc3jcrz
t?a=1&p=24661455&t=17517774
Figure 3. The age specific incidence rate (per 100,000) of 
notified measles cases in 2012 by case classification
Figure 2. Number of notified measles cases in 2012 by age 
group and case classification
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In 2012, 66 cases (1.4/100,000) cases of invasive 
In 2012, 66 cases (1.4/100,000) cases of invasive 
meningococcal disease (IMD)  were notified in 
Ireland. This continues a downward trend observed 
over the past decade since 1999, when the rate was 
14.8/100,000 population, a decline in cases of more 
than 87%.
Since 1st January 2012, a revised version of the case 
definition of meningococcal disease has come into 
effect and is detailed in the HPSC Case Definitions for 
Notifiable Diseases booklet on the HSPC website 
(www.hpsc.ie). Based on the current meningococcal 
disease case definition, 60 of the 66 cases (90.9%) 
notified in 2012 were case classified as confirmed, none 
(0%) as probable and six (9.1%) as possible. Laboratory 
confirmation of cases has improved with time. In 2012, 
90.9% (n=60/66) of cases were laboratory confirmed in 
comparison to 78.7% (n=422/536) in 1999.
Typically, most cases are diagnosed by blood/CSF 
culture testing, blood/CSF PCR testing or detection 
of Gram negative diplococci in skin lesions/culture or 
in CSF specimens. Isolation of the organism from non-
sterile sites (such as the eye, nose or throat) in clinically 
compatible cases is considered a possible case. 
In 2012, 33 of the 60 confirmed cases (55.0%) were 
laboratory tested by PCR testing alone and another 
seven confirmed cases (11.6%) were diagnosed by 
culture of sterile specimens alone. Among the remaining 
20 confirmed cases, 19 (31.7%) were diagnosed by both 
culture and PCR testing of sterile specimens and four 
(6.7%) by CSF microscopy.
Of all the 66 cases in 2012, none had a positive skin, 
nose or eye culture test result or a positive serology test 
result, but there was one positive result each of a skin 
microscopy test and a throat culture test.
In 2012, male cases (n=37) exceeded female cases 
(n=29), resulting in a male to female ratio of 1.3:1.0. 
Cases ranged in age from three months to 88 years 
(median age of 2.2 years). The incidence of IMD was 
highest in infants and young children. Age specific 
incidence rate (ASIR) was highest among infants <1 
year of age (24.9/100,000; n=18), followed by children 
in the 1-4 year (7.8/100,000; n=22), and 15-19 year age 
groups (2.5/100,000; n=7) (table 1). 
In 2012 the overall incidence of IMD in Ireland was 
highest in the HSE-SE area (2.4/100,000) with the lowest 
in the HSE-S area (0.9/100,000) (table 2). There were no 
imported cases in 2012.
1.3  Meningococcal Disease     
Summary
Number of cases, 2012: 66
Number of cases, 2011: 94
Number of cases, 2010: 114
Crude incidence rate, 2012:1.4/100,000
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Table 1. Number of cases, deaths, age-group specific incidence rates per 1000,000 population (calculated using Census 2011 
data) and case fatality ratios of IMD in Ireland, 2012
Age Group No. Cases ASIR No. Deaths %CFR
<1 18 24.9 0 0.0%
1-4 22 7.8 0 0.0%
5-9 5 1.6 0 0.0%
10-14 2 0.7 1 50.0%
15-19 7 2.5 0 0.0%
20-24 1 0.3 0 0.0%
25+ 11 0.4 1 9.1%
All ages 66 1.4 2 3.0%
ASIR, age specific incidence rate per 100,000 population 
% CFR, case fatality ratio
Neisseria meningitidis serogroup B was the pathogen 
most commonly associated with IMD in 2012 and 
accounted for 58 of the 66 (87.9%) notifications (figure 
1). Since 2003 serogroup B has accounted for more than 
80% of annual IMD notifications (figure 1). 
IMD due to serogroup C has remained at very low levels 
over the last decade with five cases or less occurring 
annually. In 2012 no MenC cases were notified (figure 
1). There have been no true vaccine failures since 2009 
when three failures were reported. Between 2005 and 
2008, one true vaccine failure was reported in each year.
The absence of MenC vaccine failures in the past three 
years is a measure of the positive impact with which the 
MenC conjugate vaccine continues to have since first 
introduced in October 2000. Prior to the introduction 
of this vaccine, the serogroup C incidence rate in 1999 
was 3.7 per 100,000 total population. The National 
Immunisation Advisory Committee (NIAC) since 
September 2011 has recommended a booster dose of 
the MenC vaccine for close contacts of cases that have 
completed a course more than one year before, details 
of which are available at http://www.ndsc.ie/hpsc/A-Z/
VaccinePreventable/Vaccination/Guidance/
There were two IMD related notified deaths in 2012 
(case fatality ratio (%CFR) of 3.0%), the same number 
as in 2011. This compares to an annual average of 6.2 
deaths between 2005 and 2010. In 2012, the %CFR was 
highest amongst cases 10-14 years of age (50.0%) as a 
result of one death among two cases (table 1). The next 
highest %CFR at 9.1% (n=1/11) in adults aged 25+ years 
(table 1).
One of the IMD deaths in 2012 was due to serogroup B 
disease (age 10-14 years); the other due to a serogroup 
Y infection (age 85+ years). This is in marked contrast to 
the 13 deaths due to serogroup B out of all 25 deaths 
reported in 2000. In the same year, 11 deaths were 
due to serogroup C disease. The decline in deaths 
associated with meningococcal disease since 2000 has 
been significant, partly due to the decrease in MenC as 
a result of the vaccination programme and also partly 
due to decline in meningococcal B disease (table 3). 
Despite a marked decline in the overall incidence over 
the past decade, IMD is still an important public health 
concern due to its associated severity, high mortality 
rate and serious adverse sequelae. 
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Figure 1. Number of invasive meningococcal disease (IMD) notifications in Ireland by serogroup and proportion of cases 
attributable to serogroup B with 95% confidence intervals, 1999-2012
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Table 2. Age specific incidence rates per 100,000 population (calculated using Census 2011 data) of IMD by HSE area and age 
group, 2012
HSE Area <1 1-4 5-9 10-14 15-19 20-24 25+ Total
E 26.9 6.1 0.9 0.0 3.1 0.0 0.1 1.1
M 41.5 5.2 0.0 0.0 0.0 6.0 0.0 1.4
MW 52.6 13.2 3.8 0.0 0.0 0.0 0.4 2.1
NE 26.0 9.6 2.9 0.0 3.7 0.0 0.7 2.0
NW 25.7 0.0 0.0 0.0 0.0 0.0 0.6 0.8
SE 39.2 12.9 2.8 2.9 0.0 0.0 0.9 2.4
S 0.0 7.5 0.0 2.3 2.5 0.0 0.2 0.9
W 0.0 7.6 3.2 0.0 7.2 0.0 0.7 1.6
Ireland 24.9 7.8 1.6 0.7 2.5 0.3 0.4 1.4
Effective vaccination is necessary for the complete 
prevention and control of IMD. Effective vaccines are 
available against serogroups A, C, W135 and Y forms 
of the disease. In 2012, a vaccine against serogroup 
B disease was recommended for approval by the 
European Medicines Agency. Marketing authorisation 
for the vaccine was granted in January 2013 for both 
child and adult administration. The decision regarding 
introducing this vaccine into the national immunisation 
programme is under consideration (at the time of 
writing) by the National Immunisation Advisory 
Committee. 
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 29th July, 2013. 
These figures may differ from those published previously 
due to ongoing updating of notification data on CIDR.
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Figure 2. Crude incidence rates per 100,000 population with 95% confidence 
intervals for IMD notifications by HSE area, 2012
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Table 3. Number of cases, deaths and case fatality ratios (%CFR) by year of meningococcal serogroups B and C disease in 
Ireland, 1999-2012
Meningococcal B Meningococcal C
Year No. Cases No. Deaths %CFR No. Cases No. Deaths %CFR
1999 292 12 4.1% 135 5 3.7%
2000 258 13 5.0% 139 11 7.9%
2001 245 8 3.3% 35 3 8.6%
2002 199 8 4.0% 14 0 0.0%
2003 206 11 5.3% 5 1 20.0%
2004 163 7 4.3% 5 1 20.0%
2005 169 5 3.0% 5 0 0.0%
2006 168 5 3.0% 4 0 0.0%
2007 157 6 3.8% 2 0 0.0%
2008 149 6 4.0% 4 1 25.0%
2009 119 6 5.0% 5 0 0.0%
2010 93 4 4.3% 4 0 0.0%
2011 84 2 2.4% 2 0 0.0%
2012 58 1 1.7% 0 0 0.0%
% CFR, case fatality ratio
In total, there were 163 (3.6/100,000) mumps cases 
notified in 2012.  This is very similar to 2011 when 165 
cases were notified but a decline compared to the 
years 2008/2009 and 2004/2005 when large outbreaks 
occurred (figure 1).  The number of cases notified in 
2012, however, is still nearly four-fold higher compared 
to the years 1998 to 2003 when there was an average of 
43 cases notified each year.
In 2012, of the 163 mumps cases notified 26% (n=43) 
were classified as confirmed and 74% (n=120) were 
classified as possible.
The largest number of cases was notified in the HSE-E 
while the highest crude incidence rate was in the HSE-W 
(table 1).
In 2012, the median age of cases was 21 years and the 
mean was 24 years (range one to 83 years, age was 
unknown for two cases).  The number of cases by age 
group and the age specific incidence rates are shown in 
figures 2 and 3.  The highest age specific incidence rates 
were in those 20-24 years followed by those 15-19 years 
and 0-4 years.  Of the 163 mumps cases, 53% (n=86) 
were female and 47% (n=77) were male.
Of the 163 mumps cases, 18% (n=29) were 
unvaccinated, 23% (n=38) had one dose of the measles-
mumps-rubella vaccine (MMR), 28% (n=46) were 
reported to have received two doses of MMR while for 
31% (n=50) of cases the number of doses of MMR was 
not reported.  The vaccination date was reported for 
63% (n=24/38) of cases reported to have received one 
dose of MMR.  Both vaccination dates were reported 
for 28% (n=13/46) of cases vaccinated with two doses of 
MMR.  Thirteen percent (n=6/46) of the cases reported 
1.4 Mumps 
Summary
Number of cases, 2012: 163
Number of cases, 2011: 165
Crude incidence rate, 2012: 3.6/100,000
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Year of notification 
MMR1 introduced in 1988 
MMR2 introduced in 1992 
for those aged 10-14 
years
In 1999 the age of MMR2
vaccination  changed to 4-5 
years
MMR vaccination campaign started in April 2009 for 
students in 4th, 5th and 6th year of second level 
schools
MMR catch-up 
campaign started in 
October 2012 
Figure 1. Number of mumps notifications by year 
MMR1- first dose of MMR
MMR2- second dose of MMR
1988-June 2000 data collated by DoHC
July 2000-2012 data collated by HPSC
to have received two doses of MMR were classified 
as confirmed; only two of these cases had MMR 
vaccination details such as vaccination dates reported.
Nine cases were hospitalised, representing six percent 
(n=9/163) of all cases and eight percent (n=9/109) of 
cases where hospitalisation data were provided.  The 
number of days hospitalised was reported for all nine of 
the hospitalised cases; the median and mean number of 
days hospitalised was five days (range one to 11 days).  
Reported complications of mumps included orchitis (4%, 
n=2/46), mastitis (2%, n=2/86), meningitis (2%, n=2/86) 
pancreatitis (2%, n=2/83), deafness (1%, n=1/84), 
nephritic syndrome (n=1) and rigours and raised liver 
function tests (n=1).
The setting where the case most likely acquired 
mumps was reported for 23% (n=38/163) of cases. 
The identified settings for these cases were: social 
setting for 71% (n=27/38) of cases; international travel 
for 11 percent (n=4/38); university/college for eight 
percent (n=3/38); day-care/preschool for five percent 
(n=2/38); family/household for three percent (n=1/38) of 
these cases and hospital out-patient for three percent 
(n=1/38).
Two localised outbreaks of mumps were notified during 
2012 with a total of seven associated cases of illness; 
both outbreak locations were in private houses. 
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 17th July 2013.  
These figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR.  
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Figure 2. Number of notified mumps cases in 2012 by age group 
and case classification
Figure 3. The age specific incidence rates (per 100,000) of notified 
mumps cases in 2012
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Table 1. Number of mumps cases notified and the crude 
incidence rate per 100,000 population (CIR) by HSE Area in 
2012
HSE Area Number CIR
HSE-E 71 4.4
HSE-M 9 3.2
HSE-MW 6 1.6
HSE-NE 12 2.7
HSE-NW 12 4.6
HSE-SE 15 2.4
HSE-S 16 3.0
HSE-W 22 4.9
Total 163 3.6
Apart from Neisseria meningitidis, which is the most 
common cause of bacterial meningitis in Ireland, other 
pathogens cause this disease including those caused by 
non-notifiable organisms, details of which are presented 
below. For information on invasive meningococcal 
disease (Neisseria meningitidis), see the other chapter 
within this report. Information on bacterial meningitis 
caused by specified notifiable diseases is summarised 
below and further pathogen-specific data is available 
in the relevant chapter. The figures presented in 
this chapter are based on data extracted from the 
Computerised Infectious Disease Reporting (CIDR) 
system on 29th July, 2013. These figures may differ from 
those published previously due to ongoing updating of 
notification data on CIDR. Furthermore, since 1st January 
2012, a revised version of the case definition of bacterial 
meningitis has come into effect and is detailed in the 
HPSC Case Definitions for Notifiable Diseases booklet 
on the HSPC website (www.hpsc.ie).
Bacterial meningitis caused by diseases not otherwise 
specified:
In total, 29 cases of meningitis under this disease 
category were notified in 2012, among which two 
patients (age range 20-59 years) died (one of which was 
classified as probable case and the other as possible). 
The causative pathogens were identified in 41% 
(n=12/29) of cases, but not among those two cases 
that died. No causative pathogen was identified in the 
remaining 59% (n=17) cases. 
Prior to 1st January 2012, all cases of S. agalactiae were 
notifiable under the ‘Bacterial Meningitis (NOS)’ disease 
category. In 2012 this changed when Streptococcus 
agalactiae in children < 90 days of age was notifiable 
in its own right, including those which were meningitis-
related. This has meant that the overall number of 
bacterial meningitis NOS in 2012 has fallen compared 
to the previous year because it does not include 11 
meningitis–related cases of Streptococcus agalactiae 
in children < 90 days of age (table 1). Furthermore, 
there is evidence of an additional seven meningitis-
related cases of this disease in this same age group 
where Streptococcus agalactiae was isolated from or 
detected in CSF specimens from patients that were not 
categorised as ‘meningitis’; these cases have not been 
included in table 1.
Among the bacterial meningitis (not otherwise specified) 
cases notified in 2012 were seven cases of Escherichia 
coli (age range 1-4 weeks; none of which had serotype 
details) and one case each of the following (age range 2 
weeks-77 years): Staphylococcus aureus, Enterococcus 
faecium, Group C Streptococcus, Proteus mirabilis 
and a combined infection of Staphylococcus aureus/
Staphylococcus capitas. 
Bacterial meningitis caused by specified notifiable 
diseases:
Haemophilus influenzae
Three cases of meningitis due to H. influenzae were 
notified in 2012 and these infections were attributable 
to one case each of types b and f and one non-
typeable/non-capsulated strain. The age range was 
three months to 77 years. No deaths were reported. See 
the chapter on invasive H. influenzae disease for further 
details.
Leptospira species
In 2012, one case of leptospirosis meningitis was 
reported in a male aged 20-24 years. See a separate 
chapter on non-IID zoonotic diseases for further details.
Listeria species
Two male cases of listeriosis meningitis were notified 
in 2012: one with a serotype 4b infection was aged 80-
84 years with an underlying medical condition and the 
other with a 1/2a infection in a middle aged adult aged 
55-59 years. See the chapter on listeriosis disease for 
further details.
Streptococcus pneumoniae
In 2012, 37 cases of pneumococcal meningitis were 
notified, compared to 23 in 2011. The age range of the 
37 cases was one month to 87 years (median 42 years). 
1.5  Other Forms of Bacterial Meningitis*    
(*excluding meningococcal disease)
Summary
Bacterial meningitis, not otherwise specified (NOS)
Number of cases, 2012:  29
Number of cases, 2011:  35
Number of cases, 2010:  42
Crude incidence rate, 2011: 0.6/100,000
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Eight (21.6%) pneumococcal meningitis related 
deaths were reported in 2012 with an age range of 6 
months-87 years (median 29 years). Four of the eight 
deaths were attributable to the infection itself, one was 
not, one is still awaiting a coroner’s report at the time 
of writing and the cause of death for the remaining two 
cases has not yet been specified. 
Of the eight cases that died, three were vaccinated, 
one each with the PCV7, PCV13 and PPV23 vaccines. 
Of these three that were vaccinated, two had serotype 
details cases: the PCV7 vaccinated case had a 22F 
type infection, the PCV13 vaccinated case had a 15A 
type infection, neither of which were vaccine failures. 
The PPV23 vaccinated case had an untyped infection. 
Four of the remaining five deaths had their infections 
serotyped: one each of types 22F and 23F and two 
each of type 7F. Serotypes 23F and 7F both feature in 
the PCV23 vaccine. See a separate chapter on invasive 
pneumococcal disease for further details.
Mycobacterium species
In 2012, three tuberculosis meningitis cases were 
notified (provisional). Cases ranged in age from 42 to 68 
years. Two cases had a history of living abroad, one of 
which died. See the chapter on tuberculosis for further 
details.
-25-HPSC Annual Report 2012 1. Vaccine Preventable Diseases
Table 1. Annual notifications of bacterial meningitis (specified and not otherwise specified) except meningococcal disease, 
2008-2012
Notified under Causative organism 2008 2009 2010 2011 2012 2008-2012
Haemophilus influenzae disease (invasive) Haemophilus influenzae 3 3 2 4 3 15
Leptospirosis Leptospira spp. 2 1 0 1 1 5
Listerosis Listeria spp. 3 1 3 1 2 10
Salmonellosis Salmonella enteritidis 0 1 0 0 0 1
Streptococcus pneumoniae infection (invasive) Streptococcus pneumoniae† 27 22 16 23 37 125
Streptococcus Group A infection (invasive) 
(iGAS)
Streptococcus pyogenes 2 0 2 0 1 5
Streptococcus Group B infection (invasive) 
(Group B Strep) < 90 days of age
Streptococcus agalactiae† n/a n/a n/a n/a 11 11
Tuberculosis* Mycobacterium spp.* 6 8 9 2 3 28
Total Bacterial Meningitis, Specified  43 36 32 31 58 200
Bacterial Meningitis, Not Otherwise Specified
Streptococcus agalactiae** 6 7 11 16 0 40
Escherichia coli 11 3 2 1 7 24
Staphylococcus aureus 3 2 6 2 1 14
Enterococcus faecalis 1 1 0 0 0 2
Streptococcus bovis biotype 
II/2
0 2 0 0 0 2
Citrobacter koseri 1 0 0 0 0 1
Enterococcus faecium 0 0 0 0 1 1
Group C Streptococcus 0 0 0 0 1 1
Klebsiella oxytoca 0 0 0 1 0 1
Mycoplasma pneumoniae 0 0 1 0 0 1
Proteus mirabilis 0 0 0 0 1 1
Serratia liquefaciens 1 0 0 0 0 1
Staphylococcus aureus & 
Staphylococcus capitis
0 0 0 0 1 1
Staphylococcus capitis 0 0 1 0 0 1
Unknown 2 1 1 1 1 6
Not specified 15 24 20 14 16 89
Total Bacterial Meningitis, Not Otherwise 
Specified
 40 40 42 35 29 186
Total Bacterial Meningitis, Specified & Not 
Otherwise Specified
 83 76 74 66 87 386
†Streptococcus pneumoniae meningitis numbers are provisional for 2008-2012 and are subject to change
*Tuberculosis meningitis figure for 2012 is provisional
**Streptococcus agalactiae for all ages between 2008 and 2011 and for cases > 90 days of age only in 2012
†Streptococcus agalactiae < 90 days of age in 2012 figures do not include seven meningitis-related cases where the causative organism was 
isolated from or detected in CSF specimens from patients that were not clinically categorised as having ‘meningitis’
n/a not applicable
Following the introduction of pertussis vaccine in the 
1950s the number of pertussis cases notified declined, 
however, following a pertussis vaccine scare in the mid-
1970s, with a decline in pertussis vaccination uptake, 
the notifications started to increase again (figure 1).  
This trend was reversed in the 1990s as notifications 
decreased again to a low of 40 cases in 2003 (figure 
1).  Between 2004 and 2010 there was on average 87 
cases notified each year.  The number of pertussis cases 
notified doubled in 2011 (n=229) compared to 2010 
(n=114) (figure 2).  In 2012, the number of pertussis 
cases notified doubled again with 458 cases notified 
(figure 2).  
Pertussis cases in 2012 by week of notification are 
shown in figure 3. The majority of the cases in Weeks 
16 and 26 relate to an outbreak over several months in 
which clinical cases were notified in two batches to the 
HSE-NW. 
Of the 458 cases in 2012, 58% (n=264) were classified as 
confirmed, 12% (n=56) were classified as probable and 
30% (n=138) were classified as possible.
1.6 Pertussis
Summary
Number of cases, 2012: 458
Number of cases, 2011: 229
Crude incidence rate, 2012: 10.0/100,000
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Figure 1. Number of notified pertussis cases in Ireland by year, 1948-2012
1948-June 2000 data collated by DoHC
July 2000-2012 data collated by HPSC
Figure 2. Number of notified pertussis cases in Ireland by year, 2000-2012
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The largest number of cases was notified in the HSE-E 
while the highest crude incidence rate was in the HSE-
NW (table 1).
In 2012, the largest number of cases (n=162/458, 
35%) and the highest age-specific incidence rate 
(224/100,000) were in children aged less than one year 
with nearly a third (n=143/458, 31%) of all cases aged 
less than six months (figures 4 and 5).  Fifty-four percent 
of cases (n=247) were female and 46% (n=211) were 
male.
Two deaths occurred in children less than three months 
of age, both children were born prematurely.  
In Ireland it is recommended that children be vaccinated 
with an acellular pertussis-containing vaccine at two, 
four and six months of age and a booster dose at four 
to five years of age.  In 2008 the National Immunisation 
Advisory Committee (NIAC) recommended a booster 
with low dose acellular pertussis vaccine for children 
aged 11-14 years.  The adolescent pertussis booster 
was introduced into the school programme (in 19 LHOs) 
in 2011 and to all schools in 2012.  In August 2012, 
an additional pertussis booster was recommended for 
health care workers and pregnant women; please see 
www.immunisation.ie for additional information on 
pertussis vaccination recommendations.  
In 2012, the vaccination status was reported for two-
thirds (n=308/458, 67%) of pertussis cases.  Nearly one 
third of cases (n=145/458, 32%) were unvaccinated; 
these cases ranged in age from four weeks to 72 years, 
with 71% (n=105/145) of these cases aged less than 
six months.  Twenty-eight percent of the unvaccinated 
cases (n=41/145) were less than two months of age and 
were therefore not eligible for pertussis vaccine in the 
Irish schedule.  
Twelve percent (n=53/458, 12%) of cases were reported 
as incompletely vaccinated, with 45% (n=24/53, 45%) 
of these less than six months of age and were therefore 
not eligible for three doses of pertussis vaccine in the 
Irish schedule.  
Twenty-four percent (n=110/458, 24%) of cases were 
reported as completely vaccinated for their age; 
49% (n=54/110) of these were reported to have had 
three doses of pertussis vaccine, 19% (n=21/54) were 
reported as having four doses while the number of 
doses was not specified for the remainder.  Of the cases 
reported as having four doses, 33% (n=7/21, 33%) were 
classified as confirmed.
Forty-four localised pertussis outbreaks were notified 
during 2012, with 164 associated cases of illness.  Forty 
one were family outbreaks (with 107 ill), two were 
Figure 3. Number of notified pertussis cases in 2012 by week and month of notification.
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Table 1. Number of pertussis cases notified and the crude 
incidence rate per 100,000 population (CIR) by HSE Area in 
2012
HSE Area Number CIR
HSE-E 159 9.8
HSE-M 13 4.6
HSE-MW 13 3.4
HSE-NE 21 4.8
HSE-NW 74 28.6
HSE-SE 54 8.1
HSE-S 79 15.9
HSE-W 45 10.1
Total 458 10.0
community outbreaks (with 54 ill) and one was a crèche 
outbreak (with three ill).
                                 
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 2nd August 2013.  
These figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR.
Figure 4. Number of notified pertussis cases in 2012 by age group and case 
classification.
“Mo” in graph indicates months i.e. 0-5 months and 6-11 months, the remaining age 
groups are in years
Figure 5. The age specific incidence rate (per 100,000 population) of notified 
pertussis cases in 2012 by case classification
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In 2012, nine cases (0.2/100,000) of rubella were notified 
in Ireland (table 1) compared to four cases in 2011. 
In 2012, new case definitions were introduced in 
Ireland.  Changes to the rubella case definition included 
changes to the definition of probable and confirmed 
cases.  Under the previous case definition a rubella case 
classified as probable was a clinically compatible case 
with an epidemiological link to a laboratory confirmed 
rubella case while a case classified as confirmed was a 
clinically compatible case that was laboratory confirmed. 
Under the new 2012 rubella case definition a rubella 
case classified as probable is any person meeting the 
clinical criteria and with an epidemiological link to a 
laboratory confirmed rubella case and/or with a rubella 
virus specific antibody response (IgM) identified.  Under 
the new 2012 rubella case definition a case classified 
as confirmed is any person not recently vaccinated and 
meeting the laboratory criteria for case confirmation 
and in the case of recent vaccination, a person with 
detection of wild-type rubella virus strain. Under both 
case definitions laboratory results were interpreted 
according to the vaccination status and history of recent 
vaccination. The case definitions are available at 
www.hpsc.ie. 
One of the cases in 2012 was classified as probable 
(figure 1).  This case was serum IgM positive and 
probable country of infection was recorded as the 
United Kingdom.  Eight cases in 2012 were classified 
as possible; half of these were less than three years of 
age (figure 1).  The age specific incidence rates by case 
classification are shown in figure 2.
Of the nine rubella cases five (56%) were male and four 
(44%) were female.  
Rubella vaccine in Ireland is available as part of the 
combined measles-mumps-rubella (MMR) vaccine.  
In Ireland, vaccination with the first dose of MMR is 
routinely recommended for all children at twelve months 
of age and the second dose at four to five years of 
age.   Vaccination status was reported for seven (78%) 
1.7 Rubella
Summary
Number of cases, 2012: 9
Number of confirmed cases, 2012: 0
Crude incidence rate, 2012: 0.2/100,000
Crude confirmed incidence rate, 2012: 0.0/100,000
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Table 1. Number of rubella cases notified and the crude 
incidence rate per 100,000 population (CIR) by HSE Area in 
2012
HSE Area Number CIR
HSE-E 5 0.3
HSE-M 1 0.4
HSE-MW 0 0.0
HSE-NE 0 0.0
HSE-NW 0 0.0
HSE-SE 0 0.0
HSE-S 1 0.2
HSE-W 2 0.4
Total 9 0.2
of the rubella cases in 2012.  Four cases (n=4/9, 44%) 
were unvaccinated; one of these was aged less than 12 
months of age.  Two cases (n=2/9, 22%) were reported 
as completely vaccinated for their age, both of these 
were aged less than or equal to two years of age.  One 
case was reported as incompletely vaccinated for their 
age as this case was aged greater than five years but 
had only received one dose of MMR.  The probable 
case (adult) had no history of MMR vaccination and was 
of an age when a rubella containing vaccine was unlikely 
to have been administered.
The diagnosis of rubella based solely on clinical signs 
and symptoms is often unreliable because there are 
many other causes of fever and rash illness which 
may resemble rubella infection. Therefore, diagnostic 
samples (serum, oral fluid, urine) should always be 
obtained from patients in order to accurately diagnose 
rubella. In 2012 the laboratory criteria for case 
confirmation of rubella required the identification of 
rubella virus specific antibody response (IgG) in serum 
or saliva virus or detection of rubella virus nucleic 
acid in a clinical specimen or isolation of rubella virus 
from a clinical specimen.  Isolation of rubella virus is 
not routinely performed in Ireland but can be done 
following consultation with the laboratory. Laboratory 
results always need to be interpreted according to the 
vaccination status and history of recent vaccination.  
In 2012 the laboratory criteria for a probable case 
required the identification of rubella virus specific 
antibody response (IgM); again laboratory results 
need to be interpreted according to the vaccination 
status. When rubella in pregnancy is suspected, further 
confirmation of a positive rubella IgM results is required 
(e.g. a rubella specific IgG avidity test showing a 
low avidity).  In certain situations, such as confirmed 
rubella outbreaks detection of rubella virus IgM can be 
considered confirmatory in non-pregnant cases.
Accurate and detailed information on all notified rubella 
cases is needed to monitor progress towards the WHO 
European Measles and Rubella Elimination Strategy (for 
2015). HPSC is currently working with the HSE Areas 
to improve rubella surveillance data and during 2013 
implemented enhanced surveillance of this disease 
using the Computerised Infectious Disease Reporting 
(CIDR) system.  
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 25th July 2013.  
These figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR.
Figure 2. The age specific incidence rate (per 100,000 
population) of notified rubella cases in 2012 by case 
classification
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Figure 1. Number of notified rubella cases in 2012 by age 
group and case classification
Background
Invasive Streptococcus pneumoniae infection is a 
notifiable disease in Ireland; clinicians and laboratories 
are legally obliged to notify this infection.  For the 
purposes of this report the term invasive pneumococcal 
disease (IPD) will be used to describe these infections.  
IPD includes meningitis and blood stream infection (BSI) 
with and without pneumonia. 
A number of different initiatives are in place in Ireland 
for the surveillance of IPD.  Data on IPD notifications 
are collated in the Computerised Infectious Disease 
Reporting (CIDR) system.  Enhanced surveillance on 
IPD notifications is undertaken by Departments of 
Public Health particularly on children and adolescents 
<15 years and these data are also collated in CIDR.  A 
separate surveillance strand (EARS-Net project) involving 
the microbiology laboratories and the HPSC is used to 
monitor in detail the antimicrobial resistance profiles 
of invasive S. pneumoniae isolates from blood and/
or CSF.  Since April 2007, the National Pneumococcal 
Typing Laboratory has been offering a typing service to 
Irish laboratories for all invasive S. pneumoniae isolates 
submitted.  This is a collaborative project involving 
the RCSI/Beaumont Hospital, the Children’s University 
Hospital, Temple Street and the HPSC. In addition, since 
August 2012 Health Protection Surveillance Centre 
(HPSC) is participating in a European Centre for Disease 
Prevention and Control (ECDC) project called SpID-net. 
The project aims to strengthen or set up long term active 
population based IPD surveillance in order to estimate 
the impact of the pneumococcal conjugate vaccines in 
children less than five years of age in Europe.
In September 2008, the 7-valent pneumococcal 
conjugate vaccine (PCV7) was introduced into the Irish 
infant immunisation schedule at 2, 6 and 12 months of 
age.  A catch-up campaign was also implemented at that 
time, targeting children <2 years of age.  In December 
2010, PCV13 replaced PCV7 in the infant schedule. 
Uptake of three doses of PCV by 24 months of age for 
2012 was 91%.
IPD notification data was extracted from CIDR on 26th 
June 2012. These figures may differ slightly from those 
previously published due to ongoing updating of 
notification data on CIDR.  For the 2012 notifications, the 
2012 HPSC case definition for IPD was used.  In brief, 
isolation or detection of S. pneumoniae from a normally 
sterile site was classified as confirmed; detection of 
S. pneumoniae antigen from urine was classified as 
possible case. Since 2012 the previously used probable 
case definition is no longer applicable used and any case 
in which S. pneumonia antigen is detected from a sterile 
site is now categorized as confirmed.
Results
All IPD notifications
In 2012, 427 cases of IPD (9.3/100,000) were notified 
in Ireland.  There was no significant increase in IPD 
notifications in 2012 compared with 2011 (425 cases; 
9.3/100000).  
In 2012, 81% (n=347) of notifications were classified as 
confirmed and 19% (n=80) as possible. The majority of 
possible cases (72%, n=58/80) were notified by HSE-SE.  
These figures do not necessarily indicate a higher burden 
of IPD in this area relative to other areas, but rather it 
1.8 Streptococcus pneumoniae (invasive)
Summary
Number of cases in 2012: 427
Number of cases in 2011: 425
Number of deaths in 2012: 37
Number of deaths in 2011: 11
Crude incidence rate, 2012: 9.3/100,000
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Figure 1.  Number of confirmed invasive pneumococcal disease 
notifications by typing status and the incidence rate (IR) of 
confirmed IPD with 95% confidence intervals, 2008-2012
Data source: CIDR
may reflect more consistent reporting of positive urinary 
antigen cases from that area. 
Confirmed IPD notifications
Focusing specifically on the confirmed IPD notifications, 
347 cases were notified in 2012 (7.6/100,000; 95% CI 
6.8 - 8.4/100,000) (figure 1).  There was no increase in 
incidence compared with 2011 (7.6/100,000; 95% CI 
6.8 - 8.4/100,000; 349 cases). However the incidence 
of confirmed IPD in 2012 significantly declined by 
20% compared with 2008 (9.5/100,000; 95% CI 8.6 – 
10.5/100,000; 404 cases; p<0.05) (figure 1).
In 2012, 85% of the confirmed IPD notifications had an 
isolate submitted for serotyping, a slight improvement to 
the proportion in 2011 (81%) and a marked improvement 
from 2008 and 2009 when 79% of notifications had 
an isolate typed (figure 1).  In 2012 however, 37% of 
notifications (16/43) relating to children <5 years of age 
did not have an isolate submitted for serotyping.  For six 
of the 16 the cases were confirmed by PCR only and no 
isolate was available. For the remaining ten no isolate 
from a sterile site was available for typing.
Incidence rates by HSE area ranged from 6.4 per 
100,000 in HSE-NE to 10.5 per 100,000 in HSE-MW 
with the incidence higher in the HSE NW and HSE S and 
highest in HSE MW (figure 2).  However, the incidence 
rates in each of the eight HSE areas were not statistically 
different from the national one.
A clinical diagnosis was reported for just 176 of the 347 
confirmed cases (51%), which included meningitis (n=36), 
blood stream infection (BSI) with pneumonia (n=80) and 
other BSI for the remainder (n=60).
More cases occurred in males than in females, 52% of 
cases in the former (n=182). Cases ranged in age from 
1 month to 96 years, with an average age of 55.6 years 
(median age 65 years).  Those aged 65 years and older 
accounted for more than half of cases (51%, n=160). The 
age specific incidence rate (ASIR) was highest in those 
85 years of age and older (63/100,000; n=37), followed 
by those in the 75-84 years age group (41/100,000; 
n=71) and 65 and 74 year age group (22/100,000; n=68) 
(figure 3).  In children < 2 years of age the ASIR was 
11 cases per 100,000 population (n=16).  A statistically 
significant decline (74%) in IPD incidence was seen in 
this age group when compared with 2008 (42/100,000; 
n=52; p<0.0001), highlighting the positive impact the 
introduction of PCV7 in September 2008 to the infant 
schedule and  replaced by  PCV13 in December 2010 
has had on reducing the burden of IPD in young children 
(figure 3). 
The medical risk factor field was completed for 
123 (35%) confirmed cases; for the remainder this 
information was either unknown or not specified.  Based 
on the 123 cases with information reported, 85 (69%) 
had an underlying medical risk factor, with some patients 
having multiple risk factors.  The main risk factors 
reported included immunosuppressive condition or 
therapies (n=45), chronic lung disease (n=35), chronic 
heart disease (n=31) chronic liver disease (n=19) and 
renal diseases (n=17). It should also be noted that being 
elderly, aged 65 years and older is also a recognised IPD 
risk factor; 176 cases in 2012 were in this age group.  
Apart from being elderly, 69 cases in this age group also 
had a reported medical risk factor.
IPD death notifications
Outcome was reported on 47% (n=202) of the IPD 
notifications in 2012.  Therefore, these figures may 
underestimate the burden of IPD in terms of mortality. 
Based on the data available, 37 deaths in individuals 
with IPD in 2012 were reported.  The cause of death 
was reported as directly due to IPD in six cases, not 
due to IPD in five cases and for the remaining 26 the 
cause of death was not specified or was unknown.  
Therefore, based on the outcome data available, IPD 
was potentially the cause of death in 32 patients, giving 
an IPD case fatality rate of 16% (32/202).  Twenty nine 
Figure 2.  Incidence rate of confirmed invasive pneumococcal 
disease notifications by HSE area, 2012
Data source: CIDR
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Figure 3.  Age specific incidence rate of confirmed invasive 
pneumococcal disease notifications by age group, 2008-2012
Data source: CIDR
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deaths occurred in adults, ranging in age from 46-91 
years and three deaths occurred in children (aged 6 
months; one and 11 years).  Thirty of the 32 deaths were 
in confirmed cases and two deaths each in a possible 
IPD cases. 
The apparent increase in IPD death notifications in 2012 
(37 cases in 2012 versus 11 cases in 2011) is most likely 
related to the additional information that was available 
by linking CIDR data to the Enhanced Surveillance 
of Blood Stream Infections (ESBI) database. Missing 
information on outcome in CIDR was identified and then 
the CIDR database was updated by HSE areas. 
Impact of pneumococcal conjugate vaccines (PCV)
Data from the National Pneumococcal Typing Laboratory 
were used to assess the impact of introducing PCV on 
the distribution of S. pneumoniae serotypes associated 
with IPD and on the burden of IPD in Ireland.  In 2012, 
of the 347 confirmed IPD notifications reported in 
CIDR, 296 had isolates sent for typing (85%).  Fourteen 
percent of IPD infections were due to serotypes covered 
by PCV7 (4, 6B, 9V, 14, 18C, 19F and 23F), 38% were 
associated with the six additional serotypes included 
in PCV13 (1, 3, 5, 6A, 7F and 19A) and the remaining 
48% of infections were due to non-vaccine types (NVTs, 
serotypes excluding the 13 covered by PCV13).  
Since introducing PCV7 to the Irish childhood 
immunisation schedule towards the end of 2008, there 
has been a 17% reduction in the overall burden of IPD 
disease.  In particular, reductions in the incidence of IPD 
due to PCV7 serotypes have been seen in all age groups 
(figure 4a).  Overall, the incidence of IPD due to PCV7 
serotype has significantly declined in 2012 compared 
with 2008 (76% decline, p<0.001).  The greatest 
impact was seen in children <2 years of age where 
the incidence of the disease due to PCV7 serotypes 
has declined by 97% (p<0.01) (figure 4a).  In 2012 the 
incidence of disease due to the additional six serotypes 
in PCV13 declined by 44% in the <2 year olds compared 
with 2008 (figure 4b).  This decline was not observed in 
any of the other age groups, but rather the incidence of 
disease increased compared with previous years (figure 
4b). An increase in incidence due to the NVTs was also 
seen in 2012, particularly in those aged 65 years and 
greater with an increase in incidence evident since 2009. 
There has been little change in the incidence of NVTs   
among other age groups (figure 4c).  
The predominant serotypes in circulation in 2012, were 
7F and 19A (both included in PCV13) and then followed 
by serotypes 22F, 8 (both NVTs) and 3 (included in 
PCV13).  In children <2 years of age, the predominant 
serotypes were 19A, 15A and 7F accounting for a half of 
the isolates serotyped in this age group (figure 5).
For ongoing updates, see “Slides – Impact of 
PCV in Ireland” at http://www.hpsc.ie/hpsc/A-Z/
VaccinePreventable/PneumococcalDisease/
PostersPresentations/
PCV vaccine failures
Based on data obtained through the IPD enhanced 
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Figure 4.  Age specific incidence rate by age group of 
confirmed invasive pneumococcal disease cases due to (a) 
PCV7 serotypes, (b) the additional six serotypes covered 
by PCV13 (PCV13-7) and (c) non-vaccine types (non-PCV13 
serotypes), 2008-2012
Data source: National Pneumococcal Typing Laboratory
Figure 4a Figure 4b
Figure 4c
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surveillance system, two PCV vaccine failures were 
reported in 2012. One vaccine failure was due to 
serotype 19F (PCV7); another due to serotype 19A (PCV 
13).In addition, since 2008, four vaccine failures have 
been reported, two due to serotype 14 and two due to 
19F.
Penicillin non-susceptible S. pneumoniae (PNSP)
In 2012, the proportion of penicillin non-susceptible 
invasive S. pneumoniae (PNSP) was 19.6%, (4.0% and 
15.6% with high and intermediate level resistance, 
respectively) while 16.9% of isolates were resistant to 
erythromycin (Data source: HPSC/EARS-Net Ireland).  In 
the UK, the PNSP proportion in 2012 was 4.9% (0.7% 
and 4.2%, with high and intermediate level resistance, 
respectively). 
In 2012, Ireland had one of the highest proportions of 
PNSP in Europe ranking 9th out of 28 countries overall.  
Although, 34 different serotypes were identified in 2012, 
only 15 serotypes were associated with being penicillin 
non-susceptible. The predominant PNSP serotypes in 
2012 were 19A, 35B and 6B whereas in 2008 serotypes 
9V and 14 were the leading ones.  For details on the 
antimicrobial resistance patterns of S. pneumoniae, 
please see the chapter on Antimicrobial Resistance 
within this report.  
Discussion
Although there was no significant changes in the 
incidence of confirmed cases of IPD in Ireland in 2012 
compared with 2011, PCV7 has had a significant impact 
in reducing the overall burden of the disease in the total 
population.  There has been a decline in IPD in all age 
groups due to serotypes covered by PCV7, indicating 
the indirect/herd immunity effect the vaccine confers 
on the population.  The greatest impact has been in 
children <2 years of age where the disease incidence 
due to PCV7 serotypes has been reduced by over 97%.  
The impact due to PCV13 vaccine, which was introduced 
in December 2010 was observed in children <2 years of 
age amongst whom the reduction in the incidence of 
disease due to the additional six serotypes covered by 
PCV13 was 44%, the same as in 2011.
However, despite these reductions in IPD burden, the 
incidence of disease due to non-PCV7 serotypes has 
increased in all age groups.  There has been a shift in 
the prevalent serotypes associated with invasive disease. 
Serotypes 7F, 19A, and 22F have been predominant 
serotypes as in 2011.  
To accurately assess the impact of PCV on immunisation 
programmes and to monitor for vaccine failures in 
Ireland, it is crucial that laboratories continue to send 
all invasive S. pneumoniae isolates for typing to the 
National Pneumococcal Typing Laboratory.  Although 
85% of confirmed notifications had an isolate submitted 
for serotyping in 2012, 15% (n=51) did not, including 
16 cases in children <5 years of age.  In six of these 
16 cases an isolate was not available for typing and 
confirmation was by PCR only.  The overall concern 
is that serotype information is unavailable for 37% of 
confirmed notifications in this age group.
Continued good quality IPD surveillance including the 
monitoring of invasive S. pneumoniae serotypes is 
crucial in identifying any epidemiological changes in the 
disease, assessing the impact of PCV13 on public health 
and in guiding further vaccination strategies as newer 
expanded valency vaccines are made available.  For 
example, due to the incomplete data we do not know 
the impact of IPD on mortality and this is a key metric 
in assessing the true impact of this disease and the 
effectiveness of interventions, including new vaccines.
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Figure 5. Serotype distribution of invasive Streptococcus pneumoniae isolates by age group 
(years) in Ireland, 2012
* Denotes serotypes included in PCV7
*^ Denotes additional six serotypes included in PCV13 (PCV13-7)
Data source: National Pneumococcal Typing Laboratory
-34-HPSC Annual Report 2012 1. Vaccine Preventable Diseases
0
5
10
15
20
25
30
35
40
45
50
7F
*^
22
F
19
A
*^ 3*
^ 8
35
B
1*
^
14
*
15
A
23
F*
33
F
6A
*^
11
A
23
A
6B
*
19
F*
10
A
15
B
18
C
*
6C 2
0
23
B 34 4
*
17
F 31 9N 9V
*
12
F
16
F
35
F 38
15
C N
T 7A
N
um
be
r o
f I
PD
 is
ol
at
es
Serotype
<2 2+
0
5
10
5
20
25
30
35
40
45
50
7F
*^
22
F
19
A
*^ 3*
^ 8
35
B
1*
^
14
*
15
A
23
F*
33
F
6A
*^
11
A
23
A
6B
*
19
F*
10
A
15
B
18
C
*
6C 2
0
23
B 34 4
*
17
F 31 9N 9V
*
12
F
16
F
35
F 38
15
C N
T 7A
N
um
be
r o
f I
PD
 is
ol
at
es
Serotype
<2 2+
Health Protection Surveillance Centre   Annual Report 2012
Respiratory and Direct Contact Diseases
02
HPSC has worked in collaboration with the National 
Virus Reference Laboratory (NVRL), the Irish College 
of General Practitioners (ICGP) and the Departments 
of Public Health on the influenza sentinel surveillance 
project since 2000. Sixty-one general practices (located 
in all HSE-Areas) were recruited to report electronically, 
on a weekly basis, the number of patients who 
consulted with influenza-like illness (ILI). Sentinel GPs 
were requested to send a combined nose and throat 
swab to the NVRL on one ILI patient per week. The 
NVRL also tested respiratory non-sentinel specimens, 
referred mainly from hospitals. 
Other surveillance systems set up to monitor ILI/
influenza activity include: 
•  Surveillance of all calls to GP out-of-hours (OOHs) 
centres, monitored for self-reported influenza. These 
data were provided by HSE-NE.  
•  Surveillance of all confirmed influenza notifications, 
including hospitalisation status reported to the 
Computerised Infectious Disease Reporting System 
(CIDR) in Ireland. 
•  Enhanced surveillance of hospitalised influenza cases 
aged 0-14 years.   
•  Intensive Care Society of Ireland (ICSI) enhanced 
surveillance of all critical care patients with confirmed 
influenza and enhanced surveillance of all severe acute 
respiratory infections (SARI) at two ICU sites, one adult 
and one paediatric.  
•  Enhanced surveillance of all confirmed influenza 
deaths. 
•  A network of sentinel hospitals reporting admissions 
data
The data presented in this summary were based on all 
data reported to HPSC by the 17th October 2013. Due 
to the current legislation regarding the registration 
of deaths in Ireland; there can be significant delays 
between the date of death and the registration of 
deaths and subsequent reporting to HPSC.
Sentinel GP Clinical Data
Influenza activity in Ireland was low to moderate during 
the 2012/2013-influenza season, with sentinel GP ILI 
consultation rates peaking twice, at 59.3 per 100,000 
population during week 1 2013 (January) and again 
at 59.1 per 100,000 population during week 6 2013 
(February) (figure 1). ILI rates first increased above 
baseline levels (21.0 per 100,000) during week 50 2012 
and remained there for 14 consecutive weeks, one of 
the longest seasons on record, with the exception of 
the pandemic period. The highest age specific ILI rates 
were reported in the 5-14 year age group (peaking at 
100.3/100,000), followed by those aged 15-64 years 
(70.8/100,000), 0-4 years (39.6/100,000) and those aged 
65 years or older (39.3/100,000).
Virological Data - Influenza
The NVRL tested 932 sentinel specimens for influenza 
virus during the 2012/2013 season. Five hundred and 
sixteen (55.4%) sentinel specimens were positive for 
influenza: 151 influenza A (86 A (H3), 51 A (H1)pdm09 
and 14 A unsubtyped) and 365 influenza B. 
The NVRL tested 7,199 non-sentinel respiratory 
specimens during the 2012/2013 season, 1033 (14.3%) 
of which were positive for influenza: 669 influenza A 
(412 A(H3), 170 A(H1)pdm09 and 87 A (unsubtyped)) 
and 364 influenza B. 
Influenza B was the predominant influenza virus 
circulating until February 2013, followed by influenza 
A(H3) and influenza A(H1)pdm09 for the remainder 
of the season. Influenza A accounted for 52.9% of all 
influenza positive specimens and influenza B for 47.1% 
during the 2012/2013 season. Of the 719 influenza 
A sentinel and non-sentinel specimens that were 
subtyped, influenza A(H3) accounted for 69.3% and 
influenza A(H1)pdm09 for 30.7%. 
The NVRL genetically characterised 66 influenza 
viruses during the 2012/2013 influenza season. Of 43 
influenza B viruses analysed, 38 (88.4%) belong to the B/
Yamagata lineage (which is included in the 2012/2013 
influenza vaccine) and five (11.6%) belong to the B/
Victoria lineage. Seventeen influenza A(H3N2) viruses 
were genetically characterised and were similar to the 
vaccine strain A/Victoria/361/2011. Sequence analysis of 
2.1 Influenza and Other Respiratory Viruses
Summary
2012/2013 influenza season summary:
Peak influenza-like illness rate: 59.3 /100,000 population
Total confirmed influenza cases hospitalised: 471
Total confirmed influenza cases admitted to ICU: 38
Total influenza-associated deaths: 32 
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six influenza A(H1N1)pdm09 viruses identified them as 
related to the vaccine strain A/California/07/2009.
Virological Data - Other respiratory viruses 
During the 2012/2013 season, of 7,199 non-sentinel 
specimens tested by the NVRL, 669 (9.3%) positive 
detections of respiratory syncytial virus (RSV) were 
reported, peaking at 35.9% during week 52 2012. A 
total of 220 (3.1%) positive detections of parainfluenza 
virus type 3 (PIV-3) were reported, peaking towards 
the end of the season, at 11.3% during week 17 2013. 
Positive detections of human metapneumovirus (n=165; 
2.3%) also peaked at the end of the season, at 9.4% 
during week 20 2012. 138 (1.9%) positive detections 
of adenovirus were reported, nine (0.1%) parainfluenza 
virus type 1 (PIV-1) and eight (0.1%) parainfluenza virus 
type 2 (PIV-2). 
Outbreaks, GP OOHs & Sentinel hospital data
Seventy-two influenza/ILI outbreaks were reported: 
influenza was confirmed for 63 of these outbreaks. 
Of the 63 outbreaks predominantly associated with 
influenza, 52 were associated with influenza A (42 
A(H3), 6 A (H1)pdm09 and 4 with influenza A (subtyping 
not reported) and 11 with influenza B. No pathogens 
were identified for nine ILI outbreaks. One third of the 
influenza/ILI outbreaks were reported from HSE-E (table 
1). The majority of outbreaks were associated with the 
elderly, in health care facilities/residential institutions. 
In total 23 deaths were recorded during these 72 
outbreaks, 10 of these deaths were officially reported as 
influenza-associated deaths (all in those over 75 years of 
age). 
A further 13 acute respiratory infection (ARI) general 
outbreaks (negative for influenza) were reported 
during the 2012/2013 influenza season, four associated 
with human metapneumovirus (hMPV), two with 
parainfluenza viruses, one with respiratory syncytial virus 
(RSV) and six associated with unidentified pathogens. 
The majority of cases associated with these ARI 
outbreaks displayed atypical ILI symptoms.
The percentage of influenza-related calls to GP out-of-
hours services in Ireland, peaked during week 1 2013 at 
6.0% (coinciding with the first peak in ILI activity, which 
was associated with influenza B). During the peak of 
activity, each service received on average, 1.7 calls per 
hour relating to influenza.
Hospital respiratory admissions in sentinel hospitals 
peaked during week 50 2012, with 413 respiratory 
admissions reported during that week. Respiratory 
admissions remained at elevated levels between week 
49 2012 and week 1 2013. Total emergency admissions 
reported from sentinel hospitals also peaked during 
week 50 2012, at 2820. 
Influenza and RSV notifications
A total of 1619 confirmed influenza notifications were 
reported on CIDR during the 2012/2013 influenza 
season. Of the 1619 notifications, 488 (30.1%) were 
influenza A(H3), 218 (13.5%) were influenza A(H1)
pdm2009, 132 (8.2%) were influenza A (not subtyped) 
and 781 (48.2%) were influenza B. A total of 1608 
RSV notifications were reported on CIDR during the 
2012/2013 season, peaking at 253 during week 1 2013. 
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Figure 1: ILI sentinel GP consultation rates per 100,000 population, baseline ILI threshold rate, and  number of positive influenza 
A and B specimens tested by the NVRL, by influenza week and season. Source: Clinical ILI data from ICGP and virological data 
from the NVRL. 
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Confirmed influenza cases hospitalised 
Four hundred and seventy one cases with confirmed 
influenza were hospitalised during the 2012/2013 
influenza season. The highest age specific rate in 
hospitalised cases for the 2012/2013 season was in 
those less than one year of age (56.6 per 100,000 
population), followed by those aged 1-4 years of age 
(28.2 per 100,000) and those aged 65 years or older 
(19.1 per 100,000) (table 2). Of the 471 hospitalised 
cases, 130 (27.6%) were influenza A(H3), 79 (16.8%) 
were influenza A(H1)pdm09, 39 (8.3%) were influenza A 
(not subtyped) and 223 (47.3%) were influenza B. 
Confirmed influenza cases admitted to ICU 
Of the 471 hospitalised confirmed influenza cases, 
38 (8.1%) were admitted to critical care (28 adults 
and 10 paediatric cases). Of the 38 critical care cases, 
five (13.2%) were associated with influenza A (H3), 
16 (42.1%) were influenza A(H1)pdm09, two (5.3%) 
influenza A (not subtyped) and 15 (39.5%) were 
influenza B. Age specific rates for patients admitted to 
ICU were highest in those aged less than 1 year of age 
(5.5 per 100,000 population)  followed by those aged 
65 years and over (1.5 per 100,000 population) (table 2). 
The median age of paediatric cases was 17 months of 
age and the median age of adult cases was 51.5 years. 
Twenty-five (25/28, 89.3%) adults and nine (9/9, 100%) 
paediatric cases had pre-existing medical conditions. 
Pre-existing medical conditions were unknown for 
one paediatric case, aged 2 months old. The most 
frequently reported underlying medical condition for 
adults was chronic heart disease (7/25, 28.0%), followed 
by immunosuppression/malignancy (6/25, 24.0%). Four 
adult cases were pregnant. Seven (25.0%) adult cases 
were reported as current/former smokers. Underlying 
medical conditions for paediatric cases included chronic 
respiratory disease (n=3), neurological/neuromuscular 
conditions (n=3), cardiovascular conditions (n=2), and 
metabolic disorder (n=1). Nineteen (19/22, 86.4%) 
adults and nine (9/9, 100.0%) paediatric cases were 
ventilated during their stay in ICU. Ventilation status was 
unknown for six adult cases and one paediatric case. 
The median length of stay in ICU for adult cases was 9 
days (ranging from 1 - 17 days) and for paediatric cases 
was 5.0 days (ranging from 1 - 85 days). Vaccination 
status was only known for nine of the 38 cases admitted 
to ICU, three cases were vaccinated (all three had 
underlying medical conditions) and six were not (four 
did have underlying medical conditions and two did 
not). Eleven deaths in confirmed influenza cases were 
reported from ICU units, two of these deaths were due 
to influenza. 
Mortality data
During the 2012/2013 influenza season, 32 influenza-
associated deaths† were reported. The case classification 
of influenza was confirmed for 21 of these cases, 
probable for three cases and possible for eight cases. Of 
the 21 cases with known virology, eight were associated 
with influenza A(H3), one with influenza A(H1)pdm09, 
five influenza A (not subtyped) and seven with influenza 
B. The median age of cases who died during the 
2012/2013 influenza season was 86 years, ranging 
from <1 year – 95 years. Ten of the 32 deaths (31.3%) 
were associated with influenza outbreaks. Vaccination 
status was known for nine of the 32 (28.1%) cases. Five 
(55.6%) cases were vaccinated and four (44.4%) were 
not vaccinated with the 2012/2013 influenza vaccine. 
Of these 32 cases, 26 were known to have underlying 
medical conditions. Data on underlying medical 
conditions was unknown for six cases, with an age range 
of 84 - 94 years. 
Summary tables of confirmed influenza hospitalised and 
critical care cases and influenza-associated deaths for all 
ages are detailed in tables 3 & 4.
Overview of the 2012/2013 season 
During the 2012/2013 influenza season, although 
influenza activity in Ireland rose to relatively low levels, 
activity was prolonged, and reached levels higher than 
those reported during the previous season. Influenza-
like illness (ILI) GP consultation rates were above 
baseline levels for 14 consecutive weeks, a longer than 
average period. A mix of influenza viruses meant both 
children and adults were affected; influenza B was 
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Table 1: Number of influenza/ILI outbreaks by HSE-Area for the 2012/2013 influenza season (n=72).* 
*It should be noted that only 10/23 of the deaths reported in these outbreaks were officially reported as influenza-associated 
deaths. 
† Influenza-associated deaths include all deaths where influenza is reported as the primary/main cause of death by the physician or if influenza 
is listed anywhere on the death certificate as the cause of death.
HSE-Area No. of outbreaks Total number ill
Total number hos-
pitalised
Total number 
dead
Total number lab 
confirmed
Total number lab 
investigated
HSE-E 24 815 16 10 132 93
HSE-M 6 152 11 6 19 16
HSE-MW 4 39 50 0 9 11
HSE-NE 3 22 4 3 6 16
HSE-NW 14 146 9 0 40 62
HSE-SE 4 77 6 1 16 29
HSE-S 10 130 9 2 7 21
HSE-W 7 136 20 1 11 9
Total 72 1517 125 23 240 257
predominantly circulating until February 2013, followed 
by influenza A(H3) co-circulating with influenza A(H1)
pdm09 for the remainder of the season. The unusual 
pattern of influenza B circulating prior to influenza A, 
was also reported in England, Northern Ireland and 
Wales but not in Scotland. The number of influenza/
ILI outbreaks during the 2012/2013 season reached 
the highest number ever reported to HPSC, with the 
exception of the pandemic period. These outbreaks 
mainly affected the elderly in healthcare/residential 
care facilities, the majority of which were associated 
with influenza A(H3). An increase in influenza severity 
was observed relative to the 2011/2012 influenza 
season with a higher number of hospitalisations, ICU 
admissions and influenza-associated deaths. As in 
previous seasons, hospitalisations and ICU admissions 
mainly affected those under 5 years of age and those 
aged 65 years and older. Cumulative excess all-cause 
mortality was high in the elderly, with the highest 
levels reported since the 2008/2009 influenza season, 
coinciding with high levels of influenza A(H3) activity in 
the elderly. 
Globally, the majority of influenza A viruses 
characterised during 2012/2013 influenza season 
were antigenically related to those contained in the 
2012/2013 influenza vaccine. Among influenza B viruses 
characterised globally, 10-30% of reported B viruses 
were of the Victoria lineage. The remainder were of the 
Yamagata lineage, and were antigenically related to the 
vaccine recommended component. For the 2013/2014 
influenza season in the northern hemisphere, WHO 
have recommended trivalent influenza vaccines contain 
the following strains: an A/California/7/2009 (H1N1)
pdm09-like virus, an A(H3N2) virus antigenically like the 
cell-propagated prototype virus A/Victoria/361/2011 
(with a recommendation for A/Texas/50/2012) and a B/
Massachusetts/2/2012-like virus (Yamagata
lineage).1
Early estimates of influenza vaccine effectiveness in 
Europe undertaken by the IMOVE consortium reported 
an early adjusted influenza vaccine effectiveness (VE) of 
78.2% (95% CI: 18.0 to 94.2) against influenza B, 62.1% 
(95% CI: −22.9 to 88.3%) against A(H1)pdm09, 41.9 
(95% CI: −67.1 to 79.8) against A(H3N2) and 50.4% 
(95% CI: −20.7 to 79.6) against all influenza types in 
the target groups for influenza vaccination. These early 
estimates suggest a moderate VE against all influenza 
viruses. By type and subtype, the highest VE was 
against influenza B and the lowest against influenza 
A(H3N2). As in 2011/12, the results suggest a low-to-
moderate VE for influenza A(H3N2). Efforts to improve 
influenza vaccines should continue to better protect 
those at risk of severe illness or complications. 2
Positive proportions of parainfluenza virus type 3 and 
adenovirus were higher than those reported to HPSC 
in previous seasons. Activity from other circulating 
respiratory viruses during the 2012/2013 season was 
similar to previous seasons. Two novel respiratory 
viruses emerged during the 2012/2013 season, 
Middle East Respiratory Syndrome coronavirus (MERS-
CoV) in the Middle East and avian-origin influenza 
A(H7N9) in Eastern China. Both have high reported 
case fatality ratios, with the source of both viruses 
yet to be fully established. No cases of MERS-CoV or 
influenza A(H7N9) were identified in Ireland during 
the 2012/2013 season. Surveillance procedures for 
these viruses will continue while the risk remains. 
Information on MERS-CoV is available on the ECDC 
website. Further information and guidance documents 
are also available on the HPSC and WHO websites. For 
up to date information on human infection with avian 
influenza A(H7N9) virus in China including the current 
case numbers and the WHO assessment of the situation 
please see here.
For the 2013/2014 influenza season, existing 
surveillance systems in Ireland have been strengthened. 
A number of additional measures have been put 
in place to improve the surveillance of influenza/ILI 
outbreaks, severe influenza and influenza-associated 
deaths. Work is also in progress to improve reporting of 
influenza vaccine uptake in health care workers and risk 
groups for influenza. HPSC are continuing participation 
in a WHO pilot project to automatically calculate the 
intensity of influenza each week using sentinel GP ILI 
consultation rates. Surveillance of influenza notifications 
(including hospital status), ILI/influenza outbreaks, 
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Table 2: Age specific rate for confirmed influenza cases hospitalised and admitted to critical care during the 2012/2013 
influenza season. Age specific rates are based on the 2011 CSO census
Hospitalised Admitted to ICU
Age (years) Number Age specific rate per 100,000 pop. Number Age specific rate per 100,000 pop.
<1 41 56.6 4 5.5
1-4 80 28.2 4 1.4
5-14 64 10.3 2 0.3
15-24 21 3.6 0 0.0
25-34 52 6.9 5 0.7
35-44 51 6.8 7 1.0
45-54 34 5.9 3 0.5
55-64 26 5.6 5 1.1
65+ 102 19.1 8 1.5
Total 471 10.3 38 0.8
and enhanced surveillance of confirmed hospitalised 
influenza cases (aged 0-14 years) and of confirmed 
influenza cases in critical care units (all ages) will 
continue for the 2013/2014 season. Additional projects 
include an all-cause mortality monitoring project 
associated with the European mortality monitoring 
group (EuroMOMO), participation in a European 
influenza vaccine effectiveness study (I-MOVE project) 
and a project on severe acute respiratory infections 
(SARI) cases admitted to two critical care units, one 
adult and one paediatric. Work is in progress to 
automate the extraction of data on SARI cases from 
one paediatric intensive care unit (PICU). The work at 
this PICU site should hopefully pave the way for further 
automation of SARI data extraction from similar sites. 
Data from all of these surveillance systems will assist in 
guiding the management and control of influenza and 
any future epidemics or pandemics.  www.hpsc.ie
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Table 3: Summary table of confirmed influenza cases hospitalised and admitted to ICU for all ages by influenza season: 2009-
2013. It should be noted that risk factor data were not available for hospitalised cases in all age groups (with the exception of 
the pandemic period). Rates are based on the 2011 CSO census
Hospitalised  Admitted to ICU
Pandemic 
period
2010/2011 2011/2012 2012/2013
Pandemic 
period
2010/2011 2011/2012 2012/2013
Total cases 1059 945 146 471 100 121 15 38
Crude rate 
/100,000 pop. 
23.1 20.6 3.2 10.3 2.2 2.6 0.3 0.8
Age range (years) 0-84 0-97 0-97 0-99 0-79 0-80 0-80 0-88
Median age (years) 17 29 27 32 34 49 60 39
Females 
533 513 83 270 50 64 12 17
50.3% 54.3% 56.8% 57.3% 50.0% 52.9% 80.0% 44.7%
Cases with risk 
factor
507
No data No data No data
81 90 13 34
47.9% 81.0% 74.4% 86.7% 89.5%
Table 4: Summary table of influenza-associated deaths for all ages by influenza season: 2009-2013. It should be noted that risk 
factor data were not available for all cases during the 2011/2012 and 2012/2013 seasons. Rates are based on the 2011 CSO 
census. 
Influenza-associated deaths
Pandemic period 2010/2011 2011/2012 2012/2013
Total cases 29 38 13 32
Crude rate /100,000 pop. 0.6 0.8 0.3 0.7
Age range (years) 8-83 2-83 81-98 0-95
Median age (years) 54 57 88 86
Females 
15 18 5 16
51.7% 47.4% 38.5% 50.0%
Cases with risk factor
27/29 32/38 7/8 26/26
93.1% 84.2% 87.5% 100.0%
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In 2012, there were 15 cases of Legionnaires’ disease 
notified in Ireland, a rate of 3.3 per million population, 
an increase from the rate of 1.5 per million seen in 2011. 
Three deaths were reported, of which one was reported 
as due to Legionnaires’ disease.
Seven cases were reported from HSE East, four from 
HSE West, three from HSE Mid-West and one from HSE 
North East.
Just over half of the cases were male (53.3%). The 
median age was 68 years with a range from 38 to 87 
years.
All fifteen cases were classified as confirmed. Thirteen 
of the 15 cases were diagnosed by urinary antigen 
test (UAT) and three had the organism cultured. The 
organism involved in the 13 cases confirmed by UAT 
and cultured in one of those cases was Legionella 
pneumophila serogroup 1. Legionella pneumophila 
serogroup 3 was cultured in the remaining two cases. 
Monocloncal subtyping information was not available.
 
Eight cases were travel-associated. Countries of travel 
included France (2), Ireland (1), Italy (1), Spain (2) and 
the USA (2). Three of these cases were linked to travel 
related clusters. Of the seven remaining cases, two 
were healthcare-associated and the remaining five were 
assumed to be community acquired.
The peak month for notifications was October when 
three cases were notified.
2.2 Legionellosis
Summary
Number of cases in 2012: 15
Crude incidence rate: 3.3 per million
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Table 1. Number of Legionnaires’ disease cases per million population in Ireland, 2005-2012
Age group 
(years)
2005 2006 2007 2008 2009 2010 2011 2012
<30 0 0 1 0 0 1 0 0
30-39 2 0 3 0 0 0 0 1
40-49 3 7 4 2 0 2 0 1
50-59 1 2 2 3 2 1 1 1
60-69 1 1 3 4 3 3 4 6
70+ 1 2 2 2 2 4 2 6
Total 8 12 15 11 7 11 7 15
CIR 1.9 2.8 3.5 2.6 1.5 2.4 1.5 3.3
For details of denominator data used, please see Explanatory Notes section at the end of this document
Notifications 
One hundred and twenty-two cases of invasive Group A 
streptococcal (iGAS) disease were notified in 2012.  This 
corresponds to 2.66 iGAS cases per 100,000 population 
[95% confidence interval (CI), 2.21 to 3.17 per 100,000], 
which is higher than in 2011 when the iGAS rate was 
1.46 per 100,000 population (95% CI, 1.13 to 1.85 per 
100,000). This increase is considered to be statistically 
significant as the confidence intervals do not overlap. 
One hundred and eighteen cases were confirmed, 
defined as patients with Group A streptococcus (GAS), 
or Streptococcus pyogenes, isolated from a sterile site. 
Four cases were probable, defined as patients with 
streptococcal toxic shock syndrome (STSS) and GAS 
isolated from a non-sterile site (e.g. throat, sputum, 
vagina).
Patient demographics
Of the 122 cases, 59 (48%) were males and 63 (52%) 
were females, with ages ranging from 2 weeks to 92 
years (mean, 44 years; median, 42 years). iGAS was 
more common in young children and older adults 
(Figure 1). 
Geographic spread and seasonal variation
Table 1 outlines the numbers and crude incidence rates 
(CIRs) of iGAS disease by HSE area from 2006 to 2012. 
Of note, the highest number of cases and CIR in 2012 
occurred in the HSE-East (n=51; CIR, 3.15 per 100,000 
population). The numbers of cases and CIRs increased 
in all HSE Areas, with the HSE-North-East reporting the 
biggest increase (up by over 10-fold on 2011).
In 2012, the peak periods were January-February (21 
cases) and April-July (66 cases), which is broadly similar 
to the data from previous years with the peak typically 
occurring during the first half of the year (Figure 2). 
Comparing monthly data between 2011 and 2012, the 
first signs of an increase in notifications in 2012 occurred 
in April (n=11; 2011, n=6), with the highest number of 
monthly notifications reported to date following in May 
(n=21; previously the highest monthly figure was 12) 
(Figure 3).  Note: the data presented here are based on 
the date the case was notified to public health and not 
on the date the case was first detected.
Isolate details
GAS was isolated from a sterile site in 103 of 118 
2.3  Invasive Group A Streptococcal 
 Disease
Summary
Number of cases, 2012:  122
Crude incidence rate, 2012: 2.66 per 100,000 
population
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Figure 1.  Age and sex specific rates of iGAS disease in 2012
confirmed cases (no data on the source were available 
for the other 15 cases), primarily from blood cultures 
(n=83 isolates, 91%), but also deep tissue (n=8), 
abscesses (n=6), joints (n=2), pleural aspirates (n=2), 
bone (n=1) and cerebrospinal fluid (CSF) (n=1).  For 
8 cases, GAS was isolated from another sterile site 
in addition to blood: abscesses (n=3), CSF (n=2), 
deep tissue (n=1) and pleural fluid (n=1). For the four 
probable cases, GAS source was wound swabs.
Typing data, based on sequencing of the emm genes 
that encode the M protein (the major virulence 
factor), were available on 108 isolates submitted from 
27 laboratories: emm-types 1.0 (n=50; 46%), 12.0 
(n=10; 9%) and 28.0 (n=8; 7%) comprised 63% of all 
the isolates typed. Nineteen other emm-types (each 
represented by four isolates or less) were also detected. 
Of the 24 patients with STSS for which emm-typing was 
undertaken, 17 of the GAS isolates belonged to emm-
type 1.0 (71%) and three to type 12.0 (13%). 
Enhanced surveillance data 
Enhanced data fields were entered for 112 (92%) of the 
122 iGAS cases, which is similar to 2011 (90%, 61 of 
67 cases). The source laboratory could be ascertained 
for all cases. As in previous years, a wide variation in 
completed fields was observed. 
Clinical details
Clinical presentation data were provided for 111 of the 
122 cases. As in 2011 and previous years, bacteraemia 
(n=84 cases, including cases where bacteraemia was 
not specifically stated but GAS was isolated from blood) 
and cellulitis (n=40) were the most common clinical 
presentations, followed by STSS (n=26; seven of which 
were implied based on the information provided on the 
clinical presentation), pneumonia (n=16), necrotising 
fasciitis (n=7), septic arthritis (n=7), myositis (n=4), 
erysipelas (n=3), puerperal sepsis (n=3), meningitis (n=3) 
and peritonitis (n=1). Note that cases could have more 
than one clinical manifestation of infection.  
Risk factors
Risk factor data were provided for 105 of the 122 cases. 
Risk factors associated with iGAS disease included age 
≥65 years (n=42), presence of skin or wound lesions 
(n=29), malignancy (n=10), varicella infection (n=8), 
steroid use (n=7), childbirth (n=6), intravenous drug 
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Table 1. Numbers (n) and Crude Incidence Rates (CIRs) per 100,000 population of iGAS disease by HSE Area, 2006-2012
HSE Area 2006 2007 2008 2009 2010 2011 2012
 n  CIR   n   CIR    n   CIR    n   CIR    n   CIR    n   CIR    n   CIR    
HSE-E 37 2.47 28 1.87 31 2.07 32 1.98 22 1.36 29 1.79 51 3.15
HSE-M 2 0.79 0 0.00 0 0.00 2 0.71 2 0.71 5 1.77 7 2.48
HSE-MW 2 0.55 2 0.55 3 0.83 5 1.32 6 1.58 6 1.58 8 2.11
HSE-NE 5 1.27 3 0.76 10 2.54 3 0.68 7 1.59 1 0.23 11 2.50
HSE-NW 1 0.42 3 1.27 3 1.27 1 0.39 8 3.10 2 0.77 5 1.94
HSE-SE 4 0.87 10 2.17 8 1.74 8 1.20 5 0.75 7 1.05 16 2.41
HSE-S 3 0.48 4 0.64 5 0.80 5 1.00 12 2.41 12 2.41 14 2.81
HSE-W 7 1.69 7 1.69 10 2.41 4 0.90 6 1.35 5 1.12 10 2.25
IRELAND 61 1.44 57 1.34 70 1.65 60 1.31 68 1.48 67 1.46 122 2.66
CIRs for 2006-2008 calculated using the 2006 census; CIRs for 2010-2012 calculated using the 2011 census
Figure 2.  Monthly distribution of iGAS cases, 2008-2012
use (IDU) (n=6), diabetes mellitus (n=5), alcoholism 
(n=5) and non-steroidal anti-inflammatory drug (NSAID) 
use (n=2). Note that cases could have one or more 
associated risk factors: 63 cases had one risk factor, 22 
had two risk factors, three had three risk factors, one 
had four risk factors and one had five risk factors. No 
risk factors were identified for 15 cases. Among the 26 
patients with STSS, risk factor data were provided for 
25 cases. Skin or wound lesions were identified as a risk 
factor in 15 cases, age 65 years and over in 10 cases, 
alcoholism in four cases, varicella in three cases, and 
childbirth, steroid and NSAID use in one case each. No 
risk factors were identified for two STSS cases. 
Clinical management
Surgical intervention was required for 24 patients 
(compared to 8 in 2011), ranging in age from 17 months 
to 81 years.
Forty patients, ranging in age from 2 weeks to 84 years, 
were admitted to an intensive care unit (ICU) (compared 
to 11 in 2011). This included 18 patients with STSS, one 
patient with necrotising fasciitis and five patients with 
both STSS and necrotising fasciitis.
Risk factors for patients admitted to an ICU included 
skin and wound lesions (n=18), age over 65 years 
(n=12), varicella infection (n=5), alcoholism (n=4), 
diabetes mellitus (n=2), NSAID use (n=2), steroid use 
(n=3), childbirth (n=2) and malignancy (n=2). Twenty 
patients had one risk factor, nine had two risk factors 
and one each had three, four and five risk factors, 
respectively. No risk factors were identified in four 
patients. No risk factor data were available for four 
patients.
Length of ICU stay was provided for 21 cases, ranging 
from one to nine days (mean, 3.6 days; median, 3 days).
 
Other epidemiological information
Three cases (one with bacteraemia; one with 
bacteraemia and cellulitis; and one with STSS and 
peritonitis) were reported as hospital-acquired 
(compared to two in 2011). 
In 2012, one family outbreak of iGAS was notified 
(compared to none in 2011). In addition, there were two 
reported outbreaks of scarlet fever in 2012 (compared 
to one in 2011), and one reported outbreak of non-
invasive GAS infection (strep throat) in 2012 (compared 
to none in 2011). 
Outcome
Outcome at seven-days following GAS isolation was 
reported for 64 cases: 
• 55 were still alive 
•  Nine patients died: GAS was the main or contributory 
cause of death for eight patients 
The seven-day case fatality rate (CFR) for iGAS disease 
was 13% in 2012 (similar to that in 2011; 12%).
Of the twenty-six STSS cases, five patients died due to 
GAS resulting in a CFR of 19%.  Two other patients with 
STSS died but GAS was not identified as the cause of 
death.
Antimicrobial susceptibility
Antimicrobial susceptibility data were reported on 80 
iGAS isolates (72 from blood and eight from other 
specimens) by 20 laboratories in 2012 (note: these were 
reported via the EARS-Net Antimicrobial Resistance 
Surveillance Network). All isolates tested were 
susceptible to penicillin (n=78) and vancomycin (n=58).  
Resistance to erythromycin was reported in four (5%) 
of 80 isolates, to clindamycin in two (6%) of 34 isolates 
and to tetracycline in five (17%) of 29 isolates.
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Figure 3.  Cumulative monthly numbers of iGAS cases, 2008-2012
Conclusion
In 2012, 122 cases of iGAS infection were notified in 
Ireland, which is the highest annual number reported to 
date and represents an increase of 82% on 2011 (n=67). 
The crude incidence rate increased from 1.46 per 
100,000 population in 2011 to 2.66 per 100,000 in 2012 
and this was found to be statistically significant. 
iGAS is a potentially life-threatening disease with an 
overall case fatality rate (CFR) of 13%, and even higher 
CFR (19%) for patients presenting with STSS, in 2012.  
Last year, more patients presented with STSS than in 
previous years: 26 cases, comprising 23% of 111 cases 
for which clinical presentation was provided, the highest 
proportion reported to date.
Emm-typing was undertaken on a national basis for 
the first time in 2012 with the establishment of a GAS 
typing service by the Epidemiology and Molecular 
Biology Unit (EMBU), Children’s University Hospital, 
Temple Street. Laboratories were asked to submit 
all iGAS isolates for 2012, and 2011 if possible, for 
comparison purposes. In 2012, one emm-type, type 1.0 
(representing 50 of 108 isolates), comprised 46% of all 
isolates typed, compared with 29% (8 of 28 isolates) 
in 2011. Certain emm-types, including type 1.0, are 
associated with STSS, and STSS in turn is strongly 
associated with increased mortality. Although typing 
data were available for just 42% of isolates in 2011, it 
is likely that the large increase in iGAS cases in 2012 is 
in part at least due to the proliferation of GAS isolates 
belonging to emm-type 1.0. 
Ongoing surveillance is essential, specifically 
completion of the enhanced data questionnaire, to 
gain a greater understanding of iGAS, to enable early 
detection of clusters/outbreaks, to ensure prompt 
implementation of infection prevention and control 
precautions and appropriate management of contacts. 
Epidemiological typing as provided by the EMBU 
is another vital element to help us understand what 
is happening with GAS as certain emm-types are 
associated with greater morbidity and mortality. 
Antimicrobial susceptibility data confirm that iGAS 
remains susceptible to penicillin and that penicillin 
should continue to be the first line treatment where 
iGAS is suspected.  
HPSC would like to thank participating microbiology 
laboratories and public health departments for their 
contribution to the iGAS enhanced surveillance scheme. 
All microbiology laboratories are encouraged:
•  to return enhanced iGAS surveillance forms for all 
patients with iGAS 
•  to submit all iGAS isolates to the Epidemiology and 
Molecular Biology Unit (EMBU) at the Children’s 
University Hospital, Temple Street for emm-typing 
•  to submit antimicrobial susceptibility data on all iGAS 
cases along with their EARS-Net quarterly returns
The enhanced surveillance form can be downloaded 
from the HPSC web site at: www.hpsc.ie/hpsc/
A-Z/Other/GroupAStreptococcalDiseaseGAS/
SurveillanceForms/
Further information on iGAS disease in Ireland, 
including factsheets for patients and contacts, 
national guidelines and a new quarterly report, 
is available at: www.ndsc.ie/hpsc/A-Z/Other/
GroupAStreptococcalDiseaseGAS/
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Diseases Reporting (CIDR) System on 26th August 2013. 
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 Background
Invasive Group B streptococcal (iGBS; Streptococcus 
agalactiae) infections in infants <90 days old or 
stillborn infants have been notifiable in Ireland via the 
Computerised Infectious Diseases Reporting (CIDR) 
system since January 2012.
In neonates two syndromes exist:
•  Early-onset disease (EOD; age at onset/diagnosis <7 
days old)
•  Late-onset disease (LOD; age at onset/diagnosis 7-89 
days old)
Both include sepsis, pneumonia and meningitis. Stillbirth 
associated with isolation/detection of Streptococcus 
agalactiae from the placenta or amniotic fluid is also 
notifiable.
Notifications
In 2012, there were 77 iGBS cases, of which 58 and 
19 cases represented EOD and LOD, respectively 
(Figure 1). The EOD and LOD rates were 0.80 and 
0.26 per 1,000 live births, respectively (72,225 live 
births, CSO 2012 data obtained from http://www.
cso.ie/en/statistics/birthsdeathsandmarriages/
numberofbirthsdeathsandmarriages/) 
Nineteen cases presented with meningitis (meningitis 
was specifically mentioned as a case presentation for 11 
cases and inferred from eight cases where the specimen 
type tested included CSF).
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Diseases Reporting (CIDR) System on 23rd August 2013. 
2.4  Invasive Group B Streptococcal 
Infections
Summary
Number of cases, 2012: 77 
 • 58 cases of early-onset disease (EOD)
 • 19 cases of  late-onset disease (LOD)
EOD rate per 1,000 live births, 2012: 0.80
LOD rate per 1,000 live births, 2012: 0.26
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Figure 1. Number of cases of invasive Group B streptococcal infection by age at 
onset/diagnosis: early-onset disease (<7 days) and late-onset disease (7-89 days)
In 2011, 413 cases of tuberculosis (TB) were notified in 
Ireland, corresponding to a crude notification rate of 9.0 
per 100,000 population, which remains stable compared 
to 2010 (9.2/100,000 population). A summary of the 
epidemiology of TB in Ireland during 2011 is shown in 
table 1 while the number of cases and crude incidence 
rates from 1991 to 2012* with three-year moving 
averages are shown in figure 1. 
The highest crude incidence rates were reported 
by HSE-S (12.6/100,000 population) and HSE-E 
(11.6/100,000 population) while the lowest rates were 
reported by HSE-NW (5.0/100,000 population) and HSE-
NE (5.7/100,000 population). 
Cases ranged in age from one to 91 years of age, with 
a median age of 39 years. The highest age-specific 
rate in 2011 occurred among those aged 25-34 years 
(14.4/100,000 population) followed by those aged 65 
years and over (12.7/100,000 population). The rate 
among males (10.5/100,000 population) was higher 
than that among females (7.5/100,000 population). 
Rates among males were higher than females for all 
age groups except in the 0-14 year age group where 
the rate in males was lower (3.1/100,000 population 
in females compared to 0.8/100,000 population in 
males). The highest rate among males (18.5/100,000 
population) was in the group aged 65 years and 
older while the highest rate in females (12.7/100,000 
population) was in the 25-34 year age group. The male 
to female ratio (1.4:0.7) reported in 2011 was consistent 
with the ratio reported in previous years. 
2.5 Tuberculosis, 2011
Summary
Number of cases in 2011: 413
Crude incidence rate in 2011: 9.0/100,000
Number of cases in 2012*: 364
Crude incidence rate in 2012*: 7.9/100,000
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*Data for 2012 are provisional data which may change significantly following validation
Figure 1: Notified cases of TB in Ireland with crude rates per 100,000 population, 1991 to 2012* and 
3-year moving averages, 1992-2011
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Geographic origin
During 2011, 46.7% (193 cases) of TB cases were 
born outside Ireland. This is the highest proportion of 
foreign-born cases reported annually since TB enhanced 
surveillance began in 2002(range: 21.9%-43.3%). The 
crude rate in the foreign-born population increased 
slightly to 25.2 per 100,000 population, compared to 
22.3 per 100,000 population reported in 2010. The 
crude rate in the indigenous population was 5.7 per 
100,000 population, which decreased slightly compared 
to 6.5 per 100,000 population reported in 2010. There 
was a notable difference in age between those born in 
Ireland and those born outside Ireland, with a median 
age of 48 years and 32 years respectively. 
Site of infection 
Pulmonary TB was reported in 288 (69.7%) cases and 
122 (29.8%) had exclusively extrapulmonary disease. Of 
the extrapulmonary cases reported in 2011, there were 
two cases of TB meningitis corresponding to a rate of 
0.04/100,000 population (0.4/million population).
Microbiology
Of the 413 cases reported in 2011, 66.3% (274 cases) 
were culture confirmed. Of the 274 culture confirmed 
cases, species identification showed M. tuberculosis in 
92.7% (254 cases), M. tuberculosis complex‡ in 5.1% 
(14 cases) and M. bovis in 2.2% (6 cases). Of the 288 
cases with a pulmonary component, 214 (74.3%) were 
reported as culture confirmed, and 119 (41.3%) were 
reported as smear positive. 
Drug sensitivity 
Information on antibiotic sensitivity testing was available 
for 250 (91.2%) of the 274 culture confirmed cases. Of 
these, resistance was documented in 24 (9.6%) cases, 
three (0.7% of total cases) of which were MDR-TB cases. 
Mono-resistance to isoniazid was recorded in nine cases, 
to streptomycin in six and to pyrazinamide in one case. 
Further details on the resistance profiles of TB cases 
reported in 2011 will be available in the HPSC Report on 
the Epidemiology of TB in Ireland, 2011 (www.hpsc.ie).
Outcome
In 2011, information on treatment outcome was 
provided for 74.8% (309) of cases, a decrease compared 
to 88.1% in 2010. Treatment outcome was reported 
as completed for 243 (58.8%) cases, 28 (6.8%) cases 
died, 22 (5.3%) were lost to follow up, seven (1.7%) had 
treatment interrupted, six were still on treatment (1.5%) 
and two cases transferred out (0.5%). Nine (32.1%) of 
the 28 deaths were attributable to TB. During 2011, 
the reported treatment success rate was 65.6% for new 
culture confirmed pulmonary TB cases and 59.8% for 
new smear-positive pulmonary TB cases. 
Outbreaks 
The introduction of the amendment to the Infectious 
Disease Regulations 1981 on January 1st 2004, made 
outbreaks, unusual clusters or changing patterns of 
illness statutorily notifiable by medical practitioners and 
clinical directors of laboratories to the medical officer of 
health. Standard reporting procedures for surveillance 
of TB outbreaks were formally agreed in 2007. 
During 2011, five outbreaks of TB were reported to 
HSPC, with 38 cases of active TB, 15 with latent TB 
infection (LTBI) and 13 hospitalisations. Three outbreaks 
were reported by HSE-E, one by HSE-NE and one by 
HSE-S. There were three general outbreaks, one of 
which occurred in a school, one was associated with a 
public house and the remaining outbreak occurred in a 
prison. There were also two family outbreaks, both of 
which occurred across extended families. The number 
of outbreaks reported during 2011 remained stable 
in comparison to 2010, however the number of cases 
of LTBI reported as associated with the outbreaks 
decreased. Figure 2 shows a summary of TB outbreaks 
from 2004 to 2012 by year of outbreak, number of 
active TB cases and number of persons with LTBI. Please 
note that numbers of LTBI for outbreaks reported during 
2012 are provisional and may increase as outbreak 
investigations continue.
Provisional 2012 data
There were 364 cases of TB provisionally notified in 
2012, corresponding to a crude rate of 7.9 per 100,000 
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‡ Species of mycobacteria not specified
Table 1: Summary of the epidemiology of TB in Ireland, 2011
Parameter Number % of Total cases
Total number of cases 413
Crude notification rate per 100,000 9.0
Cases in indigenous population† 214 51.8
Cases in foreign-born persons† 193 46.7
Culture positive cases 274 66.3
Pulmonary cases 288 69.7
Smear positive pulmonary cases 119 28.8
Multi-drug resistant cases 3 0.7
Mono-resistant to isoniazid 9 2.2
Deaths attributable to TB 9 2.2
Outcomes reported in cases 308 74.6
TB meningitis cases 2 0.5
†Country of birth was unknown for 6 cases
population. It is important to note that these data are 
provisional and may change significantly following 
validation. 
Of the 364 cases provisionally notified in 2012, 
•  Pulmonary TB was diagnosed in 220 cases (60.4%), 
extrapulmonary TB in 105 cases (28.8%) and 
pulmonary and extrapulmonary TB in 31 cases (8.5%). 
Diagnostic type was not reported for eight cases 
(2.2%).
•  Of the 251 cases with a pulmonary disease 
component, 209 (83.3%) were culture positive and 116 
(46.2%) were smear positive.
•  There were three cases of TB meningitis provisionally 
notified corresponding to a rate of 0.07 per 100,000 
population (0.65/million population).
•  There were 201 (55.2%) cases born in Ireland and 158 
(43.4%) were foreign-born. Country of birth was not 
reported for 5 (1.4%) cases.
•  There were 145 cases (39.9%) notified in females and 
218 cases (60.1%) in males. 
•  The mean age of cases was 43.2 years (range: 0 to 90 
years).
•  Resistance was reported in 21 cases, 10 of which were 
mono-resistant to isoniazid. Five cases of MDR-TB 
were reported during 2012. Fifteen (71.4%) of the 21 
resistant cases (including all five MDR cases) were born 
outside Ireland. 
•  There were seven TB outbreaks reported to HPSC 
during 2012, with 23 active TB cases, four cases of 
latent TB infection and 6 hospitalisations. No deaths 
were reported from these outbreaks. Please note 
that numbers of LTBI for outbreaks reported during 
2012 are provisional and may increase as outbreak 
investigations continue.
Further details on the epidemiology of TB cases 
reported in 2011 will be available in the HPSC Report on 
the Epidemiology of TB in Ireland, 2011 (www.hpsc.ie). 
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Figure 2: TB outbreak summary by year, 2004-2012
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Chickenpox-hospitalised cases
The Health Act, 1947 entitles the Minister for Health and 
Children to specify by regulation diseases that are infectious, 
covered by legislation and that require notification to a 
medical officer of health.  The infectious diseases notifiable 
in Ireland are regulated in the 1981 Infectious Diseases 
Regulations. The amendment S.I. No. 452 of 2011 to these 
regulations specified for the first time the disease chickenpox 
(hospitalised cases only) as notifiable.  Chickenpox is caused 
by varicella-zoster virus. The case definition is available at 
www.hpsc.ie. 
In 2012, 80 (1.7/100,000) hospitalised chickenpox cases 
were notified in Ireland.  The largest number of cases and 
largest crude incidence rate was in the HSE-E (table 1).  Of 
the 80 cases, 57 (71%) were classified as confirmed and 23 
(29%) as possible.  The largest number of cases and the 
highest age specific incidence rate was in the age group one 
to two years (figures 1 and 2).  Of the 80 cases, 50 (63%) 
were male, 29 (36%) were female while gender was not 
reported for one case.
Chickenpox/Varicella outbreaks
The amendment S.I. No. 707 of 2003 to the infectious 
disease regulations specified that unusual clusters or 
changing patterns of illness that may be of public health 
concern must be reported.  Therefore, outbreaks of 
chickenpox must be notified regardless of hospitalisation 
status.  One outbreak of chickenpox was notified in 2012.  
This outbreak occurred in a crèche with 23 ill.
The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 30th July 2013.  These figures 
may differ slightly from those published previously due to 
ongoing updating of notification data on CIDR.
2.6 Chickenpox-hospitalised cases
Summary
Number of cases, 2012: 80
Number of confirmed cases, 2012: 57
Crude incidence rate, 2012: 1.7/100,000
Crude confirmed incidence rate, 2012: 1.2/100,000
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Figure 1. Number of notified hospitalised chickenpox cases in 
2012 by age group and case classification
Figure 2. The age specific incidence rate (per 100,000 
population) of notified hospitalised chickenpox cases in 2012 
by case classification
Table 1. Number of notified hospitalised chickenpox cases and the 
crude incidence rate per 100,000 population (CIR) by HSE Area in 
2012
HSE Area Number CIR
HSE-E 43 2.7
HSE-M 2 0.7
HSE-MW 4 1.1
HSE-NE 7 1.6
HSE-NW 1 0.4
HSE-SE 11 0.9
HSE-S 6 2.2
HSE-W 6 1.3
Total 80 1.7
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Infectious Intestinal Diseases
03
Campylobacteriosis became a notifiable disease 
in Ireland in 2004 under the Infectious Diseases 
regulations. Prior to this, data on laboratory-confirmed 
cases of Campylobacter infection in humans were 
collected nationally as part of the EU Zoonoses 
Regulations (while some cases were included in the 
former category of “Food Poisoning (bacterial other 
than Salmonella)”). It is an acute zoonotic bacterial 
disease characterised by diarrhoea, abdominal pain, 
malaise, fever, nausea and vomiting. Symptoms 
generally last for only a few days. Campylobacteriosis 
is the commonest bacterial cause of gastroenteritis in 
Ireland and Europe. In the EU it is estimated that 9.2 
million cases occur annually, resulting in a public health 
impact of 0.35 million disability adjusted life years 
(DALYs) per year and an annual cost of approximately 
€2.4 billion.1
During 2008, a European Union-wide baseline survey of 
Campylobacter in broiler batches and broiler carcasses 
was carried out by The European Food Safety Authority 
(EFSA). This survey found that 75.8% of broiler carcasses 
sampled were contaminated with Campylobacter while 
98% of Irish broiler carcasses sampled were positive 
for Campylobacter.2 EFSA currently estimates that 
handling, preparation and consumption of broiler meat 
may account for 20-30% of human campylobacteriosis 
while 50-80% of cases may be attributed to the broiler 
reservoir as a whole.3 The importance of poultry meat 
as a source of human Campylobacter infection was 
supported by the food-borne outbreak data reported 
to EFSA during 2011, where 56.7% of food-borne 
outbreaks of campylobacteriosis (with strong evidence 
and a specified food item) were poultry related.4  In 
response to such evidence, the food Safety Authority 
of Ireland (FSAI) published “Recommendations for a 
Practical Control Programme for Campylobacter in the 
Poultry Production and Slaughter Chain” during 2011.5
Findings of an all-Ireland case control study that 
investigated risk factors for sporadic Campylobacter 
infections, showed that consuming chicken and lettuce, 
and eating in takeaways were important risk factors for 
3.1 Campylobacter 
Summary
Number of cases: 2,388
Crude incidence rate: 52.0/100,000
-52-HPSC Annual Report 2012 3. Infectious Intestinal Diseases
Figure 1: Campylobacteriosis 2012 CIR compared to 2004-2011 mean CIR by HSE area (CIDR)
contracting the disease in Ireland. Contact with sheep, 
peptic ulcer, hiatus hernia and lower bowel problems 
were also independently associated with infection. 
However mains water supply showed protective effect 
from contracting the illness.6
During 2012, levels of campylobacteriosis remained 
elevated with 2,388 notifications reported to HPSC. 
This corresponded to a crude incidence rate of 
52.0/100,000 population, which is comparable with the 
2011 European crude incidence rate of 50.3 per 100,000 
population.7 
Historically, variation in campylobacteriosis crude 
incidence rates (CIRs) has been reported between HSE 
areas. During 2012, the highest CIRs occurred in HSE-M 
(66.2/100,000 population) and HSE-MW (64.3/100,000 
population). The lowest CIR was reported by HSE-W 
(38.8/100,000 population), which was the only region 
during 2012 where the CIR decreased in comparison 
to the mean rate for 2004 to 2011. However it is 
important to note that due to resource constraints, 
University College Galway Hospital ceased testing 
for Campylobacter for between late June 2012 and 
mid-January 2012 which has likely affected rates in 
the western part of the country. Figure 1 compares 
the campylobacteriosis CIRs in 2012 with the mean 
campylobacteriosis incidence rates for 2004 to 2011 by 
HSE area. 
Campylobacteriosis occurs in all age groups with the 
highest rate of notification reported in the 0-4 year 
age group. This preponderance in younger children 
is a well described characteristic of the disease and is 
also observed at European level. The highest European 
notification rate during 2010 was reported in males in 
the 0-4 year age group (155.5/100,000 population).7
In Ireland between 2004 and 2011, the highest mean 
ASIR occurred in the 0-4 year age group (155.8/100,000 
population) followed by the 25-34 year age group 
(40.6/100,000 population) and the 5-14 year age group 
(38.8/100,000 population). A comparison of the mean 
age-specific incidence rate between 2004-2011 and the 
number of notifications in 2012 showed an increase of 
>40% in the 15-24 year age group (42.7%) and those 
aged 65 years and older (41.6%). Figure 2 compares the 
campylobacteriosis age specific rates (ASIR) for 2012 
with the mean campylobacteriosis ASIR for 2004 to 
2011. 
During 2012, 44.8% of all cases were male, 55.2% of 
cases were female and sex was not reported for 0.2% 
of cases. Further analysis of the age-sex distribution of 
campylobacteriosis cases shows that the highest ASIRs 
for both males and females were observed in the 0-4 
year and 20-24 year age groups. 
Campylobacteriosis has a well documented seasonal 
distribution with a peak in summer. In Ireland, 
campylobacteriosis notifications typically peak during 
May to August. While there was the usual warm-
season peak in campylobacteriosis notifications in 
2012, large increases were also seen outside this 
period. A comparison of the mean monthly number of 
notifications between 2004 and 2011 and the monthly 
number of notifications in 2012 showed an increase of 
>50% in February (93.9%) and August (65.8%). Figure 
3 compares the monthly number of campylobacteriosis 
notifications for 2012 to the mean monthly number of 
campylobacteriosis notifications between 2004 and 
2011. 
Of the cases notified in Ireland during 2011, 99.9% were 
laboratory confirmed. However, as there is currently 
no national reference facility for routine typing of 
Campylobacter isolates, information on Campylobacter 
species is strikingly incomplete. In 2012, 36.2% (n=864) 
of isolates were speciated. Of the 864 speciated 
isolates, 90.7% of isolates were C. jejuni, 8.9% were 
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Figure 2: Campylobacteriosis ASIR 2012 compared to 2004-2011 mean ASIR (CIDR)
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C. coli and 0.3% were C. lari. The remaining 63.8% 
(n=1,523) of Campylobacter isolates identified were 
not further speciated. This compares with 51.8% of 
Campylobacter isolates in Europe reported to ECDC 
during 2010 remaining unspeciated.7 
During 2012, there were four outbreaks of 
campylobacteriosis reported to HPSC with 13 associated 
cases of illness, one of whom was hospitalised. This is 
slightly lower than the average number of outbreaks per 
annum between 2004 and 2011. All four outbreaks were 
family outbreaks occurring in private houses, as is typical 
of previous years. Two reported mode of transmission 
as food-borne while mode of transmission was unknown 
for the remaining two outbreaks. During 2011, 16 
European countries reported 596 food-borne outbreaks 
of campylobacteriosis which accounted for 10.6% of the 
total food-borne outbreaks reported to EFSA. These 
outbreaks comprised 1,205 associated cases of illness 
and 191 hospitalisations.4
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Figure 3: Campylobacteriosis notifications by month during 2012 compared to mean monthly 
notifications 2004-2011 (CIDR)
Table 1: Campylobacteriosis outbreaks summary, 2012 (CIDR)
Mode of transmission Outbreak location Number outbreaks Number ill Number hospitalised Number dead
Food-borne Private house 2 8 0 0
Unknown Private house 2 5 1 0
Total 4 13 1 0
Cryptosporidium is a protozoal parasite that causes a 
diarrhoeal illness in humans known as cryptosporidiosis. 
It is transmitted by the faecal-oral route, with both 
animals and humans serving as potential reservoirs. 
Human cryptosporidiosis became a notifiable disease 
in Ireland in 2004, and the case definition in use is 
published on the HPSC website. 
In 2012, 556 cases of cryptosporidiosis were notified 
in Ireland, a crude incidence rate (CIR) of 12.12 per 
100,000 population (95% CI 11.11-13.13), with 40% of 
notified cases reported as hospitalised for their illness. 
There were no reported deaths.
This was a 30% increase on the number of cases notified 
in 2011 (Figure 1), the third highest annual crude 
incidence rate since the disease became notifiable in 
2004. In 2010 (the most recent year for which data are 
available), the ECDC reported an incidence rate overall 
of 2.29 per 100,000 population in the European Union, 
with Ireland reporting the second highest rate among 
those countries reporting on this disease at the time.1 
The highest incidence rate among EU Member States in 
2010 was reported by the United Kingdom at 7.37 per 
100,000.
Consistent with previous years, the highest reported 
incidence was in children under 5 years, with around 85 
cases per 100,000 population in this age group (Figure 
2). While there is likely to be a bias towards testing of 
diarrhoeal stool specimens from children (as opposed 
to adults) for Cryptosporidium, it is also likely that this 
distribution reflects to some extent a true difference in 
risk between adults and children.
The crude incidence (CIR) rates by HSE area for 2012 
are reported in Figure 3. As in previous years, there 
was a strong urban-rural divide, with the HSE-E having 
a much lower reported incidence rate (2.1 per 100,000) 
than all other HSE areas. The HSE- MW and HSE-W 
reported the highest crude incidence rates this year 
(22.41 and 22.0 per 100,000 respectively). Compared to 
2011, all areas except HSE-W reported increased rates.
As in previous years, the highest number of cases was 
recorded in spring (Figure 4), although the number 
of cases from August onwards was slightly elevated 
compared to the same time period in previous years. 
Risk factors
Reviewing case-based enhanced surveillance data, 
exposure to farm animals or their faeces either by virtue 
of residence on a farm or by visiting a farm during the 
3.2 Cryptosporidiosis
Summary
Number of cases, 2012: 556
Number of cases, 2011: 428
Crude incidence rate, 2012: 12.12/100,000
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Figure 1: Annual number and crude incidence rate 
cryptosporidiosis, Ireland 2004-2012      
Figure 2: Age-specific incidence rate cryptosporidiosis, Ireland 
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potential incubation period were common among cases; 
32.4% and 32.0% reported these exposures respectively 
(Table 1). This is consistent with the low incidence of 
cryptosporidiosis among residents in the largely urban 
HSE-E population and the higher incidence recorded in 
more rural parts of the country. 
Unlike salmonellosis, foreign travel plays only a minor 
role in cryptosporidiosis in Ireland (Table 1), with the 
majority of infections acquired indigenously (92.5%). 
Although, like the United Kingdom, a higher proportion 
of cases from late summer/early autumn were reported 
as being acquired abroad (Figure 5).
Table 2 shows the distribution of notified cases by home 
water supply type. It appears that persons who are not 
served by public water supplies have an increased risk 
of cryptosporidiosis as they are over-represented among 
the cases relative to the distribution of households 
by water supply type nationally; this was particularly 
noticeable for private well users. However, it should be 
borne in mind that persons whose household drinking 
water is not from a public supply are more likely to be 
rural dwellers who may also have a higher likelihood of 
exposure to farm animals and rural environments which 
is also likely to increase their risk. 
Outbreaks
In 2012, there were three general and 21 family 
outbreaks in total (Figure 6). The increase in the 
number of outbreaks in 2011 and 2012 is most likely 
due to increased recognition of small family outbreaks 
following the introduction of enhanced surveillance for 
cryptosporidiosis cases late in 2010. 
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Figure 3: Regional crude incidence rates cryptosporidiosis, 
Ireland 2009-2012. 
Figure 4. Seasonal distribution of cryptosporidiosis cases, 
Ireland 2012 compared to the mean for 2009-2011 
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Table 1: Number of cases (and percentage of cases where information available) where selected risk factors were reported for 
cryptosporidiosis cases, Ireland 2012
Risk factor Yes (% of known) No Unknown Not Specified Total
Travel 36 (7.5%) 442 4 74 556
Lives/cared for on farm 143 (32.4%) 299 11 103 556
Visited farm 2132 (32.0%) 280 5 139 556
Lives/works on or visited farma 250 (58.8%) 175 11 120 556
Swimming pool visit 112 (25.2%) 332 7 105 556
Pets 281 (64.4%) 155 6 114 556
Other water based activities 19 (5.1%) 356 8 173 556
aComposite of 2 previous variables
Table 2: Number of cases (and percentage of cases where information available) by home water supply type compared to the 
number and percentage of households in Ireland by water supply type, Ireland 2012. 
Home water supply of 
notified cases
Number of 
cases
% of known
No. households served by these 
water supply types in the general 
population 2011 (Census 2011)
% of known
Fishers exact P 
value
Group water scheme (private) 18 3.8% 45,774 2.9%
P<.001
Group water scheme (public) 45 9.8% 144,428 9.0%
Other 1 0.2% 2,080 0.1%
Private well 114 24.4% 161,532 10.1%
Public water supply 290 62.0% 1,247,185 77.9%
Unknown 7
Not specified 81 48,409
Total 556 100% 1,649,408 100%
Comparing the proportion of cases and households served by public water supplies versus all other supply types: X2=78.3, P<.001
The most common mode of transmission reported in 
2012 was person-to-person spread (eight outbreaks due 
solely to person-to-person transmission resulted in 16 
illnesses), with animal contact being the second most 
common transmission route reported (contact with 
animals contributed to transmission in four outbreaks 
resulting in 17 cases) (Table 3 and Figure 7). 
The twenty-one family outbreaks ranged in size from 
two to five persons ill, and the majority occurred 
in private households, with one reported as being 
associated with travel to Spain. Among the three 
general outbreaks reported, one was waterborne, one 
was due to animal contact and one was reported to be 
transmitted by person-to-person spread. 
For the general waterborne outbreak, 12 confirmed 
cases were reported, three of whom were hospitalised. 
A public water supply was implicated on the basis 
of strong descriptive epidemiological evidence, and 
evidence of failure of the water treatment process; 
Cryptosporidium was found in the treated drinking 
water; however the strain identified was not the same 
species as identified in human cases. Remedial action 
was taken at the water treatment plant. 
The second general outbreak occurred among 
third level students and was reported to be due to 
animal contact on a farm.  Six students reported 
gastrointestinal symptoms, one of whom required 
hospitalisation, and four were confirmed as having 
cryptosporidiosis. The students spent several days 
on the farm studying livestock skills. While the farm 
included a variety of animal species, the most likely 
cause of the outbreak was contact with calves that were 
reported to have had diarrhoea. 
In the third general outbreak, person-to-person spread 
in a hospital setting resulted in an outbreak with two 
persons ill.
Summary
The crude incidence of cryptosporidiosis in Ireland in 
2012 was the highest since 2007, with a 90% increase 
in incidence over the last two years. However, the 
seasonal, age and regional distribution in incidence 
reported in 2012 was typical of previous years; 
consistently there has been a higher incidence in 
springtime, in young children and in non HSE-E areas. 
Increases in incidence were also reported in the United 
Kingdom, Germany and the Netherlands in 2012, 
particularly in the latter part of the year; these were 
attributed to a range of possible factors including 
climatic drivers, such as the increased rainfall in 
the summer of 2012 in these countries, or a widely 
distributed commonly consumed product. 2
Person-to-person spread appears to be an important 
mode of transmission within family outbreaks, while 
both enhanced surveillance data and outbreak 
surveillance data are consistent with animal contact 
Figure 5. Seasonal distribution of cryptosporidiosis cases by 
Country of Infection, Ireland 2012
Figure 6: Number of cryptosporidiosis outbreaks notified by 
type, Ireland 2004-2012
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Table 3: Number of outbreaks, number ill and number 
laboratory-confirmed cases by transmission route, Ireland 2012
Transmission mode
Number of 
outbreaks
Total 
number ill
Number lab 
confirmed
Animal contact 3 12 8
Person-to-person 8 16 13
P-P and Animal 1 5 2
P-P and Waterborne 2 4 2
Waterborne 1 12 12
Unknown 8 20 16
Not Specified 1 2 -
Total 24 71 53
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being an important risk factor for cryptosporidiosis in 
Ireland. Unlike in the United Kingdom, travel-associated 
disease is reported infrequently, and is likely to be a 
minor contributor to transmission, as is transmission 
associated with food or swimming pools. 
While there have been fewer general waterborne 
outbreaks reported between 2008 and 2012 relative 
to earlier years, exposure to water from non-public 
supplies may present a higher risk of cryptosporidiosis; 
from the enhanced dataset, persons who are not served 
by public water supplies were over-represented among 
the cases relative to the distribution of households 
by water supply type nationally. The EPA drinking 
water reports provide information on improvements 
in the public water supply sector in relation to 
Cryptosporidium.3
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Note: In this figure, reported transmission routes were grouped for 
simplicity. Any outbreak where food contributed was reported as 
foodborne, any outbreak where water contributed was reported as 
waterborne, any outbreak where animal contact contributed was 
reported as Animal contact. Person-to-person outbreaks include only 
those outbreaks reported as being due only to person-to-person 
transmission.
Figure 7: Number of cryptosporidiosis outbreaks notified by 
reported transmission route, Ireland 2004-2012
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Introduction
The reported verotoxigenic E. coli (VTEC) incidence rate 
in Ireland is generally high relative to other European 
countries. In 2011 (the latest year for which data are 
published), the overall VTEC incidence rate in the 
European Union was 1.93 per 100,000.1 For several 
years, Ireland has reported the highest VTEC incidence 
rate of any Member State in the EU, although Germany 
reported the highest rate in 2011 due to the large VTEC 
O104 outbreak linked with fenugreek seeds.2-3 
The dominant transmission routes reported for VTEC 
infection in Ireland have been person-to-person spread, 
especially in childcare facilities and among families with 
young children, and waterborne transmission associated 
with exposure to water from untreated or poorly treated 
private water sources. 4-7 Other important transmission 
routes identified internationally include food (often 
minced beef products or fresh produce such as lettuce 
and spinach), and contact with infected animals or 
contaminated environments.3, 8-10
Materials and Methods
Infection with verotoxigenic E. coli became a notifiable 
disease in 2012; prior to that VTEC were notifiable 
under the category Enterohaemorrhagic E. coli (EHEC) 
since 2004. Enhanced epidemiological information was 
supplied as in previous years by HSE personnel, and 
the National VTEC Reference Service  at the Public 
Health Laboratory HSE Dublin at Cherry Orchard 
Hospital (-PHL-Dub.) provided the VTEC confirmation 
and typing data. Data from all sources are maintained in 
the Computerised Infectious Disease Reporting (CIDR) 
system. Outbreaks of VTEC are notifiable since 2004 
and data are provided to CIDR by regional public health 
departments. 
Data from the CSO 2011 census were used to provide 
denominators for the calculation of national, regional 
and age-specific incidence rates in 2012.
Results
Incidence
In 2012, there were 554 notifications of VTEC, equating 
to a crude incidence rate (CIR) of 12.07 per 100,000 
(95% CI 11.07-13.08). This compares to an overall rate 
of 6.2 per 100,000 in 2011, an increase of 96%. 408 
notifications in 2012 were reported as confirmed cases 
(CIR 8.89 95% CI 8.03-9.76), 144 were probable and 
there were two cases reported in the new possible 
case class. The criteria under which notified cases 
were reported in 2012 under the VTEC case definition 
is outlined in Table 1. As the classification of VTEC 
cases changed significantly upon the amendment of 
the Irish VTEC case definition in 2012, it is not valid to 
directly compare the number of notifications by case 
classification with previous years. 
Of the 535 cases with laboratory evidence of infection, 
229 cases were reported as being infected with E. coli 
3.3 Verotoxigenic E. coli 
Summary
Number of VTEC cases, 2012: 554
Crude incidence rate, 2011: 12.07/100,000
Number of VTEC-associated HUS 2012: 32
Number of VTEC cases, 2011: 283
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Table 1. Number of VTEC notifications by criteria for notification, Ireland 2012 
Notification criteria Confirmed Probable Possible Total
Culture confirmationa 382 122 504
Laboratory confirmation by PCRb 24 5 29
Serodiagnosis (valid for HUS only) 2 2
Reported solely on the basis of epidemiological link 17 17
Clinical HUS not meeting laboratory or epidemiological criteria 2 2
Total 408 144 2 554
a Symptomatic culture confirmed cases are classified as confirmed cases, while asymptomatic culture confirmed cases are classified as probable 
cases
b  Symptomatic PCR-confirmed cases are classified as confirmed cases, while asymptomatic PCR-confirmed cases are classified as probable 
cases
O157 (5.0 per 100,000 (95% CI 4.3-5.6), 207 with E. coli 
O26 (4.5 per 100,000 (95% CI 3.9-5.1), 91 with other 
VTEC strains, and 8 cases had mixed VTEC infections, 
being infected with more than one VTEC strain. Of 
the 17 probable cases reported on the basis of an 
epidemiological link to a confirmed case, 8 were linked 
to E. coli O157 outbreaks, and 9 were linked to E. coli 
O26 outbreaks. Figure 1 illustrates the distribution of 
VTEC cases in Ireland by serogroup since 1999. The 
serogroup distribution this year represents a 16% 
increase in O157 infections and a 315% increase in 
non-O157 infections compared to 2011.
Severity of illness
Four hundred and twenty eight of the 554 notified 
cases were symptomatic (77.3%), 151 (35.3%) of which 
developed bloody diarrhoea (42.5% when only cases 
with this variable completed are included). Thirty-two 
individuals (5.8%) developed HUS, an increase of 68% 
on 2011. No deaths were reported, however one HUS 
case developed long-term sequelae. Where reported 
(n=504), 159 (31.5%) of notified cases were hospitalised 
(37.1% of symptomatic cases). 
Thirteen HUS cases were infected with E. coli O157, 
with a further HUS case epidemiologically linked to an 
E. coli O157 outbreak. Nine had laboratory evidence 
of VTEC O26 infection, with a further two HUS cases 
epidemiologically linked to E. coli O26 outbreaks. One 
had a mixed VTEC O26/O145 infection, two had VTEC 
O145 infections and two were infected with other VTEC 
strains. The remaining two HUS cases were reported as 
possible VTEC notifications (table 2).
Seasonal distribution
Figure 2 shows the seasonal distribution of notifications 
in 2012 relative to the mean monthly number of cases in 
the years 2009-2011. Despite the very large increase in 
the number of notifications, the typical summer seasonal 
peak was maintained - albeit possibly slightly earlier 
than usual - with the highest number of cases being in 
August. 
There was variation in the seasonal distribution by 
serogroup, with VTEC O157 showing the typical peak 
in numbers in late summer; in contrast, VTEC O26 
notifications peaked in June during 2012 (figure 3).
Regional distribution
The highest VTEC incidence rates were reported in the 
HSE-M followed by the HSE-MW and the HSE-S, where 
the rates were two to two and half times the national 
crude rate (Table 3). The HSE-E reported the lowest 
overall crude incidence rate (Table 3), followed by the 
HSE-SE and HSE-NE. The rate of VTEC associated HUS 
in the HSE-M was also higher than all other areas, and 
was six times the national rate. Over one third of all 
VTEC-associated HUS cases in 2012 were reported in 
HSE-M.
In 2012, the national annual incidence rate for non-O157 
infections exceeded the rate for VTEC O157 infections 
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Figure 1. Annual number of VTEC cases by serogroup, Ireland 
1999-2012
Note: For simplicity in this figure, cases with mixed VTEC O157/other 
serogroup infections are included in the data for O157, as are probable 
cases linked to known E. coli O157 outbreaks. Non-O157 data includes 
cases with mixed non-O157 infections and probable cases linked to 
known O26 outbreaks
Figure 2. Seasonal distribution of VTEC notifications, Ireland 
2012 compared to the mean number of notifications 2009-
2011
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Table 2. Number of VTEC notifications by infecting serogroup and HUS status, Ireland 2012 
Serogroup HUS non-HUS Total
O157 or epi-linked to O157 outbreak 14 223 237
O26 or epi-linked to O26 outbreak 11 205 216
Other 5 94 99
No organism 2 0 2
Total 32 522 554
for the first time; when reviewed by HSE-area, the 
crude rate for non-O157 infections was higher than for 
VTEC O157 in five HSE-areas (Table 3; Figure 4). This 
geographic variation in serogroup distribution is likely to 
have been influenced by regional variation in diagnostic 
practices.
Laboratory typing
In 2012, the serogroup and verotoxin profiles of VTEC 
isolates referred to the PHL HSE Dublin Mid Leinster, 
Cherry Orchard Hospital are displayed in Table 4. The 
most common serogroup reported was VTEC O157, 
followed by VTEC O26. Among the other serogroups 
listed by the WHO as having the highest association 
with HUS internationally, there were six VTEC O103 
cases, six VTEC O111 and 24 VTEC O145.
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Figure 3: Seasonal distribution of VTEC notifications by 
serogroup, Ireland 2012
Table 3. Number and crude incidence rate VTEC by serogroup and HSE area, and number and crude incidence rate VTEC-asso-
ciated HUS by HSE-area, Ireland 2012
HSE-area a Number [CIR (95% CI)] VTEC 
O157 b
Number [CIR (95% CI)] 
non-O157 VTEC c
Number [CIR (95% CI)] all 
VTEC d
Number [CIR (95% CI)] VTEC-
associated HUS
East 40 [2.5 (1.7-3.2)] 15 [0.9 (0.5-1.4)] 55 [3.4 (2.5-4.3)] 4 [0.3 (0.0-0.5]
Midlands 34 [12.0 (8.0-16.1)] 48 [17.0 (12.2-21.8)] 82 [29.0 (22.8-35.3)] 12 [4.3 (1.85-6.7)]
Mid-West 18 [4.8 (2.6-6.9)] 69 [18.2 (13.9-22.5)] 87 [22.9 (18.1-27.8)] 3 [1.8 (-0.1-1.7)]
North-East 30 [6.8 (4.4-9.2)] 1 [0.2 (-0.2-0.7)] 31 [7.0 (4.6-9.5)] 2 [0.5 (-0.2-1.1)]
North-West 13 [5.0 (2.3-7.8)] 24 [9.3 (5.6-13.0)] 38 [14.7 (10.0-19.4)] 2 [0.8 (-0.3-1.9)]
South-East 18 [3.6 (2.0-5.3)] 5 [1.0 (0.1-1.9)] 23 [4.6 (2.7-6.5)] 2 [1.4 (-0.2-1.0)]
South 58 [8.7 (6.5-11.0)] 91 [13.7 (10.9-16.5)] 150 [22.6 (19.0-26.2)] 6 [0.9 (0.2-1.6)]
West 30 [6.7 (4.3-9.2)] 58 [13.0 (9.7-16.4)] 88 [19.8 (15.6-23.9)] 1 [0.2 (-0.2-0.7)]
Ireland 241 [5.3 (4.6-5.9)] 311 [6.8(6.0-7.5)] 554 [12.1 (11.1-13.1)] 32 {0.7 (0.5-0.9)]
a Rates per 100,000 calculated using CSO census 2011 for denominator data
b For simplicity, cases with mixed VTEC O157/other serogroup infections are included in the data for O157, as are probable cases linked to 
known E. coli O157 outbreaks. 
c Non-O157 data includes cases with mixed non-O157 infections and probable cases linked to known O26 outbreaks. 
d  Possible cases (i.e. those with no associated organism are also included in this column), and therefore the total in this column will not always be 
the sum of the previous two columns.
Table 4. Serotype and verotoxin (VT) profiles for strains associated with laboratory confirmed VTEC cases, as determined at the 
PHL HSE Dublin Mid Leinster, Cherry Orchard Hospital in 2012 
Serogroup VT1 VT1+VT2 VT2 Not applicable Total
O157 37 190 2 a 229
O26 83 104 20 207
Ungroupable 17 9 14 40
O145 1 23 24
O103 2 2 2 6
O111 5 1 6
O146 1 1 1 3
O182 3 3
O130 2 2
O55 2 2
O104 1 1
O121 1 1
O153 1 1
O166 1 1
O84 1 1
Mixed serogroup 4 4 8
Total 118 155 260 2 535
aNo vt type for two VTEC O157 cases as diagnosed by serodiagnosis
As usual among VTEC O157 in Ireland, isolates 
containing the genes for verotoxin 2 (vt2) were more 
common (84%) than strains containing both vt1 and vt2. 
VTEC O26 strains containing only vt1 made up 40% of all 
VTEC O26 reported, with 50% of VTEC O26 containing 
the genes for both vt1 and vt2, and those containing vt2 
making up the remaining 10% of VTEC O26. 
Risk factors
Under enhanced surveillance for VTEC, risk factor 
information is routinely collected on VTEC notifications 
(Table 5).
Exposure to farm animals or their faeces and exposure 
to private well water were relatively common among 
cases; 45.5% and 46.6% reported these exposures 
respectively. This is consistent with the low incidence 
of VTEC infection among residents in the largely urban 
HSE-E population and the higher incidence recorded in 
more rural parts of the country. According to CSO data, 
in the general population, around 10.1% of households 
are served by private wells, indicating that, on a national 
basis, exposure to private wells is likely to be more 
common among VTEC cases than among the general 
population.
Unlike salmonellosis, foreign travel plays only a minor 
role in VTEC infection in Ireland, with the overwhelming 
majority of infections acquired indigenously. 
Where the information was available, around a quarter of 
VTEC cases in 2012 were reported to attend a Childcare 
Facility (CCF). When these analyses were restricted to 
notified VTEC under five years of age, half reported 
attendance at a childcare facility. This is slightly higher 
than the proportion of children in the general population 
who use non-parental childcare (42%) as reported by the 
Central Statistics Office. 19
Outbreak and environmental investigations
The outbreak surveillance system plays a key role in our 
understanding of VTEC transmission in Ireland. Ninety-
seven VTEC outbreaks were notified in 2012, which 
included 334 of the 554 VTEC notifications. 47 outbreaks 
were due to VTEC O157, 39 to VTEC O26, two were 
mixed VTEC strain outbreaks, and nine were caused by 
other VTEC strains. 
The majority of outbreaks (82%) were family outbreaks, 
with seventeen general outbreaks notified. The 80 family 
outbreaks resulted in 156 persons becoming ill, an 
average of 2.0 (range 1-6) persons ill per outbreak, while 
the seventeen general outbreaks resulted in 126 persons 
becoming ill, an average of 7.4 (range 1 to 30) persons ill 
per outbreak. 
The suspected modes of transmission are listed in Table 6.
Person-to-person spread is consistently the most 
common mode of VTEC transmission reported in 
Ireland, particularly between young children, and was 
suspected to have played a role in 34 (35%) VTEC 
outbreaks in 2012 in which 111 persons were reported ill 
(Table 6 and Figure 5). Twenty seven of these outbreaks 
were reported as being solely due to person-to-
person transmission, including seven of the outbreaks 
associated with CCFs. 
The second most common transmission route reported 
was waterborne transmission, which was reported to 
have contributed to 21 outbreaks (22%) with 83 persons 
ill. Four were general outbreaks and 17 were family 
outbreaks; these 21 outbreaks were linked to 17 private 
wells, one water scheme serving a private housing 
development, two group water schemes and exposure 
to river water. Microbiological evidence was obtained 
in ten outbreaks, where an indistinguishable strain 
was identified in both the implicated water supply and 
among the outbreak cases. For two further outbreaks, 
VTEC other than that identified in the outbreak cases 
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Figure 4: Crude incidence rate VTEC O157 and non-O157, 
Ireland 2012
Table 5. Number of cases of VTEC (and percentage where known) for selected risk factors, Ireland 2012
Risk factor Number ‘Yes’ and % where 
reported
Number ‘No’ and % where 
reported
Number where risk factor was 
unknown or not reported
Food suspected 28 (8.8%) 287 (92.2%) 239
Exposure to farm animals or their faeces 195 (45.5%) 233 (54.5%) 126
Exposure to private well watera 207 (46.6%) 237 (53.4%) 110
Travel-associatedb 13 (2.8%) 451 (97.2%) 90
Attendance at a CCFc 101 (25.8%) 291 (74.2%) 162
Attendance at a CCFc (among <5 yrs) 95 (50.5%) 93 (49.5%) 61
aComposite variable recoded from two different water supply exposure enhanced variables in CIDR
bInferred from CIDR core variable Country of Infection
c Childcare Facility
were found in the implicated supply. Evidence was 
circumstantial for water supplies suspected in 8 further 
drinking water associated outbreaks, and for one 
outbreak suspected to be associated with exposure to 
river water.
Three outbreaks (four person ill in total) were reported 
as being suspected to be foodborne; no definitive 
evidence was reported implicating any food vehicles, 
although one outbreak which was foreign travel 
related was suspected to be due to chicken. Animal/
environmental contact being reported as the suspected 
mode of transmission in an additional three family 
outbreaks; contact with a goat was reported as the 
suspected source of infection in one of these outbreaks. 
For 44% (n=43) of VTEC outbreaks in 2012, the 
transmission route was reported as unknown or not 
specified (Table 6 and Figure 5).
Focus on general outbreaks
Eight of the 17 general outbreaks were associated 
with childcare facilities/arrangements (CCFs), six were 
reported as community outbreaks, one foreign travel 
related general outbreak was linked to a hotel, one was 
reported in a private house and one reported among 
an extended family. This is the highest number of 
general VTEC outbreaks reported in a single year since 
surveillance for VTEC infection commenced in 1999.
Five of the outbreaks associated with CCFs were 
reported as being due to person-to-person spread. 
The mode of transmission for the remaining three CCF 
outbreaks was unknown. The number of cases per 
outbreak ranged from 1 to 30 (median 3). There was 
epidemiological and microbiological evidence linking 
two CCF outbreaks in the HSE-M. 14 Between the two 
outbreaks, there were 31 laboratory confirmed cases, 
and four cases developed HUS. Both outbreaks were 
reported to be due to person-to-spread with attack 
rates of 30-40%. 14
Among the community VTEC outbreaks, three 
waterborne outbreaks was reported in the HSE-M, 
with 46 person ill (20 laboratory confirmed) between 
them. Six persons required admission to hospital and 
one person developed HUS.  A community outbreak 
primarily centred in the HSE-MW but including cases 
from HSE-W and HSE-S, was investigated by the Dept. 
of public health HSE-MW. Fourteen persons developed 
illness and 17 persons had laboratory confirmed 
infection. Five cases required admission to hospital and 
two children developed HUS. The outbreak was caused 
by VTEC O26 VT2 and occurred over an 11 week period 
in early spring 2012. Foodborne transmission was 
suspected but no food item was identified; secondary 
person-to-person spread in private homes and in a 
childcare facility was also reported. 
Four persons (age range 12-72) were reported ill over 
a nine day period in a community outbreak in the 
HSE-E; three required hospital admission and one adult 
developed HUS. Neither the source of infection nor the 
transmission route were identified. A sixth community 
outbreak was reported in HSE-W and there were two 
persons ill; the transmission route was also reported as 
unknown.
The remaining general outbreaks included (i) a travel-
associated suspected foodborne outbreak (1 ill, 2 
laboratory-confirmed) associated with a hotel; no 
specific food was reported as being responsible, (ii) an 
extended family outbreak in which six persons became 
ill and for which microbiological and epidemiological 
evidence suggested exposure to a private well as the 
source of infection, and (iii) a private house associated 
outbreak with two persons ill where no transmission 
route was reported.. 
Summary
There was a notable increase in the number of VTEC 
notifications in 2012 relative to previous years, with the 
reported number of cases almost doubling compared 
to 2011. The great majority of this increase was 
accounted for by non-O157 VTEC infections, which 
increased by 315% relative to 2011.  This development 
was accompanied by more widespread use of methods 
that detect both VTEC O157 and non-O157 VTEC, for 
example, PCR (followed by culture confirmation where 
possible) and chromogenic agars. In addition, 2012 was 
notable for its high rainfall, which may have contributed 
to the rise through a range of mechanisms, including 
contamination of drinking water.
Surveillance for VTEC in the United Kingdom largely 
centres on surveillance for VTEC O157. The incidence 
rate of 5.0 per 100,000 for VTEC O157 in Ireland was 
around 11% higher than that for Scotland (4.5 per 
100,000) and around double that reported in England 
and Wales in 2012.11  In contrast, the VTEC O157 
incidence rate in Northern Ireland was around twice that 
in Ireland in 2012, in part due to occurrence of a large 
outbreak in Belfast in late 2012.12  
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Figure 5. Number of VTEC outbreaks by suspected transmission 
route and year, Ireland 2004-2011
Note: In this figure, reported transmission routes were grouped for 
simplicity. Any outbreak where food contributed was reported as 
foodborne, any outbreak where water contributed was reported as 
waterborne, any outbreak where animal contact contributed was 
reported as Animal contact. Person-to-person outbreaks include only 
those outbreaks reported as being due only to person-to-person 
transmission.
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Within the European context, the latest available 
data shows that the overall incidence rate for VTEC in 
Europe in 2011 was 1.93 (range 0.0-6.8).1  Germany, 
Ireland, the Netherlands and Sweden reported the 
highest incidence rates at that time. It seems likely 
when the data are available across Europe for 2012, 
that Ireland will have one of the highest reported 
incidence rates in Europe again.
The HSE-M reported both the highest overall incidence 
of VTEC and the highest incidence of VTEC-associated 
HUS in 2012. Two large crèche outbreaks and two large 
outbreaks linked to private drinking water supplies 
contributed to this overall high incidence; 13, 14  the 
HSE-M however, consistently reports one of the highest 
VTEC incidence rates each year. 
Transmission by person-to-person spread between 
young children in childcare facilities was a feature 
in other HSE-areas too, with 8 general and 2 family 
outbreaks reported in 2012 associated either with 
crèches or families and their childcare arrangements. 
This is the same number of outbreaks associated with 
childcare as in 2011, but is higher than in previous 
years. Active follow-up of facilities when VTEC cases 
are reported who attend a crèche/childminders remains 
a key public health intervention for VTEC given the 
greater potential for transmission in these situations 
because of the less developed hygiene skills in general 
of small children and because of the higher vulnerability 
of this group to the more severe manifestations of 
VTEC infection such as HUS. Guidance for crèche 
owners and management in the prevention of infectious 
disease spread in CCFs 15 and guidance for Public 
Health professionals on the management of VTEC cases 
and outbreaks in CCFs 16 have been published in 2012 
and 2013 respectively.
This year, water was reported to have contributed to 
transmission in 21 outbreaks (38% of outbreaks with 
a reported transmission route); this is the highest 
annual number and percentage of VTEC outbreaks to 
be reported as waterborne since outbreaks became 
notifiable in 2004. As in previous years, all drinking 
water associated outbreaks reported were linked 
with private water supplies. Exposure to water from 
contaminated untreated or poorly treated private water 
supplies has previously been recognized as a strong 
risk factor for VTEC infection in Ireland.6,7 This has been 
particularly pronounced following periods of heavy 
rainfall. Ireland experienced record rainfall amounts in 
many parts of the country in 2012, and this is likely to 
have contributed to the large number of waterborne 
VTEC outbreaks reported. 
Private water supplies in Ireland include small water 
schemes managed by trustees or other private 
individuals, and private wells/springs serving one-off 
houses or business premises which are the responsibility 
of the home/business owner. These sources of water 
present a risk to public health when they have not 
been designed and managed appropriately, and those 
responsible should be mindful of the requirements 
for their maintenance and protection.  In 2013, the 
HSE published a leaflet for well owners outlining the 
infectious disease risks associated with drinking water 
from private wells, providing advice on actions that can 
be taken including: checking the supply, water testing 
and treatment, and what to do in the event their well 
water is found to be contaminated .18 Further advice on 
private wells is available from both HSE Environmental 
Health Service and local authorities, and at  
www.hpsc.ie/hpsc/A-Z/Gastroenteric/VTEC/VTECandwater/  
Foodborne outbreaks were reported infrequently in 
the Irish VTEC dataset, but may be underestimated as 
evidence that an outbreak is foodborne can be difficult 
to establish. Within households, family members 
can have similar food histories making it difficult to 
conclude if a particular food item within the household 
was responsible for the outbreak. Moreover, it is 
rare for there to be food leftover for analyses in the 
household by the time an investigation commences. For 
general outbreaks that are suspected to be foodborne, 
unless a single food premises or meal is reported by 
the majority of cases, finding the source of foodborne 
outbreaks can be challenging, especially if the food 
is a widely distributed common food item or if it is an 
ingredient which has been incorporated into lots of 
different dishes reported by cases. The suspected food 
bourne general outbreak in the MW was not found 
to be associated with any particular food premises or 
retail outlet, an no specific food item was identified as 
a potential vehicle. The proportion of VTEC outbreaks 
where no suspected transmission route is reported 
remains very high. 
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Table 6. VTEC outbreaks by suspected mode of transmission, Ireland 2012
Suspected mode of transmission Number of outbreaks Number ill Number of associated events
Person-to-person 27 103 138
Waterborne 15 75 51
Person-to-person and waterborne 4 4 14
Waterborne and animal contact 2 4 6
Animal contact 1 3 3
Person-to-person and animal contact 1 1 2
Foodborne 1 1 2
Person-to-person and foodborne 2 3 5
Environmental/Fomite 1 2 2
Unknown 38 77 97
Not Specified 5 10 14
Total 97 283 334
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Hepatitis A virus causes an acute, usually self-limiting 
disease of the liver. It is primarily transmitted from person to 
person via the faecal-oral route and is associated with poor 
hygiene and sanitation. Common source outbreaks due to 
contaminated food or water also occur.
The incidence of hepatitis A in Ireland has been low in recent 
years and remained low in 2012, with 30 cases notified. 
This corresponds to a crude notification rate of 0.7/100,000 
population and is higher than in 2011 when 19 cases were 
notified (figure 1). Case classification was reported for all 
cases. Twenty eight were laboratory confirmed and two were 
classified as probable.
Fifty seven percent of cases were female (n=17) and 43% 
were male (n=13). Most age groups were affected but the 
highest notification rates were in children (figure 2). 
Eleven cases were linked to travel outside of Ireland and a 
further three cases had a history of recent travel outside of 
3.4 Hepatitis A
Summary
Number of cases, 2012: 30
Crude notification rate, 2012:  0.7/100,000 population
Number of cases, 2011: 19
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Figure 1. Number of hepatitis A notifications, 1998-2012
Figure 2. Age and sex-specific notification rates/100,000 population for hepatitis A, 2012
Ireland but could also have been infected in Ireland. Seven 
further cases were reported as infected in Ireland.  Country of 
infection was not known for the remaining nine cases.
Four hepatitis A outbreaks were reported in 2012. One 
outbreak in the HSE-East involved two children and was 
associated with travel to Sudan. No source of infection was 
identified in a further outbreak affecting two children in the 
HSE-East, but this outbreak was not associated with travel. 
There were two outbreaks in the HSE-South, each involving 
two people. One involved adult household contacts, and the 
other involved young siblings. No source of infection was 
identified for either, but the cases were not associated with 
travel.
The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) System on 29th August 2013. These figures 
may differ from those published previously due to ongoing 
updating of notification data on CIDR.
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Rotavirus is the commonest global cause of paediatric 
gastrointestinal infection and causes sporadic, seasonal 
and occasionally severe gastroenteritis of infants and 
young children, characterised by vomiting, fever and 
watery diarrhoea. Transmission is usually person-to-
person, mainly via the faecal-oral route. Children 
less than two years of age are most susceptible to 
infection, although cases are often seen in elderly and 
immunocompromised adults, particularly in institutional 
settings. By the age of six years old, virtually all 
children will have had at least one episode of rotavirus 
infection. Symptoms usually last for only a few days but 
in severe cases hospitalisation may be required due to 
dehydration. In developed countries, mortality due to 
rotavirus is low; however, the morbidity and economic 
costs associated with infection are significant. Three 
primary serogroups of rotaviruses infect humans; A, B 
and C; A being the commonest infecting serogroup. 
Given the universal distribution of rotavirus, the 
numbers of notifications will always represent an 
underestimate of the true incidence and are likely to 
be more reflective of habits of presentation to medical 
practitioners and of styles of investigation, notification 
and testing.
Since 2004, rotavirus, although not specifically listed, 
has been a notifiable disease in Ireland under the 
Acute Infectious Gastroenteritis (AIG) disease category. 
Prior to 2004, rotavirus caress were notified in the 
former notification category of “Gastroenteritis in 
children under two years”. In April 2008 the case 
definition of AIG was amended specifying definitions 
for both rotavirus and the newly notifiable Clostridium 
difficile associated disease. On 4th May 2008 these 
amended definitions formally replaced the previous 
AIG case classification. Rotavirus became notifiable as 
a disease in its own right under the Infectious Diseases 
(Amendment) Regulations 2011 (S.I. No. 452 of 2011).
3.5 Rotavirus
Summary
Number of cases:  2,652
Crude incidence rate: 57.8/100,000 population
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Figure 1: Rotavirus 2012 CIR compared to 2004-2011 mean CIR by HSE area (CIDR).
Rotavirus case definition:
A case of rotavirus infection is defined as a patient with 
acute onset of vomiting followed by watery diarrhea 
with fever, which typically lasts between three and eight 
days, AND one of the following laboratory criteria for 
diagnosis:
• Detection of rotavirus by antigen assay
• Detection of rotavirus-specific RNA
• Detection of rotavirus by electron microscopy 
• Isolation of rotavirus
During 2012, there were 2,652 cases of rotavirus 
notified in Ireland, corresponding to a national crude 
incidence rate (CIR) of 57.8 per 100,000 population and 
representing an increase of 8.2% compared to 2011. 
Significant geographical variation was observed in 
regional rotavirus CIR. The highest regional CIRs were 
observed in HSE-M (104.8/100,000 population), HSE-SE 
(92.8/100,000 population) and HSE-NW (83.2/100,000 
population). The lowest regional CIR was observed in 
HSE-E at 28.7 per 100,000 and HSE-NE at 44.5 per 
100,000 population. Figure 1 illustrates the rotavirus CIR 
by HSE area for 2012 compared to the mean CIR during 
2004-2011. 
Rotavirus infection has a well documented seasonal 
pattern in Ireland with the number of cases typically 
peaking during March to May. During 2012, rotavirus 
notifications peaked during April (n=559) and May 
(n=788). Figure 2 illustrates the seasonal variation 
in rotavirus cases by month of notification for 2012 
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Figure 2: Rotavirus notifications by month during 2012 compared to mean monthly notifications, 2004-2011 (CIDR).
Figure 3: Number of cases of rotavirus in children less than two years of age by year, 2001 to 2012
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compared to the mean monthly number of notifications 
reported during 2004 to 2011. Rotavirus is the most 
common cause of acute gastroenteritis in children 
worldwide with children generally affected in the first 
2-3 years of life. In 2012, 69.7% (n=1,848) of cases were 
aged two years or under. Data from 2004 to 2012 show 
that the peak incidence of clinical disease occurred 
in the 6-18 month age group, with 49.1% of total 
notifications in this age group. Figure 3 presents the 
number of cases of rotavirus in children less than two 
years of age by year, 2001 to 2012.
During 2012, 1,227 cases (46.3%) were female and 
1,419 (53.5%) were male. Sex was not reported for 6 
(0.2%) cases. This represented a ratio of females: males 
of 0.9:1.2, which was similar to the ratio observed in 
previous years.
There were nine outbreaks of rotavirus notified 
during 2012 with 18 cases of associated illness, 15 
of whom were hospitalised. All nine outbreaks were 
family outbreaks occurring in private homes. Mode of 
transmission was reported as person to person spread 
for eight outbreaks while the remaining outbreak 
reported transmission as unknown. Table 1 summarises 
the number of rotavirus outbreaks by location and 
month during 2012.
Table 1: Summary of rotavirus outbreaks by location and month, 2012 
Month Location Number of outbreaks Number ill Number hospitalised Number dead
Feb Private house 1 2 2 0
Mar Private house 1 2 2 0
Apr Private house 2 4 4 0
May Private house 1 2 2 0
Jun Private house 2 4 3 0
Aug Unknown 1 2 2 0
Nov Private house 1 2 0 0
Total 9 18 15 0
Salmonellosis typically presents clinically as an acute 
enterocolitis, with sudden onset of; abdominal pain, 
diarrhoea, nausea, headache and occasionally vomiting. 
Fever is almost always present. Dehydration, especially 
amongst vulnerable populations such as infants, the 
immunocompromised and the elderly, may be severe. 
Invasive infection occurs in a proportion of cases. S. 
Typhi and S. Paratyphi can cause enteric fever, a severe 
systemic life threatening condition, but these are not 
common in Ireland and are almost invariably travel-
associated.
Notification data (CIDR)
There were 314 cases of salmonellosis in reported in 
2012, 309 of which were laboratory confirmed. The 
national crude incidence rate (CIR) for salmonellosis 
in 2012 was 6.8 per 100,000 population which was a 
remained stable in comparison to 2011 (6.8/100,000) 
as shown in figure 1. Figure 2 illustrates the regional 
variation in CIR during 2012. The highest CIR occurred 
in HSE-M (10.3/100,000), representing an increase of 2.1 
per 100,000 population compared to 2011. The lowest 
CIR occurred in HSE-S (4.7/100,000), which remains 
stable compared to 4.1 per 100,000 population during 
2011. The largest decrease in regional CIR during 2012 
was observed in HSE-MW, with a decrease of -5.5 per 
100,000 population. 
The female:male ratio for 2012 was 0.90:1.11. In 
terms of age distribution, 28.3% of cases occurred in 
children under five. This is likely to be, at least in part, 
a reflection of clinicians more readily seeking clinical 
samples in that age group. This is also reflected in the 
age specific incidence rate (ASIR) with the 0-4 age 
group having the highest ASIR nationally (23.5/100,000 
in females and 26.4/100,000 in males) in both sexes 
(figure 3). 
The seasonality of salmonellosis notifications in Ireland 
during 2012 is shown in figure 4, with the highest 
3.6 Salmonella 
Summary
Number of confirmed cases: 309
Number of probable cases: 5
Crude incidence rate: 6.8/100,000
Figure 1: Salmonellosis notifications and crude incidence rate per 100,000 population by year of notification (CIDR)
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number of notifications occurring between June and 
September. During 2012, the peaks observed during 
June and July were largely due to a high proportion of 
travel associated salmonellosis, which are anticipated 
seasonal increases that correlate with peak holiday 
periods and resultant increase of people travelling 
abroad. However, a peak in indigenous notifications was 
also observed during August and September due to an 
outbreak of monophasic S. Typhimurium U323.
Of the 314 cases notified on CIDR during 2012, travel 
history was provided for 269 cases (85.7%). Of the 269 
cases where travel history was reported, 142 (52.8%) 
of salmonellosis cases were indigenous to Ireland and 
127 cases (47.2%) reported a recent history of travel. 
Where travel history was documented, the three 
countries with highest occurrence of recent travel and 
subsequent development of salmonellosis were; Spain 
(n=21), Thailand (n=15) and Philippines (n=7). The 
popularity of a country as a travel destination is likely 
to be an important factor in determining the number of 
cases associated with each country. When serotyping 
data were analysed by travel history, 31.5% of all travel 
associated cases were S. Enteritidis (compared with 
17.8% of all cases) whereas 54.2% of cases indigenous 
to Ireland are S. Typhimurium* (compared with 37.9% 
of all cases). Thus relatively speaking S. Enteritidis is 
over represented in travel associated salmonellosis, 
where as S. Typhimurium is under represented in travel 
associated cases (table 1). 
NSSLRL data:
The National Salmonella, Shigella and Listeria 
Reference Laboratory (NSSLRL) based in Galway has 
been providing reference services nationally since 2000. 
In 2012, the NSSLRL analysed 319 human Salmonella 
isolates referred for further typing, identifying 55 
serotypes. Table 2 presents the most dominant 
Figure 2: Salmonellosis notifications and crude incidence rate per 100,000 population by HSE area, 2012 (CIDR)
Figure 3: Salmonellosis notifications and age specific incidence rate per 100,000 population by age group (years) 
and sex, 2012 (CIDR)
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*Includes monophasic S. Typhimurium.
serotypes detected during 2012. S. Typhimurium† 
(n=122) was the most common serotype, followed by S. 
Enteritidis (n=56). 
The NSSLRL conducted phage typing analysis on all 122 
S. Typhimurium and all 56 S. Enteritidis isolates. Phage 
types U323 (23.8%), DT193 (13.9%), untypable (11.5%) 
and DT104 (11.5%) were the commonest phage types 
observed among S. Typhimurium isolates while phage 
types PT8 (26.8%), PT1 (17.9%), PT21 (14.3%) and PT4 
(10.7%) were the dominant types observed among S. 
Enteritidis isolates. 
Of the 319 human isolates analysed by the 
NSSLRL, 168 (52.7%) were fully susceptible to all 
antimicrobials tested. The remaining 151 isolates 
exhibited some degree of antimicrobial resistance. 
The three commonest resistance patterns** seen were 
resistance to ampicillin, streptomycin, sulphadiazine 
and tetracycline (ASSuT, n=47, 14.7% of total and 
31.1% of resistant isolates), resistance to ampicillin, 
chloramphenicol, streptomycin, sulphadiazine and 
tetracycline (ACSSuT, n=22, 6.9% of total and 14.6% 
of resistant isolates), followed by resistance to nalidixic 
acid (Na, n=18, 5.6% of total and 11.9% of resistant 
isolates). All human isolates with a resistance profile of 
ACSSuT or ASSuT were S. Typhimurium (including 44 
monophasic isolates) while 61.1% of human isolates 
with a resistance profile of Na were S. Enteritidis. 
One S. Typhimurium isolate was resistant to 10 
antibiotics tested, one S. Concord isolate was resistant 
to eight antibiotics tested and three S. Typhimurium 
isolates and one S. Java isolate were resistant to seven 
antibiotics tested. A further 11 isolates were resistant 
to six antibiotics tested (including four S. Typhimurium 
isolates, two S. Kentucky isolates and one isolate each 
of S. Agona, S. Anatum, S. Give, S. Newport and S. 
Rissen). Please refer to the NSSLRL’s Annual Report 
2012 for more detailed analysis of results1. The pattern 
of antimicrobial resistance observed is broadly similar to 
previous years. To date carbapenemase production in 
salmonella has not been detected in Ireland.
Outbreaks:
There were six outbreaks of salmonellosis during 
2012 which is a decrease compared to the number 
of salmonellosis outbreaks reported in 2011 (n=13). 
These outbreaks resulted in 39 cases of illness and an 
associated hospitalisation rate of 23.1% (n=9 cases). 
Table 3 outlines the number of salmonellosis outbreaks 
and number ill by outbreak location and outbreak 
transmission mode during 2012.
Table 1: Percentage of Salmonellosis notifications by serotype and travel history, 2012 (CIDR)
Figure 4: Salmonellosis notifications by month of notification and travel history, 2012 (CIDR)
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Salmonella serotype Travel associated Indigenous Travel history unknown Total
S. Enteritidis (%) 31.5 7.0 13.3 17.8
S. Typhimurium* (%) 20.5 54.2 35.6 37.9
Other serotypes (%) 43.3 32.4 40.0 37.9
Serotype not specified (%) 4.7 6.3 11.1 6.4
All serotypes (%) 40.4 45.2 14.3 100.0
All serotypes (n) 127 142 45 314
†This includes 56 S. Typhimurium isolates with serotype 4,5,12:1
**Where A= Ampicillin, C= Chloramphenicol, Na = Nalidixic acid, S= Streptomycin, Su= Sulphonamide and T= Tetracycline
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There were four family outbreaks during 2012, two 
of which were in private houses and two were travel 
associated. Of the two travel associated family 
outbreaks, one reported exposure in China and the 
other reported exposure in Spain. Two family outbreaks 
were reported as food-borne transmission, one was 
reported as animal contact while transmission was 
unknown for the remaining family outbreak.
There were two general outbreaks during 2012, one was 
an international outbreak in a community setting and 
one was a national outbreak in a community setting. 
In January 2012, a cluster of four cases of S. Newport 
indistinguishable by molecular typing Pulsed Field Gel 
Electrophoresis (PFGE) were identified by the NSSLRL. 
Concurrently this PFGE profile was reported in S. 
Newport case clusters in England & Wales (30 cases), 
Scotland (5 cases), and Germany (15 cases) during 
December 2011 and January 2012. Epidemiological 
investigations at the time indicated a potential link with 
watermelon consumption. Among the four Irish cases, 
three (75%) reported watermelon consumption during 
their incubation periods.
In September 2012, a national cluster of monophasic 
S. Typhimurium U323 was detected by the NSSLRL. 
A total of 26 cases spread over six HSE areas were 
investigated. Isolates were predominantly 3-12-11-NA-
211 (or a single locus variant) MLVA pattern and were 
resistant to Ampicillin, Streptomycin, Sulphonamides 
and Tetracycline (ASSuT). Cases matching this profile 
were also detected in the UK and Germany. Mode of 
transmission for this outbreak was not identified but 
was almost certainly food-borne due to the diffuse 
geographical nature.
Typhoid/Paratyphoid:
In 2012 there were eight cases of S. Typhi reported and 
five cases of S. Paratyphi. 
Of the eight S. Typhi, seven reported a recent history of 
travel outside Ireland. Two travelled to Bangladesh, two 
to Pakistan, two to India and one to the Philippines. One 
case reported country of infection as Ireland, following 
secondary transmission from a recently returned traveller 
to an endemic area. In the S. Paratyphi cases three had 
a recent travel history to Indonesia, one to India and one 
to South America.
References: 
1.  National Salmonella Reference Laboratory of Ireland, Annual Report 
for 2012. Available at: http://www.nuigalway.ie/research/salmonella_
lab/reports.html 
2. De Jong B and Ekdahl K. The comparative burden of salmonellosis 
in the European Union member states, associated and candidate 
countries. BMC Public Health 2006, 6:4. Available at:   
www.ncbi.nlm.nih.gov/pmc/articles/PMC1352352/pdf/1471-2458-6-4.pdf 
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international outbreak of Salmonella Newport. HPSC, 2012. Epi-
Insight, vol. 12, issue 13. Available at: http://ndsc.newsweaver.ie/epii
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‡  This includes 56 (16.3%) S. Typhimurium isolates with serotype 4,5,12:1
§  Unamed is not a serotype.  The term refers to a very diverse group of isolates where the complete antigenic formula cannot be determined 
and which therefore can not be formally designated as belonging to any specific serovar 
† † Includes 1 outbreak reported as Person to Person and Foodborne
Table 2: Number and percentage of human Salmonella 
isolates by serotype, NSSLRL 2012 
Salmonella serotype Number of isolates % Isolates
Typhimurium‡ 122 38.2
Enteritidis 56 17.6
Stanley 11 3.4
Typhi 9 2.8
Newport 8 2.5
Infantis 7 2.2
Bredeney 6 1.9
Dublin 6 1.9
Unnamed§ 6 1.9
Braenderup 6 1.9
Saintpaul 5 1.6
Other 77 24.1
Total 319 100.0
Table 3: Number of salmonellosis outbreaks and number ill by outbreak location and outbreak transmission mode, 2012 (CIDR)
Location Food-borne3 Animal contact Unknown Total
No. 
outbreaks
No. ill No. 
outbreaks
No. ill No. 
outbreaks
No. ill No. 
outbreaks
No. ill
Community outbreak 1 3 0 0 1 27 2 30
Private house 0 0 1 2 1 2 2 4
Travel related 2 5 0 0 0 0 2 5
Total 3 8 1 2 2 29 6 39
Listeriosis 
Eleven cases of human listeriosis were notified in 2012, 
higher that the seven cases reported in 2011. This 
equates to a crude incidence rate of 0.24 (95% CI 0.10-
0.28) per 100,000, below the EU average of 0.32 per 
100,000 in 2011.  
Among these, there were one pregnancy-related and 
two neonatal cases. This is one less than the number of 
pregnancy-associated cases reported in 2011 (Figure 
1).  Both infants developed bloodstream infections. The 
pregnancy-related case resulted in miscarriage. 
The number of adult/juvenile cases was higher than last 
year, but similar to the numbers reported in the previous 
five years. Seven of the eight adult/juvenile cases were 
more than 65 years of age, with the eighth being in the 
55-64 years age group. Half were male. Four developed 
bloodstream infection, two developed meningitis, while 
the clinical presentation was described as ‘other’ for the 
remaining two adult cases. The outcome was reported 
as recovered/recovering for three cases, while the out-
come was unknown or not specified for the remaining 
five adult cases.
Since 2007, the National Salmonella, Shigella and 
Listeria Reference Laboratory in Galway has offered a 
national service for typing of Listeria strains. In 2012, 
isolates from nine of the eleven notified cases were 
referred. The serotypes for these nine cases are listed in 
table 1 below. 
3.7  Less common gastroenteric 
 infections
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Table 1. Listeriosis notifications by case type and serotype, Ireland 2012 -typing data provided courtesy of Prof Martin Cormican 
and staff at the NSSLRL
Type Serotype 1/2a Serotype 1/2b Serotype 4b
Not referred for 
serotyping
Total
Adult or juvenile 2 0 4 2 8
Pregnancy-related 0 0 1 0 1
Neonatal 0 2 0 0 2
Total 2 2 5 2 11
Figure 1: Number listeriosis notifications by case type, Ireland 2006-2012
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Listeria in Ireland remains a hazard for the elderly, 
persons with underlying illness, and other vulnerable 
groups such as pregnant women and neonates.
Giardiasis
In 2012, there were 54 cases of giardiasis notified; 
slightly lower than the 57 cases notified in 2011. This 
equates to a crude incidence rate of 1.18 (95% CI 0.86-
1.49) per 100,000. 
Cases ranged in age from 1-83 years (median age=33 
years) with only 13 cases reported in children under 15 
years of age.  According to CDC, Giardia infects nearly 
2% of adults and 6% to 8% of children in developed 
countries worldwide so it is likely that there is a high de-
gree of underreporting of the illness in Ireland 1. Lower 
numbers of females (n=23) were affected than males 
(n=31), which differs from the three previous years when 
females were more numerous than males. Hospitaliza-
tion rates were low with nine cases admitted out of 50 
(18%) for which this information was available. 
The number of cases for which travel status was re-
ported has improved markedly over the last five years 
from 11% of cases in 2006 to 66% of cases this year 
(Figure 2). Twenty-seven cases (50% of all cases; 75% of 
those with known travel status) were reported as being 
associated with foreign travel: the countries of infection 
reported were India (n=11), Ethiopia (n=3), Nepal (n=3), 
South Africa (n=2), and there was one case each report-
ed associated with travel to Afghanistan, Cuba, Kenya, 
Mexico, Spain, Pakistan, Poland, and Sudan. Nine cases 
were reported as being acquired in Ireland, and for the 
remaining 18 cases, country of infection was unknown or 
not specified. 
No outbreaks of giardiasis were notified in 2012  
Giardiasis in Ireland is mainly identified among adults, 
unlike countries such as the United States, Australia and 
the United Kingdom where children are mainly affected. 
And if the travel histories of those with known Country 
of infection are representative of all reported giardiasis 
cases in Ireland, then as many as three-quarters may 
be related to foreign travel. Among these cases, Asia 
and Africa figure most prominently as reported travel 
destinations. 
1 http://www.cdc.gov/parasites/giardia/epi.html 
Yersiniosis 
In 2012, there were  two cases of yersiniosis. Both were 
female, and included one adult and one paediatric case. 
One was reported as being infected with Y. enteroco-
litica and one with Y. spp. The reported incidence of 
yersiniosis in Ireland is low relative to the EU as a whole, 
and to Northern Europe in particular. 
Yersiniosis is commonly associated with consumption of 
pork products however, in Spring 2011, an outbreak was 
reported in Norway associated with salad leaves.1
1  E MacDonald et al. 2011. Yersinia enterocolitica O:9 infections 
associated with bagged salad mix in Norway, February to April 2011. 
Eurosurveillance, Volume 16, Issue 19, 12 May 2011
Foodborne intoxications 
Notifications of foodborne intoxications in Ireland are 
uncommon. In 2012, there were no cases or outbreaks 
of Clostridium perfringens (type A) food-borne disease, 
staphylococcal food poisoning, botulism or Bacillus 
cereus food-borne infection/intoxication notified. 
Figure 2: Number Giardiasis Notifications by Travel Status, Ireland 2006-
2012
Note: Travel status is inferred from Country of Infection variable on CIDR
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Summary
Number of cases 2012: 29
Crude incidence rate 2012: 0.63/100,000
Number of cases 2011: 42
In the last twenty years, the number of cases of 
shigellosis in Ireland has been low in comparison to 
the number of cases notified in the early 1990s (Figure 
1). Shigellosis, however, remains a common cause of 
gastrointestinal illness in developing countries, and 
many cases notified in Ireland are now identified as 
being travel-associated.  
While person-to-person spread is an important 
transmission route between children, risks also remain 
from food, with at least four general outbreaks having 
been reported in Scandinavia in 2009 associated with 
imported fresh produce.1-5  Transmission between men 
who had sex with men (MSM) has been reported.6, 7
Twenty-nine cases of shigellosis were notified in Ireland 
in 2012 (CIR 0.63 per 100,000, 95% CI 0.40-0.86), all 
of which were laboratory confirmed. This compares to 
42 cases in 2011 and 60 cases in 2010 (Figure 1). Of 25 
cases where hospitalisation status was recorded, five 
(20%) were reported as hospital in-patients.
Cases ranged in age from two to 70 years (median 
age=33 years). Like 2009 to 2011, more males (n=18) 
than females (n=11) were notified (Figure 2). 
Information on travel history is very valuable when 
reviewing surveillance data for possible indigenous 
clusters, and data on country of infection in the national 
dataset continues to improve, being available for 
86% of shigellosis notifications this year. Sixteen cases 
were reported associated with foreign travel (Table 1). 
3.8 Shigellosis
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Figure 1: Annual number of notifications shigellosis, Ireland 1991-2012 
Table 1: Number of notifications shigellosis by species and country of infection, Ireland 2012
Organism Carribean Africa Asia Other Europe Ireland Not specified Total
Shigella dysenteriae 0 0 2 0 0 0 2
Shigella flexneri 0 2 1 0 3 1 7
Shigella sonnei 1 2 6 2 6 3 20
Total 1 4 9 2 9 4 29
(Data source: CIDR)
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The countries of infection reported were India (n=7), 
Morocco (n=2), Spain (n=2) with one case associated 
each with travel to Pakistan, Tanzania, Nigeria, 
Dominican Republic and Nepal.  Nine infections were 
reported as being acquired in Ireland, while no country 
of infection information was available for four cases. 
Shigella sonnei was the most common species reported 
(n=20), followed by S. flexneri (n=7), with two S. 
dysenteriae reported. The species distribution of cases 
by country of infection is reported in Table 1. 
More detailed typing of Shigella isolates can provide 
useful information on the relatedness of strains 
which can be used by public health personnel to 
outrule/provide evidence for links between cases 
during investigations of case clusters. The National 
Salmonella, Shigella and Listeria Reference Laboratory 
(NSSLRL) in University College Hospital, Galway can 
provide laboratory services for speciation, serotyping, 
antimicrobial resistance profiling, and where 
appropriate, Pulsed Field Gel Electrophoresis (PFGE) of 
Shigella isolates.
In 2012, 20 human Shigella isolates were referred to the 
NSRL, 69% of the isolates from all notified cases. The 
species/serotype of these cases are reported in Table 2. 
There was one shigellosis outbreak notified in 2012, 
a family outbreak with three persons ill, caused by 
Shigella flexneri. The mode of transmission was 
reported as person-to-person.
Although foreign travel is a major risk factor for 
shigellosis among Irish residents, indigenous risks are 
likely to be through person-to-person spread (in some 
instances from persons who have contracted shigellosis 
abroad), and from food, as demonstrated by the 
Scandinavian outbreaks associated with imported foods 
in recent years. 
Figure 2: Age-sex distribution shigellosis notifications, Ireland 2012 relative to 2006-2011
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Table 2: Species/serotypes of Shigella isolates referred to 
NSSLRL in 2012 (Data courtesy of Martin Cormican, Niall de 
Lappe and Jean O Connor at NSSLRL) 
Serotype Number by serotype
Shigella dysenteriae 2
Shigella flexneri 2a 1
Shigella flexneri 3a 1
Shigella flexneri 4a 1
Shigella flexneri 6 3
Shigella sonnei 12
Total 20
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Vectorborne and Zoonotic Diseases
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In 2012, the number of malaria cases in Ireland 
increased slightly to 65 from 61 cases in 2011 (6% 
increase), but stayed low relative to the annual number 
of malaria cases in the three years prior to that (Figure 
1). The incidence rate now stands at 1.42 per 100,000 
population. Among European Member (EU) States 
reporting malaria data to the European Centre for 
Disease Control, Ireland had the third highest incidence 
rate for imported malaria in 2010 (the latest year 
for which comparative data are available); only the 
United Kingdom and Luxembourg had higher reported 
incidence rates. Despite the decreased incidence in 
2011 and 2012, it is likely that Ireland will continue to 
have one of the highest reported incidence rates in the 
EU for 2011-2012. 1
In common with the rest of the EU, males predominated 
(male: female ratio 1.5:1), with the highest numbers 
of cases among males aged between 35 and 54. The 
number of paediatric cases reported this year is the 
same as last year (n=8), but represents a 70% decrease 
on 2006 (n=26), the year in which notifications of 
paediatric malaria cases peaked in Ireland (Figure 
1). Seven of the paediatric cases reported ‘visiting 
family in country of origin’ as their reason for travel; 
there was no information on reason for travel for the 
remaining paediatric case. All seven visited sub-Saharan 
Africa, staying for between 3 and 7 weeks duration. At 
least four were children born in Ireland to immigrant 
4.1 Malaria 
Summary
Number of cases malaria, 2012: 65
Crude incidence rate malaria 2012: 1.42/100,000
Number of cases malaria, 2011: 61
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Figure 1. Annual number of malaria notifications by age, Ireland 2001-2012
Table 1. Number of malaria notifications by reason for travel and country of birth, Ireland 2012
Reason for travel
Country of Birth
Nigeria Ireland Other Africa Asia Unk/NS Total
Visit family country origin 21 4 4 0 2 31
Business/Professional Travel 1 3 2 0 0 6
Irish citizen living abroad 0 6 0 0 0 6
New entrant to Ireland 1 0 0 1 0 2
Other 2 1 0 0 1 4
Not reported 3 1 1 0 11 16
Total 28 15 7 1 14 65
Unk/NS =Unknown/Not specified
parents, and only two were reported to have taken any 
prophylaxis for their travel. 
The group most affected in Ireland continued to be 
African immigrants and their families who were exposed 
while returning to ‘visit family in country of origin’ (Table 
1). This almost certainly reflects the greater frequency 
with which this group travels to malarious areas, but 
also reflects Ireland’s importance as a destination for 
those emigrating from English speaking West Africa. 
Sixty-three per cent of cases with a known reason for 
travel in 2012 cited ‘visiting family in country of origin’, 
with at least 80% of these being of African origin (Table 
1). 
The second most commonly cited reasons for travel this 
year were ’Business/professional travel’ (n=6) and ‘Irish 
Citizens Living Abroad’ (n=6), each making up 12% of 
cases with known reason for travel in 2012. There were 
no cases reported associated with holiday travel - the 
first time since enhanced malaria records began in 2001. 
Figure 2 shows the distribution of cases by reason for 
travel 2006-2012. During that time period ‘visiting 
family in country of origin’ remained the most common 
reason for travel, with new entrant and holidaymaker 
case numbers declining. The numbers of cases in 
persons exposed during business/professional travel 
has increased as has the number of notifications in Irish 
citizens living abroad.
Nigeria remained the country most frequently visited 
-51% of all cases [58% of those with country of infection 
reported (Table 2)]. The majority of the remaining cases 
were exposed in other countries within Africa, with only 
one case each reporting exposure in Asia and South 
America. 
The majority of cases who reported travel to Nigeria 
were ‘visiting family in country of origin’ (24/29 with 
known reason), whereas visitors to other parts of Africa 
reported a variety of reasons for travel.
Plasmodium falciparum accounted for 80% of infections 
in 2012, reflecting the dominance of exposure in Africa 
as the source of the majority of notifications.  P. ovale 
was the second most common species (n=5). The one P 
vivax case reported in 2012 is considerably lower than 
the 10 cases reported in 2011 but not atypical relative 
to previous years.
There has been a welcome decline in malaria 
notifications in Ireland over the last two years. While 
this report has highlighted the high incidence among 
persons travelling to ‘visit family in their country of 
origin’, malaria prevention messages should also be 
targeted at tourists, business travellers and other 
travellers with little previous exposure to malaria. 
Children can be particularly at risk. It is important that 
persons born in Western and Central Africa who take up 
residence in Ireland and who return to their country of 
origin with their Irish-born children are made aware of 
the fact that their children have no innate immunity to 
malaria (and their own immunity will likely have waned 
considerably), and must complete their full course of 
advised chemoprophylaxis while taking steps to ensure 
they avoid mosquito bites. 
HPSC resources for health professional include a poster 
which can be downloaded from the HPSC website for 
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Table 2. Number of cases malaria by infecting species and country of infection, in Ireland 2012
Organism
Country of Infection
Total
Nigeria Other Africaa Other Unknown/Not specified
P.falciparum 29 16 1 11 57
P.ovale 2 3 0 0 5
P.vivax 0 0 1 0 1
P. malariae 0 1 0 0 1
Not Specified 0 0 0 1 1
Total 31 20 2 12 65
aIncludes cases associated with Ghana (n=5), Cameroon (n=3), Siera Leone (n=3), Uganda(n=2), Sudan (n=2), and one each with Tunisia, 
Mozambique, Zambia, DR Congo and Africa Unspecified.
Figure 2: Annual number of notifications malaria by reason for 
travel, Ireland 2006-2012
display in GP surgeries, maternity hospitals, paediatric 
hospitals and A&E departments, advising immigrant 
families travelling to Africa to consult their doctor 
about malaria before travelling. A leaflet for intending 
travellers, available in English and French, highlights the 
value of antimalarial prophylaxis and protection against 
mosquito bites. The poster and leaflet are available 
here.
Finally, one pertinent recent development at European 
level is the re-emergence of indigenous malaria due 
to P. vivax in Greece, particularly in 2011 and 2012.2,3 
However, case numbers are very low and have been 
identified in areas not usually associated with tourism. In 
a European Centre for Disease Control and Prevention 
Risk Assessment of the situation, the risk to travellers 
to the country was deemed limited, with general advice 
for travellers to take prophylaxis not recommended, 
although travellers to Greece should take standard 
measures against mosquito bites to protect against this 
and other mosquito-borne diseases.4 Moreover, health 
professionals who see cases of febrile illness returning 
from the affected parts of Greece should be alert to the 
possibility of malaria (NaTHNaC).5 
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Fifteen cases of leptospirosis were notified in Ireland 
in 2012, similar to the 16 cases notified in 2011 (Figure 
1). This equates to a crude incidence rate of 0.33 per 
100,000 (95% CI 0.16-0.49). The latest year for which 
data is available across the European Union is 2010. 
Among the 26 countries that reported leptospirosis 
incidence in 2010, Ireland reported the joint fourth 
highest incidence rate after Romania, Slovakia and 
Slovenia. The incidence in the EU as a whole was 0.13 
per 100,000. 
The leptospirosis notification dataset is typically 
dominated by adult males, and this year was no 
exception (Table 1). Eleven cases (73.3%) were male and 
the age range was 20-62 (mean age =44 years, median 
age=48 years). This is consistent with the exposures 
most commonly associated with leptospirosis in 
temperate regions, e.g. occupational contact with farm 
animals, and watersports.
Among the 14 cases for which hospital admission status 
was reported, 13 (93%) required hospitalization. One 
person died but their death was due to another medical 
condition. 
Eight cases (53%) were believed to have acquired 
their illness occupationally –four were either farmers 
or reported contact with farm environments, one 
worked in an abattoir, two reported exposure to 
outdoor environments during the course of their work 
and the eighth case reported seeing rats in their work 
environment. Four (27%) cases were reported as being 
associated with recreational activities: one with travel 
to a tropical destination, one with kayaking, and two 
with freshwater swimming in rivers. One case (7%) was 
exposed to a rat in their garden, while for two cases 
(13%), it was not possible to obtain information on risk 
factors. 
Figure 2 shows the trend in notifications by exposure 
group. The decrease in case numbers reported over the 
last five years appears to be due to a reduction in the 
number of recreational cases, with occupational cases 
now making up the largest proportion of cases in the 
last three years.
While a number of regional hospital laboratories offer 
a diagnostic service for leptospirosis, around two 
thirds of cases are diagnosed by the National Virus 
Reference Laboratory each year. Positive specimens 
are generally referred to the United Kingdom’s 
Leptospirosis Reference Unit (LRU) for confirmation 
4.2 Leptospirosis           
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Figure 1: Annual number of leptospirosis notifications, Ireland 
1991-2012
(data source: CIDR)
Summary
Number of cases, 2012: 15
Crude incidence rate, 2012: 0.33/100,000
Number of cases, 2011: 16
Table 1: Leptopirosis notifications by age and sex, Ireland 2012
Age group Male Female Total
<5 yr 0 0 0
5-14 yrs 0 0 0
15-24 yrs 1 2 3
25-44 yrs 3 1 4
45-64 yrs 7 1 8
65+ yrs 0 0 0
Total 11 4 15
Figure 2: Annual number of leptospirosis notifications by 
exposure group, Ireland 2004-2012
(data source: CIDR)
and for typing where possible. In 2012, species 
information was available on CIDR for only three cases 
(20%)–two Leptospira icterohaemorrhagiae, and one L. 
saxkoebing. For many cases, serovar is not determined. 
Failure to provide follow-up samples is likely to be one 
contributory factor in this. 
Activities that continue to be associated with 
leptospirosis risk in Ireland include recreational activities 
such as water sports, and farming. In recent years, travel 
to Asia and other tropical destinations has emerged as 
a risk factor for leptospirosis. 
HPSC and NVRL recently published a review of 
leptospirosis in Ireland in the journal Epidemiology 
and Infection, which is available at http://journals.
cambridge.org/action/displayAbstract?fromPag
e=online&aid=8963217&fulltextType=RA&fileId
=S0950268813001775 
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Toxoplasmosis
During 2012, 36 cases of toxoplasmosis were notified 
compared to 32 in 2011 and 36 cases in 2010.  
One congenital case was reported. The remaining 31 
cases ranged in age from 15 to 61 years (median, 31 
years).  As in previous years, female cases were more 
common (64%). The high number of cases reported 
among women of child-bearing age is probably a reflec-
tion of enhanced testing during pregnancy (Table 1). 
Q Fever
One probable and five confirmed cases of Q fever were 
notified during 2012, three of which were admitted to 
hospital (50%). 
There were five male cases and one female case (Table 
2), and they ranged in age from 35 to 70 years (median 
age, 60 years). Cases were reported from five different 
HSE-areas: two in HSE-S and one each in HSE-E, HSE-M, 
HSE-SE, and HSE-MW.  
Although no details are collected on potential sources 
of infections for notified cases in Ireland, the disease is 
commonly acquired through occupational exposure to 
infected sheep and other small ruminants, e.g. by farm-
ers, veterinarians, and abattoir workers. 
Brucellosis
During 2012, there were two cases of brucellosis noti-
fied, one paediatric and one adult. This compares with 
between one and three cases per annum over the previ-
ous four years. Both cases were reported as Brucella 
species, and one case was associated with travel to Asia. 
Despite the reporting of a paediatric case this year, the 
age and sex distribution for brucellosis in recent years in 
Ireland has tended towards adult males, suggesting that 
occupational exposure is likely to be a major transmis-
sion route for this disease. 
Echinococcosis
In 2012, there were no notifications of echinococcosis. 
Prior to this there have only been four cases of  echino-
coccosis notified in Ireland since the disease became no-
tifiable in 2004; in 2008, two adult cases were notified, 
and one adult case was notified each in 2009 and 2010. 
Because of the long incubation period for this disease, 
it is possible that these infections occurred many years 
ago. 
Trichinosis
No cases of trichinosis were notified in Ireland in 2012.
4.3 Other Non-IID Zoonotic Diseases
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Table 1: Toxoplasmosis notifications by age and sex, Ireland 2012
Age group Male Female Total
<1 yr 0 1 1
1-4 yrs 0 0 0
5-14 yrs 0 0 0
15-24 yrs 4 0 4
25-44 yrs 7 20 27
45-64 yrs 2 2 4
65+ yrs 0 0 0
Total 13 23 36
Table 2: Q fever notifications by age and sex, Ireland 2012
Age group Male Female Total
<5 yr 0 0 0
5-14 yrs 0 0 0
15-24 yrs 0 0 0
25-44 yrs 1 1 2
45-64 yrs 1 0 1
65+ yrs 3 0 3
Total 5 1 6
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Four vectorborne diseases were added to the notifiable 
disease list in Ireland from the beginning of 2012. This 
chapter summarises the information gathered on these 
notifications in the first year of formal surveillance. The 
case definitions for these diseases are outlined on the 
HPSC website at      
www.hpsc.ie/hpsc/NotifiableDiseases/CaseDefinitions/.
Lyme neuroborreliosis
Lyme neuroborreliosis is an infection caused by a spiral-
shaped bacterium called Borrelia burgdorferi that is 
transmitted to humans by bites from ticks, generally 
hard-bodied ticks (Ixodidae). 
Lyme neuroborreliosis is the notifiable disease entity, 
and in 2012, eight cases of lyme neuroborreliosis were 
notified in Ireland, four male and four female. Two were 
for cases less than 15 years of age, while the remaining 
six notifications were for adult cases. Six patients were 
admitted to hospital, one was reported as a day-patient, 
with the hospitalization status of the eighth case not 
specified.
Cases were distributed along the western seaboard, 
with three reported from HSE-MW, two each from 
HSE-S and HSE-NW, and one from HSE-W. None were 
reported as being acquired abroad.
Dengue Fever
Seven confirmed cases of dengue fever were notified 
during 2012, two of which were reported as being 
admitted to hospital. Cases ranged in age from 23-63 
years of age (median 32 years), and four were female.
Dengue is found commonly throughout the tropics and 
subtropics and is endemic in about 100 countries.  Three 
of the notified cases in 2012 were associated with travel 
in India, two in Thailand, while the country of infection 
was not specified for the remaining two cases. These 
destinations probably reflect the frequency of travel by 
Irish residents to dengue endemic countries. 
Chikungunya fever and West Nile 
fever 
No cases of chikungunya or west nile fever were notified 
in Ireland in 2012. 
4.4 Other Vectorborne Diseases
Health Protection Surveillance Centre   Annual Report 201205
Blood-borne and 
Sexually Transmitted Infections
Hepatitis B is a vaccine preventable disease caused by the 
hepatitis B virus. It is transmitted through percutaneous 
or mucocutaneous contact with the blood or body fluids 
of an infected person. Over 90% of people infected in late 
childhood and adulthood clear the virus within a year of 
infection, but there is a high probability of developing 
chronic infection if hepatitis B is acquired in infancy (approx. 
90%) or when aged under five years (approx. 30%).1 Between 
15 and 40% of people with chronic infection ultimately 
develop cirrhosis, liver failure or hepatocellular carcinoma 
(liver cancer).2
The prevalence of hepatitis B in the general population in 
Ireland is low (less than 1%). Most cases fall into defined 
risk groups such as people with multiple sexual partners, 
household or sexual contacts of known cases, injecting drug 
users and people who were born in countries of intermediate 
(2-7%) or high ( >8%) hepatitis B endemicity.
The number of hepatitis B cases reported in Ireland 
increased by 11% in 2012, with 580 cases (12.6/100,000 
population) notified compared to 525 in 2011 (figure 
1). However, the hepatitis B notification rate has been 
decreasing in Ireland in recent years and the 2012 figure was 
lower than the numbers reported annually between 2004 
and 2010. Sixty two percent (n=361) of the 2012 cases were 
from the HSE-East, corresponding to a notification rate of 
22/100,000 population. All cases were laboratory confirmed 
and 96% contained information on acute/chronic status. 
Where status was known, 7% of cases were acute (n=37) and 
93% were chronic (n=522). Both acute and chronic cases of 
hepatitis B are notifiable in Ireland.
Acute cases (recent infections)
Of the 37 acute cases notified in 2012, 81% (n=30) were 
male and 19% (n=7) were female. The highest notification 
rates were in young to middle aged adults, and 95% (n=35) 
5.1 Hepatitis B
Summary
Number of cases, 2012: 580
Crude notification rate, 2012: 12.6/100,000 population
Number of cases, 2011: 525
HPSC Annual Report 2008  
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Figure 1. Number of hepatitis B notifications by acute/chronic status, 1997-2012
of acute cases were aged between 20 and 54 years when 
notified (figure 2). Male cases were younger than females 
overall, with a median age of 32.5 years compared to 35 
years for females.
Information on risk factor was available for 97% (n=36) of 
acute cases. Of these, 78% (n=28) were likely to have been 
sexually acquired. Thirteen were heterosexual, nine were 
men who have sex with men and sexual orientation was not 
known for six cases. No risk factors were identified for five 
cases (14%) despite public health follow up being carried 
out. Where information on reason for testing was available 
(97%, n=36), most acute cases were identified because they 
were symptomatic (64%, n=23) or through STI screening 
(25%, n=9).
Country of birth was known for 87% (n=32) of acute cases. 
Of these, 66% (n=21) were born in Ireland and 13% (n=4) 
were born in Eastern or Central European countries. Country 
of infection was available for 73% (n=27) of acute cases. 
Most were infected in Ireland (63%, n=17), but a significant 
number were infected in Thailand (19%, n=5). 
The number of acute cases of hepatitis B notified in Ireland is 
generally relatively low and decreased by 18% in 2012 (n=37) 
compared to 2011 (n=45). 
Chronic cases (long-term infections)  
Of the 522 chronic cases notified in 2012, 55% (n=290) were 
male, 42% (n=218) were female and sex was not reported for 
3% (n=14). Eighty one percent (n=422) of chronic cases were 
aged between 20 and 44 years when notified (figure 3). The 
median age at notification for male cases was 33 years and 
the median age for females was 29 years. 
Some data on risk factor, country of birth or asylum seeker 
status were available for 48% (n=250) of the chronic cases 
notified in 2012. Of these, 64% (n=161) were born in hepatitis 
B endemic countries or were identified as asylum seekers. No 
further detail is available on the actual mode of transmission 
in their country of origin. Risk factors identified in other 
cases included sexual acquisition (18%, n=44), vertical 
transmission (5%, n=13), attending an intellectual disability 
institution (2%, n=6) and injecting drug use (2%, n=5).
Data on country of birth were available for 44% (n=227). 
Of these, only 8% (n=17) were born in Ireland. The most 
common regions of birth were Eastern or Central Europe 
(35%, n=80), Sub-Saharan Africa (26%, n=59) and Asia 
(25%, n=57). 
The reason for testing was known for 63% (n=326) of 
chronic cases. Of these, 30% (n=98) were identified through 
antenatal screening programmes, 16% (n=53) were tested 
in STI settings, 17% (n=54) were diagnosed as a result 
of routine health screens and 7% (n=24) were identified 
through asylum seeker screening centres.  
There was a 14% increase in chronic hepatitis B notifications 
in 2012 (n=522) compared to 2011 (n=457). However 
the number of cases was similar to 2010 (n=555) and 
notifications of chronic hepatitis B and hepatitis B overall 
have been decreasing in recent years. 
The large increase in hepatitis B notifications between 1997 
and 2008 (figure 1) was mostly due to increased numbers 
of people immigrating to Ireland from hepatitis B endemic 
countries.  The current economic climate has most likely 
contributed to reduced immigration to Ireland between 
2009 and 2012, which correlates with an overall decrease in 
hepatitis B notifications over this time period. 
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Figure 2. Age and sex-specific notification rates/100,000 population for acute cases of hepatitis B, 2012
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Co-infections
Co-infections with HIV or hepatitis C can lead to more severe 
liver disease and an increased risk of liver cancer in people 
with hepatitis B infection. Fourteen of the hepatitis B cases 
notified in 2012 were also known to be infected with HIV. Two 
were born in Ireland and nine of the remaining twelve were 
born in countries in Sub-Saharan Africa. Seven hepatitis B 
cases notified in 2012 were also known to be infected with 
hepatitis C. Two cases had hepatitis B, hepatitis C and HIV 
infections.
The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) System on 29th August 2013. These figures 
may differ from those published previously due to ongoing 
updating of notification data on CIDR.
References
1. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis 
HS.A mathematical model to estimate global hepatitis B 
disease burden and vaccination impact. Int J Epidemiol. 2005 
Dec;34(6):1329-39.
2. Wright TL. Introduction to chronic hepatitis B infection. Am J 
Gastroenterol. 2006;101 Suppl 1:S1-6. 
-91-HPSC Annual Report 2012 5 Blood-borne and Sexually Transmitted Infections
Figure 3. Age and sex-specific notification rates/100,000 population for chronic cases of hepatitis B, 2012
0
5
10
15
20
25
30
35
0-4 5-9 10-14 15-19 20-24 25-34 35-44 45-54 55-64 65+ 
N
ot
ifi
ca
tio
n 
ra
te
 p
er
 1
00
,0
00
 
Age group (years) 
Male Female
Hepatitis C
Hepatitis C is a major cause of liver disease worldwide. The 
hepatitis C virus is primarily transmitted through sharing 
contaminated equipment when injecting drugs or through 
receipt of unscreened blood or blood products (this is no 
longer a risk in Ireland). Sexual, occupational and perinatal 
transmission can also occur but are less common. 
Infection is initially asymptomatic in most cases, but 
approximately 75% of those infected fail to clear the virus and 
develop chronic infection. Between 5 and 20% of chronically 
infected individuals develop cirrhosis of the liver after 20 
years of infection. Of those with cirrhosis, 1.5 to 2.5% will go 
on to develop hepatocellular carcinoma (liver cancer) each 
year.1 Treatment with a combination of peginterferon and 
ribavirin induces sustained virologic response (SVR) rates 
of 40-50% in those with genotype 1 and of 80% or more in 
those with genotype 2 and 3 infections. Recently introduced 
new treatment regimes, which include protease inhibitors, 
have greatly improved SVR rates. An SVR is regarded as a 
virologic cure and is associated with improved morbidity and 
mortality.2 
The overall prevalence of chronic hepatitis C in Ireland is 
comparable to other Northern European countries, and is 
estimated to be between 0.5 and 1.2%. The prevalence in the 
general population is low and most cases fall into defined 
risk groups such as injecting drug users, people who received 
unscreened blood or blood products in the past and people 
who were born in hepatitis C endemic countries.3
Hepatitis C notifications decreased by 18% in 2012 (n=1036, 
22.6/100,000 population) compared to 2011 (n=1,255, 
27.4/100,000 population) (figure 1). There was a strong 
predominance of males: 66% (n=686) of cases were male, 
33% (n=343) were female and sex was not reported for seven 
cases (figure 1). The highest notification rates were in young 
to middle aged adults. Eighty two percent (n=851) of cases 
were aged between 25 and 54 years (figure 2). The median 
5.2 Hepatitis C
Summary
Number of cases, 2012:  1,036
Crude notification rate, 2012:  22.6/100,000 population
Number of cases in 2011: 1,255
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Figure 1. Number of hepatitis C notifications, 2004-2012
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age at notification for females was younger (35 years) than 
that for males (38 years). 
The geographic distribution of cases was skewed, with the 
HSE-East reporting 74% of the cases notified in 2012 (n=762, 
47/100,000 population) (figure 3).
Data on most likely risk factor were available for 63% of 
cases (n=655). The most common risk factors reported 
were injecting drug use (74%, n=485), sexual exposure (7%, 
n=43), being an asylum seeker/born in an endemic country 
(6%, n=41), vertical transmission (5%, n=32) and receipt of 
blood or blood products (4%, n=26) (figure 4).
 
The vertically acquired infections do not all represent recent 
births in Ireland. Eighteen of the thirty two were born in 
Ireland, five were born in other countries and country of 
birth was not available for the remaining nine. Only four of 
the Irish-born cases were children aged less than two years. 
Thirteen were older children and one was an adult. These 
cases were previously diagnosed but were notified for the 
first time in 2012.
Of those who were infected through contaminated blood 
or blood products, nine were infected in Ireland, four were 
infected in other countries and no country of infection was 
available for the remaining thirteen. The Irish infections 
occurred many years in the past, but were notified for the 
first time in 2012. 
Data on country of birth were only available for 21% of cases 
(n=219). Where information was available, the most common 
countries of birth were Ireland (46%, n=101), Latvia (8%, 
n=18), Poland (8%, n=18), Lithuania (6%, n=14), the United 
Kingdom (6%, n=14) and Pakistan (5%, n=11).
Co-infections
Co-infections with HIV or hepatitis B can lead to more severe 
liver disease and an increased risk of liver cancer in those 
with hepatitis C infection. Twenty two of the hepatitis C cases 
notified in 2012 were known to be co-infected with HIV. Of 
the fourteen of these for whom country of birth was known, 
seven were born in Ireland and five of the remaining seven 
were born in countries in Eastern or Central Europe. Eight of 
the 2012 hepatitis C cases were also known to be co-infected 
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Figure 3. Notification rates/100,000 population for hepatitis C by HSE area, 2009-2012
Figure 2. Age and sex-specific notification rates/100,000 population for hepatitis C, 2012
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with hepatitis B. Two cases had hepatitis B, hepatitis C and 
HIV infections.
The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) System on 29th August 2013. These figures 
may differ from those published previously due to ongoing 
updating of notification data on CIDR.
1. Global Burden of Hepatitis C Working Group. 
Global burden of disease (GBD) for hepatitis C.J Clin 
Pharmacol. 2004 Jan;44(1):20-9.
2. Ghany MG, Nelson DR, Strader DB, Thomas DL, 
Seeff LB. An update on treatment of genotype 1 
chronic hepatitis C virus infection: 2011 practice 
guideline by the American Association for the Study 
of Liver Diseases. Hepatology 2011;54(4):1433-4. 
3. Thornton L, Murphy N, Jones L, Connell J, Dooley 
S, Gavin S et al. Determination of the burden of 
hepatitis C virus infection in Ireland. Epidemiol 
Infect. 2011 Sep 19:1-8
Injecting drug user, 
74.0%
Possible sexual exposure, 
6.6%
Born in endemic country/
asylum seeker, 6.3% 
Vertical transmission, 
4.9%
Received blood/blood 
products, 4.0% 
Other, 
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Figure 4. Most likely risk factor for hepatitis C, where data available (63%, n=655 cases), 2012
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A total of 341 new HIV diagnoses (244 men and 97 
women) were reported to HSPC during 2012. This 
compares with 321 in 2011 and represents a 7% 
increase. The rate of newly diagnosed HIV infection 
in Ireland in 2012 was 7.4 per 100,000 population 
(10.7 per 100,000 in men and 4.2 per 100,000 in 
women).  Previously, the annual number of newly 
diagnosed HIV infections had been decreasing since 
2008. A rate of 5.7 per 100,000 population (ranging 
from 0.9 to 27.3) was reported in the European Union 
and European Economic Area (EU/EEA) in 2011 (1). 
 
5.3 HIV
Summary - 2012 cases 
-95-HPSC Annual Report 2012 5 Blood-borne and Sexually Transmitted Infections
Figure 1: New HIV diagnoses by year of diagnosis (2003 to 2012) 
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Number of new diagnoses 341
Rate (per 100,000 population) 7.4
Age Median Age 33 years
Age Range 3 to 71 years
Gender Males 244 (71.6%)
Females 97 (28.4%)
Male: female ratio 2.5
Prob Route of Transmission MSM 166 (48.7%)
Heterosexual 130 (38.1%)
IDU 13 (3.8%)
Mother to Child Transmission 5 (1.5%)
Unknown 27 (7.9%)
Geographic origin Born in Ireland 123 (36.1%)
Born Abroad 162 (47.5%)
Stage of Infection Late (CD4 <350 cells/mm3) 119/249 (47.8%)
Very late (CD4 <200 cells/mm3) 60/249 (24.1%)
Concurrent AIDS diagnosis 34 (10.0%)
Co-infections With an STI 53 (15.5%)
With Hepatitis C 25 (7.3%)
With Hepatitis B 17 (5.0%)
Cumulatively, to the end of 2012, 6,629 people have 
been newly diagnosed with HIV in Ireland since the early 
1980’s. This number does not however represent the 
number of people living with HIV (PLHIV) in Ireland, as it 
does not take factors such as death and migration into 
account. The prevalence of HIV in the Irish population 
is currently unknown. A recent study found that 3,254 
patients accessed HIV outpatient care in six centres in 
Ireland over a 12 month period in 2009/2010 (2). 
Figure 1 shows the number of HIV cases diagnosed 
annually in Ireland from 2003 to 2012, in males and 
females.
Probable route of transmission
The predominant route of transmission of HIV in Ireland 
in 2012 was sex between men, accounting for 49% 
of new diagnoses. Heterosexuals accounted for 38% 
and injecting drug users (IDUs) for 4%. There were five 
cases where the route of transmission was identified 
as mother to child transmission (MTCT). The probable 
route of transmission was unknown or unreported for 
7% of cases. 
Figure 2 shows probable route of transmission among 
the three major risk groups; MSM, heterosexual contact 
and IDUs between 2003 and 2012. 
Men who have sex with men (MSM)
The commonest route of transmission was men who 
have sex with men, accounting for 49% of cases in 
2012. This proportion has been increasing since 2004.
The median age among MSM diagnosed in 2012 was 
32 years (range 18-71 years) with 43% of MSM newly 
diagnosed aged between 25 and 35 years old. Fifty 
six percent of MSM were born in Ireland, 13% in South 
America, 10% in Western Europe and 5% in Central 
and Eastern Europe.
One in four MSM (27%) newly diagnosed with HIV 
in 2012 was co-infected with a sexually transmitted 
infection (STI) (chlamydia/gonorrhoea/syphilis). In 
relation to syphilis, this included all stages of infection, 
including evidence of infection at some time, as well as 
current infection. 
Where CD4 count was reported, 39% of MSM were 
diagnosed late (CD4 count <350 cells/mm3) including 
13% who were severely immuno-compromised (CD4 
count <200 cells/mm3). A higher proportion of older 
MSM (aged 50 years and older) were diagnosed late 
compared with younger MSM (75% v 35%, p=0.006). 
Thirteen MSM (8%) were diagnosed with an AIDS 
defining illness at the time of their HIV diagnosis in 
2012. The most common indicative illnesses among 
MSM were Pneumocystis Carnii Pneumonia (PCP) (54%) 
and Kaposi’s sarcoma (38%).
Heterosexual transmission
In 2012, 38% of newly diagnosed cases (n=130) were 
infected via heterosexual sex. Among the heterosexual 
cases, 63% were born in countries with generalised 
epidemics, 8% had a high-risk partner or a partner 
known to be HIV positive, and 6% had a partner from 
a country with a generalised epidemic.* The number 
of heterosexual cases originating in a country with a 
generalised HIV epidemic had been decreasing since 
2008 but increased slightly in 2012. 
Sixty five percent of the new diagnoses among 
heterosexuals were female, and 35% were male. The 
median age was 35 years (range 16 to 73), 36 years 
in men (range 16 to 73 years) and 33 years in women 
(range 20 to 55 years).
 
Where CD4 count was available, a high proportion 
of heterosexual cases (59%), were diagnosed late 
and 42% were severely immuno-compromised at the 
time of diagnosis. The proportion diagnosed late 
was higher in male heterosexuals (64%) than female 
heterosexuals (56%). Nineteen heterosexual cases 
(15%) were diagnosed with an AIDS defining illness 
at the time of their HIV diagnosis in 2012. The most 
common indicative illnesses among heterosexuals were 
pulmonary TB (21%) and extrapulmonary TB (21%).
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Figure 2: New HIV diagnoses in Ireland by probable route of transmission 
(2003 to 2012)
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*  A generalised HIV epidemic is where greater than 1% of the gen-
eral population is HIV positive. 
Injecting Drug Users (IDUs)
Four percent of new diagnoses were among IDUs and 
this proportion has been declining since 2004. Of the 
13 IDU cases, 10 were men and three were women. The 
median age was 34 years (range 22 to 50 years). Five 
were born in Ireland, three were born in Central and 
Eastern Europe and two were born in Western Europe.
Where CD4 count was reported, 63% of IDUs in 2012 
were diagnosed late including 38% who were severely 
immuno-compromised at diagnosis.
Almost 70% of IDUs were co-infected with hepatitis C 
at the time of their HIV diagnosis.
Mother to Child Transmission (MTCT)
Five MTCT cases were newly diagnosed in 2012. 
The probable countries of infection for all cases 
were in sub-Saharan Africa. No MTCT cases were 
identified in children born in Ireland in 2012 (Personal 
Communication; Michelle Goode, Rainbow Clinic, Our 
Lady’s Children’s Hospital, Crumlin).
Discussion
The overall trend in newly diagnosed HIV cases 
in Ireland for the period 2003 to 2012 has been 
relatively stable with most cases occurring in 
specific subgroups of the population, namely MSM, 
heterosexuals from a country with a generalised 
epidemic and IDUs. However, the proportion of cases 
in MSM has been increasing and sex between men has 
been the commonest mode of transmission since 2010. 
Sex between men is also reported as the predominant 
mode of transmission in EU/EEA countries and 
accounted for 39% of the total number of diagnoses 
in 2011 (1). Numbers among heterosexuals in Ireland 
have been decreasing in recent years due to decreasing 
number of cases among those born in a country with 
a generalised HIV epidemic. This trend was reversed 
slightly in 2012. 
Late HIV diagnosis, where a person is unaware of their 
HIV status for many years, carries an increased risk of 
HIV-related illness and death (3). In addition, prompt 
HIV diagnosis and appropriate treatment can provide 
an opportunity to prevent further HIV transmission. In 
2012 (where CD4 count available; 73% of cases), 48% 
were reported as late presenters compared with 52% 
in 2011 (where CD4 count available; 70% of cases). This 
compares with 49% in EU and EEA countries in 2011(1). 
The proportion of those diagnosed late varied by risk 
group and was highest among heterosexual males 
(64%) and IDUs (63%). In 2012, 24% of people were 
severely immuno-compromised at diagnosis compared 
with 33% in 2011. The overall reduction seen in late 
diagnoses between 2011 and 2012 is encouraging, 
but the proportion needs to continue to drop further. 
Strategies to improve uptake of testing in persons 
coming from countries with a generalised epidemic 
need to be strengthened.  There is however a limitation 
in the use of CD4 counts, in that our figures report 
on the number of cases newly diagnosed in Ireland. 
In 2012, 19% of cases counted were reported to have 
tested positive for HIV previously in other countries 
and this should be borne in mind when interpreting 
the data. When these cases were removed from the 
analysis, the proportions late and very late increased to 
49.5% and 26.3% respectively.
In 2012, for the first time, data on co-infections with 
HIV was available. People co-infected with HIV and 
STIs are more likely to transmit HIV during sex (4). In 
2012 overall, 16% of individuals newly diagnosed with 
HIV were co-infected with one or more STI (Chlamydia/
Gonorrhoea/Syphilis). In relation to syphilis, this 
included all stages of infection, including evidence of 
infection at some time, as well as current infection. 
The surveillance information available on newly 
diagnosed cases in 2012 allows us to monitor trends in 
the epidemiology of HIV, and timeliness of diagnosis. 
The detailed 2012 report and slide set are available at 
http://www.hpsc.ie/hpsc/A-Z/HIVSTIs/HIVandAIDS/
SurveillanceReports/.
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This chapter describes data from the antenatal HIV 
screening programme in Ireland in 2012. Background 
information on the system and a copy of the HIV 
antenatal data collection form can be found at  
http://www.hpsc.ie/hpsc/A-Z/HIVSTIs/HIVandAIDS/
AntenatalHIVTesting/ 
Eighteen of twenty maternity hospitals/units provided 
antenatal HIV screening data for 2012. Table 1 describes 
the data collected from maternity hospitals between 
2006 and 2012. Table 2 describes the 2012 data by HSE 
area. 
In 2012, the national reported uptake of HIV antenatal 
screening was 99.9%, ranging from 98% to 100% among 
participating hospitals. However, antenatal screening 
data were only available for 64,803 women in 2012. 
There were 72,225 births in 2012 and while these 
figures are not directly comparable, there is a shortfall 
in returns for approximately 10% of antenatal women. 
Data were not available from two hospitals (one with 
private patients only) and nine hospitals provided data 
on public patients only. 
One hundred and five women tested HIV positive at 
their antenatal screen, giving a HIV prevalence rate 
of 0.16%, the same as 2011. The prevalence of HIV 
infection among pregnant women varied among HSE 
areas, ranging from 0.10% in HSE South to 0.29% in 
HSE Dublin Northeast. Of the 105 HIV cases, 22 were 
newly diagnosed at their antenatal screen (i.e. HIV 
infection was not previously known). The prevalence of 
newly diagnosed HIV infection was 0.03%. Since HIV 
antenatal screening began in 2002, the number of newly 
diagnosed cases has decreased steadily and has been 
stable for the last 3 years (see Figure 1). 
Some hospitals can only provide estimates or proxy 
measures for the number of women booked and/or 
5.4  Voluntary antenatal HIV testing in 
Ireland: 2012
Key Points
National reported uptake rate: 99.9% 
Number HIV positive cases: 105
Prevalence rate: 0.16%
Number new HIV positive cases: 22
Table 1: Results of the antenatal screening programme, 2006 to 2012
2006 2007 2008 2009 2010 2011 2012
No. of hospitals participating 19/21 19/20 18/20 19/20 19/20 20/20 18/20
No. of live births per year (CSO) 65,425 71,389 75,173 75,554 75,174 74,650 72,225
No. of women booked 52,434 60,111 66,558 68,378 70,024 68,111 64,803
No. offered test 52,434 60,052 66,558 68,026 69,615 67,849 64,803
No. tested 51,649 59,522 66,210 67,694 69,292 67,135 64,781
Uptake of HIV antenatal test (%) 98.5 99.0 99.5 99.0 99.0 98.6 99.9
No. HIV positive 113 117 123 140 118 109 105
Prevalence (%) 0.22 0.20 0.19 0.21 0.17 0.16 0.16
No. newly diagnosed HIV positive 34 38 34 32 21 17 22
Prevalence of new diagnoses (%) 0.07 0.06 0.05 0.05 0.03 0.03 0.03
the number offered HIV testing. Booking data was 
retrieved from a variety of sources including maternity 
IT systems (5 hospitals) patient administrations systems 
(5 hospitals), manual extraction (4 hospitals) and 
laboratory systems (2 hospitals).
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Table 2: Results of the antenatal screening programme by HSE area, 2012
HSE area Total number of 
women booked
Uptake of test (%) Prevalence (%) Prevalence of newly diagnosed (%)
Dublin Mid Leinster 23,099 100.0 0.14 0.03
Dublin Northeast 14,466 100.0 0.29 0.08
South 15,043 100.0 0.10 0.03
West 12,195 99.8 0.12 0.01
Ireland 64,803 99.9 0.16 0.03
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
%
 P
os
iti
ve
Year
Prevalence (%) Prevalence of newly diagnosed (%)
Figure 1: Prevalence of HIV and newly diagnosed HIV among pregnant women, 
2002 to 2012
Technical Note:  
*    Percent uptake is calculated as the number of women tested divided by the number of 
women booked, multiplied by 100
**  Prevalence of HIV infection is calculated as the number of women testing positive 
divided by the number of women tested, multiplied by 100
Summary
There were 12,719 notifications of sexually transmitted 
infections (STIs) in 2012, corresponding to a crude 
notification rate of 277.2 per 100,000 population. This 
represents a decrease of 5.4% when compared with 
2011 (n=13,442; rate = 293.0/100,000). The highest 
age-specific rate (1,142/100,000 population) was 
observed among those aged 20 to 29 years in 2012 
(see table 1 and figure 1). In line with previous years, 
Chlamydia trachomatis was the most frequently notified 
STI in 2012, accounting for 48.4% of notifications. 
A significant increase was seen in the number of 
notifications of gonorrhoea, particularly in the HSE East 
region. 
A more detailed report on STIs in 2012 is available on 
the HPSC website at www.hpsc.ie/hpsc/A-Z/HIVSTIs/
SexuallyTransmittedInfections/Publications/STIReports/
Chlamydia:
There were 6,162 Chlamydia notifications in 2012, 
corresponding to a notification rate of 134.3 per 
100,000 population, which was a slight decrease 
compared to the rate of 139.6 reported in 2011. Both 
rates are below the peak rate of 148.4 per 100,000 
recorded in 2008 (see figure 2). Where sex was 
reported, Chlamydia was more frequently reported 
among women (53.6%) than men (44.0%), continuing 
the trend seen in previous years. Chlamydia was most 
frequently reported in those aged 20-29 years (59.1%); 
there has been a slight increase in notifications in those 
aged 30 years and older since 2008.
Gonorrhoea:
The number of gonorrhoea notifications continued to 
increase (+32.9%) in 2012. The notification rate now 
stands at 24.1 per 100,000 population, the highest ever 
recorded for gonorrhoea in Ireland. This rate is also 
much higher than the latest data available from Europe; 
the rate for 28 EU/EEA Member States was 12.6 per 
100,000 population1 in 2011. In Ireland, the majority 
of gonorrhoea notifications continue to be reported 
in men (n=864; 78.0%). In line with previous years, 
the majority of gonorrhoea notifications in 2012 were 
reported in those aged 20-29 years (55.6%). During 
2012 the age-specific rate in the 20-29 year age group 
increased to 93.6 per 100,000 population, compared 
to 70.5 during 2011. Rates also increased in the 0-19 
and 30-39 year age groups. The notification rates in 
each HSE area from 2009 to 2012 are shown in figure 3. 
The rate was highest in the HSE East area and has risen 
significantly year on year. 
5.5  Sexually Transmitted Infections  
 (STIs), 2012
Summary
Total number of STI notifications in 2012: 12,719
Crude notification rate, 2012: 277.2/100,000
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Table 1: STI notifications and percentage change, 2011-2012
STI 2011 2012 % change
Ano-genital warts 2605 1981 -24.0
Chancroid 0 0 0.0
Chlamydia trachomatis 6407 6162 -3.8
Gonorrhoea 834 1108 +32.9
Granuloma inguinale 0 0 0.0
Herpes simplex (genital) 1263 1326 +5.0
Lymphogranuloma venereum 2 4 +100.0
Non-specific urethritis 1603 1539 -4.0
Syphilis 653 518 -20.7
Trichomoniasis 75 81 +8.0
Total 13442 12719 -5.4
Ano-genital warts:
Ano-genital warts was the second most frequently 
reported STI in 2012, accounting for 15.6% of all STI 
notifications. The number of notifications (n=1,981) 
represents a 24% decrease compared to 2,605 
notifications reported in 2011 (table 1). There were 
more notifications among men (56.6%) and 61.3% of 
cases were aged 20-29 years.
Herpes simplex (genital):
Notifications of herpes simplex (genital) increased by 
5.0% between 2011 and 2012 (table 1). The notification 
rate was 28.9 per 100,000; the highest rate recorded 
since genital herpes was added to the list of notifiable 
diseases in 1985. The increase in notifications seen in 
recent years may be due to improved detection as a 
result of the introduction of molecular testing which 
is more sensitive than viral culture. Herpes simplex 
(genital) was reported among more women (65.3%) than 
men (32.7%) and was most frequently reported among 
20-29 year olds (51.1%).
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Figure 1: STI notification rates, age specific notification rates, and percentage of cases in which age group data 
was missing, 1995-20121
Figure 2: Chlamydia trachomatis notification rates by gender, 1995-2012
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Lymphogranuloma venereum (LGV) 
Four cases of LGV were reported in 2012 all in men 
aged 20-39 years old. Although LGV rarely occurs in 
Western Europe, outbreaks among MSM have occurred 
in the United Kingdom and the Netherlands in the past 
few years. 
Non-specific urethritis 
Non-specific urethritis (NSU) notifications decreased by 
4% during 2012 (n=1,539) compared to 2011 (n=1,603) 
(table 1). 
Trichomoniasis 
There were 81 cases of trichomoniasis notified in 
2012. Where sex was reported, notifications were all 
female. Trichomoniasis continues to be reported more 
commonly among older age groups, with just 28.4% of 
case reported in those aged 20-29 years, while 70.4% of 
cases were aged 30 years or older. 
Data on syphilis, HIV and hepatitis B are presented 
elsewhere in this report.
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Figure 3: Gonorrhoea notification rates by HSE area and year with 95% confidence intervals, 2009-2012
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In 2012, all cases of syphilis notified from laboratories 
and clinicians were entered into the Computerised 
Infectious Disease Reporting System, CIDR.  Enhanced 
information was sought on all notified cases, including 
demographic information, reason for attending, stage 
of infection, ethnicity, presence of symptoms, and 
probable country of infection. From July 2012, an 
additional question was added regarding whether the 
case had a history of treated syphilis with no current 
indication of current infection 
During 2012, there were 561 notification of syphilis 
made via CIDR and enhanced surveillance forms were 
received for 50% of cases (279 forms). Of the 561 cases 
notified, it was indicated that 43 cases had a history 
of previously treated syphilis with no evidence of 
recent infection, including one case of tertiary syphilis 
and these cases were excluded from further analysis. 
The remaining 518 cases were included for analysis, 
giving a crude incidence rate (CIR) of 11.3 per 100,000 
population. Of the 518 notifications, there were 116 
early infectious syphilis cases (primary, secondary 
and early latent), 28 were late syphilis (27 were late 
latent and one was tertiary), 103 were latent cases of 
undetermined duration, 12 were of unknown stage 
and the stage of infection was not specified for the 
remaining 259 cases. There were no congenital syphilis 
cases notified in 2012. 
Figure 1 shows the trend in CIR for all cases and 
early cases from 2000 to 2012 and Table 1 shows the 
breakdown of all notified cases of syphilis in 2012 by 
stage of infection and HSE area. 
Early infectious syphilis
One hundred and sixteen cases of early infectious 
syphilis were notified in 2012, giving a crude incidence 
rate of 2.5 per 100,000 population (see figure 1 for 
trends). This compares to 171 early infectious cases 
in 2011 (CIR: 3.7 per 100,000) and represents a 31% 
decrease in notifications of early infectious syphilis. A 
summary of early infectious syphilis cases diagnosed in 
2010, 2011 and 2012 is shown in Table 2. 
Of the 116 early infectious cases notified in 2012
•   61 (52.6%) were classified as primary syphilis, 31 
(26.7%) as secondary syphilis and 24 (20.7%) as early 
latent. 
5.6 Syphilis, 2012
Summary
Total number of syphilis notifications: 518
Number of early infectious syphilis cases: 116
Crude incidence rate of early infectious syphilis:
2.5 per 100,000 population
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Figure 1: Crude incidence rate of total syphilis and early infectious syphilis (per 100,000 
population), 2000-2012
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•   Rates varied throughout the country, with the rate 
in HSE East (Dublin, Kildare and Wicklow) twice the 
national rate (4.8 per 100,000 versus 2.5 per 100,000)
•   The majority of cases (87.9%) occurred in males with 
a male to female ratio of 9:1. 
•   The most frequently reported age group was 25-
29 years (20.7%) and the median age was 33 years 
(range 19-68 years). 
•   The majority of cases (71%) were among men 
who have sex with men (MSM) and a significant 
proportion of MSM (29%) were co-infected with HIV 
at the time of their syphilis diagnosis. The proportion 
has increased since 2011, when it was 21%. 
•   Twenty one percent were among heterosexuals. Eight 
percent of heterosexuals were co-infected with HIV. 
•   The proportion of re-infections was 18.1% overall 
with the proportion amongst MSM at 24.4% and no 
re-infections among heterosexuals. 
Discussion
In 2012, there was a fall in both the total and early 
infectious syphilis case numbers. Rates dropped from 
14.3 per 100,000 for total cases and 3.7 per 100,000 
for early cases in 2011 to 11.3 per 100,000 and 2.5 per 
100,000 respectively in 2012. 
The enhanced data available in 2012 demonstrate that 
cases of infectious syphilis are concentrated in the MSM 
population, with evidence of ongoing risky behaviour 
in some of those affected. They also illustrate the need 
for targeted health promotion and primary prevention 
activities for MSM and the importance of regular 
screening in this group. 
Planned changes to syphilis surveillance, commencing 
January 2014 will focus enhanced surveillance on early 
infectious cases only, thereby hopefully leading to an 
improvement in the quality of the enhanced surveillance 
data. 
A more detailed analysis of syphilis in Ireland in 2012 is 
available in the report Syphilis in Ireland, 2012, which is 
available on the HPSC website www.hpsc.ie.
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Table 1: Number of syphilis cases by HSE area and stage of infection1, 2012 
Stage of infection HSE E HSE M HSE MW HSE NE HSE NW HSE S HSE SE HSE W Total
Congenital 0 0 0 0 0 0 0 0 0
Primary 45 3 6 1 2 0 4 0 61
Secondary 20 3 1 1 1 0 2 3 31
Early latent 12 1 2 2 2 0 5 0 24
Early syphilis 77 7 9 4 5 0 11 3 116
Late latent 17 1 4 0 0 1 2 2 27
Tertiary 0 0 1 0 0 0 0 0 1
Late syphilis 17 1 5 0 0 1 2 2 28
Latent of undetermined duration 65 5 16 2 1 0 11 3 103
Unknown 5 1 2 0 2 0 1 1 12
Not specified 228 3 6 14 1 2 0 5 259
Total 392 17 38 20 9 3 25 14 518
1 Excludes 43 cases with a history of treated syphilis
Table 2: Summary of early infectious syphilis cases, 2010, 2011 and 2012
2010 2011 2012
No. % No. % No. % 
Number of early infectious 
cases
139 - 171 - 116 -
Male 127 91.4 154 90.1 102 87.9
Men who have sex with men 111 79.9 136 79.5 82 70.7
Symptomatic 63 45.3 70 40.9 48 41.4
Infection acquired in Ireland 110 79.1 118 69.0 73 62.9
Born in Ireland 96 69.1 97 56.7 83 71.6
HIV positive 34 24.5 32 18.7 27 23.3
Re-infections 28 20.1 23 13.5 21 18.1
Pregnant at diagnosis 4 2.9 9 5.3 3 2.6
Median age (years) 33 - 31 - 33 -
Age Range (years) 18-70 - 17-68 - 19-68 -
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Other infections
Encephalitis due to viruses not otherwise specified 
(NOS) in the Irish Infectious Disease (Amendment) (No. 
3) Regulations 2011 (SI No. 452 of 2011) are notifiable 
under the disease viral encephalitis. Since 1st January 
2012, a revised version of the case definition of viral 
encephalitis, NOS has come into effect and is detailed 
in the HPSC Case Definitions for Notifiable Diseases 
booklet on the HSPC website (www.hpsc.ie). (Details 
of viral encephalitis cases caused by other notifiable 
diseases, if any, are presented in other chapters in this 
report). Clinicians and laboratories (the latter since 
2004) are legally obliged to notify all cases of viral 
encephalitis.
In 2012, 18 cases of viral encephalitis (NOS) were 
notified in Ireland (0.4/100.000 population). This was 
five cases less than that 23 reported in the previous year 
(figure 1). 
There were twice as many viral encephalitis (NOS) 
cases among females (n=12), than males (n=6) giving 
a male to female ratio of 0.5:1.0. Cases ranged in age 
from seven months to 85 years with a median age of 55 
years. The majority of the notifications occurred in those 
aged 45-64 years (50%; n=9; 0.9/100,000 population) 
followed by the 65+ years age group (27.8%; n=5; 
0.9/100,000 population) (table 1). 
In 2012, seven of the eight HSE areas notified cases 
of viral encephalitis (NOS) (range 1-3), with HSE-E 
accounting for 33.3% (n=6/18) of cases. There were no 
cases reported in HSE-NW in 2012. The national crude 
incidence rate in 2012 was 0.4 (95% CI 0.3–0.7) cases 
per 100,000 population with the rate in HSE-E being 0.4 
(95%CI 0.1–0.7) cases/100,000 population.
Of the 18 cases reported in 2012, all were laboratory 
tested positive and case classified as confirmed.
In recent years herpes simplex virus (HSV) and varicella 
virus have been the two main causative agents of viral 
encephalitis, NOS notifications in Ireland (figure 2). 
Notifications due to HSV and varicella have fluctuated 
considerably between 2010 and 2012: in 2010 there 
6.1 Viral Encephalitis
Summary
Number of cases 2012: 18
Number of cases 2011: 23
Number of cases 2010: 22
Crude incidence rate, 2012: 0.4/100,000
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Table 1. Number, age-specific incidence rates and proportion of viral encephalitis (NOS) cases by age group, 2012
 Causative pathogen  
Age Group
Herpes 
simplex 
virus
Human 
Herpes virus 
type 6
Varicella 
virus Enterovirus Total ASIR % Proportion
<1 0 1 0 0 1 1.38 5.6
1-4 0 1 0 1 1 0.35 5.6
5-14 0 0 0 0 0 0.00 0.0
15-24 0 0 0 0 0 0.00 0.0
25-44 1 0 0 0 1 0.07 5.6
45-64 8 1 0 0 9 0.86 50.0
65+ 3 0 2 0 5 0.93 27.8
All ages 12 3 2 1 18 0.39 100
% total cases 66.7 16.7 11.1 5.6 100.0   
ASIR, age specific incidence rate per 100,000 population of total cases
were 10 HSV cases, in 2011 there were 20 and in 2012 
there were 12. Similarly with varicella, there were 11 
cases reported in 2010, but only one and two cases 
reported in 2011 and 2012, respectively. Of the 12 
HSV encephalitis cases notified in 2012, 10 were 
reported as HSV type 1, one as type 2 and the typing 
details of the remaining case were not reported.
There no reported deaths associated with viral 
encephalitis in 2012 nor were there any imported 
cases in the same year.
In summary the numbers of viral encephalitis 
notifications in Ireland between 2011 and 2012 fell by 
21.7%. During the same period, there was a marked 
decline in viral encephalitis notifications associated 
with HSV from 20 to 12.
The figures presented in this report are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 29th July, 2012. These 
figures may differ from those published previously due 
to ongoing updating of notification data in CIDR.
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Figure 1. Annual number of viral encephalitis (NOS) cases by age group, 1997-2012
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Figure 2. Annual number of viral encephalitis (NOS) cases by causative pathogen, 1997-2012
Meningitis due to viruses not otherwise specified (NOS) 
in the Irish Infectious Disease (Amendment) (No. 3) 
Regulations 2011 (SI No. 452 of 2011) are notifiable 
under the disease viral meningitis. Since 1st January 
2012, a revised version of the case definition of viral 
meningitis, NOS has come into effect and is detailed 
in the HPSC Case Definitions for Notifiable Diseases 
booklet on the HSPC website (www.hpsc.ie). (Details 
of viral meningitis cases caused by other notifiable 
diseases (such as mumps and influenza viruses, if any) 
are presented in other separate chapters in this report). 
Clinicians and laboratories (the latter since 2004) are 
legally obliged to notify all cases of viral meningitis.
In 2012, 235 cases of viral meningitis (NOS) were 
notified in Ireland, the highest number recorded since 
1997 (figure 1). One death as a direct cause by viral 
6.2 Viral Meningitis
Summary
Number of cases 2012: 235
Number of cases 2011: 220
Number of cases 2010: 168
Crude incidence rate, 2012: 5.1/100,000
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Figure 1. Number of viral meningitis (NOS) cases by age group (<25, >25 
years of age) and year, 1997-2012 
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Table 1. Number, age-specific incidence rates and proportion of viral meningitis (NOS) notifications by age group and causative 
pathogen, 2012
 Causative pathogen    
Age
 Group
enterovirus
human 
herpes 
virus
varicella 
virus
herpes 
simplex 
virus
echovirus adenovirus
coxsacki-
evirus
parechovirus unk Total ASIR
% 
Proportion
<1 87 17 0 1 1 0 1 1 3 111 153.3 47.2
1-4 14 3 0 0 0 1 0 0 2 20 7.0 8.5
5-14 11 1 1 0 0 0 0 0 1 14 2.2 6.0
15-24 18 0 2 0 0 0 0 0 4 24 4.1 10.2
25-34 34 0 1 1 0 0 0 0 1 37 4.9 15.7
35-44 17 0 0 1 1 0 0 0 2 21 3.0 8.9
45-54 2 0 1 0 1 0 0 0 1 5 0.9 2.1
55-64 1 0 0 0 0 0 0 0 0 1 0.2 0.4
65+ 1 0 1 0 0 0 0 0 0 2 0.4 0.9
All ages 185 21 6 3 3 1 1 1 14 235 5.1 100
% total 
cases
78.7 8.9 2.6 1.3 1.3 0.4 0.4 0.4 6.0 100.0   
ASIR, age specific incidence rate per 100,000 population; unk, unknown/organism not reported
meningitis (NOS) was reported in an infant <2 years of 
age in 2012. Another death in 2012 was also reported in 
a case that had viral meningitis, but it is unknown if the 
infection was the cause of death. Since 1997 only seven 
deaths have been reported in cases of viral meningitis, 
only one of which was attributable to the infection.
Of the 235 cases notified in 2012, 220 were classified 
as confirmed (93.6%), 11 as probable (4.7%) and four as 
possible (1.7%). There were more cases among males 
(n=130) than in females (n=103), giving a male to female 
ratio of 1.3:1.0. Two cases were reported with unknown 
gender details.
Children and young adults were most commonly 
affected with a median age of 1.7 years (range one 
week to 86 years). Nearly 72% of cases (n=169) occurred 
in those under 25 years of age (figure 1, table 1). 
The highest age specific incidence rate (ASIR) was in 
infants <1 year of age (153.3/100,000; n=111). The 
next highest ASIR was in the 1-4 years age group 
(7.0/100,000; n=20). Lowest rates were reported in 
the older age groups 55-64 and 65+ with rates of 
0.2/100,000 (n=1) and 0.4/100,000 (n=2), respectively 
(table 1). 
The national crude incidence rate in 2012 was 5.1 (95% 
CI 4.5 – 5.8) cases per 100,000 population, a 6.8% 
increase compared with 2011 when 220 cases were 
notified (4.8/100,000). The incidence rate in 2012 was 
highest in HSE-E at 8.0/100,000 (95%CI 6.7–9.4) and 
lowest in HSE-S at 2.1/100,000 (95%CI 1.0-3.2), both of 
these rates were significantly different from the national 
rate (figure 2).
In 2012, enterovirus was the most common pathogen 
associated with viral meningitis, accounting for nearly 
78.9% (n=185/235) of all notifications (figure 3, table 
1). Human herpes virus (type 6) (HHV) was the causative 
pathogen for 8.9% (n=21) notifications; varicella 
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Figure 2. Crude incidence rates per 100,000 population with 95% confidence 
intervals for viral meningitis (NOS) cases by HSE area, 2012
Figure 3. Number of viral meningitis (NOS) cases by organism type and year, 
1997-2012
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for 2.6% (n=6) and herpes simplex virus (HSV) and 
echovirus each accounted for 1.3% (n=3 each) (figure 3, 
table 1).
Enterovirus was also the most common pathogen in 
infants under one year of age with viral meningitis 
(NOS) in 2012 with 87 of the 111 cases (78.3%) in 
this age group (figure 4). Between 2008 and 2012 
enteroviruses accounted for 70.5% (n=608/862) of all 
viral meningitis (NOS) cases, with a distinct seasonal 
peak observed in the period June to August (figure 5).
 
The figures presented in this report are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 29th July, 2013. These 
figures may differ from those published previously due 
to ongoing updating of notification data in CIDR.
 
Figure 5. Three-month moving average of the annual number of enterovirus 
notifications, 2008-2012
Figure 4. Number of enterovirus cases notified by age group and gender, 2012
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Five cases of Creutzfeldt-Jakob disease (CJD) were 
notified in 2012 compared to seven cases in 2011.  All 
cases in 2012 were sporadic CJD cases.  Two of the 
cases were in the age group 45-54 years and three 
cases were in the age group ≥65 years.  Two cases were 
female and three were male.
In total, 63 cases of CJD were notified since CJD was 
first specified as a notifiable disease in December 1996 
(figure 1).  Figure 2 shows the 63 CJD notifications by 
age group.  The majority (81%, n=51) of the cases were 
aged greater than 54 years.  Of the 63 cases, 34 were 
male and 29 were female.  Sixty cases were sporadic 
CJD, two were familial CJD and one was iatrogenic 
CJD.
Variant CJD (vCJD) is specified as a separate notifiable 
disease.  No cases have been notified since 2006.  In 
total, four cases of vCJD were notified since vCJD 
became notifiable in December 1996.  A summary of 
these four cases was provided in the 2006 HPSC annual 
report. 
Data presented in this summary are based on 
notifications from HSE Areas and from the Irish National 
Creutzfeldt-Jakob Disease Surveillance Unit.  Annual 
figures published here are based on the year the 
notification was entered on the Computerised Infectious 
Disease Reporting (CIDR) system and consequently may 
differ from annual figures published by the Irish National 
Creutzfeldt-Jakob Disease Surveillance Unit.
6.3 Creutzfeldt-Jakob disease  
Summary
Number of cases, 2012: 5
Number of cases, 2011: 7
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Figure 1.  Number of CJD notifications by year from December 
1996 to 2012
Figure 2.  Number of CJD notifications (n=63) from December 
1996 to 2012 by age group
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One case of tetanus was notified in 2012.  This is 
the first case notified since 2008.  The case was 
unvaccinated, in the age group 10-14 years and 
the risk factor for infection was a foot wound 
injury from a thorn.  The case was hospitalised but 
recovered following treatment with antibiotics and 
immunoglobulin. 
Summary of case data since 1981:
Thirteen cases of tetanus were reported since tetanus 
became notifiable in November 1981.  The number of 
tetanus cases notified by age group is shown in figure 1. 
Two deaths were reported, both cases were aged >60 
years.  
Of the 13 tetanus cases, eight (62%) were male, three 
(23%) were female while gender was unreported for two 
(15%).
The following wound injuries (n=9) were reported 
among the 13  notified cases: wound injuries from a 
road traffic accident (n=1), wound from a fall outdoors 
(n=1), wound associated with dog bite (n=1), wound 
from kitchen knife (n=1), gardening associated leg 
wound (n=1), leg scratches in an avid gardener (n=1), 
hand wound associated with a clean piece of wood 
(n=1), a farming associated hand wound (n=1) and a 
foot wound from a thorn (n=1)
Vaccination data was reported for four of the 13 cases.  
Two cases were unvaccinated.  One case, in the age 
group 15-19 years, was reported to have received three 
doses of tetanus vaccine as a child and a booster at 
four years and again at five-six years of age.  One case 
was reported to have received a single tetanus vaccine 
around 40 years prior to infection.  
Tetanus vaccine provides protection in 90-95% 
of children who are fully vaccinated. However, as 
protection declines over time up to 50% of 20-year-olds 
and up to 70% of 70-year-olds may be unprotected 
if they have not received boosters.  The childhood 
immunisation schedule in Ireland recommends children 
receive a dose of tetanus toxoid-containing vaccine at 
two, four and six months of age and booster doses at 
four-five years and 11-14 years of age.  For vaccinated 
persons who have received five doses of tetanus toxoid, 
booster doses may be considered every 10 years. This 
is based on concern regarding the decline of antibody 
6.4 Tetanus
Summary
Number of cases, 2012: 1
Number of cases, 2011: 0
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Figure 1.  Tetanus cases notified (n=13) from 1982 to 2012 by age group
levels with age and potential failure of single booster 
doses to produce protective levels in older individuals.  
For more detailed information on tetanus immunisations 
please see the document Immunisation Guidelines for 
Ireland available at www.immunisation.ie.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 25th July 2013.  
These figures may differ from those published 
previously due to ongoing updating of notification data 
on CIDR.
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Infectious Disease Outbreaks
During 2012, 518 outbreaks of infectious diseases 
were reported with 6,622 associated cases of illness, 
including 1,473 (22.2%) cases hospitalised and 20 
deaths.* Regional variation in outbreaks was observed 
between HSE areas with the highest rates observed 
in HSE-NW (22.5/100,000 population) and HSE-M 
(17.4/100,000 population) while the lowest rate was 
observed in HSE-MW at 8.7 per 100,000 population. 
Table 1 details the regional distribution of all outbreaks 
of infectious disease, outbreaks of infectious intestinal 
disease (IID) and outbreaks of non-IID.
General outbreaks accounted for 65.4% (n= 339) of 
all outbreaks notified during 2012. The remaining 
outbreaks (34.6%, n= 179) were reported as family/
household outbreaks. Similar to previous years, 
person-to-person spread† was reported as the mode 
of transmission for the majority of outbreaks in 2012 
(68.9%, n=357). Most of these outbreaks were due 
to norovirus, acute infectious gastroenteritis (AIG), 
pertussis and verotoxigenic E. coli (VTEC). 
The most frequently reported outbreak locations in 
2012 were private houses (n=161, 31.1%), residential 
institutions (n=110, 21.2%) and community hospital/ 
long-stay units (n=90, 17.4%). The highest numbers ill 
were reported from outbreaks in hospitals (n=1,978), 
residential institutions (n=1,790) and community 
hospital/long-stay units (n=1,534). Table 2 details the 
number of IID and non-IID outbreaks and numbers ill by 
outbreak location for outbreaks reported during 2012. 
Infectious intestinal disease (IID) outbreaks:
During 2012, 405 IID outbreaks were reported, which 
was an increase of 43.6% compared to the number of 
IID outbreaks reported during 2011 (n=282). However, 
the percentage of IID outbreaks as a proportion of total 
outbreaks remained stable at 78.2% when compared 
to recent years (74.4% in 2011 and 77.7% in 2010). The 
Table 3 details the regional distribution of outbreaks of 
infectious intestinal disease (IID) during 2012.
7. Outbreaks
Summary
Number of outbreaks: 518
Number of IID outbreaks: 405
Number of non-IID outbreaks: 113
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Table 1:  Number of outbreaks by HSE area, 2012
HSE area Number of 
outbreaks
Outbreak rate 
per 100,000
Number ill Number 
hospitalised
Number of 
deaths
Number of IID 
outbreaks
Number of 
Non-IID 
outbreaks
HSE-E 162 10.0 3,284 934 1 112 50
HSE-M 49 17.4 435 21 0 42 7
HSE-MW 33 8.7 262 117 1 28 5
HSE-NE 43 9.8 469 42 2 38 5
HSE-NW 58 22.5 633 139 8 46 12
HSE-SE 50 10.0 647 11 1 40 10
HSE-S 62 9.3 413 21 4 47 15
HSE-W 60 13.5 452 182 3 51 9
HPSC 1 - 27 6 0 1 0
Total 518 11.3 6,622 1473 20 405 113
*Outbreak data extracted from CIDR on 07/08/2013.
† Including 87 outbreaks reported as person to person and airborne transmission and 2 person-to-person and animal contact
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Figure 1:  Number of norovirus/suspected viral outbreaks§ and number of non-norovirus IID outbreaks by year, 2001-2012
Table 2: Number of IID and non-IID outbreaks and number ill by outbreak location, 2012
Outbreak location
IID Non-IID Total outbreaks
Number of 
outbreaks
Number ill
Number of 
outbreaks
Number ill
Number of 
outbreaks
Number ill
Comm. Hosp/Long-stay unit 75 1,312 15 222 90 1,534
Community outbreak 9 99 5 63 14 162
Crèche 9 88 7 57 16 145
Extended family 5 26 4 13 9 39
Guest house / B & B 1 1 0 0 1 1
Hospital 60 1,879 8 99 68 1,978
Hotel 11 249 0 0 11 249
Other 5 60 7 41 12 101
Private house 112 235 49 133 161 368
Residential institution 99 1,531 11 259 110 1,790
Restaurant / Cafe 3 38 0 0 3 38
School 2 42 7 116 9 158
Travel related 5 28 0 0 5 28
University/College 1 6 0 0 1 6
Unknown 2 4 0 0 2 4
Not Specified 6 21 0 0 6 21
Total 405 5,619 113 1,003 518 6,622
Table 3: IID outbreak summary by HSE area 2012
HSE area Number of outbreaks Outbreak rate per 
100,000
Number ill Number hospitalised Number of deaths
HSE-E 112 6.9 2,890 866 0
HSE-M 42 14.9 367 18 0
HSE-MW 28 7.4 246 105 1
HSE-NE 38 8.6 397 34 0
HSE-NW 46 17.8 447 122 1
HSE-SE 40 8.0 612 7 0
HSE-S 47 7.1 269 7 0
HSE-W 51 11.5 364 165 0
HPSC 1 - 27 6 0
Total 405 8.8 5,619 1,330 2
§ Includes all norovirus outbreaks and AIG outbreaks where organism was suspected norovirus, suspected viral or not specified
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Figure 2: Number of IID and non-IID outbreaks by month of notification, 2012
Table 5: Non-IID outbreak summary by HSE area, 2012
HSE area Number of 
outbreaks
Outbreak rate per 
100,000
Number ill Number hospitalised Number of deaths
HSE-E 50 3.1 394 68 1
HSE-M 7 2.5 68 3 0
HSE-MW 5 1.3 16 12 0
HSE-NE 5 0.0 72 8 2
HSE-NW 12 4.6 186 17 7
HSE-SE 10 2.0 35 4 1
HSE-S 15 2.3 144 14 4
HSE-W 9 2.0 88 17 3
Total 113 2.5 1,003 143 18
Table 4:  Number of general and family IID outbreaks by disease, 2012
Outbreak disease/pathogen
Family outbreak General outbreak Total IID outbreaks
Number of 
outbreaks
Number ill
Number of 
outbreaks
Number ill
Number of 
outbreaks
Number ill
AIG 2 22 85 1,000 87 1,022
Campylobacter infection 4 13 0 0 4 13
C. difficile infection 0 0 7 40 7 40
Cryptosporidiosis 21 51 3 19 24 70
Food poisoning (bacterial other 
than salmonella)
0 0 1 9 1 9
Hepatitis A (acute) 2 4 0 0 2 4
Listeriosis 1 2 0 0 1 2
Noroviral infection 2 7 162 4,108 164 4,115
Rotavirus infection 9 16 9 16
Salmonellosis 4 9 2 30 6 39
Shigellosis 1 3 0 0 1 3
Typhoid 2 3 0 0 2 3
VTEC 80 157 17 126 97 283
Total 128 287 277 5,332 405 5,619
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Table 6: Number of family and general non–IID outbreaks by disease, 2012
Outbreak disease/pathogen
Family outbreak General outbreak Total Non-IID outbreaks
Number 
outbreaks
Number ill
Number 
outbreaks
Number ill
Number 
outbreaks
Number ill
Pertussis 38 100 3 57 41 157
Influenza 0 0 19 402 19 402
Tuberculosis 4 12 3 11 7 23
Respiratory Illness 0 0 6 61 6 61
Measles 0 0 3 68 3 68
Viral meningitis 2 4 1 3 3 7
Suspected pertussis 3 7 0 0 3 7
Hand foot and mouth disease (HFMD)/ suspected 
HFMD
0 0 3 22 3 22
Hepatitis B (acute and chronic) 1 6 1 1 2 7
Mumps 1 2 1 5 2 7
Respiratory syncytial virus infection 0 0 2 14 2 14
Human metapneumovirus 0 0 2 67 2 67
MRSA 0 0 2 12 2 12
Scarlet fever 0 0 2 20 2 20
Parvovirus B19/ suspected parvovirus B19 0 0 2 8 2 8
Scabies/ suspected scabies 0 0 2 17 2 17
Hepatitis C 1 2 0 0 1 2
Streptococcus group A infection (invasive) 1 3 0 0 1 3
Syphilis 0 0 1 4 1 4
Acute respiratory illness 0 0 1 17 1 17
Coxsackievirus 0 0 1 11 1 11
Influenza-like illness 0 0 1 13 1 13
Linezolid resistant VRE 0 0 1 6 1 6
Neisseria gonorrhoeae 0 0 1 4 1 4
Parvovirus B20 0 0 1 6 1 6
Streptoccus Group A 0 0 1 3 1 3
Suspected parvovirus 0 0 1 12 1 12
Varicella chickenpox 0 0 1 23 1 23
Total 51 136 62 867 113 1003
Norovirus/ suspected viral outbreaks, accounted for 
62.0% of all IID outbreaks reported in 2012. Figure 1 
compares norovirus/ suspected viral outbreaks with 
non-norovirus IID outbreaks by year from 2001 to 2012. 
Norovirus/ suspected norovirus was also responsible 
for the seven largest outbreaks during 2012. Numbers 
ill ranged from two cases to 336 cases. This was the 
highest number of norovirus/ suspected norovirus 
outbreaks reported since outbreak surveillance was 
initiated in Ireland in 2001.
After noroviral infection (n=164), the next most 
commonly reported IID outbreaks during 2012 were 
VTEC (n=97), AIG (n=87), and cryptosporidiosis (n=24). 
The number of general and family outbreaks of IID and 
numbers ill, are outlined in Table 4.  
The most frequently reported locations for IID 
outbreaks were private houses (n=112), residential 
institutions (n=99) and community hospital/long 
stay facilities (n=75). The most commonly reported 
outbreak in private houses was VTEC (n=72) and 
cryptosporidiosis (n=20). In community hospital/long 
stay facilities the most commonly reported outbreaks 
were of noroviral infection (n=42) and AIG (n=33). In 
residential institutions the most commonly reported 
outbreaks were of norovirus (n=60) and AIG (n=37).
Person-to-person (P-P) spread‡ was the most frequently 
reported mode of transmission implicated in IID 
outbreaks during 2012 (64.4%, n=261). 
In 2012, the number of IID outbreaks peaked during 
November and December. This peak was mainly due 
to high numbers of norovirus/ suspected norovirus 
outbreaks, with 51 norovirus/ suspected norovirus 
outbreaks reported during November and 54 during 
December. Figure 2 illustrates the number of IID and 
non-IID outbreaks by month of notification during 2012.
Non-IID outbreaks:
During 2012, 113 outbreaks of non-IID diseases were 
reported, representing 21.8% of all outbreaks notified 
nationally. The most common non-IID outbreak diseases 
were pertussis (36.3%, n=41) and influenza (16.8%, 
n=19). Table 5 details the regional distribution of non-
‡Including 63 IID outbreaks reported as person to person and airborne transmission and 2 reported as person-to-person and animal transmission.
**Including 24 non-IID outbreaks reported as person to person and airborne transmission
IID outbreaks while the number of general and family 
outbreaks of non-IID disease and numbers ill are 
outlined in Table 6. The number of non-IID outbreaks 
peaked during April and May 2012. The April peak 
was mainly due to influenza, influenza-like illness (ILI) 
and acute respiratory outbreaks while the May peak 
was due to high numbers of pertussis outbreaks 
reported (figure 2). 
The most frequently reported locations for non-IID 
outbreaks were private houses (n=49), Comm. Hosp/
Long-stay units (n=15) and residential institutions 
(n=11) as shown in table 2. Non-IID outbreaks in 
these locations were most frequently caused by 
pertussis, influenza and ILI. Person-to-person (P-P) 
spread** was the most frequently reported mode of 
transmission implicated in non-IID outbreaks during 
2012 (85.0%, n=96). 
The information gathered from outbreaks reported 
is used to inform public health professionals on 
the causes and factors contributing to outbreaks, 
to target prevention strategies and to monitor the 
effectiveness of prevention programmes. For further 
information on disease specific outbreaks, please 
refer to the individual disease chapter.
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Immunisation Uptake
In 2012, the HSE Areas provided HPSC with quarterly 
immunisation uptake data for their Area and for each of 
the Local Health Offices (LHOs) in their Area.  HPSC col-
lated these data and quarterly reports were produced 
which are available on the HPSC website.  The annual 
immunisation uptake rates presented here represent 
the collation of the 2012 quarterly data.  The propor-
tion of children who completed the recommended 
childhood immunisation schedule by 12 months (born 
between 01/01/2011 and 31/12/2011) and 24 months 
(born between 01/01/2010 and 31/12/2010) of age in 
2012 are reported.  
Since September 1st 2008 the new primary childhood 
immunisation schedule has been implemented for 
children born on or after July 1st 2008 (table 1).  These 
children should receive one dose of vaccine against 
tuberculosis (BCG vaccine) at birth or by one month of 
age; three doses of vaccines against diphtheria (D3), 
tetanus (T3), pertussis (P3),  Haemophilus influenzae type 
b (Hib3), polio (Polio3) and Hepatitis B (HepB3) with one 
dose of each given at two, four and six months of age; 
three doses of pneumococcal conjugate vaccine (PCV3) 
given at two, six and 12 months of age and three doses 
of meningococcal group C (MenC3) vaccine given at 
four, six and 13 months of age.  Also at 12 months of 
age a dose of MMR (MMR1) is recommended and at 13 
months a dose of Hib (Hibb) is recommended.  Further 
vaccinations are recommended for older children and 
adults; please see www.immunisation.ie for complete 
information on the Irish immunisation schedule.
In children who reached 12 months of age in 2012 (born 
between 01/01/2011 and 31/12/2011) uptake of BCG, 
D3, T3, P3, Hib3, Polio3, HepB3 and two doses of PCV 
(PCV2) and MenC (MenC2) were measured.  In children 
who reached 24 months of age in 2012 (born between 
01/01/2010 and 31/12/2010) uptake of D3, T3, P3, Hib3, 
Polio3, HepB3, MenC3, PCV3, MMR1, Hibb, one dose of 
vaccine against meningococcal group C (MenCb) on or 
after twelve months of age and one dose of vaccine 
against pneumococcal conjugate vaccine (PCVb) on or 
after twelve months of age were measured.  
The immunisation uptake rates are reported here by 
HSE Area and LHO.  While there are 32 LHOs the im-
munisation uptake rates for the LHOs of North Lee and 
South Lee are reported as a combined figure.
Caveats to data
Not all HSE Areas were able to provide data during 
2011 and 2012.  BCG uptake data were available for the 
HSE-M, HSE-MW, HSE-NW, HSE-SE and HSE-S Areas in 
Quarters 1-4 2011 and the HSE-W in Quarters 3-4 2011. 
In Quarters 3 and 4 2011 the HSE-W reported BCG up-
take data (4%), for children at 12 months of age for the 
first time, resulting in a low national uptake rate (85%) 
compared to previous years.  This is not a true decline 
as uptake rates are based on available data and the 
HSE-W BCG data were not available previously. Tradi-
tionally BCG was given at age 10 - 12 years in the HSE-
W.  BCG uptake data were available for the HSE-M, 
HSE-MW, HSE-NW, HSE-SE, HSE-S and HSE-W Areas in 
Quarters 1-4 2012.  The available national BCG cohort 
data may be around 48% of the national birth cohort in 
8.1 Immunisation Uptake
Summary
Among children 12 months of age in 2012 uptake of:
D3, T3, P3, Hib3, Polio3, HepB3, MenC2 and PCV2 was 
91% 
Among children 24 months of age in 2012 uptake of:
D3, T3, P3, Hib3, Polio3 and HepB3 reached the target 
of 95% 
MMR1 was 92%
PCV3 was 91%
Hibb was 89%
MenC3 was 85%  
MenC3 and Hibb uptake are considerably lower than 
the uptake of the other recommended vaccines.  The 
childhood immunisation schedule is shown in table 1. 
Five GP visits are required to ensure children receive 
all their recommended doses of vaccine.  
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2011 and 52% of the national birth cohort in 2012 (these 
figures are estimates only).  HSE-W BCG data were not 
available by LHO.  
As uptake of MenC3 and Hibb were low since Q3 2010 
and as those over 12 months need only one dose of 
MenC and those aged 12-23 months need only one 
dose of PCV, data on MenCb (one dose of MenC on 
or after twelve months of age) and PCVb (one dose of 
PCV on or after twelve months of age) was requested in 
2012 for the first time.  Six HSE Areas (HSE-E, M, MW, 
NW, SE and S) were able to provide data representing 
approximately 81% (estimate only) of the national birth 
cohort.
Immunisation uptake rates at 12 months
National immunisation uptake rates, in children 12 
months of age in 2012, were 91% for D3, T3, P3, Hib3, Po-
lio3, HepB3, MenC2 and PCV2 and 80% (based on avail-
able data) for BCG (table 2).  Compared with 2011, the 
uptake rates for D3, P3, T3, Hib3, Polio3, HepB3, MenC2 
and PCV2 increased by one percent in 2012.  
In Quarters 3 and 4 2011 the HSE-W reported BCG up-
take data (4%) for the first time, resulting in an apparent 
decline in reported national uptake in 2011 (85%).  The 
HSE-W BCG uptake in 2012 (Quarters 1-4) was 5%.  Na-
tional uptake of BCG was 80% in 2012.  This is not a true 
decline in 2012 as national uptake rates are based on 
available data and the HSE-W BCG data were not avail-
able previously for all four quarters.
Among the HSE Areas, uptake rates for D3, T3, P3, Hib3, 
Polio3 and HepB3 ranged from 90% to 94% and MenC2 
and PCV2 ranged from 88% to 94% (table 2).  Among 
the LHOs, uptake rates for D3, T3, P3, Hib3, Polio3 and 
HepB3 ranged from 83% to 97%, PCV2 ranged from 82% 
to 98% and MenC2 ranged from 82% to 97% (table 3).  
The target uptake of 95% was reached or exceeded in 
Longford/Westmeath and Roscommon for D3, T3, P3, 
Hib3, Polio3, HepB3, MenC2 and PCV2, in Sligo/Leitrim 
for D3, T3, P3, Hib3, Polio3 and HepB3 and in Tipperary 
NR/East Limerick for MenC2 (table 3).  The target uptake 
of 95% was reached or exceeded for BCG in 12 LHOs 
reporting data (table 3).
Immunisation uptake rates at 24 months
National annual immunisation uptake rates, in children 
24 months of age in 2012, reached the target of  95% 
for D3, T3, P3, Hib3, Polio3 and HepB3 and were 92% for 
MMR1, 91% for PCV3, 89% for Hibb and 85% for MenC3 
(table 2).  Compared with 2011, the uptake rates for 
Hibb, MenC3 and PCV3 increased by one percent while 
D3, T3, P3, Hib3, Polio3 and HepB3 were unchanged (figure 
1).  This is the second year national annual uptake rates 
reached the target of 95% for D3, T3, P3, Hib3, Polio3 and 
HepB3.    
Six of the eight HSE Areas were able to provide uptake 
data on MenCb (one dose of MenC at ≥12 months of 
age) and PCVb (one dose of PCV at ≥12 months of age) 
in 2012. These Areas cover approximately 81% of the na-
tional birth cohort. Where data were available, national 
uptake was 90% for MenCb and 93% for PCVb.  
Since September 1st 2008 the new primary childhood 
immunisation schedule has been implemented for 
children born on or after July 1st 2008 (table 1); children 
who were 24 months of age in Quarter 3 2010 were 
born between July 1st and September 31st 2008 
and were the first children recommended the new 
immunisation schedule.  Under the new immunisation 
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Age Children born before 01/07/2008                      Children born on or after 01/07/2008
Birth BCG BCG
2 months DTaP/Hib/IPV (5 in 1) + MenC DTaP/Hib/IPV/HepB (6 in 1) + PCV
4 months DTaP/Hib/IPV (5 in 1) + MenC DTaP/Hib/IPV/HepB (6 in 1) + MenC
6 months DTaP/Hib/IPV (5 in 1) + MenC DTaP/Hib/IPV/HepB (6 in 1) + PCV + MenC
12 months MMR + Hib MMR + PCV
13 months - MenC + Hib
Please see www.immunisation.ie for complete information on the Irish childhood immunisation schedule including vaccinations for older 
children and adults
BCG  Bacille Calmette Guerin vaccine 
DTaP  Diphtheria, Tetanus and acellular Pertussis vaccine
HepB  Hepatitis B vaccine
Hib  Haemophilus influenzae type b vaccine
IPV  Inactivated Polio Virus vaccine
MenC   Meningococcal group C vaccine
MMR  Measles, Mumps and Rubella vaccine
PCV  Pneumococcal Conjugate Vaccine
Table 1.  Change in primary childhood immunisation schedule (introduced on September 1st 2008)
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Figure 1.  National annual immunisation uptake rates (based on available data) at 24 months, 1999-2012
Since T3 and Polio3 uptake identical to D3 uptake only D3 uptake figures presented.
P3 uptake could not be calculated accurately during 1999-2001 as DTaP/DT uptake was reported as a combined value for the HSE-NE during 
1999, Quarters 3 and 4 2000 and Quarter 1 2001 and the HSE-NW in 2000 and 2001. The 2002 MenC3  figure is based on uptake rates for 
Quarter 3 and Quarter 4 2002 only. The 2005 MMR1 uptake figure is incomplete as the HSE-E was unable to provide MMR data for Quarter-4 
2005, due to technical problems with extraction of MMR1 data from the HSE-E database.  The 2006 MMR1 figure includes the Quarter-1 2006 
HSE-E figure, which is an estimate only due to technical problems with extraction of MMR1 data from the HSE-E database.  The 2007 national 
Hibb figure is incomplete, as the HSE-W data for Quarter 1 2007 and the HSE-NW data for Quarter 3 2007 were not available.  The 2007 nation-
al Hibb figure also includes the HSE-SE data which are an underestimate due to data extraction methods.  The 2008 Hibb figure is incomplete as 
the HSE-SE data for Q2 2008 and the HSE-MW data for Quarter 3 2008 were not available.  The 2008 national MenC3 figure is incomplete as 
the HSE-E and HSE-MW MenC3 data for Quarter 3 2008 were not available. The 2009 data are incomplete as the following were unavailable: 
the Quarter 1 2009 HSE-E D3, T3, P3 and Polio3 data for those born on the 31/03/2007; the Quarter 2 2009 HSE-E Dublin North Hibb uptake data 
and; the Quarter 4 2009 HSE-MW data, HSE-E Dublin North Hibb data and HSE-SE Hibb data for those given a Hib dose as part of the five in 
one or six in one vaccine after 12 months of age.  The 2010 data are incomplete as the following were unavailable: the Quarter 1 2010 HSE-M 
and HSE-S data and the HSE-E Dublin North Hibb data; the Quarter 2 2010 HSE-M data and; the Quarter 4 2010 HSE-NE data. As a new child-
hood immunisation schedule was introduced in 2008, for those born on or after July 1st 2008, the 2010 HepB3 and PCV3 data at 24 months are 
for those born between July 1st and December 31st 2008 (i.e. Quarters 3 and 4 2010 data) only.  The MenCb and PCVb data were available for 
only six of the eight HSE Areas.
Table 2.  Annual immunisation uptake rates (based on available data) by HSE Area for children 12 and 24 
months of age in 2012
% Uptake at 12 months
Cohort born 01/01/2011 - 31/12/2011
% Uptake at 24 months
Cohort born 01/01/2010 - 31/12/2010
D3 HepB3 MenC2 PCV2 BCG D3 Hib3 Hibb HepB3 MenC3 MenCb PCV3 PCVb MMR1
HSE-E 90 90 90 90 na 95 95 88 95 84 87 90 92 92
HSE-M 94 94 94 94 96 97 97 97 97 91 95 94 95 96
HSE-MW 94 94 94 94 97 95 95 90 95 86 90 91 93 93
HSE-NE 91 91 90 90 na 95 95 86 94 84 na 91 na 91
HSE-NW 94 94 94 94 96 97 96 92 96 87 93 91 95 93
HSE-SE 93 93 92 93 96 97 96 95 96 89 93 93 95 94
HSE-S 91 90 88 88 94 96 95 85 95 86 89 91 93 93
HSE-W 91 91 90 91 5 95 95 89 95 82 na 90 na 90
Ireland 91 91 91 91 80 95 95 89 95 85 90 91 93 92
na=not available
Where T3, P3 and Hib3 uptake identical to D3 uptake only D3 uptake figures presented
Polio3 uptake identical to D3 except HSE-SE Polio3 uptake at 24 months was 96%
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Table 3.  Immunisation uptake (%) at 12 months of age in 2012 (i.e. cohort born 01/01/2011-31/12/2011) by LHO and HSE Area
HSE Area Local Health Office/HSE Area
Number in 
cohort for 
BCG *
Number in 
cohort for D3, T3 
& P3 †
Immunisation Uptake (%)
BCG D3 HepB3 MenC2 PCV2
HSE-E
Dublin South na 1738 na 92 92 92 92
Dublin South East na 1792 na 90 90 89 90
Dublin South City na 1808 na 93 93 92 93
Dublin South West na 2789 na 93 93 92 93
Dublin West na 2906 na 91 90 90 90
Dublin North West na 4065 na 83 83 83 82
Dublin North Central na 1891 na 89 89 89 89
Dublin North na 4406 na 91 91 91 91
Kildare/West Wicklow na 4185 na 92 92 92 92
Wicklow na 1885 na 90 90 89 90
HSE-E Total na 27465 na 90 90 90 90
HSE-M
Laois/Offaly 2676 2676 96 94 94 94 94
Longford/Westmeath 1966 1966 95 95 95 95 95
HSE-M Total 4642 4642 96 94 94 94 94
HSE-MW
Clare 1729 1752 97 94 94 93 94
Limerick 2058 2071 98 93 93 93 93
Tipperary NR/East Limerick 1967 1974 97 94 94 95 94
HSE-MW Total 5754 5797 97 94 94 94 94
HSE-NE
Cavan/Monaghan na 2253 na 93 93 91 91
Louth na 2003 na 90 89 88 88
Meath na 3719 na 91 91 90 90
HSE-NE Total na 7975 na 91 91 90 90
HSE-NW
Donegal 2296 2296 95 94 93 94 94
Sligo/Leitrim 1394 1394 97 95 95 94 94
HSE-NW Total 3690 3690 96 94 94 94 94
HSE-SE
Carlow/Kilkenny 2105 2105 97 91 91 91 92
South Tipperary 1399 1399 98 94 94 94 94
Waterford 1985 1985 95 93 92 92 92
Wexford 2261 2261 96 93 93 92 93
HSE-SE Total 7750 7750 96 93 93 92 93
HSE-S
North Cork 1525 1494 93 90 90 88 88
North South Lee 6114 5992 95 92 91 89 89
West Cork 768 765 94 85 85 82 82
Kerry 2063 2037 93 91 90 88 87
HSE-S Total 10470 10288 94 91 90 88 88
HSE-W
Galway na 4014 na 89 89 89 90
Mayo na 1773 na 90 90 89 90
Roscommon na 913 na 97 97 97 98
HSE-W Total 6701* 6700 5 91 91 90 91
Ireland 39007 74307 80 91 91 91 91
na=not available
* HSE-W BCG data were not available by LHO. 
†As the denominator/number in cohort varied slightly according to vaccine. The most commonly used number is reported here. 
Since T3, P3, Polio3 and Hib3 uptake identical to D3 uptake only D3 uptake figures are presented 
Please note while North Lee and South Lee are two separate Local Health Offices their combined immunisation uptake data are reported here.
schedule children are now recommended HepB vaccine 
and PCV.  In addition, there is a change in timing of the 
MenC and Hibb vaccines (table 1). The changes to the 
schedule mean that three injections (6 in 1, PCV and 
MenC vaccines) are now recommended at six months 
of age and two GP visits are required on or after 12 
months; the first dose of MMR and the third dose of 
PCV should be given at 12 months of age and at 13 
months of age the third dose of MenC vaccine and Hibb 
should be given (table 1).  MenC3 uptake was 93% in 
Quarter 1 2010 but declined to 80% in Quarter 3 2010 
and was 82% in Quarter 4 2010 (figure 2).  During 2011 
and 2012, MenC3 increased from 83% in Quarters 1 
and 2 2011 to 87% in Quarter 4 2012.  Hibb was 87% in 
Quarters 1 and 2 2010 but declined to 84% in Quarters 
3 and 4 2010 (figure 2). During 2011 and 2012 Hibb 
uptake increased from 86% in Quarter 1 2011 to 91% 
in Quarter 4 2012.  There was also low uptake of PCV3 
in 2010 (combined Quarters 3 and 4 data was 88%).  
During 2011 and 2012, PCV3 increased from 90% during 
Quarters 1 and 2 2011 to 92% during Quarter 4 2012.
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Table 4.  Immunisation uptake (%) at 24 months of age in 2012 (i.e. cohort born 01/01/2010-31/12/2010) by LHO and HSE Area
HSE Area
Local Health Office/
HSE Area
Number in 
cohort for 
D3, T3 & P3 *
Immunisation Uptake (%)
D3 Hib3 Hibb Polio3 HepB3 MenC3 MenCb PCV3 PCVb MMR1
HSE-E
Dublin South 1739 94 94 90 94 94 87 90 90 92 91
Dublin South East 1706 93 93 89 93 93 86 88 90 91 91
Dublin South City 1802 96 96 86 96 96 82 86 89 91 91
Dublin South West 2665 96 96 90 96 96 84 89 90 94 94
Dublin West 2937 92 92 80 92 92 75 79 87 90 89
Dublin North West 4054 93 93 83 93 93 81 83 87 89 88
Dublin North Central 1737 96 96 90 96 96 85 90 88 92 92
Dublin North 4481 95 95 91 95 95 88 91 92 93 93
Kildare/West Wicklow 4400 96 96 94 96 96 90 93 93 95 94
Wicklow 2122 94 94 83 94 94 79 83 89 91 90
HSE-E Total 27643 95 95 88 95 95 84 87 90 92 92
HSE-M
Laois/Offaly 2764 97 97 97 97 97 91 95 93 95 96
Longford/Westmeath 2107 97 97 97 97 97 92 95 94 96 96
HSE-M Total 4871 97 97 97 97 97 91 95 94 95 96
HSE-MW
Clare 1716 95 95 93 95 95 89 93 92 94 94
Limerick 2041 94 94 89 94 94 85 89 90 92 91
Tipperary NR/East 
Limerick
2090 96 96 89 96 96 85 88 92 94 93
HSE-MW Total 5847 95 95 90 95 95 86 90 91 93 93
HSE-NE
Cavan/Monaghan 2037 96 96 88 96 94 85 na 92 na 92
Louth 1958 94 94 84 94 94 82 na 89 na 90
Meath 3404 95 95 87 95 95 84 na 91 na 91
HSE-NE Total 7399 95 95 86 95 94 84 na 91 na 91
HSE-NW
Donegal 2360 97 97 92 97 96 87 93 91 95 93
Sligo/Leitrim 1428 96 96 93 96 96 86 93 90 95 95
HSE-NW Total 3788 97 96 92 97 96 87 93 91 95 93
HSE-SE
Carlow/Kilkenny 2144 96 96 94 96 96 87 93 92 94 94
South Tipperary 1389 97 97 95 97 97 89 94 94 95 95
Waterford 2081 96 96 94 96 96 89 92 93 94 94
Wexford 2245 97 97 97 97 96 90 95 93 96 95
HSE-SE Total 7859 97 96 95 96 96 89 93 93 95 94
HSE-S
North Cork 1589 97 96 84 97 94 85 87 90 91 92
North South Lee 5998 97 96 86 97 95 87 90 93 94 94
West Cork 768 89 88 75 89 89 76 80 83 86 86
Kerry 1906 97 97 86 97 96 88 91 92 94 94
HSE-S Total 10261 96 95 85 96 95 86 89 91 93 93
HSE-W
Galway 4147 94 94 91 94 94 79 na 89 na 89
Mayo 1800 96 96 82 96 96 82 na 91 na 91
Roscommon 946 98 98 96 98 98 95 na 98 na 96
HSE-W Total 6893 95 95 89 95 95 82 na 90 na 90
Ireland 74561 95 95 89 95 95 85 90 91 93 92
*As the denominator/number in cohort varied slightly according to vaccine. The most commonly used number is reported here. 
Since T3 and P3 uptake identical to D3 uptake only D3 uptake figures are presented
Please note while North Lee and South Lee are two separate Local Health Offices their combined immunisation uptake data are reported here.
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Figure 2.  National quarterly immunisation uptake rates at 24 months
Note scale ranges from 60-100%
P3 uptake could not be calculated accurately during 1999-2001 as DTaP/DT uptake was reported as a combined value for the HSE-NE during 
1999, Quarters 3 and 4 2000 and Quarter 1 2001 and the HSE-NW in 2000 and 2001. The Q4-2005 MMR1 figure is based on data from seven 
of the eight HSE-Areas.  The Q1-2006 MMR1 figure includes the HSE-E figure that is an estimate only.  The Q1-2007, Q3-2007, Q2-2008 and 
Q3-2008 Hibb figures are based on data from seven of the eight HSE Areas.  In Q1-2008 the HSE-SE changed their Hibb data extraction method 
compared to previous quarters; in Q1-2008 the uptake of Hibb in the HSE-SE was 83% compared to 53% in Q4-2007.  The Q3-2008 MenC3 fig-
ure is based on data from six of the eight HSE Areas.  The Q1-2009 HSE-E D3, P3, T3, Polio3 and MMR1 uptake figures exclude those born on the 
31/03/2007.  The Q2-2009 HSE-E Hibb uptake figures exclude uptake figures from Dublin North.  The Q4-2009 figures are based on data from 
seven of the eight HSE Areas.  The Q4-2009 Hibb figures also exclude uptake figures from Dublin North and HSE-SE Hibb data for those given 
a Hib dose as part of the five in one or six in one vaccine after 12 months of age.   The Q1-2010 figures are based on data from six of the eight 
HSE Areas.  The Q1-2010 Hibb figures also exclude uptake figures from HSE-E Dublin North.  The Q2-2010 and Q4-2010 figures are based on 
data from seven of the eight HSE Areas.  MenCb and PCVb figures are based on data form six of the eight HSE Areas.
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Uptake rates among the HSE Areas, for children at 24 
months of age in 2012, for D3, T3, P3, Hib3 and Polio3 
ranged from 95% to 97%, HepB3 ranged from 94% to 
97%, MMR1 ranged from 90% to 96%, PCV3 ranged 
from 90% to 94%, Hibb ranged from 85-97% and MenC3 
ranged from 82% to 91% (table 2).  Among the six Areas 
in a position to provide data MenCb uptake ranged from 
87% to 95% and PCVb uptake ranged from 92% to 95%. 
The target uptake of 95% was reached or exceeded in 
all HSE Areas for the first time during 2012 for D3, T3, P3, 
Hib3 and Polio3 and in seven Areas for HepB3.  In addi-
tion, the target uptake of 95% was reached or exceeded 
in the HSE-M for Hibb, MenCb, PCVb and MMR1, in the 
HSE-NW for PCVb and in the HSE-SE for Hibb and PCVb 
(table 2).
D3, Hibb, MenC3 and MMR1 uptake rates are mapped 
by LHO in figure 3.  Among the LHOs the uptake 
rates ranged from 89% to 98% for D3, T3, P3, Polio3 and 
HepB3, 88% to 98% for Hib3, 86% to 96% for PCVb and 
MMR1, 83% to 98% for PCV3, 79% to 95% for MenCb, 
75% to 97% for Hibb and 75% to 95% for MenC3 (table 
4).  The target uptake of 95% was reached or exceeded 
in 22 LHOs for D3, T3, P3, Hib3 and Polio3, in 20 LHOs for 
HepB3, in seven LHOs for PCVb, in six LHOs for MMR1, 
in five LHOs for Hibb, in three LHOs for MenCb and in 
one LHO for MenC3 and PCV3 (table 4).  Roscommon 
was the only LHO to reach and exceed the target of 
95% for D3, T3, P3, Hib3, Polio3, HepB3, Hibb, MenC3, PCV3 
and MMR1 at 24 months.   
There was a large decline in MenC3 and a decline in 
Hibb uptake at 24 months in Quarters 3 and 4 2010 i.e. 
children who were born between July 1st and Decem-
ber 31st 2008 and were the first recommended the new 
immunisation schedule.  There was a change in timing 
of the MenC and Hibb vaccines under the new immuni-
sation schedule (table 1).  The uptake of MenC3 (85%) 
and Hibb (89%) in 2012 were still considerably lower 
than the uptake of the other recommended vaccines.  
In addition, to low uptake of MenC3 and Hibb, MMR1 
(92%) and PCV3 (90%) uptake in 2012 are lower than the 
target uptake of 95%.
In contrast in 2012, annual national uptake rates at 24 
months for D3, T3, P3, Hib3, Polio3 and HepB3 reached 
the target rate of 95%.  This is the second year national 
annual uptake rates reached the target of 95% for these 
vaccines.  All eight HSE Areas reached or exceeded the 
target uptake of 95% for D3, T3, P3, Hib3 and Polio3 at 24 
months during 2012.  Roscommon reached or exceed-
ed the target of 95% for D3, T3, P3, Hib3, Polio3, HepB3, 
MenC3, PCV3, Hibb and MMR1 uptake at 24 months of 
age.
 
The immunisation reports for Quarters 1 to 4 2012 are 
available on the HPSC website in Topics A-Z under the 
heading vaccination. 
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D3
MenC3
Hibb
MMR1
Figure 3.  D3, Hibb, MenC3 and MMR1 immunisation uptake rates (%) in those 24 months of age in 2012 by Local Health Office 
(LHO)
LHOs in Dublin are highlighted separately for ease of viewing
North Lee and South Lee are separate LHOs, however, their combined (labelled NSL on the map) immunisation uptake rate is reported here
Please see table 5 to translate LHO abbreviations
Local Health Office 
Abbreviations
Local Health Office
CE Clare
CN/MN Cavan/Monaghan
CW/KK Carlow/Kilkenny
DL Donegal
DN Dublin North
DNC Dublin North Central
DNW Dublin North West
DS Dublin South
DSC Dublin South City
DSE Dublin South East
DSW Dublin South West
DW Dublin West
G Galway
KE/WW Kildare/West Wicklow 
KY Kerry
L Limerick
LD/WD Longford/Westmeath
Local Health Office 
Abbreviations
Local Health Office
LH Louth
LS/OY Laois/Offaly
MH Meath
MO Mayo
NC North Cork
NSL* North South Lee*
RN Roscommon
SO/LM Sligo/Leitrim
TN/EL Tipperary North /East Limerick
TS South Tipperary
WC West Cork
WD Waterford
WX Wexford
WW Wicklow 
*Please note while North Lee and South Lee are two separate LHOs 
their combined immunisation uptake data are reported
Table 5.  Local Health Office (LHO) abbreviations used in this chapter 
Background
Following a recommendation from the National 
Immunisation Advisory Committee, that human 
papillomavirus (HPV) vaccine should be given to 12 
year old girls, a routine Health Service Executive (HSE) 
school HPV vaccination programme began in May 2010 
for girls in the first year of second level school and age 
equivalent in non second level schools (see below for 
cohort details). The aim of the programme is to protect 
girls from their future risk of developing cervical cancer. 
A catch-up campaign for girls in sixth year of second 
level schools and their age equivalents in non-second 
level schools (see below for cohort details) was added in 
the academic year 2011/2012, this catch-up campaign 
will continue until 2013/2014.
Quadrivalent HPV vaccine, which protects against HPV 
types 6, 11, 16 and 18 associated with 70% of cervical 
cancer, is used in the school vaccination programme. A 
schedule of three vaccine doses given over a six month 
period is required. The HPV vaccine does not protect 
against all cervical cancers, so regular cervical screening 
is still needed.  
The vaccinations are provided by vaccination teams from 
the Local Health Offices (LHOs) who go into schools in 
their areas to vaccinate or provide vaccination clinics 
free of charge for girls in the target cohorts. Please see 
the HSE-National Immunisation Office (NIO) website at 
www.immunisation.ie for detailed information on the 
HPV school vaccination programme.  
The Health Information and Quality Authority and 
HSE target for uptake of three doses of vaccine for 
the routine HPV vaccination programme is >80% and 
the HSE target for the catch-up programme is >60% 
uptake.1
HPV vaccinations provided through the schools 
immunisation programme are entered onto a database.  
Here we report on the uptake of HPV vaccine, provided 
through the school immunisation programme and 
recorded on the database, in the academic year 
2011/2012 in Ireland.  This is the first HPV report 
from the database which is the result of collaboration 
between NIO, School Immunisation Teams, Immunisation 
System Administrators, Immunisation Coordinators, 
Immunisation administrative staff, HPV vaccine working 
groups and HPSC.  
Uptake for 2009/2010 and 2010/2011 cohorts of first 
year girls vaccinated from May 2010 was measured by 
manual reports and national uptake for the combined 
cohort was estimated at 81.9%.2
Cohort for vaccination in the academic year 
2011/2012
The routine and catch-up cohorts for the 2011/2012 HPV 
vaccination programme as agreed with the Department 
of Education and Skills was as follows: 
Routine HPV Vaccination programme 
Ø	 All girls in first year of second level schools 
Ø	 and their equivalents i.e. those who were born 
between 01/09/1999 and 31/08/2000 
• attending special schools or
•  registered with the National Education and 
Welfare Board to be home schooled.
Catch up HPV Vaccination Programme 
Ø	 All girls in sixth year of second level schools 
Ø	 and their equivalents i.e. those  who were born 
between 01/09/1993 and 31/08/1994 and
• attending special schools*  or
•  registered with the National Education and 
Welfare Board to be home schooled* or
•  attending Youthreach and Community 
8.2 HPV vaccine uptake 2011/2012
Summary
In the academic year 2011/2012 uptake of at least 
HPV stage 3 was:
85.5% among first year girls in second level schools 
71.5% among sixth year girls in second level schools
In addition, 1,131 girls were recorded as having 
received at least HPV stage 3; of these 563 were 
recorded in the first year routine and sixth year 
catch up age equivalent cohorts in non-second level 
schools (i.e. special schools, Youthreach, Community 
Training Centres, home schooled or out of school) 
and 568 were recorded as being outside the cohorts 
recommended for vaccination.
-128-HPSC Annual Report 2012 8. Immunisation Uptake
Training Centres funded by the Department 
of Education and Skills*.
*  As the catch up programme will run until the end of 
the academic year 2013/2014, areas could choose to 
vaccinate the total cohort in these groups in 2011/2012 
i.e. girls who reached 15 - 18 years of age between 1st 
September 2011 and 31st August 2012 for operational 
reasons. (However, those who were not in the cohort’s 
equivalent to sixth year of second level schools were to 
be recorded on the immunisation database as outside 
cohort in the academic year 2011/2012.)
Terminolgy used in this report
At least stage 1 -  means a girl had a stage 1 HPV 
vaccine recorded on the database, this girl may or 
may not have had a stage 2 or a stage 3 HPV vaccine 
recorded on the database.
At least stage 2 - means a girl had a stage 2 HPV 
vaccine recorded on the database, she may or may not 
have had stage 1 or a stage 3 HPV vaccine recorded on 
the database.
At least stage 3 - means a girl had a stage 3 HPV 
vaccine recorded on the database, she may or may not 
have had a stage 1 or a stage 2 HPV vaccine recorded 
on the database.
Girls with at least stage 3 are considered to have 
completed a course of vaccination.
Home schooled - refers to girls registered with the 
National Education and Welfare Board to be educated 
at home. These girls were recorded on the database and 
reported here as home schooled.  
Out of school - refers to vaccinated girls who were 
neither enrolled in a second level school, special school, 
Youthreach or Community Training Centre nor registered 
with National Education and Welfare Board as “home 
schooled”. 
Local Health Office (LHO) - refers to the LHO the school 
is located in (it does not refer to the LHO the girl is 
resident in).  
Outside cohort - refers to those who were vaccinated 
but who were not in first year or sixth year of second 
level schools or their equivalents. 
The denominator for girls in second level schools was 
defined as the number of girls on the school roll on 30th 
September 2011 for first year in the routine programme 
and for sixth year in the catch-up programme. 
The denominator for age equivalent to first years 
in second level schools in the routine programme 
was defined as girls born between 01/09/1999 and 
31/08/2000 on the school roll of special schools or 
registered with the National Education and Welfare 
Board on 30th September 2011. The denominator for 
age equivalent to sixth years in second level schools 
in the catch-up programme was defined as girls born 
between 01/09/1993 and 31/08/1994 on the school 
roll of special schools or registered with the National 
Education and Welfare Board or attending Community 
Training Centres or Youthreach on 30th September 
2011.  All the denominator data was entered on 
the immunisation database by the relevant System 
Administrator.
Results 
The figures presented in this summary are based on 
data recorded on the immunisation system on the 21st 
August 2013.  These figures are provisional and subject 
to change due to ongoing updating of data on the 
database. 
First year girls in second level schools
In Ireland, 85.5% of girls in first year in second level 
schools were recorded as having received at least HPV 
stage 3 (considered to have completed a three dose 
course) (Table 1).   Among the 32 Local Health Offices 
(LHOs) uptake of at least HPV stage 3 ranged from 
73.3% to 91.7%; with four recording ≥90.0% uptake and 
five recording <80.0% uptake.  
Sixth year girls in second level schools
In Ireland, 71.5% of girls in sixth year in second level 
schools were recorded as having at least HPV stage 3 
(Table 2).  Among the 32 LHOs uptake of at least HPV 
stage 3 ranged from 54.7% to 85.5%; with four recording 
≥80.0% uptake and two recording <60.0% uptake.  
Some girls in the catch-up cohort were vaccinated 
privately by General Practitioners or other medical 
agencies following the licensing of HPV vaccines in 
2006/2007 and prior to the announcement in early 2011 
that there would be a HPV catch-up programme.
First and Sixth year second level equivalent cohorts 
in non-second level schools/Outside cohort/Out of 
school
In addition, 1,131 girls were recorded as having received 
at least HPV stage 3 (Table 3); of these 563 were 
recorded in the first year routine and sixth year catch up 
age equivalent cohorts in special schools, Youthreach, 
Community Training Centres, home schooled or out 
of school and 568 were recorded as being outside the 
cohorts recommended for vaccination. 
The target cohort of girls in special schools, Community 
Training Centres, Youthreach, and home schooled 
were identified by birth cohort either equivalent to first 
years (born between 01/09/1999 and 31/08/2000) or 
equivalent to sixth years (born between 01/09/1993 and 
31/08/1994).  For operational reasons HSE vaccinating 
staff did not adhere strictly to these birth cohorts.  Many 
of the vaccinations in these school settings were actually 
“outside cohort”.  The identification of denominator 
data for the target birth cohorts in these settings was 
difficult and staff focused on vaccinations rather than 
defining cohort numbers accurately.  Therefore, this 
report gives the number of girls vaccinated in these 
settings reflecting activity in these settings rather than 
HPV vaccine uptake.
Total doses administered
A total of 139,646 administered vaccine doses were 
recorded.
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Discussion 
The uptake of HPV vaccine in Ireland is very encouraging 
and reflects the huge effort and support put in by all 
staff and schools involved in the school vaccination 
programme.  Uptake of HPV vaccine in Ireland 
compares very favourably with estimates in other 
countries that have introduced and monitored HPV 
vaccination.3,4,5,6,7,8,9,10,11,12
Acknowledgements
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the school HPV vaccination programme.
Table 1 HPV vaccine uptake in the academic year 2011/2012 among first year girls in second level schools
HSE Region
Local Health Office/
HSE Region
2011/2012
First Year (routine HPV vaccination programme)**
Denominator
Numbers Vaccinated with: % Vaccinated with:
At least 
Stage 1
At least 
Stage 2
At least 
Stage 3
At least 
Stage 1
At least 
Stage 2
At least 
Stage 3
Dublin Mid 
Leinster
Dublin South 922 817 816 808 88.6% 88.5% 87.6%
Dublin South East 622 538 535 531 86.5% 86.0% 85.4%
Dublin South City 838 652 651 649 77.8% 77.7% 77.4%
Dublin South West 791 667 661 631 84.3% 83.6% 79.8%
Dublin West 941 823 817 758 87.5% 86.8% 80.6%
Kildare/West Wicklow 1580 1397 1384 1367 88.4% 87.6% 86.5%
Wicklow 731 644 639 625 88.1% 87.4% 85.5%
Laois/Offaly 1021 951 946 930 93.1% 92.7% 91.1%
Longford/Westmeath 936 839 835 818 89.6% 89.2% 87.4%
Total Dublin Mid Leinster 8382 7328 7284 7117 87.4% 86.9% 84.9%
Dublin 
North East
Dublin North 1441 1278 1272 1244 88.7% 88.3% 86.3%
Dublin North Central 695 610 608 597 87.8% 87.5% 85.9%
Dublin North West 1121 1078 1064 1004 96.2% 94.9% 89.6%
Cavan/Monaghan 901 835 833 826 92.7% 92.5% 91.7%
Louth 1023 912 905 894 89.1% 88.5% 87.4%
Meath 1239 1104 1093 1079 89.1% 88.2% 87.1%
Total Dublin North East 6420 5817 5775 5644 90.6% 90.0% 87.9%
South
North Cork 574 489 486 472 85.2% 84.7% 82.2%
North Lee - Cork 1192 1049 1040 996 88.0% 87.2% 83.6%
South Lee - Cork 1200 982 972 939 81.8% 81.0% 78.3%
West Cork 372 283 281 277 76.1% 75.5% 74.5%
Kerry 913 816 805 796 89.4% 88.2% 87.2%
Carlow/Kilkenny 907 832 829 818 91.7% 91.4% 90.2%
South Tipperary 555 482 475 463 86.8% 85.6% 83.4%
Waterford 824 756 752 743 91.7% 91.3% 90.2%
Wexford 1075 948 943 930 88.2% 87.7% 86.5%
Total South 7612 6637 6583 6434 87.2% 86.5% 84.5%
West
Donegal 1173 1045 1042 1036 89.1% 88.8% 88.3%
Sligo/Leitrim 602 540 537 534 89.7% 89.2% 88.7%
Galway 1573 1337 1324 1312 85.0% 84.2% 83.4%
Mayo 798 598 593 585 74.9% 74.3% 73.3%
Roscommon 348 296 296 289 85.1% 85.1% 83.0%
Clare 730 652 647 633 89.3% 88.6% 86.7%
Limerick 967 890 886 865 92.0% 91.6% 89.5%
Tipperary NR/
East Limerick
895 788 786 775 88.0% 87.8% 86.6%
Total West 7086 6146 6111 6029 86.7% 86.2% 85.1%
Ireland 29500 25928 25753 25224 87.9% 87.3% 85.5%
The figures presented in this table are based on data recorded on the immunisation system on the 21st August 2013.  These figures are provisional 
and subject to change due to ongoing updating of data on the database. 
Local Health Office refers to the Local Health Office of the school.
‘At least stage 1’ means a girl had a stage 1 recorded on the database, this girl may or may not have had a stage 2 or a stage 3 recorded.  
Similarily, ‘at least stage 2’ means a girl had a stage 2 recorded on the database, they may or may not have had stage 1 or a stage 3 recorded. 
Similarily, ‘at least stage 3’ means a girl had a stage 3 recorded on the database, they may or may not have had stage 1 or a stage 2 recorded.
**Please see Background section of report for details of cohorts recommended HPV vaccine during the academic year 2011/2012.
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Table 2 HPV vaccine uptake in the academic year 2011/2012 among sixth year (catch up campaign) girls in second level schools
HSE Region
Local Health Office/
HSE Region
2011/2012
Sixth Year (catch up campaign)**
Denominator
Numbers Vaccinated with: % Vaccinated with:
At least 
Stage 1
At least 
Stage 2
At least 
Stage 3
At least 
Stage 1
At least 
Stage 2
At least 
Stage 3
Dublin Mid 
Leinster
Dublin South 938 596 593 583 63.5% 63.2% 62.2%
Dublin South East 569 335 333 332 58.9% 58.5% 58.3%
Dublin South City 908 590 582 562 65.0% 64.1% 61.9%
Dublin South West 710 623 601 575 87.7% 84.6% 81.0%
Dublin West 790 607 589 535 76.8% 74.6% 67.7%
Kildare/West Wicklow 1315 972 959 941 73.9% 72.9% 71.6%
Wicklow 613 504 491 455 82.2% 80.1% 74.2%
Laois/Offaly 805 580 572 549 72.0% 71.1% 68.2%
Longford/Westmeath 925 731 725 712 79.0% 78.4% 77.0%
Total Dublin Mid Leinster 7573 5538 5445 5244 73.1% 71.9% 69.2%
Dublin 
North East
Dublin North 1268 772 747 694 60.9% 58.9% 54.7%
Dublin North Central 572 388 376 361 67.8% 65.7% 63.1%
Dublin North West 956 673 658 605 70.4% 68.8% 63.3%
Cavan/Monaghan 875 673 673 667 76.9% 76.9% 76.2%
Louth 829 583 574 549 70.3% 69.2% 66.2%
Meath 886 650 632 619 73.4% 71.3% 69.9%
Total Dublin North East 5386 3739 3660 3495 69.4% 68.0% 64.9%
South
North Cork 539 420 413 399 77.9% 76.6% 74.0%
North Lee - Cork 1236 902 886 842 73.0% 71.7% 68.1%
South Lee - Cork 965 701 689 667 72.6% 71.4% 69.1%
West Cork 326 209 209 206 64.1% 64.1% 63.2%
Kerry 945 793 788 767 83.9% 83.4% 81.2%
Carlow/Kilkenny 833 642 641 632 77.1% 77.0% 75.9%
South Tipperary 530 410 397 389 77.4% 74.9% 73.4%
Waterford 743 619 608 591 83.3% 81.8% 79.5%
Wexford 926 743 735 699 80.2% 79.4% 75.5%
Total South 7043 5439 5366 5192 77.2% 76.2% 73.7%
West
Donegal 1038 856 854 836 82.5% 82.3% 80.5%
Sligo/Leitrim 524 458 454 448 87.4% 86.6% 85.5%
Galway 1565 1227 1205 1149 78.4% 77.0% 73.4%
Mayo 782 636 632 612 81.3% 80.8% 78.3%
Roscommon 338 285 279 269 84.3% 82.5% 79.6%
Clare 659 504 498 482 76.5% 75.6% 73.1%
Limerick 923 750 734 706 81.3% 79.5% 76.5%
Tipperary NR/
East Limerick
740 578 575 562 78.1% 77.7% 75.9%
Total West 6569 5294 5231 5064 80.6% 79.6% 77.1%
Ireland 26571 20010 19702 18995 75.3% 74.1% 71.5%
The figures presented in this table are based on data recorded on the immunisation system on the 21st August 2013.  These figures are 
provisional and subject to change due to ongoing updating of data on the database.
Local Health Office refers to the Local Health Office of the school.
‘At least stage 1’ means a girl had a stage 1 recorded on the database, this girl may or may not have had a stage 2 or a stage 3 recorded.  
Similarily, ‘at least stage 2’ means a girl had a stage 2 recorded on the database, they may or may not have had stage 1 or a stage 3 recorded. 
Similarily, ‘at least stage 3’ means a girl had a stage 3 recorded on the database, they may or may not have had stage 1 or a stage 2 recorded.
**Please see Background section of report for details of cohorts recommended HPV vaccine during the academic year 2011/2012.
-131-HPSC Annual Report 2012 8. Immunisation Uptake
Table 3 HPV vaccine uptake in the academic year 2011/2012 among those in non-second level schools and those outside the 
recommended cohorts in second level schools
HSE 
Region
Local Health Office/
HSE Region
Recommended cohorts** for vaccination and those outside cohort 
in special schools, Youthreach, Community Training Centres, home 
schooled and out of school and those outside cohort in second level 
schools with:
At least Stage 1 At least Stage 2 At least Stage 3
Dublin Mid 
Leinster
Dublin South 22 22 18
Dublin South East 9 8 5
Dublin South City 69 68 51
Dublin South West 54 53 46
Dublin West 224 200 162
Kildare/West Wicklow 29 25 21
Wicklow 33 30 23
Laois/Offaly 33 26 23
Longford/Westmeath 49 49 43
Total Dublin Mid Leinster 522 481 392
Dublin 
North East
Dublin North 84 66 44
Dublin North Central 60 51 42
Dublin North West 53 37 25
Cavan/Monaghan 1 1 1
Louth 17 15 14
Meath 63 58 55
Total Dublin North East 278 228 181
South
North Cork 9 8 6
North Lee - Cork 34 33 29
South Lee - Cork 33 32 26
West Cork 2 2 0
Kerry 29 26 24
Carlow/Kilkenny 63 60 50
South Tipperary 22 20 20
Waterford 66 58 46
Wexford 87 82 71
Total South 345 321 272
West
Donegal 11 9 6
Sligo/Leitrim 58 56 56
Galway 59 53 29
Mayo 61 59 54
Roscommon 9 8 5
Clare 39 36 28
Limerick 86 79 69
Tipperary NR/
East Limerick
45 37 32
Total West 368 337 279
Homeschooled 3 3 3
Total of LHOs and Home Schooled 1516 1370 1127
Out of School 5 5 4
Total of LHOs and Home Schooled and Out of School 1521 1375 1131
The figures presented in this table are based on data recorded on the immunisation system on the 21st August 2013.  These figures are 
provisional and subject to change due to ongoing updating of data on the database.
Local Health Office refers to the Local Health Office of the school.
‘At least stage 1’ means a girl had a stage 1 recorded on the database, this girl may or may not have had a stage 2 or a stage 3 recorded.  
Similarily, ‘at least stage 2’ means a girl had a stage 2 recorded on the database, they may or may not have had stage 1 or a stage 3 recorded. 
Similarily, ‘at least stage 3’ means a girl had a stage 3 recorded on the database, they may or may not have had stage 1 or a stage 2 recorded.
**Please see Background section of report for details of cohorts recommended HPV vaccine during the academic year 2011/2012.
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1. 
9.1.1 Clostridium difficile Infection
Notifiable C. difficile infection 
In May 2008, new cases of CDI in persons two years or 
older became notifiable in Ireland under the disease 
category “acute infectious gastroenteritis” (AIG). Since 
January 2012, CDI has become a notifiable infection in 
its own category, with both new and recurrent CDI cases 
now notifiable.  
In 2012, 1,830 cases of CDI were notified to Public 
Health Departments via the Computerised Infectious 
Diseases Reporting (CIDR) system. Of those, 1,624 
(89%) were classified as new, 181 (10%) as recurrent 
and 25 (1%) of unknown case type.  All cases were 
laboratory-confirmed. Table 1 displays the number and 
crude incidence rate (CIR) of CDI notifications nationally 
and by public health region. 
The national CIR of new CDI cases in 2012 was 35.4 per 
100,000 population. This reflects a decrease of 12% 
from 40.3 per 100,000 population in 2011. Taking both 
new and recurrent cases into account, the overall CIR 
for 2012 was 39.9 per 100,000 population. Variation 
was observed in the incidence of CDI by public health 
9.1.0  Healthcare-associated infections 
(HCAI)
Key Points
•   Prior to 2012, only new cases of Clostridium 
difficile infection (CDI) were notifiable. Effective 
1st January 2012, recurrent CDI cases also 
became notifiable 
•   In 2012, 1,830 cases of CDI were notified. Of 
those, 1,624 (89%) were classified as new, 181 
(10%) as recurrent and 25 (1%) of unknown case 
type. This represents a national crude incidence 
rate of 35.4 new cases per 100,000 population, 
a decrease of 12% compared with notifications 
in 2011
•   Of the 1,830 CDI cases, 1,174 (64%) were 
reported from patients aged 65 years or older
•   The voluntary enhanced CDI surveillance scheme 
received information on 1,735 CDI cases [1,499 
(86.4%) new, 159 (9.2%) recurrent and 77 (4.4%) 
of unknown case type] from 46 acute hospitals. 
This represents a national CDI incidence rate 
in 2012 of 2.7 cases per 10,000 bed days used, 
a decrease from 3.1 in 2011. However, caution 
should be taken when interpreting trends 
in the national CDI rates due to changes in 
the numbers of hospitals participating in the 
enhanced surveillance scheme and also due to 
changes in laboratory testing protocols 
•   The majority of CDI cases (68%) originated in a 
healthcare setting (acute hospital or residential 
institution), with 17% originating in the 
community 
•   Whilst the majority of patients experienced CDI 
symptom onset in healthcare facilities (64%), 
30% had symptom onset in the community
•   Of 294 C. difficile isolates with available 
ribotyping data (17% of all cases) that were 
reported from 14 hospitals, the most frequent 
ribotypes reported were: 078 (n=26; 13%), 014 
(n=23; 11%), 005 (n=21; 10%), 002 and 015 
(n=17 each; 8%) 
Table 1.  Number of CDI cases (both new and recurrent) notified 
in 2012, CDI CIR, by public health region and overall new CDI 
notifications with CIR for 2011 and 2012 (Source: CIDR) 
Public Health Region No. of cases *CIR incl. 95% C.I.
East 941 58.1 (47.9 - 54.9)
Midlands 48 17 (10.6 - 19.8)
Mid West 163 43 (27.4 - 39)
North East 89 20.2 (12.4 - 19.8)
North West 65 25.2 (15.3 - 26.5)
South East 188 28.3 (22.6 - 30.4)
South  165 33.2 (26 - 35.8)
West 171 38.4 (30.8 - 42)
Total 2012 1830 39.9 (33.6 - 37)
Total 2012 [NEW cases only]** 1624 35.4 (33.6 - 37)
Total 2011 [NEW cases only]** 1848 40.3 (38.5 - 42.1)
* Crude incidence rates (CIR) calculated using 2011 census data
** Numbers reflect new CDI cases only. Prior to January 2012, only new 
cases of CDI were notifiable. As of 1st January 2012, recurrent cases also 
became notifiable. CIR for new cases only is provided to allow compari-
son with historical data.
region. However, this most likely reflects geographical 
differences in the distribution of acute healthcare 
facilities and differences in laboratory diagnostic and 
reporting protocols, rather than true regional variation 
in CDI incidence. Identification of seasonal patterns 
from CIDR notification data is hindered by delayed and 
batched laboratory notifications.
Figure 1 displays the gender and age breakdown of patients 
with CDI. The majority of patients were female (61%).  The 
mean patient age was 67 years (range: 2 – 101 years), with 
1,174 cases (64%) reported in patients aged 65 years and 
older.  
Regarding the patient location at the time of CDI 
diagnosis, the majority were classified as ‘hospitalised’ 
(73%), 13% from general practice, 4.4% from 
outpatients or day patients, 5.5% from the emergency 
department and 4% from either ‘other’, or ‘unknown’ 
patient location. This is similar to that reported in 2011. 
However, this data does not provide information on the 
origin or onset of CDI, as that information is collected 
as part of the enhanced CDI surveillance scheme. 
In 2012, 28 deaths were reported in patients with CDI. 
Two deaths were reported as due to CDI, 14 were 
reported as not due to CDI and for the remaining 12 
deaths, the contribution of CDI to death was unknown.
Notifiable C. difficile infection: Outbreaks
In 2012, seven CDI outbreaks, all healthcare-associated 
and involving 40 patients, were notified to Public Health 
Departments as displayed in Table 2. Five were linked 
to hospitals, and two to residential institutions.
Enhanced surveillance of C. difficile infection
Although notifiable CDI data provides important 
preliminary information on the burden of CDI in Ireland, 
it represents an underestimate of the true burden of 
CDI, as it does not capture information on the origin, 
onset or severity of CDI. National collation of C. difficile 
enhanced surveillance information commenced on a 
voluntary basis on 1st August 2009. Information on case 
type, origin, onset and infection severity is collected 
using the European Society for Clinical Microbiology 
and Infectious Diseases Study Group on C. difficile 
(ESCMID-ESGCD) interim case definitions.  To the end 
of 2012, 46 acute hospitals participated in the voluntary 
enhanced surveillance CDI scheme, comprising 40 
public hospitals (26 general (100%), nine tertiary (100%) 
and five specialist hospitals (42%)) and six private 
hospitals (50%). 
In 2012, 1,735 CDI cases were reported to the 
enhanced surveillance scheme (representing 83% of all 
the CDI cases notified to Public Health Departments via 
CIDR). Of these, 1,499 (86%) were classified as new, 159 
(7.1%) as recurrent and 77 (4.4%) of unknown CDI case 
type. 
Of the reported cases, 52% (n=894) originated within 
the reporting healthcare facility. The overall national 
CDI incidence rate of new and recurrent cases 
combined, which were acquired within the reporting 
healthcare facility was 2.7 cases per 10,000 bed days 
used (BDU), a decrease from 3.1 in 2011. The incidence 
rate of new CDI cases was 2.4 cases per 10,000 BDUs 
representing a decrease from 2.8 in 2011 while the 
incidence of recurrent cases remained at 0.2 cases, 
unchanged from 2011. 
Caution should be taken when interpreting national CDI 
trends, particularly prior to 2012 because of: 
(i) Changes in the numbers of participating hospitals 
as displayed in Figure 2.  Throughout 2012, 
the overall number of hospitals participating in 
enhanced CDI surveillance stabilised. In 2012, 
there was complete participation in CDI enhanced 
surveillance by all tertiary and general hospitals
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Figure 1: Age and gender distribution of CDI in Ireland, 2012 
(Source, CIDR)
* Rates calculated using 2011 census data 
Table 2. CDI outbreaks reported in Ireland in 2012 by public 
health region (Source, CIDR)
Public Health 
Region
Outbreak location
Total num-
ber ill
East Hospital 6
East Hospital 9
East Residential insitution 4
Mid West Hospital 6
North East Residential insitution 2
West Hospital 5
West Hospital 8
Figure 2. Quarterly national rate of healthcare-associated CDI 
(new and recurrent): 2009 – 2012.
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(ii) Changes in C. difficile laboratory testing protocols. 
Throughout 2012, there were fewer changes in 
laboratory testing protocols. Please also refer to 
the section on laboratory testing of C. difficile in 
Ireland.  
During 2012, the national CDI rate remained relatively 
stable as displayed in Figure 2. The CDI rate is based 
on the number of new and recurrent CDI cases that 
originated in the participating healthcare facility. The 
rate is calculated using acute public hospital activity 
data from the HSE Business Intelligence Unit, Corporate 
Planning and Corporate Performance (CPCP). 
There was a wide range in the incidence of CDI among 
participating hospitals in 2012 (range, 0 – 6.6 cases per 
10,000 BDU; median, 1.7 cases). The median incidence 
rate for the nine participating tertiary hospitals was 
higher compared to the 26 general hospitals (2.7 versus 
1.9 CDI cases per 10,000 BDU). The differences in CDI 
median incidence rates may reflect variation between 
hospitals with regard to patient case mix, C. difficile 
ribotypes, laboratory testing protocols, antimicrobial 
prescribing policies, antimicrobial stewardship 
interventions and surveillance resources. No obvious 
seasonal trend for CDI is distinguishable from enhanced 
surveillance data in 2012.
There were significant changes in laboratory testing 
protocols for C. difficile between 2009 and 2011. The 
vertical grey dotted line (Q1 2012) reflects a time 
beyond which there have been fewer changes in 
laboratory testing.
Severe CDI
A severe case of CDI is defined as a patient requiring 
admission to an intensive care unit (ICU) for treatment 
of CDI or its complications, a patient requiring 
colectomy or death within 30 days after diagnosis, if 
CDI is either the primary or contributory cause of death. 
The enhanced CDI surveillance scheme does not collect 
information on patient outcome. Therefore, surgery and 
ICU admission for CDI are the two markers of severity 
captured via enhanced surveillance. In 2012, 26 (1.5%) 
severe CDI cases were reported, which was similar 
to 2011 (1.4%). Three patients required both surgery 
and ICU admission, five required surgery only and 18 
required ICU admission without surgery. 
Onset & Origin of CDI
Onset: Patient location when symptoms of CDI 
commenced
Sixty-four percent (n=1,118) of patients had CDI 
symptom onset in a healthcare facility (healthcare 
onset), 30% (n=515) had symptom onset in the 
community and for 6%, location at CDI onset was 
unknown. 
Of the 1,118 patients with healthcare onset CDI, 77% 
(n=859) had onset in the reporting hospital, 3% (n=39) 
in another hospital, 17% (n=177) in a nursing home 
and for the remaining 3% (n=39) onset was in another 
unspecified healthcare facility or of unknown location. 
Over the period 2010 to 2012, there was a decrease in 
the proportion of patients with CDI symptom onset in a 
healthcare facility (73% to 64%). Conversely, there was 
an increase in the proportion of patients with symptom 
onset in the community (27% to 30%) and those with 
unknown location of symptom onset (0 – 6%) (Table 3).
Origin: Location where the patient acquired the CDI
For the majority of CDI cases, the infection was 
acquired in a healthcare setting (healthcare-associated) 
(n=1,174; 68%). Community-associated cases accounted 
for 17% (n = 303) and for 5% (n = 90) of CDI cases 
the origin could not be assigned as either healthcare 
or community-associated, as the patient had been 
discharged from a healthcare facility between 4 and 12 
weeks prior to the CDI onset date. For the remaining 
10% (n = 168) of cases the origin was unknown, an 
increase from 2010 (3%) and 2011 (4%).
Of the 1,174 healthcare-associated CDI cases, 76% 
(n=894) originated in the reporting hospital, 6% (n=71) 
originated in a hospital other than the reporting 
hospital, 15% (n=174) originated in nursing homes and 
3% (n=30) originated in another unspecified healthcare 
facility or were of unknown origin (Table 3).
Of the 1,174 cases of healthcare-associated CDI:
•  90.4% (n=1,061) experienced onset of CDI symptoms 
at least 48 hours following admission to a healthcare 
facility (healthcare-onset, healthcare-associated)
•  8.8% (n=104) experienced symptom onset in the 
community within four weeks of discharge from a 
healthcare facility (community-onset, healthcare-
associated)
•  0.8% (n = 9) had no information recorded on symptom 
onset
Of the 303 cases of community-associated CDI: 
•  91% (n=275) experienced CDI symptom onset while 
outside a healthcare facility and without a history of 
discharge from a healthcare facility within the previous 
12 weeks
•  8.2% (n=25) experienced symptom onset within the 
first 48 hours of admission to a healthcare facility, 
without a history of admission to or residence in a 
healthcare facility within the previous 12 weeks 
•  0.8% (n = 3) had no information recorded on symptom 
onset 
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Figure 3. Most frequently reported C. difficile ribotypes in 
Ireland: 2010 – 2012
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Information was captured on the location where the 
patient’s faecal specimen was taken. The reporting 
hospital accounted for the majority (75%) of patient 
specimens (n=1,306), with 9% (n=151) taken in the GP 
surgery, 9% (n=156) in nursing homes and 3% (n=50) 
in a hospital other than the reporting hospital. For the 
remaining 4% (n=72) of specimens, no information was 
provided.
The collation of national data on C. difficile through 
CIDR notifications and the enhanced CDI surveillance 
system has provided a valuable insight into the burden 
of CDI in Ireland. There was a decrease in the number 
of new CDI cases reported in 2012 compared to 2011. 
However, this may be partly due to changes in laboratory 
testing protocols for C. difficile. Please refer to section 
on laboratory testing of C. difficile in Ireland. In 2012, 
recurrent CDI accounted for 9% of notifications through 
the enhanced surveillance scheme. This reflects a small 
increase in recurrent CDI from 7% in 2011. Recurrent CDI 
may result in severe infection, places a further burden 
on limited hospital isolation resources and results in 
significant patient morbidity. 
Enhanced surveillance data collected since Q3 2009 
indicates that CDI is not confined to healthcare settings 
and is increasingly common in community and nursing 
home settings. In 2012, 30% of all CDI cases had 
symptom onset in the community an increase from 
27% in 2011 and 2010. In 2012, 17% of CDI cases were 
community-associated and 10% were associated with 
nursing homes, a figure which is similar to data from 
2011 and 2010. 
Of the 303 community-associated cases reported in 
2012, 91% of those patients experienced CDI symptom 
onset in the community, without a history of discharge 
from a healthcare facility within the previous 12 weeks. 
It is essential that CDI is considered in the differential 
diagnosis of all patients presenting with diarrhoea and 
that specimens are sent in a timely fashion for laboratory 
diagnosis.  
Patients with CDI in healthcare facilities must be 
isolated with contact precautions as outlined in national 
guidelines. All healthcare professionals must promote 
practices known to reduce the incidence of CDI 
including; compliance with infection prevention and 
control measures, awareness of local CDI surveillance 
data and prudent use of antimicrobials. The national 
guidelines for antimicrobial stewardship in hospitals in 
Ireland are available at: http://www.hpsc.ie/hpsc/A-Z/
MicrobiologyAntimicrobialResistance/
C. difficile PCR ribotyping
As part of the voluntary C. difficile enhanced surveillance 
scheme, participating hospitals are requested to provide 
C. difficile PCR ribotyping information, where available. 
Ireland does not have a national C. difficile reference 
laboratory or ribotyping service. Therefore, laboratories 
submit specimens abroad for ribotyping. In 2012, 
ribotyping data was provided for 294 C. difficile isolates 
(17% of all samples) submitted from 14 hospitals. This 
represents an increase from data reported in 2010 and 
2011 as displayed in Table 4. 
The most common ribotypes reported in 2012 were: 078 
(n=26, 13%), 014 (n=23, 11%), 005 (n=21, 10%), 015 and 
002 (both n=17, 8%). Many of these ribotypes were also 
reported as the five most common ribotypes in 2010 
and 2011 (Figure 3). In 2012, one hospital reported that 
75% of all C. difficile isolates were ribotyped. The most 
common ribotypes reported from that hospital correlate 
with the most common ribotypes reported nationally in 
2012 and include: 002 (n=23, 14%), 078 and 014 (n = 16 
each, 10%), 005 and 015 (n=13 each, 8%), 023 (n=5, 3%) 
and 027 (n=1, 1%).
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Table 3 National CDI rates and breakdown by enhanced data 
types, 2010 – 2012
2010 2011 2012
Total CDI cases reported nationally 1187 1511 1735
Cases known to have originated in a 
hospital
726 862 894
National CDI rate 2.8 3.0 2.7
National median rate 2.3 2.2 1.7
Case Type
% New cases 92% 92% 86%
% Recurrent cases 8% 7% 9%
% Unknown cases 0% 1% 4%
Age/Sex
% >65 71% 69% 66%
% M 44% 39% 41%
%F 56% 61% 59%
Origin
Healthcare-associated 77% 74% 68%
Breakdown of those that were healthcare 
associated: 
Within reporting hospital 80% 78% 76%
Other Hospital 7% 8% 6%
Nursing Home/LTCF 10% 13% 15%
Unknown 2% 1% 3%
Community-associated 20% 20% 17%
Discharged 4-12 wks from healthcare facility 0% 3% 5%
Unknown 3% 4% 10%
Onset
Healthcare-onset 73% 71% 64%
Breakdown of those that were healthcare-
onset 
Within reporting hospital 82% 78% 77%
Other Hospital 5% 6% 3%
Nursing Home/LTCF 10% 14% 16%
Unknown 2% 1% 3%
Community-onset 27% 27% 30%
Unknown 0% 2% 6%
Severity
% Severe cases 1.4% 1.4% 1.5%
Table 4.0 Increases in the National Reporting of C. difficile 
ribotyping data in Ireland, 2010 - 2012
2010 2011 2012
Total number of CDI cases 
reported
1187 1511 1735
Number (%) of cases with ribo-
type data
48 (4%) 204 (14%) 294 (17%)
Number of hospitals providing 
ribotype data
5 10 14
Laboratory Testing of C. difficile in Ireland
There have been significant changes in C. difficile 
diagnostic methods in Ireland in recent years. In 2006, 
a laboratory survey on C. difficile diagnostic practices in 
25 Irish microbiology laboratories reported that all 25 
used an enzyme immunoassay (EIA) for toxin detection.
Changes in the recommended C. difficile laboratory 
testing practice were proposed in 2009 and 2010 by 
the European Society for Clinical Microbiology and 
Infectious Diseases (ESCMID) and the United Kingdom 
(UK) National Health Service (NHS). 
The Irish laboratory survey was repeated in 2011, with 
information received from 33 laboratories performing 
on-site testing for C. difficile. Over half (58%) reported 
having changed the C. difficile testing algorithm in the 
past two years. The majority (74%) reported that the 
change in testing had involved a move from a one-step 
to a two-step testing algorithm.  
In 2012, a further survey was conducted to update 
information on current laboratory diagnostic methods 
used. Combined information from repeated surveys 
on laboratory testing methodologies has provided a 
quarterly summary of testing methods between Q1 
2010 and Q4 2012 as displayed in Figure 4. 
Over that time period, there was a large decrease in the 
numbers using the one step testing method (17 to 7) 
and contemporaneously, there was an increase in two-
step testing methods, of which there are a variety in use 
(Figure 4). 
Owing to considerable variations in current Irish 
laboratory C. difficile testing methodologies, inter-
hospital comparison of CDI rates is not recommended 
where testing methods differ, as the data in the 
national quarterly enhanced surveillance reports are 
not adjusted for differences in the sensitivities of the 
different diagnostic methodologies.
•  1 STEP: Toxin EIA - Enzyme immunoassay (EIA) for 
the detection of C. difficile TcdA and/or TcdB; 
•  2 STEP: GDH EIA AND Toxin PCR - EIA for the 
detection of glutamate dehydrogenase (GDH) of C. 
difficile as a first screening test followed by a PCR for 
the detection of TcdA and/or TcdB genes; 
•  2 STEP: GDH AND TOXIN EIA - EIA for the detection 
of GDH of C. difficile as well as or followed by an EIA 
for the detection of C. difficile TcdA and/or TcdB; 
•  2 STEP: GDH AND TOXIN EIA with TOXIN PCR 
confirmation - Same as for 2 STEP: GDH AND TOXIN 
EIA but with the addition of a confirmatory TOXIN 
PCR if the first Toxin EIA is negative.
Conclusion
As a result of changes to the Infectious Diseases 
Regulations, effective January 2012, CIDR notification 
now includes both new and recurrent cases of CDI 
in their own category. The continued excellent 
participation in the voluntary CDI enhanced surveillance 
scheme ensures that a significant amount of information 
is collected regarding the burden of CDI in Ireland. To 
maintain the quality of this information, it is important 
that all positive C. difficile laboratory results are 
discussed with the clinician responsible for the patient 
to ascertain the following information:
1. That the patient with the positive laboratory test 
result for C. difficile meets the CDI case definition 
– if the case definition is not met, the laboratory 
result is not notifiable
2. Whether the patient has previously had a positive 
C. difficile test result within the past eight weeks:
 a.  If yes, and the patient’s diarrhoea had resolved 
but has subsequently returned, this represents 
recurrent CDI
 b.  If yes, and the patient’s diarrhoea has not yet 
resolved, this is a repeat positive specimen from 
the same CDI episode
The original 2008 C. difficile national guideline was 
updated in 2012 by the Sub-Committee of the Health 
Protection Surveillance Centre (HPSC) and has been 
approved by the Scientific Advisory Committee of 
the HPSC in February 2013. The updated C. difficile 
guidelines may be accessed on the HPSC website 
at: http://www.hpsc.ie/hpsc/A-Z/Gastroenteric/
Clostridiumdifficile/Publications/ 
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9.1.2 HCAI Surveillance
9.1.2.1 National Report on the Point Prevalence Sur-
vey of Hospital-Acquired Infections & Antimicrobial 
Use in European Acute Care Hospitals: May 2012
In May 2012, 50 acute Irish hospitals (42 public and 
eight private) participated in the voluntary European 
Centre for Disease Prevention and Control (ECDC) 
point prevalence survey (PPS) of hospital-acquired in-
fections (HAI) and antimicrobial use (AMU). The national 
PPS report was published in November 2012. 
Key Points:
•  The breakdown of participating hospitals by type 
included: 15 primary/general, ten secondary/regional, 
six tertiary, 11 specialist public, one specialist private 
and seven other private hospitals
•  The average number of acute beds in the 42 public 
hospitals ranged from 135 to 603, depending on 
the hospital type. The average proportion of single 
patient rooms was lowest in public primary hospitals 
(14.8%) and highest in private hospitals (36.8%)
•  One hospital reported having no infection prevention 
and control nurse (IPCN) and 17 hospitals (34%) 
reported having no designated infection prevention 
and control doctor (IPCD). Both public and private 
hospitals reported having 0.70 IPCN per 100 beds. 
Private hospitals reported having 0.19 IPCD per 100 
beds, which was higher than the 0.11 IPCD/100 beds 
reported by public hospitals
•  Of the 9,030 eligible patients surveyed, there was a 
slight female preponderance at 53.7%, with 12% of 
the population aged <16 and 48% aged ≥65 years 
•  Eighteen percent of patients had undergone surgery 
since hospital admission and 49% had at least one 
invasive device in situ (e.g., peripheral vascular 
catheter or urethral catheter)
Hospital-Acquired Infections
•  There were 501 active HAI identified in 467 patients. 
The overall HAI prevalence was 5.2%. The majority of 
the HAI occurred in patients aged ≥16 years (92.9%)
•  The overall HAI prevalence, by hospital type was 
highest for tertiary hospitals (7.5%) and lowest for 
private hospitals (2.5%)
•  Patients with HAI were more likely to have risk factors, 
such as surgery since hospital admission and invasive 
medical devices in situ, than the overall eligible 
population
•  The prevalence of HAI was highest in augmented 
care units [adult and paediatric intensive care units 
(ICU), neonatal intensive care units (NICU) and high 
dependency units (HDU)] (16.5%), followed by surgical 
wards (6.7%). Psychiatric wards and obstetrics/
gynaecology wards had the lowest HAI prevalence 
(1.5%)
•  The top four HAI types reported were:
 1. Surgical site infection (91 cases; 18.2%)
 2. Pneumonia (86 cases; 17.2%)
 3. Urinary tract infection (75 cases; 15%)
 4. Bloodstream infection (66 cases; 13%)
•  Of the bloodstream infections, 28 (42%) were due to 
infection of an indwelling vascular catheter
•  There were 29 patients with Clostridium difficile 
infection, accounting for 5.7% of all HAI
•  The most frequent group of pathogens causing 
HAI were the Enterobacteriaceae and of those, 
one-in-four were resistant to broad spectrum third 
generation cephalosporins. Staphylococcus aureus 
was the next most frequent pathogen causing HAI, 
and 37% of Staphylococcus aureus was resistant to 
flucloxacillin (i.e., meticillin-resistant Staphylococcus 
aureus or MRSA)
Antimicrobial Use
•  The survey collected information on all patients who 
were prescribed antimicrobials, not just those being 
treated for a HAI. There were 3,108 patients who 
were prescribed 4,532 systemic antimicrobials. The 
overall AMU prevalence was 34%. The majority of 
antimicrobial use occurred in patients aged ≥16 years 
(91%)
•  The overall AMU prevalence, by hospital type was 
highest for tertiary hospitals (37.4%) and lowest for 
specialist hospitals (20.3%) 
•  The prevalence of AMU, by ward type was highest in 
augmented care units [e.g., ICU, NICU, HDU] (50.4%) 
and lowest in psychiatric units (5.5%) 
•  The parenteral (i.e., intravenous) route accounted for 
most prescribed antimicrobials (63%)
•  There was a documented indication for the 
antimicrobial prescription in 3,767 cases (83%). 
The indication for prescription was for treatment 
of infection in 78% of cases, surgical antimicrobial 
prophylaxis in 11% of cases and medical prophylaxis 
in 8% of cases
•  Treatment of community-associated infections 
represented the majority of antimicrobial prescriptions 
(69%), followed by hospital-associated infections, 
which accounted for 29% of prescriptions. The most 
common infection sites for which antimicrobials were 
prescribed included; respiratory tract (35%), skin/
soft tissue/wound (14%), abdominal (11%) and lower 
urinary tract infections (7%)
•  The majority of surgical antimicrobial prophylaxis 
(73%) exceeded single-dose and almost half (47%) 
of surgical antimicrobial prophylaxis was continued 
beyond 24 hours duration
•  Although the indication for prescription of 
antimicrobials for medical prophylaxis was not 
specifically recorded, broad spectrum agents 
including, co-amoxiclav and ciprofloxacin accounted 
for 8.6% and 4.4% of medical prophylaxis, 
respectively
•  Broad spectrum β lactam-β  lactamase inhibitor 
combination antimicrobials (i.e., co-amoxiclav and 
piperacillin-tazobactam) together accounted for 
35% of prescribed antimicrobials. Fluoroquinolones 
(ciprofloxacin, levofloxacin, moxifloxacin and 
olfloxacin) combined ranked fourth (8%) and 
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meropenem ranked tenth (3%) in the top 20 agents 
prescribed
Future priorities as recommended in the national PPS 
report
1.  Ensure all acute hospital staff have been made aware 
of the local and national results of the 2012 PPS.
2.  Provide ongoing education and training for 
healthcare workers, regarding the importance and 
impact of HAI and antimicrobial resistance.
3.  Improve hand hygiene compliance in all staff.
4.  Implement plans to prevent infections associated 
with medical devices (intravascular catheters, urinary 
catheters, devices for respiratory tract intubation and 
prosthetic surgical devices).
5.  Monitor and measure infections associated with 
medical devices and implement prospective 
surveillance programmes.
6.  Implement the core, high impact interventions to 
promote prudent antimicrobial prescribing.
7.  Ensure that frontline healthcare worker staffing levels 
reflect patient case mix and dependency levels.
8.  Ensure that key infection prevention and control, 
antimicrobial stewardship and surveillance staff 
are not diverted to tasks outside their designated 
roles and that activities related to prevention of 
antimicrobial resistance and HAI are appropriately 
resourced.
9.  Ensure that future strategic developments in Irish 
healthcare facilities include infrastructure and 
information technology that support the prevention 
of HAI and antimicrobial resistance.
10.  Plan for periodic repeat prevalence surveys, 
locally and nationally to monitor and measure 
improvements in HAI prevalence and antimicrobial 
prescribing practices.
The full national PPS report and the full list of 
recommended implementation priorities may be 
accessed on the HPSC website: 
http://www.hpsc.ie/hpsc/A-Z/Microbiology 
AntimicrobialResistance/InfectionControlandHAI/
Surveillance/HospitalPointPrevalenceSurveys/2012/
PPS2012ReportsforIreland/
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9.1.3 Hand Hygiene
9.1.3.1 Alcohol Hand Rub Consumption
Key Points
•  In 2012, the median rate of alcohol hand rub 
consumption in acute hospitals in Ireland increased 
by 10% (23.4 litres per 1,000 bed days used 
compared with 21.3 in 2011)
Hand hygiene is one of the most important actions to 
prevent HCAI.  Alcohol hand rubs (AHR) including gels 
and foam products are an effective and rapid method 
of performing hand hygiene and are recommended 
as the primary means of hand hygiene in national and 
international guidelines. Measurement of hospital-level 
AHR consumption, expressed as volume used in litres 
per 1,000 bed days used (BDU), has been shown to 
correlate with overall hand hygiene activity in hospitals. 
It is a recommended process measure of hand hygiene 
activity by both the World Health Organisation (WHO) 
and the US Centers for Disease Control & Prevention 
(CDC). 
Since 2006, the HPSC has collated data on AHR con-
sumption in acute public hospitals in Ireland. Data is 
collected quarterly. For hospitals providing AHR data 
via the pharmacy department, the data represents the 
total volume of AHR dispensed to wards, clinics and 
other hospital areas. For hospitals providing AHR data 
via the supplies or stores department, the data repre-
sents the total volume of AHR purchased. Quantities 
used for pre-operative surgical hand hygiene were 
excluded. The rate of usage per hospital is calculated 
as the total volume of AHR consumed in litres per 1,000 
BDU (Table 1). 
In 2012, the median rate of AHR consumption (L/1,000 
BDU) increased by 10% to 23.4 from 21.2 in 2011. The 
wide range of inter-hospital variation in AHR consump-
tion (12.5 – 160L/1,000 BDU) may partly be explained 
by differences in methodologies for collecting and re-
porting the data and by differences in formulations and 
brands of AHR used. 
The main limitation of this surveillance system is that 
the data refers to the use of AHR only, and does not 
take account of other hand hygiene products (e.g. med-
icated liquid soap) that may also be in use in hospitals. 
In addition, the data do not give an indication of the 
frequency with which hand decontamination is carried 
out at a given hospital nor distinguish between who has 
used the AHR (visitor, patient or healthcare worker). 
The data are also prone to reporting artefacts, par-
ticularly for hospitals that report supplies (rather than 
pharmacy dispensing) data. For example, the hospital 
with the highest rate in 2012 had undergone a change 
in suppliers and the products had been restocked in all 
areas of the hospital over a relatively short period of 
time.  It is expected that there will be outliers of this na-
ture from time to time. Using the median consumption 
figure provides a stable indicator of the national AHR 
rate over time. However, the volume of AHR consumed 
remains a crude measure of hand hygiene activity at 
individual hospital level and must be viewed with other 
indicators such as direct observation of hand hygiene 
compliance.
Further information may be found at: 
http://www.hpsc.ie/hpsc/A-Z/Gastroenteric/Handwashing/
 
Table 1. National data on AHR consumption in acute public hospitals in Ireland by year, 2006 – 2012.
 2006 2007 2008 2009 2010 2011 2012
Number of participating hospitals 52 50 50 49 45 44 42
National consumption rate* 10.5 15 18.7 22.1 19.2 21.2 23.4
Range for participating hospitals in 
litres per 1,000 bed-days used
0.5 - 29.0 5.2 - 47.1 5.9 - 52.5 7.8 - 47.7 7.6 – 36.4 10.6 - 129.4 12.5 - 160
* The consumption rate is the total volume of AHR consumed in the defined time period in litres per 1,000 bed-days used. The national 
rate represents the median of the national sample for each time period.
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9.1.3.2 Hand Hygiene Compliance Audit
Key Points
•  Two national hand hygiene compliance audits took 
place in 2012
•  For Period 3 (May/June), 45 (43 public and 2 
private) hospitals participated. In total, 9,387 
opportunities for hand hygiene were observed; 
achieving an average compliance of 82.0% (range 
= 70.3 - 94.8%) 
•  For Period 4 (October), 44 (42 public and 2 private)
hospitals participated. In total, 9,171 opportunities 
for hand hygiene were observed; achieving an 
average compliance of 84.6% (range = 68.6 - 
94.3%)
•  The overall compliance for the combined periods 
for HSE hospitals was 82.9%. This figure is below 
the 2012 HSE target of 85%. However, the 
underlying trend from the four periods of publicly-
reported hand hygiene compliance audit to the 
end of 2012 has been increasing 
•  Compliance for the two participating private 
hospitals over both periods in 2012 was 91.7%
Hand hygiene is one the most important actions to 
prevent HCAI.  Measuring hand hygiene compliance 
by direct observation is described by the World Health 
Organisation (WHO) as the gold standard. In 2011, 
public reporting of biannual hand hygiene compliance 
data from acute hospitals commenced and has 
continued in 2012. Healthcare workers (HCWs) were 
observed for their compliance against the ‘WHO 5 
moments for hand hygiene’ by trained auditors using 
the WHO methodology for hand hygiene audits. Each 
hospital was required to measure HCW compliance 
against 30 hand hygiene opportunities for each of the 
seven randomly selected wards in their facility resulting 
in a maximum of 210 opportunities per hospital per 
period.  
The 2012 audits were undertaken in May/June 
(Period 3) and October (Period 4). A total of 8,967 
opportunities for hand hygiene were observed in 43 
HSE hospitals for Period 3, and 8,799 opportunities 
in 42 facilities in Period 4. Results for the two periods 
are combined in a summary in Table 1 and Figure 1. 
In 2012, the overall compliance for HSE and private 
hospitals combined was 83.3%, and for the HSE 
hospitals was 82.9%, below the 2012 target of 85%.  
However, the underlying trend for compliance among 
HSE hospitals is rising (Figure 2) over the first four 
periods. Of the four HSE regions in 2012, HSE-West 
had the lowest (81.3%) and HSE-South had the highest 
compliance (83.8%). Two private hospitals submitted 
data for both audits in 2012, reporting an overall 
compliance of 91.7%.  
In 2012, of the four major HCW categories, medical 
Table 1:  Summary of hand hygiene compliance in acute hospitals in Ireland combined for the two national audit periods in 2012 
(Note that data from private hospitals were excluded for the Staff Categories, WHO 5 Moments and Wards sections)
 
Hand Hygiene 
Opportunities
Hand Hygiene 
Actions
Percent 
Compliance
Lower 95% 
Confidence Interval
Upper 95% 
Confidence Interval
Overall (Periods 3 & 4) 18,558 15,460 83.3% 82.8% 83.8%
HSE Hospitals 17,746 14,715 82.9% 82.4% 83.5%
Private Hospitals 812 745 91.7% 89.6% 93.5%
HSE - South 6,288 5,269 83.8% 82.9% 84.7%
HSE – DNE 3,565 2,956 82.9% 81.6% 84.1%
HSE - DML 3,768 3,135 83.2% 82.0% 84.4%
HSE - West 4,125 3,355 81.3% 80.1% 82.5%
Nurse/Midwife 10,288 8,996 87.4% 86.8% 88.1%
Auxiliary 2,647 2,167 81.9% 80.3% 83.3%
Medical 3,544 2,474 69.8% 68.3% 71.3%
Other 1,267 1,078 85.1% 83.0% 87.0%
Moment 1 4,659 3,895 83.6% 82.5% 84.7%
Moment 2 1,013 840 82.9% 80.5% 85.2%
Moment 3 1,595 1,416 88.8% 87.1% 90.3%
Moment 4 6,609 5,732 86.7% 85.9% 87.5%
Moment 5 5,366 4,169 77.7% 76.6% 78.8%
Intensive Care Unit Wards 2,023 1,729 85.5% 83.9% 87.0%
Staff category: “Auxiliary” includes healthcare assistants, porters, catering and household services; “Other” includes physiotherapists, 
radiologists, dieticians, social workers and pharmacists
Moment 1: Before touching a patient; Moment 2: Before clean/aseptic procedure; Moment 3: After body fluid exposure risk; Moment 4: After 
touching a patient; Moment 5: After touching patient surroundings
-144-HPSC Annual Report 2012 Healthcare Associated Infections
50%
55%
60%
65%
70%
75%
80%
85%
90%
95%
100%
P
er
io
ds
 3
 a
nd
 4
H
S
E
 H
os
pi
ta
ls
P
riv
at
e 
H
os
pi
ta
ls
H
S
E
 - 
S
ou
th
H
S
E
 - 
D
ub
lin
 N
or
th
-E
as
t
H
S
E
 - 
D
ub
lin
 M
id
-L
ei
ns
te
r
H
S
E
 - 
W
es
t
N
ur
se
/M
id
w
ife
A
ux
ili
ar
y
M
ed
ic
al
O
th
er
M
om
en
t 1
M
om
en
t 2
M
om
en
t 3
M
om
en
t 4
M
om
en
t 5
In
te
ns
iv
e 
C
ar
e 
U
ni
t
Overall Regions Staff Categories WHO 5 Moments Wards
C
om
pl
ia
nc
e
Compliance HSE Target 2012
Figure 1:  Summary of hand hygiene compliance in acute hospitals in 
Ireland combined for the two national audit periods in 2012. The 95% 
confidence intervals are shown in bars and the HSE target for 2012 (85%) 
is shown as a horizontal red line. Note that data from private hospitals 
were excluded for the Staff Categories, WHO 5 Moments and Wards 
sections.
Figure 2:  Summary of hand hygiene compliance 
in HSE acute hospitals in Ireland for the first four 
national audit periods in 2011 and 2012. The 
HSE target for each year is shown as red lines.
staff had the lowest (69.8%) and nursing/midwifery staff 
had the highest compliance (87.4%). 
Based on the ‘WHO 5 moments for hand hygiene’, 
compliance with moment 5 (after touching patient 
surroundings) was lowest (77.7%) and with moment 3 
(after body fluid exposure risk) was highest (88.8%). 
The majority of hand hygiene opportunities were taken 
using alcohol hand rub (61.3%), with soap and water 
accounting for 38.7% of opportunities. Data submitted 
from two private hospitals has been excluded from the 
compliance audit reports by staff categories, WHO 5 
Moments and wards sections (Table 1 and Figure 1).
Whilst standardised hand hygiene auditor training and 
validation (with inter-rater reliability testing) should 
ensure that measurement of hand hygiene should be 
comparable, these results have not been validated by 
external auditors. Furthermore, all auditors measured 
compliance in the facility in which they usually work; 
thus there may be an element of bias in the results. It 
is also possible that hand hygiene compliance auditing 
may not have been performed in a comparable fashion 
in all participating hospitals. The results may also not 
reflect HCW compliance at all times. Hand hygiene 
compliance is measured by auditors who directly 
observe HCWs workers whilst they are undertaking 
patient care. HCW may change their behaviour if they 
become aware that they are being observed (known 
as the Hawthorne effect). It is also known that the 
Hawthorne effect diminishes over time and HCWs under 
observation may not be aware of the auditor’s presence 
due to many competing demands on their attention.  
Auditors are requested to give immediate feedback 
to ward staff following an audit, thereby increasing 
awareness and knowledge of hand hygiene. This risk of 
bias should be balanced by the benefits of increasing 
local staff knowledge and awareness of hand hygiene.
 
Staff category: “Auxiliary” includes healthcare assistants, porters, catering and 
household services; “Other” includes physiotherapists, radiologists, dieticians, social 
workers and pharmacists
Moment 1: Before touching a patient; Moment 2: Before clean/aseptic procedure; 
Moment 3: After body fluid exposure risk; Moment 4: After touching a patient; 
Moment 5: After touching patient surroundings
9.1.3.3 Survey of Hygiene & HCAI Prevention Practices 
in Irish Critical Care Services 2012
In 2011, the Health Services Executive (HSE) Critical Care 
and Healthcare Associated Infection National Clinical 
Programmes convened a joint multi-disciplinary steering 
group for HCAI prevention in Irish critical care units. A 
voluntary survey was devised to obtain baseline data with 
regard to existing hygiene and HCAI prevention practices 
in Irish critical care units and circulated to all critical care 
units in January 2012.
Key Points
•  Completed surveys were received from 29 
hospitals (25 public and four private), incorporating 
36 critical care units (35 adult and one paediatric)
•  It has been over five years since 19 critical care 
units underwent reconfiguration of patient 
accommodation. In the 29 hospitals participating 
in this survey, single room accommodation 
accounted for just 28% of critical care unit beds. 
Current isolation capacity in Irish critical care units 
is inadequate. Inability to isolate patients colonised 
or infected with multi-drug resistant organisms 
increases the risk of onward transmission to a 
neighbouring patient
•  None of the HDUs, 43% of mixed ICUs and 31% 
of level 3 ICUs have an airborne infection isolation 
room (AIIR).  Prompt isolation of patients with 
suspected or confirmed infection transmitted via 
the airborne route (e.g., tuberculosis, measles, and 
varicella) is vitally important as such pathogens are 
highly infectious
•  Access to alcohol hand rub (AHR) at every bed 
space was available in 92% of units
•  Access to a formal training programme on 
preventable device-related infections (vascular 
catheters related infection (CRI), ventilator 
associated pneumonia (VAP) and catheter 
associated urinary tract infection (CAUTI) is not 
universal in Irish critical care units. Formal staff 
training on CRI prevention is provided by 86%, VAP 
prevention by 68% and CAUTI prevention by 56% 
•  Central vascular catheter (CVC) insertion checklists 
are in use in 69% and insertion packs are in use in 
66% of Irish critical care units 
•  Use of care bundles as one method to prevent 
device-related infections (peripheral catheter and 
CVC-related infections, VAP and CAUTI) is not 
universal in Irish critical care units. Care bundles 
for CVC-CRI prevention are in use in 47%, for VAP 
prevention in 45% and for CAUTI prevention in 
31% of units 
•  Ongoing prospective surveillance of potentially-
preventable HCAI (BSI, CRI, VAP & UTI) is currently 
being undertaken by only the minority of critical 
care units (35%, 36%, 14% and 8%, respectively) 
•  Access to clinical advice from an infection specialist 
is not available in all Irish critical care units. Of the 
29 hospitals participating in this survey, 20 (69%) 
have an on-site consultant microbiologist. However, 
seven critical care units (19%) report having no 
access to round-the-clock infection specialist advice 
•  A designated antimicrobial pharmacist was not 
in post in six (21%) hospitals participating in this 
survey
Key Recommendations & Implementation Proposals 
•  Ongoing investment in and capital development of the 
physical infrastructure of critical care units in Ireland 
is urgently required to bring existing units up to the 
standards outlined in national guidance documents. 
This should include increasing the overall isolation 
room capacity in critical care units and for beds not in 
isolation rooms, increasing the space between beds. 
The provision of at least one isolation room per unit 
with a ventilation design capable of accommodating 
patients with specialised requirements is also 
recommended
•  Ongoing formal education regarding impact, 
consequences and prevention of device-related 
infection (CRI, VAP, and CAUTI) should be provided to 
all healthcare workers in critical care
•  Care bundles for maintenance of vascular catheters, 
intubation equipment and urinary catheters should 
be implemented in all Irish critical care units. Where 
existing practice guidelines are available, these should 
be adapted to include recommended care bundle 
components
•  It is recommended that critical care units are supported 
in establishing HCAI surveillance modules using 
European Hospitals in Europe Link for Infection Control 
through Surveillance (HELICS) definitions. Priorities for 
HCAI surveillance include; unit-acquired bloodstream 
infection (UABSI), CRI, VAP and CAUTI. Resources to 
support the introduction of HCAI surveillance in Irish 
critical care units should be prioritised and central 
collation, analysis and reporting of surveillance data is 
recommended
•  Every critical care unit must have round-the-clock access 
to infection specialist advice and an active antimicrobial 
stewardship programme, including daily clinical 
microbiology rounds and access to a dedicated critical 
care and antimicrobial pharmacist
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•  All healthcare workers in critical care units should 
be encouraged to avail of annual seasonal influenza 
vaccine and vaccine uptake should be recorded and 
reported within each unit. Measures to promote 
and improve healthcare worker uptake of seasonal 
influenza vaccine should be encouraged
The full survey report may be accessed on 
the HPSC website: http://www.hpsc.ie/hpsc/
A-Z/MicrobiologyAntimicrobialResistance/
InfectionControlandHAI/Surveillance/HHCAISurvey2012/
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Ireland participates in ECDC’s European Surveillance of 
Antimicrobial Consumption (ESAC-Net) project which 
aims to collect systematic antimicrobial usage data from 
both the outpatient (ambulatory, community or primary 
care) and the hospital (inpatient) settings. Antimicrobial 
consumption is measured in defined daily doses (DDD), 
which is the assumed average maintenance dose per 
day for a drug used for its main indication in adults. 
Rates are calculated in DDD per 1,000 inhabitants per 
day (DID) for outpatients and DDD per 100 bed-days 
used (DBD) for inpatients. Please see “Antimicrobial 
consumption” and “Denominator data” parts of the 
explanatory notes section for further details.
3.1 Outpatient Antimicrobial Consumption
The overall outpatient antimicrobial consumption for 
Ireland in 2012 was 22.9 DID, a marginal increase of 
0.8% from the rate of 22.7 DID for 2011. In the latest 
interim ESAC-Net report (provisional 2012 data), the 
reported range of outpatient antimicrobial usage 
among European countries was 11.3 to 39.1 DID. The 
median for 27 European countries with reliable data 
was 19.8 DID, with Ireland ranking as the seventh 
highest.
The underlying trend for outpatient antimicrobial 
consumption in Ireland (Figure 1) has been increasing 
steadily since 2000. After a short dip in late 2009, the 
rate has increased to its highest level, although it has 
remained stable for the last two years. There is still 
marked seasonal fluctuation in usage, with the highest 
levels occurring during periods of increased influenza 
activity.
In Ireland in 2012, outpatient consumption of 
penicillins accounted for the largest class used (55% 
of total at 12.5 DID), followed by macrolides (18%, 
4.2 DID), tetracyclines (13%, 2.9 DID), cephalosporins 
(5%, 1.2 DID), sulphonamides (5%, 1.2 DID) and 
fluoroquinolones (4%, 0.9 DID). Other antimicrobial 
classes accounted for less than 1% of total use. 
Penicillin in combination with a beta-lactamase inhibitor 
(such as co-amoxiclav) accounted for the largest 
proportion of penicillins (54%) at 6.8 DID. Broad-
spectrum penicillin (such as amoxicillin) usage was also 
high at 29% of all penicillins (15.9 DID). See Table 1 for 
detailed breakdown by pharmacological drug groups 
for the 2012 data.
There was considerable variability in the overall 
outpatient antimicrobial usage at county level (18.5 to 
30.8 DID) as shown in Figure 2. 
3.2 Hospital Antimicrobial Consumption
Forty-one public acute hospitals provided valid 
antimicrobial usage data for 2012. The median rate of 
antimicrobial consumption was 87.0 defined daily doses 
per 100 bed days used (DBD) (range = 27.9 – 126.7). 
This represents a 5% increase from the previous year’s 
revised rate of 83.1 DBD. The overall rate was 85.9 
DBD. These levels are again mid-to-high in Europe.
The largest group of antimicrobials, penicillins 
(42.5 DBD) accounted for 49% of all inpatient 
antimicrobial usage, unchanged from 2011. The use of 
fluoroquinolones such as ciprofloxacin (representing 7% 
of all inpatient antimicrobial usage) increased by 1% 
9.2.0 Antimicrobial Consumption 
Key Points
•  In 2012, the overall rate of outpatient antimicrobial 
consumption in Ireland was 22.9 DID, a small 
increase from 2011. This rate is mid-to-high in 
comparison with other European countries
•  In 2012, the median rate of antimicrobial 
consumption of 41 acute public hospitals in Ireland 
was 87.0 DBD (range 27.9 – 126.7 DBD), a 5% 
increase from 2011. This rate is mid-to-high in 
comparison with other European countries
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in 2012 to 5.9 DBD. Consumption of cephalosporins, 
monobactams and carbapenems (representing 9% of all 
inpatient antimicrobial usage) increased by 8% in 2012 
to 7.5 DBD. Consumption of glycopeptides such as 
intravenous vancomycin, imidazoles such as intravenous 
metronidazole and nitrofurans (representing 10% of all 
inpatient antimicrobial usage) decreased by 3% in 2012 
to 8.5 DBD. Consumption of erythromycin and related 
agents (representing 14% of all inpatient antimicrobial 
usage) increased by 2% in 2012 to 12.1 DBD. Less 
frequently used agents in hospitals are tetracyclines, 
sulphonamides/trimethoprim, aminoglycosides and 
other systemic antimicrobials; collectively these drugs, 
representing 11% of all inpatient antimicrobial usage, 
increased by 6% in 2012 to 9.5 DBD. 
Hospital function was the main driver for the differences 
in the rates of antimicrobial consumption between 
hospitals. The rates for regional/tertiary and general 
hospitals (medians 84.4 and 92.2 DBD) centred around 
the median for Ireland, while the rate for single 
specialist facilities (maternity, orthopaedic or paediatric) 
was much lower (median 56.8 DBD). The lower median 
consumption in single speciality hospitals probably 
reflects differences in case-mix, compared to other 
hospitals. However it may also reflect the fact that 
DDDs are based on adult dosing and may therefore 
underestimate antimicrobial consumption in paediatric 
settings. 
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Table 1. Breakdown by pharmacological drug groups for outpatient antimicrobial use in Ireland: DDD per 100,000 population, 
2011 and 2012. 
2011 Percent of 2011 2012 Percent of 2012
Penicillins 12.3 54.0% 12.5 54.6%
    Narrow spectrum penicillins 1.0 4.4% 1.0 4.4%
    Beta-lactamase resistant penicillins 1.0 4.6% 1.0 4.6%
    Broad spectrum penicillins 3.6 15.7% 3.7 15.9%
    Penicillin with beta-lactamase inhibitor 6.7 29.3% 6.8 29.7%
Macrolides and related drugs 4.2 18.4% 4.2 18.2%
Tetracylines 2.8 12.3% 2.9 12.8%
Cephalosporins and other beta-lactam drugs 1.2 5.3% 1.2 5.2%
    First-generation cephalosporins 0.2 0.7% 0.2 0.8%
    Second-generation cephalosporins 0.9 4.1% 0.9 4.0%
    Third-generation cephalosporins 0.1 0.5% 0.1 0.4%
Quinolones 0.9 4.1% 0.9 3.8%
Sulfonamides and Trimethoprim 1.2 5.2% 1.2 5.0%
Other antibiotics 0.1 0.6% 0.1 0.5%
TOTAL 22.7 100.0% 22.9 100.0%
Figure 1. Outpatient antimicrobial consumption in Ireland by quarter, 2000-2012.
The use of intravenously administered specific 
antimicrobials (those with good oral bioavailability) 
as a proportion of total use remained unchanged at 
a median of 7.0% between 2011 and 2012, but has 
decreased steadily from 9.7% in 2007. This measure 
reflects patient acuity and also the hospital function. The 
change in the level of this measure may also reflect local 
antimicrobial stewardship interventions.
More detailed analyses of antimicrobial usage data can 
be found on the www.hpsc.ie website, through “Topics 
A-Z”, under “Antibiotic Consumption Surveillance”. 
Details of the WHO ATC/DDD system of classifying and 
measuring drug consumption can be found at 
www.whocc.no/atc_ddd_index/. The figures presented 
in this report may vary from those previously published 
owing to methodological changes.
Figure 2. Outpatient antimicrobial consumption in Ireland, by 
county, in DDD per 100 inhabitants per day for 2012.
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9.3.0 Antimicrobial Resistance
Key Points
•   In 2012, 2,450 reports of invasive E. coli 
infection were submitted from Ireland to the 
European Antimicrobial Resistance Surveillance 
Network (EARS-Net), an increase of 11% from 
2,210 reports in 2011. The proportion of E. coli 
isolates displaying resistance to third-generation 
cephalosporins (10.8%), to ciprofloxacin (25.2%), to 
aminoglycosides (12.6%) along with those reported 
to produce extended-spectrum beta-lactamases 
(8.8%) and to exhibit multi-drug resistance (13.4%) 
were at their highest levels since surveillance began
•   In 2012, there were 1,060 reports of 
Staphylococcus aureus bloodstream infection 
(BSI), a decrease of 3% from 1,095 reports in 2011. 
Of these, 242 (22.8%) were meticillin-resistant S. 
aureus (MRSA), a decrease of 8% from 263 reports 
in 2011. For acute hospitals, the rate of MRSA 
BSI was 0.060 cases per 1,000 bed days used, 
a decrease from 0.066 in 2011. Over the same 
period, the rate of meticillin-susceptible S. aureus 
(MSSA) BSI remained stable at 0.208. 
•   Enhanced surveillance data revealed that 15% of 
S. aureus BSI were associated with central vascular 
catheters (CVCs) and 11% with peripheral vascular 
catheters
•   In 2012, there were 392 reports of 
Enterococcus faecium BSI, compared with 364 
in 2011. This represents an increase of 8%. 
Vancomycin-resistant E. faecium (VREfm) accounted 
for 45.4% of reports, which was at its highest 
level since surveillance began and was the highest 
proportion among countries reporting to EARS-Net 
in 2012  
•   In 2012, there were 345 reports of invasive 
Klebsiella pneumoniae infection compared to 
312 in 2011, an increase of 11%. The proportions 
of K. pneumoniae isolates displaying resistance 
to third-generation cephalosporins (11.9%) and 
those reported to produce extended-spectrum 
beta-lactamases (8.8%) were at their highest levels 
since surveillance began. There were no reports 
of carbapenem resistant invasive K. pneumoniae 
isolates in 2012 
•   In 2012, there were 321 reports of invasive 
S. pneumoniae infection compared to 327 in 2011, 
a decrease of 2%.  Of these, 63 (19.6%) were 
penicillin-non-susceptible S. pneumoniae (PNSP), 
which is similar to the situation in 2011 (n=64; 
19.6%). The national rate of invasive pneumococcal 
infection was 7.0 per 100,000 population, which 
is comparable to 7.1 in 2011. The numbers of 
reports and rates of infection in children aged 
under two years, the target group for the 13-valent 
pneumococcal conjugate vaccine (PCV13), were 
broadly similar to those seen in 2011
•   Serotype data were available on 306 of 321 
invasive pneumococcal isolates (95%) and results 
indicate good coverage (80%) for the 23-valent 
polysaccharide (PPV23) vaccines in its target 
population (adults ≥65 years). Coverage for PCV13 
in its target population was broadly similar to 2011
•   In 2012, there were 219 reports of invasive 
Pseudomonas aeruginosa infection, compared 
to 184 in 2011, an increase of 19%. Resistance 
to piperacillin-tazobactam (17.4%), ceftazidime 
(15.2%) and meropenem (19.6%) all reached their 
highest levels since surveillance began
•   Enhanced surveillance data were provided on  
1,765 cases from nine laboratories, representing 
35% of all cases submitted to EARS-Net in 2012
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9.3.0.1 European Antimicrobial Resistance  
Surveillance Network (EARS-Net) 
Introduction
In Ireland, the European Antimicrobial Resistance 
Surveillance Network (EARS-Net), previously the 
European Antimicrobial Resistance Surveillance System 
(EARSS) collects routinely-generated antimicrobial 
susceptibility testing data on seven important bacterial 
pathogens using the EARS-Net case definition. 
Participating laboratories submit data on the “primary” 
or first isolate from blood or cerebrospinal fluid (CSF) 
per patient per quarter. EARS-Net does not distinguish 
clinically significant isolates from contaminants, nor 
does it distinguish healthcare-associated infections 
from those associated with the community. EARS-Net 
primarily serves as a surveillance system to measure 
national levels of antimicrobial resistance (AMR). In 
2012, all 41 microbiology laboratories participated in 
EARS-Net, resulting in complete coverage of the Irish 
population.
Escherichia coli
In 2012, there were 2,450 reports of invasive E. coli 
infection (2,447 from blood and three from CSF) from 
2,388 patients, an increase of 10.9% from 2,210 reports 
in 2011.  Table 1 displays the proportion of E. coli 
isolates resistant to the four “indicator” antimicrobials/
antimicrobial classes [ampicillin, third-generation 
cephalosporins (3GCs; cefotaxime, ceftriaxone, 
ceftazidime or cefpodoxime), fluoroquinolones 
(ciprofloxacin or ofloxacin) and aminoglycosides 
(gentamicin, amikacin or tobramycin)] by year since 
2004.  
Of the 2,441 isolates for which 3GC susceptibility 
testing data was reported, 264 (10.8%) were resistant 
to 3GCs, of which 195 were reported as extended 
spectrum beta lactamase (ESBL)-positive and 64 as 
ESBL-negative. Just over one quarter (25.2%); 616 
of 2,441 were ciprofloxacin resistant; and 236 (9.7%) 
of 2,437 were gentamicin-resistant [307 (12.6%) of 
2,437 were aminoglycoside-resistant (i.e. resistant to 
gentamicin, tobramycin or amikacin)]. 
In 2012, resistance to 3GCs, ciprofloxacin and 
aminoglycosides were at their highest levels since 
surveillance began (Figure 1). The trend in 3GC 
resistance has been upwards since 2004, which is highly 
significant (Chi2 trend=143, P<0.0001). 
The proportion of invasive E. coli isolates with 3GC 
resistance in Ireland is moderately-high levels (10 to 
<25%) on the EARS-Net European map (Figure 2). 
Also, 2012 data resulted in a colour change for Ireland 
on the EARS-Net European map from yellow in 2011 
(5 to <10% 3GC resistance) to orange (10 to <25% 
3GC resistance). With regard to 3GC, ciprofloxacin 
and aminoglycoside resistance Ireland ranks 18th, 12th 
and 13th, respectively, out of 30 countries reporting to 
EARS-Net in 2012. 
ESBLs are enzymes that confer resistance to most 
penicillins and cephalosporins (including 3GCs). 
ESBL-producing bacteria (including E. coli and 
K. pneumoniae) are often resistant to other classes of 
antimicrobials and have emerged as important causes 
of infections both in hospitals and the community. 
ESBLs were detected in 215 (8.8%) of 2,444 isolates 
tested. In 2012, ESBL production among E. coli isolates 
was at its highest level since surveillance began. The 
trend in ESBL production has been upwards since 2004, 
which was highly significant (Chi2 trend=161, P<0.0001). 
Of 2,428 isolates tested against all four “indicator” 
antimicrobials, 326 (13.4%), from 46 hospitals/
institutions, were identified as multi-drug resistant 
(MDR), which is defined as resistance to three or more 
of these indicator antimicrobials, a slight increase from 
13.0% in 2011. In 2012, MDR E. coli was at its highest 
level since surveillance began. Between 2009 and 
2012, the trend in MDR was upwards, which was highly 
significant (Chi2 trend=10.97, P=0.0009).
•  114 with resistance to ampicillin, 3GCs, ciprofloxacin 
and aminoglycosides (105 ESBL-positive, 9-negative)
•  85 with resistance to ampicillin, 3GCs and 
ciprofloxacin (70 ESBL-positive, 14 -negative)
•  124 with resistance to ampicillin, ciprofloxacin and 
aminoglycosides (7 ESBL-positive, 117 -negative)
•  Three with resistance to ampicillin, 3GCs and 
aminoglycosides (two ESBL-positive, one -negative)
Females were slightly more likely (1.05-times) to have 
an invasive E. coli infection than males (z=1.31, P=0.19). 
The frequency of invasive E. coli infection increased 
with age, with the majority of infections (n=1,840; 75%) 
occurring in adults over 60 years.  The median age was 
72 years (95%CI, 71-73).
Staphylococcus aureus
In 2012, there were 1,060 reports of S. aureus 
bloodstream infection (BSI) from 1,038 patients, a 
decrease of 3.2% from 1,095 reports in 2011. Of 
these, 242 (22.8%) were meticillin resistant S. aureus 
(MRSA) (Table 1).  This represents the lowest annual 
proportion since surveillance began in 1999.  In 2010, 
the proportion was 24.4%, which was the first time 
MRSA accounted for <25% of S. aureus BSI in Ireland, 
and thus marked a change from red to orange on the 
EARS-Net European map. This is the sixth successive 
year in which a decrease has been observed and the 
overall downward trend over this time period is highly 
significant (Chi2trend=196.6, P<0.0001) (Figure 3).  
Overall, there was an 8% reduction in the number of 
MRSA BSI reports compared with 2011 (242 vs. 263). 
The total number of meticillin-susceptible S. aureus 
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Table 1. Summary of EARS-Net data by pathogen and year, 2004-2012
Pathogen 2004 2005 2006 2007 2008 2009 2010 2011 2012
Number laboratories by year-end 40 41 42 44 42 43 40† 41†† 41
E. coli
Number of isolates 1256 1445 1656 1785 1926 2064 2170 2210 2450
Ampicillin-R* 65.0% 67.6% 70.7% 68.3% 70.4% 68.7% 68.4% 71.9% 69.6%
3GC-R* 2.6% 4.1% 4.2% 6.7% 7.4% 7.5% 8.3% 9.3% 10.8%
ESBL-producers* 1.1% 2.4% 2.5% 4.1% 5.0% 5.8% 6.1% 7.5% 8.8%
Ciprofloxacin-R* 12.6% 17.3% 21.5% 22.1% 23.3% 22.3% 23.6% 23.8% 25.2%
Gentamicin-R* 5.7% 8.5% 7.7% 9.9% 10.2% 7.7% 9.4% 8.7% 9.7%
Gentamicin/Amikacin/Tobramycin-R* 6.1% 8.6% 8.6% 10.6% 11.0% 9.3% 11.8% 12.2% 12.6%
Carbapenem‡-R* 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
MDR* 5.6% 7.7% 9.0% 11.4% 12.1% 10.4% 11.7% 13.0% 13.4%
Number laboratories by year-end 41 42 42 44 43 43 40† 41†† 41
S. aureus
Number of isolates 1323 1424 1412 1393 1303 1309 1251 1095 1060
Number Meticillin-R (or MRSA) 553 592 592 536 439 355 305 263 242
Meticillin-R (or MRSA) 41.8% 41.6% 41.9% 38.5% 33.7% 27.1% 24.4% 24.0% 22.8%
Number VISA 0 0 2 1 0 0 0 0 0
VISA* 0.0% 0.0% 0.1% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0%
Number laboratories by year-end 40 41 42 44 42 43 40† 41†† 41
E. faecium
Number of isolates 187 224 265 330 406 397 392 364 392
Ampicillin-R* 95.7% 92.3% 93.9% 93.1% 95.1% 92.9% 95.6% 95.9% 92.9%
Vancomycin-R 23.2% 31.7% 37.1% 33.4% 35.7% 38.3% 39.3% 37.4% 45.4%
HLG-R* 58.0% 51.4% 44.3% 35.2% 28.1% 39.1% 39.6% 36.8% 39.3%
MDR* 18.5% 25.6% 25.6% 22.7% 16.2% 26.7% 24.9% 21.1% 20.3%
Number laboratories by year-end 36 39 41 42 40† 41†† 41
K. pneumoniae
Number of isolates
No data No data
217 244 310 323 326 312 345
Ampicillin-R* 97.7% 99.2% 99.7% 99.7% 99.1% 100.0% 98.5%
3GC-R* 10.2% 9.9% 11.4% 11.2% 10.5% 8.0% 11.9%
ESBL-producers* 8.6% 3.7% 7.7% 8.2% 5.0% 5.6% 8.8%
Ciprofloxacin-R* 15.3% 18.1% 12.8% 13.0% 10.5% 13.2% 11.9%
Gentamicin-R* 7.8% 9.9% 10.7% 11.1% 6.8% 7.4% 9.9%
Gentamicin/Amikacin/Tobramycin-R* 9.2% 11.1% 10.7% 11.1% 7.1% 8.3% 9.6%
Carbapenem‡-R* 0.0% 0.6% 0.0% 0.0% 0.0% 1.6% 0.3%
MDR* 11.2% 11.9% 10.6% 11.9% 8.0% 8.4% 9.9%
Number laboratories by year-end 41 42 42 44 42 43 40† 41†† 41
S. pneumoniae
Number of isolates 400 401 407 438 447 356 314 327 321
Penicillin-NS* 10.3% 11.7% 15.7% 17.4% 23.1% 20.2% 18.2% 19.6% 19.6%
of which:   HLR 1.8% 3.0% 2.9% 5.7% 6.0% 5.6% 4.8% 6.1% 4.0%
 Int 7.0% 8.7% 12.5% 11.0% 16.8% 13.8% 12.7% 13.5% 15.6%
Erythromycin-R* 14.4% 12.1% 16.1% 16.4% 16.7% 17.3% 15.7% 18.9% 16.9%
%Penicillin-NS/Erythromycin-R 3.1% 3.2% 7.4% 7.9% 10.2% 11.9% 12.6% 13.8% 12.2%
Number laboratories by year-end 40 41 42 44 42 43 40† 41†† 41
E. faecalis
Number of isolates 242 290 294 280 301 289 298 265 298
Ampicillin-R* 0.8% 3.5% 4.5% 2.2% 0.7% 2.1% 2.0% 0.8% 4.0%
Vancomycin-R 1.3% 2.5% 3.7% 2.9% 3.7% 0.7% 0.3% 4.9% 3.0%
HLG-R* 41.3% 44.4% 42.4% 36.9% 30.5% 36.7% 29.7% 29.1% 32.9%
Number laboratories by year-end 36 39 41 42 40† 41†† 41
P. aeruginosa
Number of isolates
No data No data
128 177 199 248 222 184 219
Piperacillin/tazobactam-R* 9.4% 12.6% 9.7% 8.9% 10.0% 2.8% 17.4%
Ceftazidime-R* 10.6% 11.8% 8.7% 11.8% 9.2% 8.2% 15.2%
Imipenem/meropenem-R* 11.8% 12.2% 9.3% 10.2% 8.3% 12.0% 19.6%
Ciprofloxacin-R* 18.0% 22.9% 21.8% 12.1% 13.2% 12.6% 20.6%
Gentamicin-R* 10.2% 13.3% 9.0% 7.7% 8.7% 6.5% 11.9%
MDR* 9.5% 12.4% 11.1% 6.4% 6.5% 4.0% 13.0%
MRSA, Meticillin-Resistant S. aureus; VISA, Vancomycin-Intermediate S. aureus
R, Resistant; NS, Non-Susceptible [includes isolates with intermediate (Int) and high-level resistance (HLR)]
HLG, High-Level Gentamicin; 3GC, 3rd-Generation Cephalosporin (includes cefotaxime, ceftriaxone, ceftazidime 
and cefpodoxime); ESBL, Extended-Spectrum Beta-Lactamase; MDR, Multi-Drug Resistant
* Not all isolates tested
† In 2010, 3 laboratories stopped processing blood cultures, however coverage of acute hospitals remained at 100%
††  In Q3 2011, one additional laboratory started reporting data
‡ Carbapenems include imipenem, meropenem and ertapenem
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(MSSA) BSI reports decreased by 1.7% in 2012 
compared to 2011 (818 vs. 832). 
Despite the decrease in numbers and proportion of 
MRSA, Ireland still had one of the higher proportions 
of MRSA in Europe in 2012 (see http://ecdc.europa.eu/
en/activities/surveillance/EARS-Net/Pages/Database.
aspx for European data, including EARS-Net tables, 
charts and maps) (Figure 4). Ireland ranked 12th out of 
30 countries reporting to EARS-Net. All of the countries 
with higher MRSA proportions than Ireland are in 
Southern and Central/Eastern Europe.
No MRSA isolates with reduced susceptibility to 
vancomycin were detected by the National MRSA 
Reference Laboratory in 2012.  
The rate of MRSA BSI for all acute hospitals in 2012 was 
0.060 cases per 1,000 bed days used, representing a 
decrease from 0.066 in 2011, whilst the rate of MSSA 
BSI remained stable at 0.208 [Rates are calculated 
taking into account denominator data (bed days used) 
obtained from the Business Intelligence Unit at the 
Health Services Executive for all acute public hospitals 
and directly from the private hospitals where available, 
where both numerator (S. aureus BSI numbers) and 
denominator data have been provided]. 
Males were approximately 2.1-times more likely to get 
an invasive S. aureus infection (2.3-times for MRSA, 
z=6.72, P=0.0001; 2.1-times for MSSA, z=10.84, 
P<0.0001) than females (z=12.73, P<0.0001).  The 
frequency of invasive S. aureus infection increased 
with age, with the majority of infections (n=623; 59%) 
occurring in adults over 60 years.  The median age for 
patients with an MRSA infection was 73 years (95%CI, 
69-76) while the median age for patients with MSSA 
was 61 years (95%CI, 59-63).  This was considered to be 
a significant difference as the confidence intervals did 
not overlap.
Figure 1. Trends for E. coli. Total numbers & percentage resistance to 3GCs, ciprofloxacin/
ofloxacin (CIP/OFX), gentamicin (GEN), any aminoglycoside: gentamicin/amikacin/
tobramycin (GEN/AMK/TOB), and percentage ESBL-positive with 95% confidence intervals.
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Table 2. Age and gender breakdown of patients by organism with major resistance profiles (data from laboratories participating in 
enhanced surveillance for 2012). Proportion of isolates detected <48 hours and >5 days post-admission is also shown.
Total for  
2012
Percent 
female
Mean age 
in years
Detected <48 hours 
after admission
Detected >5 days 
after admission
Staphylococcus aureus Meticillin Resistant (MRSA) 75 32% 68.3 56% 36%
Meticillin Susceptible 250 34% 58.7 66% 20%
Streptococcus pneumoniae Penicillin non-Susceptible 31 35% 57.6 65% 26%
Penicillin Susceptible 108 40% 63.2 79% 8%
Enterococci Vancomycin Resistant 67 40% 67.4 19% 70%
Vancomycin Sensitive 179 40% 66.1 34% 50%
Escherichia coli Fluoroquinolone Resistant 225 43% 72 60% 28%
Fluoroquinolone Susceptible 637 58% 68.3 68% 16%
Klebsiella pneumoniae 122 47% 63.9 45% 41%
Pseudomonas aeruginosa 71 45% 67.9 55% 32%
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Enterococcus faecium
In 2012, there were 392 reports of E. faecium BSI 
from 386 patients, an increase of 8% from 364 reports 
in 2011. Table 1 displays the annual proportions of 
E. faecium isolates resistant to the three “indicator” 
antimicrobials (ampicillin, vancomycin and high-level 
gentamicin) by year since 2004.  
Of the 392 invasive E. faecium isolates, 178 (45.4%) 
were resistant to vancomycin. The proportion of 
isolates that were vancomycin-resistant E. faecium 
(VREfm) increased from 37.4% in 2011, which was a 
significant finding (Chi2=5.03; P=0.025). Of 389 isolates 
with reported susceptibility test results for high-level 
gentamicin, 153 (39.3%) were resistant (Figure 5).
Since 2008, Ireland has had by far the highest 
proportion of VREfm in Europe. This remained the case 
in 2012, with the next highest proportions reported 
by Portugal (23%), Greece (18%) and Germany (16%) 
(Figure 6). 
Of 389 isolates tested against the three “indicator” 
antimicrobials, 79 (20.3%) isolates from 20 hospitals 
were resistant to all three and therefore classed as 
MDR.  This represents a slight decrease from 21.1% in 
2011. 
Males were approximately 1.6-times more likely to have 
an invasive E. faecium infection than females (z=4.67, 
P=<0.0001).  The frequency of invasive E. faecium 
infection increased with age with the majority of 
infections (n=277; 71%) occurring in adults over 60 
years.  The median age was 69 years (95%CI, 67-71).
Klebsiella pneumoniae
In 2012, there were 345 reports of invasive 
K. pneumoniae infection (343 from blood and two from 
CSF) from 338 patients, an increase of 11% from 312 
reports in 2011).  Table 1 displays the proportion of 
K. pneumoniae isolates resistant to the four “indicator” 
antimicrobials (as for E. coli above) plus carbapenems 
(imipenem, meropenem or ertapenem) since 2004. 
Forty-one (11.9%) of 344 isolates were resistant to 
3GCs, 30 of which were ESBL-positive and 10 were 
ESBL-negative; 41 (11.9%) of 345 were ciprofloxacin-
resistant; and 33 (9.6%) of 345 were gentamicin-
resistant [34 (9.9%) of 345 were aminoglycoside-
resistant (i.e. resistant to gentamicin, tobramycin or 
amikacin)]. 
Between 2011 and 2012, resistance to 3GCs and 
gentamicin/aminoglycosides increased. In 2012, 
resistance to 3GCs was at its highest level since 
surveillance began.
Five isolates were reported as ampicillin-susceptible, 
an unusual finding, as K. pneumoniae are regarded as 
inherently resistant to this antimicrobial.
ESBLs were detected in 30 (8.8%) of 342 isolates 
tested, representing an increase from 5.6% in 2011. 
Figure 2. Distribution of third generation cephalosporin (3GC) resistant E. coli in 
EARS-Net countries in 2012. Map downloaded from ECDC’s TESSy database on 
16/10/2013:
http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.as
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In 2012, ESBL-production was at its highest level since 
surveillance began.
No carbapenem-resistant invasive K. pneumoniae 
isolates (termed carbapenem-resistant 
Enterobacteriaceae, or CRE) were reported in 2012. In 
2011, four invasive K. pneumoniae CRE isolates were 
reported due to carbapenemase production: three 
OXA-48 from one hospital and one KPC from another 
hospital. These carbapenemase-producing CRE isolates 
were the first reports of invasive infection due to these 
organisms in Ireland.
Thirty-four, or 9.9%, of 343 isolates tested against all 
four “indicator” antimicrobials from 21 hospitals were 
identified as MDR, an increase from 8.4% in 2011:
•  19 with resistance to ampicillin, 3GCs, ciprofloxacin 
and aminoglycosides (18 ESBL-positive, one -negative)
•  Five with resistance to ampicillin, 3GCs and 
ciprofloxacin (3 ESBL-positive, one -negative)
•  Five with resistance to ampicillin, 3GCs and 
gentamicin (all ESBL-positive)
•  Five with resistance to ampicillin, ciprofloxacin and 
aminoglycosides (all ESBL-negative) 
The number with resistance to all four “indicator” 
antimicrobials increased from 16 in 2011 to 19 in 2012.
Antimicrobial resistance levels among K. pneumoniae 
isolates in Ireland have been among the lowest in 
Europe, with Ireland ranking 26th and 25th out of 
30 countries in 2012 for 3GC and fluoroquinolone 
resistance, respectively. However, between 2011 and 
2012, aminoglycoside resistance in Ireland has increased 
from 7.6% (ranking 24th highest of 29 countries) to 
12.6% (ranking 13th of 30 countries).
Males were approximately 1.4-times more likely 
to have an invasive K. pneumoniae infection than 
females (z=3.00, P=0.003).  The frequency of invasive 
K. pneumoniae infection increased with age with the 
majority of infections (n=216; 63%) occurring in adults 
over 60 years.  The median age was 65 years (95%CI, 
63-67).
Streptococcus pneumoniae
In 2012, there were 321 reports of invasive 
S. pneumoniae infection (315 from blood and six from 
CSF) from 319 patients, a decrease of 1.8% from 327 
reports in 2011.  Table 1 displays the annual proportions 
of S. pneumoniae isolates non-susceptible/resistant to 
penicillin and erythromycin by year since 2004.  
Penicillin-non-susceptible S. pneumoniae (PNSP) 
accounted for 19.6% (n=63) of all isolates tested against 
penicillin (n=321) in 2012 (Table 1).  Of the 63 PNSP 
isolates, 48 were intermediately-resistant (Int) with a 
minimum inhibitory concentration (MIC) to penicillin 
between 0.1-1.0mg/L and 15 were high-level resistant 
(HLR) with a MIC >1.0mg/L to penicillin.  Fifty-three 
(16.9%) of 313 isolates were resistant to erythromycin.  
Between 2011 and 2012, the proportion of PNSP 
in Ireland remained stable at 19.6% (Figure 7).  The 
proportion of isolates that displayed HLR to penicillin 
decreased from 6.1% in 2011 to 4.7% in 2012.  In 
2012, Ireland had one of the highest proportions of 
PNSP (ranking 9th out of 30 countries, and 5th out of 21 
countries reporting 50 isolates or more). 
Comparison of S. pneumoniae susceptibility data 
between Ireland and other countries reporting to 
EARS-Net is increasingly problematic due to the 
possibility of different interpretive criteria being 
applied to the susceptibility testing data in different 
countries (and indeed by different laboratories within 
Figure 3. Trends for S. aureus. Total numbers of S. aureus/MRSA and percentage 
MRSA with 95% confidence intervals 
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the same country). Irish microbiology laboratories 
are currently in the process of changing over to the 
European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) guidelines. By the end of 2012, 15 
laboratories had completed the switch over from the 
American Clinical Laboratory Standards Institute (CLSI) 
guidelines. CLSI provides three sets of breakpoints for 
interpreting penicillin susceptibility of S. pneumoniae 
isolates: meningitis, non-meningitis and oral; while 
EUCAST provides two sets of breakpoints: meningitis 
and infections other than meningitis. In Ireland, 
EARS-Net data are reported using the “oral” CLSI 
breakpoints (which correspond to the original CLSI 
breakpoints) or the EUCAST breakpoints for infections 
other than meningitis, as these are broadly similar, 
for epidemiological purposes and to facilitate a more 
meaningful analysis of the data. This approach also 
permits a relatively consistent approach for comparing 
historical data. 
Moderately-high levels of erythromycin resistance were 
seen in S. pneumoniae in 2012 (with Ireland ranking 
16th out of 30 countries, and 11th out of 20 countries 
reporting 50 isolates or more), similar to the situation 
observed in much of Southern and Central/Eastern 
Europe. 
Figure 5. Trends for E. faecium. Total numbers of E. faecium and percentage resistance to 
high-level gentamicin (HLG) and vancomycin (VAN) with 95% confidence intervals
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Figure 4. Distribution of MRSA in EARS-Net countries in 2012. Map obtained from ECDC on 
16/10/2013: http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.aspx
Of isolates tested against both penicillin and 
erythromycin (n=312), 38 (12.2%) were simultaneously 
PNSP (29 Int, 9 HLR) and erythromycin-resistant in 2012.
Prior to the introduction of the 7-valent pneumococcal 
conjugate vaccine (PCV7) into the childhood 
immunisation schedule in September 2008, a national 
pilot project was established early in 2007 as a result 
of a collaborative initiative between RCSI/Beaumont 
Hospital, Children’s University Hospital, Temple 
St and HPSC with the aim of providing baseline 
serotyping data on invasive S. pneumoniae isolates.  
From September 2010, PCV7 was replaced with 
PCV13. For 2012, serotype data were available on 
306 pneumococcal isolates from all 30 laboratories 
that reported pneumococcal isolates to EARS-Net in 
2012, representing 95% of all pneumococcal isolates 
reported.  Overall, 243 (79%) isolates belonged to 
serotypes covered by the pneumococcal polysaccharide 
vaccine (PPV23; target population: adults ≥65 years 
and at risk groups), while 158 (52%) were covered 
by the conjugate vaccine (PCV13; target population: 
children <2 years).  From adults aged ≥65 years, 138 of 
172 (80%) isolates were covered by PPV23, while from 
children <2 years, 6 of 13 (46%) isolates were covered 
by PCV13 (compared with 7 of 13 isolates, or 56%, in 
2011).  Of the 63 PNSP isolates for which serotyping 
data were available, 18 of 28 (64%) from adults ≥65 
years were covered by PPV23 while three of the four 
isolates from children <2 years were covered by PCV13. 
On-going surveillance of the predominant serotypes 
is required as strains with serotypes other than those 
in the vaccine have been reported to increase in 
prevalence following the introduction of conjugate 
vaccines in other countries. Hence the need for a fully 
resourced national pneumococcal reference facility.
  The rate of invasive pneumococcal disease (IPD) in 
Ireland in 2012 was estimated to be 7.0 cases per 
100,000 population, comparable to 7.1 in 2011 (note: 
both rates calculated using the 2011 census data).  The 
highest rates of IPD were observed in children <1 year 
(12.4 cases per 100,000) and adults aged 65-74 years 
(21.7 cases per 100,000), 75-79 years (44.1 cases per 
100,000) and ≥80 years (53.7 cases per 100,000) (Figure 
8).  The rates in all age groups were broadly similar 
to the data for 2011 with the exception of the 75-79 
year age group, which increased from 31.4 cases per 
100,000.  
Males were approximately 1.1-times more likely to have 
an invasive S. pneumoniae infection than females, but 
this was not significant (z=0.84, P=0.4). The frequency 
of invasive S. pneumoniae infection increased with age 
with the majority of infections (n=210; 65%) occurring 
in adults over 60 years.  The median age was 68 years 
(95%CI, 65-71).
Enterococcus faecalis
In 2012, there were 298 reports of E. faecalis BSI from 
298 patients, an increase of 12% from 265 reports 
in 2011.  Table 1 displays the annual proportions of 
E. faecalis isolates resistant to the three “indicator” 
antimicrobials (as for E. faecium above) by year since 
2004.  
Nine (3.0%) of 298 isolates were resistant to vancomycin 
(vancomycin resistant E. faecalis – VREfa) and 95 (32.9%) 
of 289 isolates were resistant to high-level gentamicin. 
Figure 6. Distribution of vancomycin-resistant E. faecium in EARS-Net countries in 2012. Map 
downloaded from ECDC’s TESSy database on 16/10/2013:
http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.aspx
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Figure 7. Trends for S. pneumoniae. Total numbers of S. pneumoniae/PNSP and percentage 
PNSP with 95% confidence intervals. HLR = High-level resistant; I = Intermediate resistance
The highest proportion of VREfa in Ireland (4.9%) was 
reported in 2011. In 2012, Ireland had the second 
highest proportion of VREfa in Europe after Greece 
(7.9%).
Twelve isolates were reported as ampicillin-resistant, 
which suggests that these isolates were either 
misidentified as E. faecalis or misclassified as ampicillin-
resistant, as resistance to ampicillin is rare in E. faecalis.
Males were approximately two times more likely to 
have an invasive E. faecalis infection than females 
(z=6.15, P<0.0001).  The frequency of invasive 
E. faecalis infection increased with age with the majority 
of infections (n=197; 66%) occurring in adults over 60 
years.  The median age was 68 years (95%CI, 66-72).
Pseudomonas aeruginosa
In 2012, there were 219 reports of invasive 
P. aeruginosa infection (217 from blood and two from 
CSF) from 219 patients, an increase of 19% from 184 
reports in 2011.  Table 1 displays the proportion of 
P. aeruginosa isolates resistant to the five “indicator” 
antimicrobials/antimicrobial classes [piperacillin-
tazobactam, ceftazidime, carbapenems (meropenem or 
imipenem), fluoroquinolones (ciprofloxacin or ofloxacin) 
and gentamicin] since 2006.  
Thirty-eight (17.4%) of 219 isolates were resistant 
to piperacillin-tazobactam; 33 (15.2%) of 217 were 
resistant to ceftazidime; 42 (19.4%) of 216 were 
resistant to imipenem or meropenem; 45 (20.6%) of 
218 were resistant to ciprofloxacin; and 26 (11.9%) of 
218 were resistant to gentamicin [no additional isolates 
were resistant to the other aminoglycosides (amikacin 
or tobramycin)]. 
In 2012, resistance to all five indicator antimicrobials 
increased, with resistance to piperacillin-tazobactam, 
ceftazidime and meropenem reaching their highest 
levels since surveillance began. 
Twenty-eight (13.0%) of 215 isolates tested against all 
five “indicator” antimicrobials, from 14 hospitals, which 
was the highest since surveillance began:
•  Four with resistance to all five required antimicrobials
•  11 with resistance to four of the five required 
antimicrobials
•  13 with resistance to three of the five required 
antimicrobials
Antimicrobial resistance levels among P. aeruginosa 
isolates in Ireland have been increasing in comparison 
with other European countries, with Ireland ranking 
between 16th and 20th out of 30 countries for all five 
indicator antimicrobials.
Males were approximately 1.6-times more likely to 
have an invasive P. aeruginosa infection than females 
(significant; z=3.63, P<0.001).  The frequency of 
invasive P. aeruginosa infection increased with age 
with the majority of infections (n=155; 71%) occurring 
in adults over 60 years.  The median age was 71 years 
(95%CI, 68-73).
Enhanced EARS-Net Surveillance
The enhanced EARS-Net surveillance programme was 
established in 2004 and involves voluntary participation 
by hospitals that provide additional demographic, risk 
factor and clinical data on invasive pathogens causing 
BSI. In 2012, there were 1,765 individual records (cases 
or isolates under the EARS-Net definition) submitted 
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from nine participating laboratories. The total number 
of records thus far for 2012 represents 35% of the total 
core EARS-Net dataset. Demographic and other basic 
data for the major resistance profiles of EARS-Net 
pathogens are shown in Table 2. 
1. S. aureus BSI
 •  Of the S. aureus BSI, 69% of MRSA and 61% of 
MSSA were classified as healthcare-associated in 
2012
 •  Between 2010 and 2012, there was an annual 
reduction in the proportion of S. aureus BSI due 
to central vascular catheter (CVC) infection (23% 
to 15%). However, there was an increase in the 
proportion of S. aureus BSI due to peripheral 
vascular catheter infection (6% to 11%)
 •  The most common reported risk factors for S. 
aureus BSI were; recent surgery, malignancy and 
stay in an intensive care unit
 •  Endocarditis, abscess & septic arthritis were the 
most commonly recorded clinical features
2. Enterococcal BSI 
 •  Of the enterococcal BSI, the majority of 
vancomycin resistant (83%) and vancomycin 
sensitive (73%) were healthcare-associated
 •  The commonest primary sources of enterococcal 
BSI were CVCs and intra-abdominal/
gastrointestinal tract infections
 •  Between 2010 and 2012, there was an increase in 
VRE bloodstream infection due to a CVC infection
3. Pneumococcal BSI 
 •  For penicillin non-susceptible S. pneumoniae 
(PNSP), the proportion of isolates that were 
detected within two days after admission 
decreased from 95% in 2011 to 65% in 2012. For 
penicillin susceptible S. pneumoniae (PSSP) this 
also decreased from 93% in 2011 to 79% in 2012. 
Between 2011 and 2012, the proportion of isolates 
that were detected after five days post-admission 
increased from 0% to 26% for PNSP and from 5% 
to 8% for PSSP. These changes have resulted in 
an increasing proportion of PNSP BSI in particular, 
being classed as “acquired in the reporting 
hospital” (5% in 2011 to 32% in 2012). However, 
the overall number of PNSP BSI isolates for which 
there is enhanced information is small and these 
results must be interpreted with caution
 •  Respiratory tract infection remains the most 
common source of pneumococcal BSI
 •  Of pneumococcal BSI, 5% were associated with 
meningitis
4. E. coli, K. pneumoniae and P. aeruginosa BSI 
 •  The majority of fluoroquinolone resistant E. 
coli, K. pneumoniae and P. aeruginosa BSI were 
healthcare-associated, in contrast to 43% of 
fluoroquinolone susceptible E. coli BSI
 •  The most common source of E. coli BSI was 
urinary tract infection, with 5% associated with the 
presence of a urinary catheter
 •  The most common source of K. pneumoniae 
BSI was intra-abdominal/gastro intestinal tract, 
followed by urinary tract infection
 •  The most common source of P. aeruginosa BSI was 
respiratory tract infection
For further details, go to the HPSC website:   
www.hpsc.ie and click on “Topics A-Z”, then “Enhanced 
Bacteraemia Surveillance
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Figure 8. Numbers and age-specific incidence rates of patients with invasive S. 
pneumoniae infection in 2012 compared with 2011
Conclusion
Ongoing monitoring of trends in Ireland’s EARS-Net 
surveillance data provides important information. 
A welcome trend is the continued decrease in the 
proportion of S. aureus BSI due to MRSA for the sixth 
consecutive year to the lowest level yet (22.8%) in 2012. 
However, antimicrobial resistance to key antimicrobials 
in invasive infections caused by the Enterobacteriaceae 
(E. coli, K. pneumoniae), P. aeruginosa and Enterococcus 
faecium continues to increase, reaching the highest 
levels yet in 2012. Indeed, for 2012, Ireland had the 
highest proportion of VREfm (45.4%) of any EARS-Net 
country.
Improvements in infection prevention and control 
resources and interventions, along with hospital 
antimicrobial stewardship programmes, have probably 
contributed to reducing the burden of MRSA BSI in 
Ireland since 2006. The introduction of pneumococcal 
conjugate vaccines into the childhood immunisation 
programme since September 2008 has already resulted 
in a reduction in the burden of invasive pneumococcal 
disease in children.  Despite these successes, the issue 
of antimicrobial resistance remains a major problem in 
Ireland. In addition, the increasing number of reported 
invasive infections due to multi-drug resistant bacteria 
is of particular concern.  It should also be noted that 
antimicrobial resistance is an issue for other bacterial 
species (not captured within the EARS-Net surveillance) 
as well as for infections occurring at sites other than 
blood and/or CSF (not captured within the EARS-Net 
surveillance). Whilst EARS-Net surveillance data on key 
pathogens from invasive infections is extremely valuable 
in comparing antimicrobial resistance at a national level, 
it is likely to underestimate the true burden of infections 
caused by drug-resistant pathogens. 
Data collected through the enhanced EARS-Net 
surveillance programme are particularly useful in 
informing infection prevention and control programmes 
both nationally and in those hospitals that participate in 
the enhanced EARS-Net surveillance scheme. 
Infections caused by antimicrobial resistant bacteria 
result in excess patient mortality, morbidity and costs 
to the healthcare system. Rising levels of resistance 
threaten many aspects of healthcare that we currently 
take for granted. It is critical that comprehensive 
infection prevention and control and antimicrobial 
stewardship programmes continue to be developed and 
maintained at all levels and settings within the health 
service. To this end, it is vital that recommendations and 
guidelines produced by the HSE/RCPI AMR and HCAI 
Clinical Advisory Group are implemented.
HPSC thanks all the microbiology laboratories for their 
continued participation and enthusiasm for the EARS-
Net project.
The data presented in this report were taken from the 
EARS-Net database on 1st October 2013.
For further details of EARS-Net and antimicrobial 
resistance in Ireland see www.hpsc.ie 
European data are available at http://ecdc.europa.eu/en/
activities/surveillance/EARS-Net/Pages/Database.aspx
9.3.0.2 Enhanced Surveillance of Carbapenem 
resistant Enterobacteriaceae (CRE) in Ireland
Key points:
•  In 2012, enhanced surveillance data was received 
on 32 CRE cases. This represented a small decrease 
compared with 2011, when enhanced surveillance 
data was received on 37 CRE cases (out of a total of 
39 cases reported that year)
•  Six patients (19%) had a history of hospitalisation 
abroad – UK (4 VIM-type CRE, all of whom were cared 
for in the same UK hospital) and India (2 NDM-type 
CRE with no epidemiological links)
·•  The clinical significance of the CRE isolate was 
reported for 30 patients (94%), representing 
colonisation in the majority (n=27) and CRE infection 
was reported for three patients
Carbapenem resistant Enterobacteriaceae (CRE) are 
multiple-drug resistant Gram-negative bacteria that can 
be easily spread between patients in healthcare settings 
and have the ability to cause infections for which 
effective antibiotic therapy may be lacking. Most CRE 
produce carbapenemase, an enzyme that breaks down 
the carbapenem class of antibiotics (e.g. imipenem, 
meropenem). Carbapenemase production has spread 
worldwide in the past 15 years and is now a prominent 
resistance mechanism reported in many countries. 
Detection of confirmed carbapenemase-producing CRE, 
hereafter known as CRE, became notifiable in Ireland 
in March 2011, under the category of ‘unusual cluster 
or changing pattern of illness’. Upon amendment to 
the Infectious Diseases Regulations in September 
2011, invasive CRE infection (blood, CSF or normally 
sterile site) became notifiable in its own category. The 
CRE enhanced surveillance scheme was established in 
June 2011 and reporting of CRE isolates from any site, 
whether colonisation or infection is encouraged. 
In 2012, 32 confirmed cases of carbapenemase-
producing CRE and three CRE outbreaks were reported; 
1.  Two KPC outbreaks, both reported from acute 
hospitals, affecting seven and three patients, 
respectively 
2.  One OXA-48 outbreak, which occurred in a long-term 
care facility affecting two residents 
Completed enhanced surveillance forms were received 
from eight laboratories on 32 patients, 18 of whom 
were male (56%). The average age was 50 years (range: 
1 to 95 years). At the time of CRE detection, 22 patients 
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(68%) were hospitalised, eight were in the community 
(25%) and two were nursing home residents. Of the 22 
hospitalised patients, nine (41%) had been admitted 
from home, five (23%) were transfers from another 
acute hospital and the source of admission was not 
provided for the remaining eight patients. Of the five 
patients who had been transferred from another acute 
hospital, three were repatriated from hospitals abroad; 
UK (2) and India (1). 
At the time of CRE detection, 10 patients (31%) were 
already known to be colonised or infected with one or 
more other multi-drug resistant organisms (MDRO). Six 
patients (19%) had a history of recent hospitalisation 
abroad; UK (4) and India (2). 
Fifteen patients (47%) reported no foreign travel in the 
last 12 months and the travel history was unknown for 
nine patients (28%). Eight patients reported a history of 
foreign travel within the past 12 months: 
•  UK – Five patients; VIM (4) and KPC (1). Four of those 
had been hospitalised in UK
•  India; Two patients with NDM-1. Both had been 
hospitalised in India
•  Philippines; One patient with KPC who had not been 
hospitalised whilst abroad
Two patients had no identifiable risk factors for CRE 
colonisation or infection and risk factor data was not 
provided for six patients. Of the remaining 24 patients, 
14 (58%) had more than one risk factor. Reported 
risk factors included; Hospitalisation in the past 12 
months (21; 88%), history of surgery in the past six 
months (6; 25%), history of admission to intensive 
care in the last 12 months (4; 17%). Eleven patients 
(46%) had underlying co-morbidities [chronic lung 
disease, diabetes mellitus, urological abnormality or 
immunocompromise]. 
Of the 32 patients, antimicrobial exposure history prior 
to isolation of CRE was provided for 23 (72%), which 
included the majority of the 22 hospitalised patients 
(n=19; 86%). Fourteen patients had received more than 
one antimicrobial class. 
•  β lactam - β lactamase inhibitor combination agents; 
19 (83%) 
•  Cephalosporins; 8 (35%)
•  Fluoroquinolones; 6 (26%) 
•  Carbapenems; 4 (17%) 
•  Aminoglycosides; 3 (13%)
The clinical significance of the CRE isolate was reported 
for 30 patients (94%), representing colonisation in the 
majority (n=27). CRE infection was reported for three 
patients, with two cases of urinary tract infection and 
one case of respiratory tract infection. 
The majority of CRE (21; 66%) were detected from 
screening rectal swabs or faeces. Eight isolates were 
detected from urine (25%), two from superficial swabs 
and one from intra-abdominal pus. 
Outcome was reported for only one of the eight non-
hospitalised patients (survived) and for 16 of the 24 
hospitalised patients (66%). Of those, eleven (68%) 
were discharged home, two (13%) remained inpatients 
at the time the surveillance form was returned and it is 
not known whether or not those CRE colonised patients 
subsequently went on to develop CRE infection later in 
the hospital admission. Three patients died (19%). For 
one of the three deaths, the patient was reported to 
have had CRE infection. The potential contribution of 
CRE to patient death was not collected.
Of the eleven patients who were discharged home, 
length-of-stay could be calculated for nine. The median 
length-of-stay was 26 days (range: 12 to 120 days).
Klebsiella pneumoniae accounted for 23 and K. oxytoca 
for one CRE isolate. There were six cases of E. coli CRE 
and one case each of E. cloacae and C. freundii CRE 
reported. 
The reported carbapenemase enzyme types reported in 
2012 were; KPC (14 cases), OXA-48 (8 cases), NDM-1 (6 
cases) and VIM (4 cases).
•  Carbapenems; Reported minimum inhibitory 
concentrations for meropenem and ertapenem 
ranged from 1.5 to >32 mg/L 
•  Gentamicin; Reported on all 32 isolates, with 13 
resistant (40%)
•  Amikacin; Reported on 26 isolates, with 16 resistant 
(62%) and four with intermediate susceptibility
•  Fluoroquinolones; Reported on 28 isolates, with 23 
resistant (82%) 
•  Tigecycline; Reported on 25 isolates; with 10 resistant 
(40%) and five with intermediate susceptibility 
•  Colistin; Reported on 20 isolates, with one resistant 
(5%)
No case of carbapenemase-producing infection of 
blood or CSF was reported in Ireland in 2012. In 
2012, 25 of 29 EARS-Net countries reported one 
or more case of invasive carbapenem resistant K. 
pneumoniae infection, with 13 countries reporting five 
or more cases. In 2012, the proportions of invasive K. 
pneumoniae isolates with carbapenem resistance were 
highest in Greece (62%) and Italy (31%). This clearly 
illustrates that this is an evolving problem throughout 
Europe. Increases in the prevalence of CRE are largely 
related to overuse of broad spectrum antimicrobials and 
suboptimal infection prevention and control practices, 
particularly in hospital and long-term care settings. 
Prudent antimicrobial stewardship and aggressive 
infection prevention and control interventions are 
required to prevent transmission of carbapenemase-
producing Enterobacteriaceae.
In response to the emergence of CRE, screening 
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guidelines were issued in 2011. Subsequently, Irish 
guidelines for the prevention and control of multi-drug 
resistant organisms, excluding MRSA, in the healthcare 
setting have been developed under the auspices 
of the Royal College of Physicians of Ireland (RCPI) 
Clinical Advisory Group on Healthcare-Associated 
Infections and Antimicrobial Resistance. Latest available 
information on CRE in Ireland and the guidelines are 
available on the HPSC website at the following link:
http://www.hpsc.ie/hpsc/A-Z/
MicrobiologyAntimicrobialResistance/
StrategyforthecontrolofAntimicrobialResistanceinIrelandSARI/
CarbapenemResistantEnterobacteriaceaeCRE/
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Computerised Infectious Disease 
Reporting System (CIDR)
CIDR Operations
Sexually Transmitted Infections Notified from 
Laboratories using CIDR
The expansion of the schedule of notifiable diseases 
in 2011 and the use of CIDR to manage these from 
the beginning of 2012 was followed up at the end of 
2012 by a further expansion through the notification 
of case-based laboratory-identified notifiable sexually 
transmitted infections using CIDR. This will enable more 
timely analysis and reporting of these diseases. This was 
a major achievement, building on many years of work, 
since STI notifications had previously been made on an 
aggregate basis that was not timely. It is anticipated 
that this will significantly increase the volume of 
infectious disease notifications made through CIDR over 
coming years.
New Technical Architecture for CIDR
2012 saw the migration of CIDR to a new virtualised 
infrastructure. This has allowed the number of servers 
supporting the CIDR system (production, disaster 
recovery, test, training and development) to be reduced 
from 20 to 6 servers, significantly reducing the energy 
required to run this equipment. It also enables more 
efficient use of this hardware. Improved resilience and 
management are provided by the ability to more easily 
backup and restore CIDR environments and to be able 
to promote new developments more easily as well as 
allowing additional hardware resources to be readily 
added if required by an increased load associated by a 
major outbreak or pandemic.
Governance and Communications
The National CIDR Steering Group continued to provide 
guidance and oversight of CIDR through 2012 and met 
by teleconference on three occasions during the year. 
The wider National CIDR User Group convened on four 
occasions through the year, also by teleconference, 
to  discuss the ongoing use of CIDR and associated 
developments.
10. Computerised Infectious Disease 
 Reporting (CIDR)
Figure 1. The volume of  statutory infectious disease 
notifications in CIDR per year since 2005 when national 
implementation commenced.
Figure 2. The number of users of the CIDR system in 
Departments of Public Health, in diagnostic and reference 
laboratories, and in HPSC in 2012 (total=230).
Summary
•  2012 represented the first full year of CIDR 
operation following the completion of national 
rollout in 2011
•  The number of active CIDR users in 2012 was 230
•  Laboratory notifications of sexually transmitted 
infections diseases through CIDR from the end of 
2012 now allow more timely analysis and reporting 
of case-based disaggregate data for these diseases
•  New CIDR infrastructure improves energy efficiency 
and system manageability
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Appendix 1
Notifiable Infectious Diseases in Ireland
Notes:
Figures for the year 2012 presented in this appendix were extracted from the Computerised Infectious Disease 
Reporting (CIDR) system in August 2013. These figures may differ from those published previously due to ongoing 
updating of notification data on CIDR and also due to the addition of new notifiable diseases on January 1st 2012 
along with the introduction of revised versions of case definitions of certain diseases at that time.
Figures on EARS-Net pathogens and certain sexually transmitted infections (specifically, ano-genital warts, 
chancroid, Chlamydia trachomatis, gonorrhoea, granuloma inguinale, herpes simplex (genital), lymphogranuloma 
venereum, non-specific urethritis and trichomoniasis) are not presented here, since these diseases were not reported 
via the CIDR system during 2012; separate databases are used to collate data on these diseases. 
Table A1.1. List of notifiable infectious diseases and their respective causative pathogens (relevant to 2012) under Infectious 
Diseases (Amendment) (No. 3) Regulations 2011 (S.I. No. 452 of 2011)
Infectious Disease Causative Pathogen(s)
Acute anterior poliomyelitis Polio virus
Ano-genital warts Human papilloma virus
Anthrax Bacillus anthracis
Bacillus cereus food-borne infection/intoxication Bacillus cereus
Bacterial meningitis (not otherwise specified)  
Botulism Clostridium botulinum
Brucellosis Brucella spp.
Campylobacter infection Campylobacter spp.
Carbapenem-resistant Enterobacteriaceae infection 
(invasive) 
Carbapenem-resistant Enterobacteriaceae (blood, CSF or other normally 
sterile site)
Chancroid Haemophilus ducreyi
Chickenpox – hospitalised cases Varicella-zoster virus
Chikungunya disease Chikungunya virus
Chlamydia trachomatis infection (genital) Chlamydia trachomatis
Cholera Vibrio cholerae
Clostridium difficile infection Clostridium difficile
Clostridium perfringens (type A) food-borne disease Clostridium perfringens
Creutzfeldt Jakob disease  
variant Creutzfeldt Jakob disease  
Cryptosporidiosis Cryptosporidium parvum, hominis
Cytomegalovirus infection (congenital) Cytomegalovirus
Dengue fever Dengue virus
Diphtheria Corynebacterium diphtheriae or ulcerans (toxin producing)
Echinococcosis Echinococcus spp.
Enterococcal bacteraemia Enterococcus spp. (blood)
Escherichia coli infection (invasive) Escherichia coli (blood, CSF)
Giardiasis Giardia lamblia
Gonorrhoea Neisseria gonorrhoeae
Granuloma inguinale Klebsiella granulomatis
Haemophilus influenzae disease (invasive) Haemophilus influenzae (blood, CSF or other normally sterile site)
Hepatitis A (acute) infection Hepatitis A virus
Hepatitis B (acute and chronic) infection Hepatitis B virus
Hepatitis C infection Hepatitis C virus
Herpes simplex (genital) Herpes simplex virus
Human immunodeficiency virus infection Human immunodeficiency virus
Influenza Influenza A and B virus
Klebsiella pneumoniae infection (invasive) Klebsiella pneumoniae (blood or CSF)
Legionellosis Legionella spp.
Leprosy Mycobacterium leprae
Leptospirosis Leptospira spp.
Listeriosis Listeria monocytogenes
Lyme disease (neuroborreliosis) Borrelia burgdorferi
Lymphogranuloma venereum Chlamydia trachomatis
Malaria Plasmodium falciparum, vivax, knowlesi, ovale, malariae
Measles Measles virus
Meningococcal disease Neisseria meningitidis
Mumps Mumps virus
Non-specific urethritis  
Noroviral infection Norovirus
Paratyphoid Salmonella Paratyphi
Pertussis Bordetella pertussis
Plague Yersinia pestis
Pseudomonas aeruginosa infection (invasive) Pseudomonas aeruginosa (blood or CSF)
Q Fever Coxiella burnetii
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Rabies Rabies virus
Respiratory syncytial virus infection Respiratory syncytial virus
Rotavirus infection Rotavirus
Rubella Rubella virus
Salmonellosis Salmonella spp. other than S. Typhi and S. Paratyphi
Severe Acute Respiratory Syndrome (SARS) SARS-associated coronavirus
Shigellosis Shigella spp.
Smallpox Variola virus
Staphylococcal food poisoning Enterotoxigenic Staphylococcus aureus
Staphylococcus aureus bacteraemia Staphylococcus aureus (blood)
Streptococcus group A infection (invasive) Streptococcus pyogenes (blood, CSF or other normally sterile site)
Streptococcus group B infection (invasive) Streptococcus agalactiae (blood, CSF or other normally sterile site)
Streptococcus pneumoniae infection (invasive) Streptococcus pneumoniae (blood, CSF or other normally sterile site)
Syphilis Treponema pallidum
Tetanus Clostridium tetani
Toxoplasmosis Toxoplasma gondii
Trichinosis Trichinella spp.
Trichomoniasis Trichomonas vaginalis
Tuberculosis Mycobacterium tuberculosis complex
Tularemia Francisella tularensis
Typhoid Salmonella Typhi
Typhus Rickettsia prowazekii
Verotoxigenic Escherichia coli infection Verotoxin producing Escherichia coli
Viral encephalitis  
Viral haemorrhagic fevers  
Viral meningitis  
West Nile fever West Nile virus
Yellow fever Yellow fever virus
Yersiniosis Yersinia enterocolitica, Yersinia pseudotuberculosis
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Table A1.1. List of notifiable infectious diseases and their respective causative pathogens (relevant to 2012) under Infectious 
Diseases (Amendment) (No. 3) Regulations 2011 (S.I. No. 452 of 2011)
Continued
Infectious Disease Causative Pathogen(s)
Table A1.2 Number of notifiable infectious diseases, 2010-2012 and crude incidence rates of diseases, 2012
Infectious Disease 2010 2011 2012 CIR* 2012
Bacterial meningitis (not otherwise specified) 42 35 29 0.63
Botulism 0 1 0 0.00
Brucellosis 2 1 2 0.04
Campylobacter infection 1660 2427 2388 52.05
Chickenpox - hospitalised cases NA NA 80 -
Clostridium difficile infection† 1693 1848 1824 -
Creutzfeldt Jakob disease 3 7 5 0.11
Cryptosporidiosis 294 428 556 12.12
Cytomegalovirus infection (congenital) NA NA 8 0.17
Dengue fever NA NA 7 0.15
Echinococcosis 1 0 0 0.00
Giardiasis 57 57 54 1.18
Haemophilus influenzae disease (invasive) 28 44 41 0.89
Hepatitis A (acute) 46 19 30 0.65
Hepatitis B (acute and chronic) 640 522 580 12.64
Hepatitis C 1226 1255 1036 22.58
Human immunodeficiency virus infection NA NA 341 7.43
Influenza (seasonal & pandemic)‡ 275 2077 743 16.19
Legionellosis§ 11 7 15 0.33
Leptospirosis 17 16 15 0.33
Listeriosis 10 7 11 0.24
Lyme disease NA NA 8 0.17
Malaria 82 61 65 1.42
Measles 403 267 103 2.24
Meningococcal disease 114 94 66 1.44
Mumps 292 165 163 3.55
Noroviral infection 1926 990 1705 37.16
Paratyphoid 5 2 5 0.11
Pertussis 114 229 458 9.98
Q fever 9 5 6 0.13
Respiratory syncytial virus infection NA NA 1972 42.98
Rotavirus infection 2501 2451 2652 57.80
Rubella 23 4 9 0.20
Salmonellosis 356 310 314 6.84
Shigellosis 60 42 29 0.63
Streptococcus group A infection (invasive) 68 67 122 2.66
Streptococcus group B infection (invasive)** NA NA 77 -
Streptococcus pneumoniae infection (invasive) 391 425 427 9.31
Syphilis|| NA NA 561 12.23
Tetanus 0 0 1 0.02
Toxoplasmosis 36 32 36 0.78
Tuberculosis¶ NA 414 366 7.98
Typhoid 8 14 8 0.17
Typhus 0 1 0 0.00
Verotoxigenic Escherichia coli infection 199 284 554 12.07
Viral encephalitis 22 23 18 0.39
Viral meningitis 168 220 235 5.12
Yersiniosis 3 6 2 0.04
Total 12785 15265 17727
NA: Indicates that data not available in CIDR for the diseases and years indicated above
*CIR, Crude incidence rate per 100,000 total population
† Since 01/01/2012 both new and recurrent cases of Clostridium difficile infection are notifiable, prior to this only new cases were notifiable; 
please interpret comparisons between current and historical data with caution; cases under two years of age are not notifiable; C. difficile 
figures in the C. difficile chapter are presented by quarter rather than using the 2012 epidemiological calendar year as shown here
‡Includes cases caused by the influenza A (H1N1) 2009 pandemic, which lasted from 25/04/2009 – 10/08/2010
§Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
|| Syphilis data were reported via CIDR from May 2011, but syphilis data for 2011 are excluded from this appendix as they represent only a 
portion of the cases notified in 2011
¶Tuberculosis only notifiable in CIDR since 2011
**Streptococcus group B infection (invasive) infections in infants <90 days  old or stillborn infants
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 Table A1.3 Number of notifiable infectious diseases by HSE area, 2012
Infectious Disease
HSE
-E
HSE
-M
HSE
-MW
HSE
-NE
HSE
-NW
HSE
-SE
HSE
-S
HSE
-W
Total
Bacterial meningitis (not otherwise specified) 10 1 4 0 5 3 2 4 29
Brucellosis * * * * * * * * 2
Campylobacter infection 818 187 244 200 112 286 368 173 2388
Chickenpox - hospitalised cases 43 2 4 7 1 11 6 6 80
Clostridium difficile infection† 939 48 161 89 65 188 163 171 1824
Creutzfeldt Jakob disease 2 0 0 0 0 0 3 0 5
Cryptosporidiosis 34 53 85 53 50 98 85 98 556
Cytomegalovirus infection (congenital) 8 0 0 0 0 0 0 0 8
Dengue fever 4 0 0 0 1 1 0 1 7
Giardiasis 19 6 4 1 1 4 13 6 54
Haemophilus influenzae disease (invasive) 18 1 4 4 2 6 4 2 41
Hepatitis A (acute) 13 1 1 2 3 2 7 1 30
Hepatitis B (acute and chronic) 361 25 32 41 8 31 47 35 580
Hepatitis C 762 35 24 48 19 33 79 36 1036
Human immunodeficiency virus infection†† - - - - - - - - 341
Influenza 302 71 61 84 71 61 48 45 743
Legionellosis § 7 0 3 1 0 0 0 4 15
Leptospirosis 5 2 2 2 0 0 1 3 15
Listeriosis 1 1 0 2 1 0 2 4 11
Lyme disease 0 0 3 0 2 0 2 1 8
Malaria 34 5 1 6 4 6 5 4 65
Measles 24 0 2 5 3 0 64 5 103
Meningococcal disease 18 4 8 9 2 12 6 7 66
Mumps 71 9 6 12 12 15 16 22 163
Noroviral infection 915 84 169 212 55 75 75 120 1705
Paratyphoid 3 0 0 1 0 0 0 1 5
Pertussis 159 13 13 21 74 54 79 45 458
Q fever 1 1 1 0 0 1 2 0 6
Respiratory syncytial virus infection 925 153 140 147 159 280 54 114 1972
Rotavirus infection 465 296 218 196 215 462 469 331 2652
Rubella 5 1 0 0 0 0 1 2 9
Salmonellosis 116 29 19 29 16 33 31 41 314
Shigellosis 14 0 0 1 1 3 9 1 29
Streptococcus group A infection (invasive) 51 7 8 11 5 16 14 10 122
Streptococcus group B infection (invasive) 49 1 5 7 0 1 9 5 77
Streptococcus pneumoniae infection (invasive) 115 21 40 28 29 113 48 33 427
Syphilis 412 19 43 21 11 27 3 25 561
Tetanus * * * * * * * * 1
Toxoplasmosis 16 0 5 3 2 2 7 1 36
Tuberculosis 150 27 21 24 14 25 73 32 366
Typhoid 6 0 0 0 0 0 2 0 8
Verotoxigenic Escherichia coli infection 55 82 87 31 38 23 150 88 554
Viral encephalitis 6 1 3 2 0 2 3 1 18
Viral meningitis 130 10 12 17 8 27 14 17 235
Yersiniosis * * * * * * * * 2
* Data not reported to HSE area level when total number in Ireland <5 cases
§Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
†C. difficile figures in the C. difficile chapter are presented by quarter rather than using the 2012 epidemiological calendar year as shown here
††HIV figures are not broken down HSE area
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Table A1.4 Number of notifiable infectious diseases by HSE region, 2012
Infectious Disease Dublin Mid-Leinster Dublin North-East South West Total
Bacterial meningitis (not otherwise specified) 10 1 5 13 29
Brucellosis * * * * 2
Campylobacter infection 766 439 654 529 2388
Chickenpox - hospitalised cases 29 23 17 11 80
Clostridium difficile infection† 666 410 351 397 1824
Creutzfeldt Jakob disease 2 0 3 0 5
Cryptosporidiosis 76 64 183 233 556
Cytomegalovirus infection (congenital) 5 3 0 0 8
Dengue fever 3 1 1 2 7
Giardiasis 19 7 17 11 54
Haemophilus influenzae disease (invasive) 10 13 10 8 41
Hepatitis A (acute) 13 3 9 5 30
Hepatitis B (acute and chronic) 216 211 78 75 580
Hepatitis C 465 380 112 79 1036
Human immunodeficiency virus infection - - - - 341
Influenza 224 233 109 177 743
Legionellosis § 3 5 0 7 15
Leptospirosis 6 3 1 5 15
Listeriosis 2 2 2 5 11
Lyme disease 0 0 2 6 8
Malaria 27 18 11 9 65
Measles 20 9 64 10 103
Meningococcal disease 14 17 18 17 66
Mumps 55 37 31 40 163
Noroviral infection 694 517 150 344 1705
Paratyphoid 2 2 0 1 5
Pertussis 133 60 133 132 458
Q fever 1 1 3 1 6
Respiratory syncytial virus infection 733 492 334 413 1972
Rotavirus infection 637 320 931 764 2652
Rubella 5 1 1 2 9
Salmonellosis 103 71 64 76 314
Shigellosis 9 6 12 2 29
Streptococcus group A infection (invasive) 41 28 30 23 122
Streptococcus group B infection (invasive) 30 27 10 10 77
Streptococcus pneumoniae infection (invasive) 82 82 161 102 427
Syphilis 337 115 30 79 561
Tetanus * * * * 1
Toxoplasmosis 9 10 9 8 36
Tuberculosis 110 91 98 67 366
Typhoid 3 3 2 0 8
Verotoxigenic Escherichia coli infection 120 48 173 213 554
Viral encephalitis 7 2 5 4 18
Viral meningitis 92 65 41 37 235
Yersiniosis * * * * 2
*Data not reported to HSE regional level when total number in Ireland <5 cases     
†C. difficile figures in the C. difficile chapter are presented by quarter rather than using the 2012 epidemiological calendar year as shown here
§Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
††HIV figures are not broken down HSE region
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Table A1.5 Number of notifiable infectious diseases by age group (years), 2012
Infectious Disease 0-4 5-9 10-14 15-19 20-24 25-34 35-44 45-54 55-64 65+ Unknown Total
Bacterial meningitis 
(not otherwise specified)
15 0 1 1 3 2 2 1 3 1 0 29
Brucellosis 0 1 0 0 0 1 0 0 0 0 0 2
Campylobacter infection 558 162 105 116 205 342 242 216 153 283 6 2388
Chickenpox - hospitalised cases 38 11 1 1 3 6 2 5 3 8 2 80
Clostridium difficile infection† 33 14 8 24 31 107 89 99 215 1201 3 1824
Creutzfeldt Jakob disease 0 0 0 0 0 0 0 2 0 3 0 5
Cryptosporidiosis 303 129 45 18 19 19 12 3 3 5 0 556
Cytomegalovirus infection 
(congenital)
7 1 0 0 0 0 0 0 0 0 0 8
Dengue fever 0 0 0 0 1 3 1 1 1 0 0 7
Giardiasis 6 6 1 1 1 16 10 5 4 4 0 54
Haemophilus influenzae disease 
(invasive)
6 3 0 4 1 1 4 1 4 17 0 41
Hepatitis A (acute) 5 7 4 1 2 5 2 0 3 1 0 30
Hepatitis B (acute and chronic) 0 1 3 15 63 250 152 61 25 10 0 580
Hepatitis C 8 13 7 6 48 335 348 168 82 19 2 1036
Human immunodeficiency virus 
infection
1 4 0 6 32 142 99 43 11 3 0 341
Influenza 99 48 28 21 22 86 94 51 49 238 7 743
Legionellosis § 0 0 0 0 0 0 2 0 3 10 0 15
Leptospirosis 0 0 0 0 3 0 4 4 4 0 0 15
Listeriosis 2 0 0 0 0 1 0 0 1 7 0 11
Lyme disease 0 2 0 0 0 1 0 3 0 2 0 8
Malaria 2 5 1 0 2 7 30 14 2 2 0 65
Measles 28 11 28 26 4 1 5 0 0 0 0 103
Meningococcal disease 40 5 2 7 1 2 1 5 0 3 0 66
Mumps 25 18 9 21 25 25 16 5 11 6 2 163
Noroviral infection 192 14 17 8 27 78 72 79 155 1048 15 1705
Paratyphoid 0 0 0 0 0 4 1 0 0 0 0 5
Pertussis 234 37 45 18 7 27 36 35 6 11 2 458
Q fever 0 0 0 0 0 0 2 1 0 3 0 6
Respiratory syncytial virus infection 1914 13 6 2 3 8 1 7 6 10 2 1972
Rotavirus infection 2559 49 14 1 2 0 5 3 2 12 5 2652
Rubella 4 1 1 1 0 1 1 0 0 0 0 9
Salmonellosis 89 13 10 17 30 51 25 27 19 32 1 314
Shigellosis 2 0 1 0 3 10 4 6 2 1 0 29
Streptococcus group A infection 
(invasive)
20 6 1 1 4 12 19 10 7 42 0 122
Streptococcus group B infection 
(invasive)
77 0 0 0 0 0 0 0 0 0 0 77
Streptococcus pneumoniae infection 
(invasive)
45 10 3 4 4 18 29 28 64 222 0 427
Syphilis 0 0 0 6 43 199 159 95 37 19 3 561
Tetanus 0 0 1 0 0 0 0 0 0 0 0 1
Toxoplasmosis 1 0 0 2 2 20 7 3 1 0 0 36
Tuberculosis 2 2 6 21 26 79 68 57 46 57 2 366
Typhoid 0 1 1 0 1 3 2 0 0 0 0 8
Verotoxigenic Escherichia coli 
infection
249 62 27 13 17 38 61 18 24 42 3 554
Viral encephalitis 3 0 0 0 0 1 0 5 4 5 0 18
Viral meningitis 131 10 4 12 12 37 21 5 1 2 0 235
Yersiniosis 0 0 1 0 0 1 0 0 0 0 0 2
Total 6698 659 381 374 647 1939 1628 1066 951 3329 55 17727
†C. difficile figures in the C. difficile chapter are presented by quarter rather than using the 2012 epidemiological calendar year as shown here
§Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
         
Table A1.6 Number of notifiable infectious diseases by gender, 2012
Infectious Disease Male Female Unknown Total
Bacterial meningitis (not otherwise specified) 10 19 0 29
Brucellosis 2 0 0 2
Campylobacter infection 1315 1068 5 2388
Chickenpox - hospitalised cases 50 29 1 80
Clostridium difficile infection† 718 1105 1 1824
Creutzfeldt Jakob disease 3 2 0 5
Cryptosporidiosis 291 265 0 556
Cytomegalovirus infection (congenital) 4 3 1 8
Dengue fever 3 4 0 7
Giardiasis 31 23 0 54
Haemophilus influenzae disease (invasive) 20 21 0 41
Hepatitis A (acute) 13 17 0 30
Hepatitis B (acute and chronic) 332 234 14 580
Hepatitis C 686 343 7 1036
Human immunodeficiency virus infection 244 97 0 341
Influenza 295 444 4 743
Legionellosis § 8 7 0 15
Leptospirosis 11 4 0 15
Listeriosis 4 7 0 11
Lyme disease 4 4 0 8
Malaria 39 26 0 65
Measles 47 56 0 103
Meningococcal disease 37 29 0 66
Mumps 77 86 0 163
Noroviral infection 766 939 0 1705
Paratyphoid 5 0 0 5
Pertussis 211 247 0 458
Q fever 5 1 0 6
Respiratory syncytial virus infection 1133 837 2 1972
Rotavirus infection 1419 1227 6 2652
Rubella 5 4 0 9
Salmonellosis 165 149 0 314
Shigellosis 18 11 0 29
Streptococcus group A infection (invasive) 59 63 0 122
Streptococcus group B infection (invasive) 24 37 16 77
Streptococcus pneumoniae infection (invasive) 221 206 0 427
Syphilis 437 111 13 561
Tetanus 1 0 0 1
Toxoplasmosis 13 23 0 36
Tuberculosis 219 146 1 366
Typhoid 6 2 0 8
Verotoxigenic Escherichia coli infection 243 311 0 554
Viral encephalitis 6 12 0 18
Viral meningitis 130 103 2 235
Yersiniosis 0 2 0 2
Total 9330 8324 73 17727
†C. difficile figures in the C. difficile chapter are presented by quarter rather than using the 2012 epidemiological calendar year as shown here
§Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
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 Table A1.7 Number of notifiable infectious diseases by case classification, 2012
Infectious Disease Confirmed Probable Possible Total
Bacterial meningitis (not otherwise specified) 12 5 12 29
Brucellosis 2 0 0 2
Campylobacter infection 2387 1 0 2388
Chickenpox - hospitalised cases 57 0 23 80
Clostridium difficile infection† 1824 0 0 1824
Creutzfeldt Jakob disease 5 0 0 5
Cryptosporidiosis 554 2 0 556
Cytomegalovirus infection (congenital) 8 0 0 8
Dengue fever 7 0 0 7
Giardiasis 54 0 0 54
Haemophilus influenzae disease (invasive) 41 0 0 41
Hepatitis A (acute) 28 2 0 30
Hepatitis B (acute and chronic) 580 0 0 580
Hepatitis C 1036 0 0 1036
Human immunodeficiency virus infection 341 0 0 341
Influenza 676 52 15 743
Legionellosis § 15 0 0 15
Leptospirosis 15 0 0 15
Listeriosis 11 0 0 11
Lyme disease 8 0 0 8
Malaria 65 0 0 65
Measles 26 53 24 103
Meningococcal disease 60 0 6 66
Mumps 43 0 120 163
Noroviral infection 1699 6 0 1705
Paratyphoid 5 0 0 5
Pertussis 264 56 138 458
Q fever 5 1 0 6
Respiratory syncytial virus infection 1972 0 0 1972
Rotavirus infection 2652 0 0 2652
Rubella 0 1 8 9
Salmonellosis 309 5 0 314
Shigellosis 29 0 0 29
Streptococcus group A infection (invasive) 118 4 0 122
Streptococcus group B infection (invasive) 77 0 0 77
Streptococcus pneumoniae infection (invasive) 347 0 80 427
Syphilis 525 36 0 561
Tetanus 0 1 0 1
Toxoplasmosis 36 0 0 36
Tuberculosis 281 28 57 366
Typhoid 8 0 0 8
Verotoxigenic Escherichia coli infection 413 139 2 554
Viral encephalitis 18 0 0 18
Viral meningitis 220 11 4 235
Yersiniosis 2 0 0 2
Total 16835 403 489 17727
The case definitions booklet, available at http://www.hpsc.ie has been updated since 2012; case classifications are assigned to notifications as 
per the Case Definitions for Notifiable Diseases during 2012
†C. difficile figures in the C. difficile chapter are presented by quarter rather than using the 2012 epidemiological calendar year as shown here
§Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
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Explanatory Notes
Glossary of Terms
Notifiable Infectious Diseases
Computerised Infectious Disease Reporting (CIDR) 
system
For the majority of the notifiable infectious diseases 
(see Appendix 1), data were collated using the 
Computerised Infectious Disease Reporting (CIDR) 
system. During 2011, notification data were inputted 
directly by areas using the system. For areas not yet on 
CIDR, data were forwarded weekly to HPSC for input to 
CIDR. Enhanced surveillance was undertaken for certain 
diseases and these data collated on CIDR. Outbreak 
data were also collated on CIDR using the same process 
outlined above.  Since 4th May 2008, new cases of 
Clostridium difficile-associated disease (CDAD) were 
notified on CIDR under the category ‘acute infectious 
gastroenteritis’ (AIG). Weekly Reports on infectious 
disease notifications (including a separate report for AIG 
with the emphasis on C. difficile) and outbreaks were 
produced by HPSC and published on the HPSC website, 
www.hpsc.ie. Throughout the year data were cleaned 
and validated on an ongoing basis and final data checks 
and cleaning were undertaken following year end by 
HPSC and the Departments of Public Health.  Data 
analysis was performed using CIDR Business Objects 
Reporting and MS Excel. Figures for the relevant 
chapters within this report were extracted from CIDR 
between July and October 2012. These figures may 
differ from those previously published due to ongoing 
updating of data on CIDR.
Data on the notifiable infectious diseases not yet on 
CIDR were collated as follows:
National Tuberculosis Surveillance System (NTBSS)
TB notification data (including enhanced information) 
for 2010 were collated in the regional Departments of 
Public Health, where data were entered on the Epi2000 
NTBSS database. Each HSE Area provided finalised 
2010 data (with outcome information). Data were 
validated and cleaned with each area and the national 
data were collated. Validation of the 2010 TB data was 
concluded during September 2012.
Sexually Transmitted Infections (STIs)
Clinicians and laboratories notified their respective 
Departments of Public Health of probable and 
confirmed cases of STIs. Data for 2010 and 2011 were 
collated and analysed by Departments of Public Health 
and aggregated data were reported to HPSC. National 
data were collated on an MS Access database, analysis 
preformed and reports produced by HPSC.
Case-based syphilis records have been collated 
nationally since 2000. Case-based syphilis data provided 
by some clinicians is a subset of aggregate syphilis 
notification data. Forms are completed by Departments 
of Public Health in conjunction with the clinician and are 
then forwarded to HPSC. An MS Access database was 
used at HPSC for collation and analysis of the national 
syphilis case-based data.
Since 1st May, 2011, the Computerised Infectious 
Disease Reporting (CIDR) system has been used to 
record notifications of syphilis, thereby allowing the 
replacement of the case-based and aggregate syphilis 
databases previously in use in Departments of Public 
Health and at HPSC.
Other Surveillance Systems
Influenza/Influenza-like illness Surveillance Systems
Since 2000, HPSC has worked in collaboration with 
the National Virus Reference Laboratory (NVRL), the 
Irish College of General Practitioners (ICGP) and 
the Departments of Public Health on the influenza 
sentinel surveillance project. Sixty general practices 
(located in all HSE-Areas and representing 5.7% of the 
population) were recruited to report electronically, on 
a weekly basis, the number of patients who consulted 
with influenza-like illness (ILI).  ILI is defined using 
the Irish case definition for ILI which is sudden onset 
of symptoms AND at least one of the following four 
systemic symptoms: fever, malaise, headache, myalgia; 
AND at least one of the following three respiratory 
symptoms: cough, sore throat, shortness of breath. 
Sentinel GPs were requested to send a combined nasal 
and throat swab on one ILI patient per week to the 
NVRL. The NVRL also tested respiratory non-sentinel 
specimens, referred mainly from hospitals. Other 
surveillance systems set up to monitor influenza/ILI 
activity include a network of sentinel hospitals reporting 
admissions data. The Departments of Public Health also 
notified HPSC weekly of all cases of influenza (including 
hospitalisation status), all influenza/ILI outbreaks and 
enhanced surveillance data on all hospitalised cases of 
confirmed influenza in 0-14 year olds. HPSC was notified 
of all registered deaths on a daily basis from the General 
Register Office.
Several surveillance projects that were initiated/
augmented during the 2009 influenza pandemic were 
continued during subsequent influenza seasons:
•  Surveillance of all calls to GP out-of-hours (OOHs) 
centres were monitored for self-reported influenza. 
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These data were provided by HSE-NE.  
•  Intensive Care Society of Ireland (ICSI) enhanced 
surveillance of all critical care patients with confirmed 
influenza in all critical care units and enhanced 
surveillance of all severe acute respiratory infections 
(SARI) in two pilot ICU sites.  
•  Enhanced surveillance of all confirmed influenza 
deaths.
At HPSC, data were collated from the various sources, 
analysed and routine reports were produced. Influenza 
surveillance reports were posted on the HPSC website 
www.hpsc.ie. Aggregated clinical and virological data 
and annonymised data on confirmed influenza cases 
admitted to ICU and influenza-associated deaths were 
reported weekly to the European Centre for Disease 
Prevention and Control (ECDC).
HIV
HIV and AIDS surveillance in Ireland is voluntary 
and anonymised and operates in co-operation with 
laboratories, clinicians and Departments of Public 
Health.  In 2011, clinicians completed surveillance forms 
on newly diagnosed HIV cases, AIDS cases and AIDS 
related deaths and forwarded these to the appropriate 
Department of Public Health who in turn forwarded 
them to HPSC where national data were collated on an 
MS Access database.  Bi-annual analysis of these data 
were performed at HPSC and reports produced.  
Immunisation Uptake
Each HSE Area maintains a childhood immunisation 
database. In 2011, HSE Areas provided HPSC with 
immunisation uptake data for their area and for each 
of the Local Health Offices in their area on a quarterly 
basis. National data were collated and analysed at 
HPSC using a MS Excel database.  Quarterly reports 
were produced and are available on the HPSC website. 
For further details on methods used, please see the 
immunisation uptake chapter within this report.
European Antimicrobial Resistance Surveillance 
Network (EARS-Net)
Data were collected by participating EARS-Net (formerly 
the European Antimicrobial Resistance Surveillance 
System, EARSS) laboratories in 2011 on the first invasive 
isolate per patient per quarter on Staphylococcus 
aureus and Enterococcus faecalis from blood only 
and on Streptococcus pneumoniae, Escherichia coli, 
Klebsiella pneumoniae and Pseudomonas aeruginosa 
from blood and cerebrospinal fluid (CSF).  Data were 
reported quarterly to HPSC, via WHONET software, 
and collated in an MS Access database. Quarterly and 
annual reports were produced.
Note: Invasive infections due to K. pneumoniae and 
P. aeruginosa became notifiable as of 13th September 
2011.
Antimicrobial consumption
Community (outpatient) consumption data were 
obtained from IMS Health and represent wholesaler 
to retail pharmacy sales figures for Ireland. Hospital 
(inpatient) consumption data were obtained directly 
from clinical pharmacies and validated with the support 
of the Irish Antimicrobial Pharmacists Association. 
Quarterly and annual consumption trends by named 
public acute hospitals are published on the HPSC 
website. All data were stored at the HSPC in an MS 
Access database, and interpreted using the WHO 
Anatomical Therapeutic Chemicals index   
(www.whocc.no/atcddd/) in line with European 
Surveillance of Antimicrobial Consumption (ESAC) 
methodology. See relevant section for notes on the 
denominator data.
Healthcare associated infections
•  Clostridium difficile: Data on C.difficile enhanced 
surveillance were collected by participating hospitals, 
reported quarterly to the HPSC and stored in an MS 
Access database. Quarterly and annual reports were 
produced. 
•  Healthcare associated infections in long term 
care facilities (HALT): Participating Long Term Care 
Facilities (LTCFs) of the HALT project were asked to 
survey residents on one day only, thereby providing 
a snapshot of HCAI and antimicrobial use on that 
particular day. Data was entered by each LTCF onto a 
standalone Access-based IT tool developed by ECDC 
and sent to HPSC for analysis.
•  Data were also collected on the total volume of 
alcohol-based hand rub used per hospital per year/
quarter, excluding that used for pre-operative surgical 
“scrub”.  See relevant section for notes on the 
denominator data. The rate of usage per hospital was 
calculated as the total volume of hand rub consumed 
(in litres) per 1000 bed days used, and quarterly and 
annual reports were produced for publication on the 
HPSC website.
Denominator Data
To calculate disease incidence rates, Census of 
Population data were used as the denominator 
(available from the Central Statistics Office, http://www.
cso.ie).  Population figures were applied as follows: 
Census 2011 for analysis of 2009-2011 data 
Census 2006 for analysis of 2004-2008 data
Census 2002 for 2000-2003 data 
Census 1996 for 1999 data 
Monthly population changes were estimated between 
1993 and 2011 using a curve interpolation method for 
the calculation of outpatient antibiotic consumption 
rate. 
Bed-days used and other activity data for public acute 
hospitals were provided by the Performance Monitoring 
Unit of the HSE and used to calculate rates of MRSA, 
hospital antibiotic consumption and rates used in other 
hospital-based surveillance systems. Similar activity data 
were obtained directly from private acute hospitals.
HSE Areas
Although organisational changes have taken place 
in the Health Services, the term HSE Areas are used 
in this report when analysing and presenting data by 
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geographical area (equating to the eight former health 
board regions/areas). This is because operationally 
the surveillance, prevention and control of infectious 
diseases are still managed by eight Departments of 
Public Health, one in each HSE Area.
Regional Directors of Operations (RDO’s)
The range of health and personal social services 
provided by the HSE and its funded agencies are 
managed within four regions known as RDOs. Details of 
the four RDOs and their relationship with the eight HSE 
areas are shown below.
1. Dublin Mid Leinster (HSE-Midland plus CCA1-5 and 
CCA9-10 of HSE-East)
2. Dublin North East (HSE-North East plus CCA6-8 of 
HSE-East)
3. South (HSE-South and HSE-South East)
4. West (HSE-Midwest, HSE-North West and HSE-West)
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Glossary of Terms 
CIDR Computerised Infectious Diseases Reporting
DoHC Department of Health and Children
EARS-Net European Antimicrobial Resistance Surveillance Network 
ECDC European Centre for Disease Prevention and Control
EISN European Influenza Surveillance Network
FSAI Food Safety Authority of Ireland
FSPB Food Safety Promotion Board
ICGP Irish College of General Practitioners
IDU Injecting Drug User
IMMRL Irish Meningococcal and Meningitis Reference Laboratory
IPD Invasive pneumococcal disease
HCAI Healthcare associated infections
HPSC Health Protection Surveillance Centre
HSE Health Services Executive
HSE E HSE Eastern Region
HSE M HSE Midland Area
HSE MW HSE Mid-Western Area
HSE NE HSE North Eastern Area
HSE NW HSE North Western Area
HSE SE HSE South Eastern Area
HSE S HSE Southern Area
HSE W HSE Western Area
MRSA Meticillin Resistant Staphylococcus aureus
MSM Men who have Sex with Men
NSRL National Salmonella Reference Laboratory
NVRL National Virus Reference Laboratory
STIs Sexually Transmitted Infections
TB Tuberculosis
WHO World Health Organisation
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